(12) STANDARD PATENT (11) Application No. **AU 2020415711 B2**
(19) AUSTRALIAN PATENT OFFICE

(54) Title
Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof

(51) International Patent Classification(s)

C07C 41/30 (2006.01)	***C07C 209/68*** (2006.01)
A61P 17/00 (2006.01)	***C07C 211/45*** (2006.01)
A61P 17/06 (2006.01)	***C07C 227/16*** (2006.01)
A61P 35/00 (2006.01)	***C07C 231/12*** (2006.01)
C07C 43/23 (2006.01)	***C07C 233/25*** (2006.01)
C07C 51/367 (2006.01)	***C07C 279/18*** (2006.01)
C07C 65/19 (2006.01)	***C07C 303/40*** (2006.01)
C07C 201/12 (2006.01)	***C07C 311/08*** (2006.01)
C07C 205/37 (2006.01)	***C07C 319/20*** (2006.01)

(21) Application No: **2020415711** (22) Date of Filing: **2020.12.23**

(87) WIPO No: **WO21/127743**

(30) Priority Data

(31) Number	(32) Date	(33) Country
2019904976	**2019.12.23**	**AU**

(43) Publication Date: **2021.07.01**
(44) Accepted Journal Date: **2025.02.27**

(71) Applicant(s)
Kynan Duke IP, LLC

(72) Inventor(s)
DUKE, Colin Charles;DUKE, Rujee Kyokajee;TRAN, Van Hoan

(74) Agent / Attorney
FB Rice Pty Ltd, L 23 44 Market St, Sydney, NSW, 2000, AU

(56) Related Art
STEYNBERG J. P. et al., JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1. 1987, pages 1705 - 1712
HARTUNG, A. M. et al., "Stilbenes and k-Selective, Non-nitrogenous Opioid Receptor Antagonists", JOURNAL OF NATURAL PRODUCTS. 2014, vol. 77, pages 311 - 319
MUNIGUNTI, R. et al., "Screening of natural compounds for ligands to PfTrxR by ultrafiltration and LC-MS based binding assay", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS. 2011, vol. 55, pages 265 - 271
SNYDER, S. A. et al., "Total Synthesis of Diverse Carbogenic Complexity within the Resveratrol Class from a Common Building Block", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY. 2009, vol. 131, pages 1753 - 1765
QI, W.-Y. et al., "Design of Chiral Sulfoxide-Olefins as a New Class of Sulfur-Based Olefin Ligands for Asymmetric Catalysis", ORGANIC LETTERS. 2011, vol. 13, pages 3410 - 13
WO 2012/149608 A1
WANG, L.-Q. et al., "Stilbene derivatives from Gnetum montanum MARKGR. f. megalocarpum MARKGR", HELVETICA CHIMICA ACTA. 2008, vol. 91, pages 159 - 164

KOOLAJI, N. ET AL., "Synthesis of C- and O-prenylated tetrahydroxystilbenes and O-prenylated cinnamates and their action towards cancer cells", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 2013, vol. 63, pages 415 - 422
MCATEE, C. C. ET AL., "Polycyclic Aromatic Hydrocarbons via Iron(III)-Catalyzed Carbonyl-Olefin Metathesis", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY. 2017, vol. 139, pages 2960 - 2963

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
01 July 2021 (01.07.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/127743 A1

(51) International Patent Classification:

C07C 41/30 (2006.01)	*C07C 279/18* (2006.01)
C07C 43/23 (2006.01)	*C07C 303/40* (2006.01)
C07C 51/367 (2006.01)	*C07C 311/08* (2006.01)
C07C 65/19 (2006.01)	*C07C 319/20* (2006.01)
C07C 201/12 (2006.01)	*C07C 231/12* (2006.01)
C07C 205/37 (2006.01)	*C07C 233/25* (2006.01)
C07C 209/68 (2006.01)	*A61P 35/00* (2006.01)
C07C 211/45 (2006.01)	*A61P 17/00* (2006.01)
C07C 227/16 (2006.01)	*A61P 17/06* (2006.01)

(21) International Application Number:
PCT/AU2020/051431

(22) International Filing Date:
23 December 2020 (23.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2019904976 23 December 2019 (23.12.2019) AU

(71) Applicants: **KYNAN DUKE IP, LLC** [US/US]; 2307 Princess Ann Street, Greensboro, North Carolina 27408 (US). **THE UNIVERSITY OF SYDNEY** [AU/AU]; SYDNEY, New South Wales 2006 (AU).

(72) Inventors: **DUKE, Colin Charles**; 19 Titania Street, Randwick, 2031 (AU). **DUKE, Rujee Kyokajee**; 19 Titania Street, Randwick, New South Wales 2031 (AU). **TRAN, Van Hoan**; 45 The Esplanade, Guilford, 2161 (AU).

(74) Agent: **FB RICE**; LEVEL 23/44 MARKET STREET, SYDNEY, 2000 (AU).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2021/127743 A1

(54) Title: SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF

(57) Abstract: The present disclosure relates to substituted hydroxystilbene compounds and derivatives, specifically 2-substituted hydroxystilbene compounds and derivatives, the synthesis of such compounds and their use in therapy.

2020415711 20 Jan 2025


Substituted hydroxystilbene compounds and derivatives, synthesis and uses thereof

Technical Field

The present disclosure relates to substituted hydroxystilbene compounds and derivatives, specifically 2-substituted hydroxystilbene compounds and derivatives, the synthesis of such compounds and their use in therapy.

Background

WO2012/149608 discloses novel prenylated polyhydroxystilbene derivatives and methods of preparing such compounds via multiple steps. One of the steps is an O- to C-prenyl rearrangement step as generally outlined below:



The methods disclosed in WO2012/149608 have a number of disadvantages. The number of synthetic steps from common intermediates to the final prenylated polyhydroxystilbene compounds is high. The rearrangement step is problematic as it is specific mainly to a prenyl group and to a relatively narrow range of other substituent types. The rearrangement methodology requires chromatographic separation and is generally low yielding. Thus, the prior art methods are not suitable to produce a wide range of synthetic derivatives of the prenylated polyhydroxystilbene compounds and are not suitable for large scale synthesis. The content of WO2012/149608 is fully incorporated herein.

A need exists for alternate methods of producing substituted hydroxystilbene compounds and derivatives, specifically 2-substituted hydroxystilbene compounds and derivatives.


2020415711 20 Jan 2025

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present disclosure as it existed before the priority date of each of the appended claims.

Summary

In work leading up to the present disclosure the invenotrs have synthesised a wide range of 2-substituted hydroxystilbene compounds by a novel process that has provided an efficient and commercially viable pathway to a number of compounds that have importance in medical therapy. The novel process has also provided access to a range of novel comppounds that have shown to be potential candidates for use in therapy, such as in the treatment of cancer and skin diseases and disorders.

The present disclosure relates to the synthesis of a compound of formula (I):



Formula (I)

wherein:

R^{1a} is independently allyl, crotyl, prenyl, geranyl, farnesyl, benzyl or 2-alkenyl, 2-alkynyl;

R^{1b} is independently CF_3, OH or OR^2, NO_2, NHEt, NMe_2, NMeEt, NHR^3, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

R^{1c} is independently H, alkyl, alkenyl, alkynyl, alkanedienyl, prenyl, geranyl, farnesyl, or benzyl;

R^{1d} is independently CF_3, OH or OR^2, NHR^3, NO_2, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

2020415711 20 Jan 2025

R^{1e} is independently H, C_1-C_6 alkyl, OH, OR^2, NO_2, NMe_2, NHR^3, $NMeR^3$, NHC(O)H, or SR^2;

R^{1f} is independently H, OH, OR^2, NO_2, NHR^3, NHC=NH(NH_2), $COOR^2$, COOH;

R^{1g} is independently H, alkyl, CF_3,OH or OR^2;

and no more than one of R^{1e}, R^{1f} or R^{1g} can be H;

or R^{1e} and R^{1f} form a five or six-membered heterocyclic ring containing a carbonyl group or (CO)CH_2 group when R^{1e} is independently OH, NH_2 or NHMe and R^{1f} is NH_2, such that the nitrogen of R^{1f} is bridged with the carbonyl group or (CO)CH_2 group to the oxygen or nitrogen of R^{1e};

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl, $COCOOR^4$ or an O-protecting group when R^2 is attached to an O, wherein the O-protecting group is selected from the group consisting of COMe, *t*-BuSi(CH_3)$_2$, 2-(trimethylsilyl)ethoxy]methyl (SEM), CH(OEt)CH_3, tetrahydropyranyl, or C(OEt)(CH_3)$_2$;

R^3 is independently H, CH_3, OH, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $CO(CH_2)_nNH_2$, $CONH_2$, $CO(CH_2)_nCOOH$ or $COCOOR^4$,where n = 0, 1 or 2; and

R^4 is C_1-C_6 alkyl.

As referred to herein, the 2-substituted hydroxystilbene compound according to formula (I) is represented by two benzene rings which are designated as the A and B ring. The A-ring referred to herein represents the benzene ring bearing substituents, $R^{1a,}$ R^{1b}, R^{1c} and R^{1d}, and the B-ring referred to herein represents the benzene ring bearing the substituents R^{1e}, R^{1f} and R^{1g}.

The present disclosure utilises a modular approach for synthesising the compound according to formula (I). The A ring and the B ring of the 2-substituted hydroxylstilbene compound are formed from two separate modules, Module A and Module B respectively. Module A is a halo or hydroxyl benzaldehyde derivative and Module B is an aromatic phosphonate derivative. According to the present disclosure, coupling of the halo/hydroxy benzaldehyde (Module A) with the aromatic phoshonate (Module B) affords a 2-halo or 2-hydroxy substituted hydroxystilbene derivative (Module C), as referred to above.

2020415711 20 Jan 2025

Throughout the specification, 2-halo or 2-hydroxy substituted hydroxystilbene derivative (Module C) may be referred to as 2-halo/hydroxyl substituted hydroxystilbene derivative, 2-halo/hydroxyl hydroxystilbene derivative, 2-halo/hydroxyl hydroxystilbene or Mocule C and includes both 2-halo substituted hydroxystilbene derivatives and 2-hydroxy substituted hydroxystilbene derivatives and equivalent name variations as before mentioned.

The present inventors have surprisingly found that this methodology allows an alternate synthesis of 2-substituted hydroxystilbene compounds and versatility of substitution at the 2–position of 2-substituted hydroxystilbene compounds, such that the group substituted at the 2-position can be extended beyond the prenyl group. Accordingly, the present disclosure provides a process of preparing a 2-substituted hydroxystilbene compound of formula (I), as described above, where addition of a 2-alkenyl or benzyl group at the R^{1a} position occurs by direct coupling of the 2-alkenyl or benzyl group of a boronic acid/derivative or organostannane compound containing the same with a 2-halo/hyroxy substituted hydroxystilbenene derivative.

In one embodiment, the synthesis of the above compound of formula (I) is advantageously efficient in terms of having a low number of synthetic steps from prepared starting modules, and versatility and flexibility for application in preparing a wide range of synthetic derivatives. In another embodiment, each step of the synthesis starting from the prepared modules is high yielding.

In one embodiment, the method of preparing a compound of formula (I) as defined above, when R^{1a} is a prenyl group results in an improvement in the yield over the steps disclosed in WO2012/149608 which produces a mixture of products.


One embodiment of the present disclosure provides a synthetic method where the *O*- to *C*-prenyl rearrangement step disclosed in WO2012/149608 is replaced by a direct coupling of a prenyl group to an aromatic ring by way of coupling of a prenylboronic acids/esters or a prenyltributylstannane with a 2-halo or 2-hydroxyl substituted

2020415711 20 Jan 2025

hydroxystilbenene derivative. Advantageously, groups other than prenyl can be added at the R^{1a} postion of the hydroxystilebene structure.

Advantageously, the inventors are able to adopt the versatile methodology disclosed herein to efficiently prepare previously identified 2-prenyl hydroxystilbene compunds which are important in medical therapy on a commercial scale. Due to the versatility of the methodology disclosed herein , the inventors have been able to prepare a wide range of 2-substituted hydroystilbene compounds according to Formula (I) which they were previously unable to prepare using the rearrangement method. The inventors have surprisingly found that the 2-substituted hydroxystilbene compounds according to formula (I) prepared by the methodology disclosed herein, are strong candidates for the development of new therapeutic agents in the treatment of diseases such as cancer and skin diseasse and disorders such as atopic dermatitis and psoriasis.

The present disclosure provides a process of synthesising a compound according to formula (I),



Formula (I)

wherein:

R^{1a} is independently allyl, crotyl, prenyl, geranyl, farnesyl, benzyl or 2-alkenyl, 2-alkynyl;

R^{1b} is independently CF_3, OH or OR^2, NO_2, NHEt, NMe_2, NMeEt, NHR^3, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

R^{1c} is independently H, alkyl, alkenyl, alkynyl, alkanedienyl, prenyl, geranyl, farnesyl, or benzyl;

2020415711 20 Jan 2025

R^{1d} is independently CF_3, OH or OR^2, NHR^3, NO_2, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

R^{1e} is independently H, C_1-C_6 alkyl, OH, OR^2, NO_2, NMe_2, NHR^3, $NMeR^3$, $NHC(O)H$, or SR^2;

R^{1f} is independently H, OH, OR^2, NO_2, NHR^3, $NHC{=}NH(NH_2)$, $COOR^2$, COOH;

R^{1g} is independently H, alkyl, CF_3,OH or OR^2;

and no more than one of R^{1e}, R^{1f} or R^{1g} can be H;

or R^{1e} and R^{1f} form a five or six-membered heterocyclic ring containing a carbonyl group or $(CO)CH_2$ group when R^{1e} is independently OH, NH_2 or NHMe and R^{1f} is NH_2, such that the nitrogen of R^{1f} is bridged with the carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of R^{1e};


R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl, $COCOOR^4$ or an O-protecting group when R^2 is attached to an O;

R^3 is independently H, CH_3, OH, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $CO(CH_2)_nNH_2$, $CONH_2$, $CO(CH_2)_nCOOH$ or $COCOOR^4$,where n is 0, 1 or 2; and


R^4 is C_1-C_6 alkyl;

the process comprising:

i) a step of coupling a compound of formula (II) (Module A) with a compound of formula (III) (Module B) to afford a compound of formula (IV) (Module C):




Formula (II)



Formula (III)

Module A **Module B**

2020415711 20 Jan 2025



Formula (IV)

Module C

wherein,

in Formula II (Module A):

R^{2b} is independently CF_3, OH,OR^2, NO_2, NMe_2, NHEt, NMeEt, NHR^3 or $NMeR^3$;

R^{2c} is independently H, alkyl, alkenyl, alkynyl, alkanedienyl, prenyl, geranyl, farnesyl, or benzyl;

R^{2d} is independently CF_3, OH or OR^2, NO_2,NHR^3, $NMeR^3$, NHC=NH(NH_2) or $COOR^2$;

X is a halide or a hydroxyl group, wherein the halide is selected from the group consisting of F, Cl, Br, I, and At;

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl, or O-protecting group when R^2 is attached to an O; and

R^3 is independently H, OH, CH_3, (CO)H, COMe, SO_2Me, $COCH_2NH_2$, or CH_2COOR^2; and

in Formula III (Module B):

R^{3e} is independently H, C_1-C_6 alkyl, OH, OR^2, NO_2, NHMe, NMe_2, NHR^3 or $NMeR^3$, SR^2;

R^{3f} is independently H, OH, OR^2, NO_2, NHR^3, NHC=NH(NH_2), COOH or $COOR^2$;

R^{3g} is independently H, alkyl, CF_3, OH or OR^2;

and no more than one of R^{3e}, R^{3f} or R^{3g} can be H;

2020415711 20 Jan 2025

or R^{3e} and R^{3f} form a five or six-membered heterocyclic ring containing a carbonyl group or $(CO)CH_2$ group when R^{3e} is OH, NH_2 or NHMe and R^{3f} is NH_2, such that the nitrogen of R^{3f} is bridged with the carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of R^{3e};

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or O-protecting group when R^2 is attached to an O,

R^3 is independently H, CH_3, OH, (CO)H, COMe, SO_2Me, $COCH_2NH_2$, CH_2COOH or CH_2COOR^2; and

in Formula IV (Module C):

R^{4b} is independently CF_3, OH or OR^2, NO_2, NMe_2, NHEt, NMeEt, NHR^3 or $NMeR^3$;

R^{4c} is independently H, alkyl, alkenyl, alkynyl, alkanedienyl, prenyl, geranyl, farnesyl or benzyl;

R^{4d} is independently CF_3, OH or OR^2, OR^3, NO_2 or NHR^3, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

R^{4e} is independently H, C_1-C_6 alkyl, OH, OR^2, NO_2, NMe_2, NHR^3 or $NMeR^3$, SR^2;

R^{4f} is independently H, OH, OR^2, NO_2, NHR^3, $NHC{=}NH(NH_2)$, COOH or $COOR^2$;

R^{4g} is independently H, alkyl, CF_3, OH or OR^2;

and no more than one of R^{4e}, R^{4F} or R^{4g} can be H;

or R^{4e} and R^{4f} form a five or six-membered heterocyclic ring containing a carbonyl group or $(CO)CH_2$ group when R^{4e} is OH, NH_2 or NHMe and R^{4f} is NH_2, such that the nitrogen of R^{4f} is bridged with the carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of R^{4e};

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or O-protecting group when R^2 is attached to an O;

R^3 is independently H, CH_3, OH, (CO)H, COMe, SO_2Me, $COCH_2NH_2$, CH_2COOH or CH_2COOR^2; and

2020415711 20 Jan 2025

X is a halide or a hydroxyl group, wherein the halide is selected from the group consisting of F, Cl, Br, I, and At.


The 2-substituted halo/hydroxy hydroxystilbene compounds according to formula (IV) (Module C) undergo a further reaction to afford the compound of Formula (I) as herein described.

In one embodiment, the 2-substituted halo hydroxystilbene compound according to formula (IV) (Module C) undergoes a further coupling reaction with a 2-alkenyl or benzyl boronic acid or ester, a 2-alkenyl or benzyl trifluoroborate compound, or a 2-alkenyl or benzyl organostannane compound to afford the compound of Formula (I)

In another embodiment, when X is a hydroxyl in formula (IV), activation of the hydroxyl to a triflate group (OTf, trifluoromethylsilfonate) is required before coupling with a 2-alkenyl or benzyl boronic acid or ester, a 2-alkenyl or benzyl trifluoroborate compound, or a 2-alkenyl or benzyl organostannane compound to afford the compound of Formula (I).

The compound of formula (IV) or (I) may optionally undergo one or more further reactions, including but not limited to reaction with one or more $–NH_2$, NO_2 and/or -OH substituents on formula (IV) or formula (I).

The present disclosure also provides a compound according to formula (I)



Formula (I)

wherein:

2020415711 20 Jan 2025

R^{1a} is independently allyl, crotyl, prenyl, geranyl, farnesyl, benzyl, 2-alkenyl or 2-alkynyl;

R^{1b} is independently CF_3, OH or OR^2, NO_2, NHEt, NMe_2, NMeEt, NHR^3, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

R^{1c} is independently H, alkyl, alkenyl, alkynyl, alkanedienyl, prenyl, geranyl, farnesyl, or benzyl;

R^{1d} is independently CF_3, OH or OR^2, NHR^3, NO_2, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

R^{1e} is independently H, C_1-C_6 alkyl, OH, OR^2, NO_2, NMe_2, NHR^3 or $NMeR^3$, NHC(O)H or SR^2;

R^{1f} is independently H, OH, OR^2, NO_2, NHR^3, $NHC{=}NH(NH_2)$, $COOR^2$ or COOH;

R^{1g} is independently H, alkyl, CF_3, OH or OR^2;

and only one of R^{1e}, R^{1f} or R^{1g} can be H;

or R^{1e} and R^{1f} form a five or six-membered heterocyclic ring containing a carbonyl group or $(CO)CH_2$ group when R^{1e} is OH, NH_2 or NHMe and R^{1f} is NH_2, such that the nitrogen of R^{1f} is bridged with the carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of R^{1e};

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl, $COCOOR^4$ or an O-protecting group when R^2 is attached to an O, wherein the O-protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxy]methyl (SEM), $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$;

R^3 is independently H, CH_3, OH, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $CO(CH_2)_nNH_2$, $CONH_2$, $CO(CH_2)_nCOOH$ or $COCOOR^4$,. where n = 0, 1 or 2;


R^4 is C_1-C_6 alkyl; and

;

wherein the compound of formula (I) is prepared by a process according to the first aspect as disclosed herein.

2020415711 20 Jan 2025

, The present disclosure further provides a compound according to formula (I)



Formula (I)

wherein:

R^{1a} is independently allyl, crotyl, prenyl, geranyl, farnesyl, benzyl, 2-alkenyl or 2-alkynyl;

R^{1b} is independently CF_3, OH, OR^2, NO_2, NHEt, NMe_2, NMeEt, NHR^3, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

R^{1c} is independently H, alkyl, alkenyl, alkynyl, alkanedienyl, prenyl, geranyl, farnesyl, or benzyl;

R^{1d} is independently CF_3, OH, OR^2, NO_2, NHR^3, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

R^{1e} is independently H, C_1-C_6 alkyl, OH, OR^2, NO_2, NMe_2, NHR^3 or $NMeR^3$, NHC(O)H and SR^2;

R^{1f} is independently H, OH, OR^2, NO_2, NHR^3, $NHC{=}NH(NH_2)$, $COOR^2$, COOH;

R^{1g} is independently H, alkyl, CF_3, OH or OR^2;

and only one of R^{1e}, R^{1f} or R^{1g} can be H;

or R^{1e} and R^{1f} form a five or six-membered heterocyclic ring containing a carbonyl group or $(CO)CH_2$ group when R^{1e} is OH, NH_2 or NHMe and R^{1f} is NH_2, such that the nitrogen of R^{1f} is bridged with the carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of R^{1e};

R^2 is independentlymethyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl, $COCOOR^4$or O-protecting group when R^2 is attached to an O,

2020415711 20 Jan 2025

wherein the O-protecting group is selected from the group consisting of COMe, *t*-BuSi(CH_3)$_2$, 2-(trimethylsilyl)ethoxy]methyl (SEM) acetal, CH(OEt)CH_3, tetrahydropyranyl, or C(OEt)(CH_3)$_2$;

R^3 is independently H, CH_3, OH, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $CO(CH_2)_nNH_2$, $CONH_2$, $CO(CH_2)_nCOOH$ or $COCOOR^4$, where n is 0, 1 or 2;

R^4 is C_1-C_6 alkyl;

halide is selected from the group consisting of F, Cl, Br, I, and At; and

only one of R^{1e}, R^{1f} or R^{1g} can be H,

provided that

when R^{1a} and/or R^{1c} is prenyl, R^{1d} is OH, R^{1f} is OH, R^{1g} is H and R^{1e} is OH, OMe or OEt, then R^{1b} cannot be OH or OR^2 where R is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *t*-butyl, or benzyl.


The present disclosure provides a method for treating cancer comprising administering a therapeutically effective amount of a compound according to the second or third aspect of the present disclosure or a pharmaceutically acceptable salt, solvate or pharmaceutical composition including said compounds to a patient in need.

The present disclosure also provides a method for treating a skin disease or disorder comprising administering a therapeutically effective amount of a compound according to the second or third aspect of the present disclosure or a pharmaceutically acceptable salt, solvate or pharmaceutical composition including said compounds to a patient in need.

2020415711 22 Jan 2025

Aspects

In a first aspect, there is disclosed a process of synthesising a compound of formula (I):



Formula (I)

wherein:

R^{1a} is independently allyl, crotyl, prenyl, benzyl or 2-alkenyl;

R^{1b} is independently CF_3, OR^2 or NHR^3;

R^{1c} is H;

R^{1d} is independently OH, O-protecting group, NHR^3 or NO_2;

R^{1e} is independently C_1-C_6 alkyl, OH, OR^2, NO_2, NHR^3, $NMeR^3$ or SR^2;

R^{1f} is independently H, OH, O-protecting group, NO_2, NHR^3, $N(OH)(CO)CH_3$, $NHC{=}NH(NH_2)$ or COOH;

R^{1g} is independently H, C_1-C_6 alkyl, OH;

R^{1b} and R^{1d} are not the same;

no more than one of R^{1f} or R^{1g} can be H;

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or trifluoromethyl;

protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxymethyl (SEM), $CH(OEt)CH_3$, tetrahydropyranyl and $C(OEt)(CH_3)_2$;


R^3 is independently H, CH_3, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $CO(CH_2)_nNH_2$, $CONH_2$, $CO(CH_2)_nCOOH$ or $COCOOR^4$, where n is 0, 1 or 2; and

R^4 is C_1-C_6 alkyl;


2020415711 22 Jan 2025

or R^{1e} and R^{1f} form a five-membered heterocyclic ring containing a carbonyl group when R^{1e} is independently OH, NH_2 or NHMe and R^{1f} is NH_2, such that the nitrogen of R^{1f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{1e} and R^{1g} is H;

the process comprising a step of coupling a compound of formula (II) (Module A) with a compound of formula (III) (Module B) to afford a compound of formula (IV) (Module C):




Formula (II)



Formula (III)

Module A **Module B**



Formula (IV)

Module C

wherein,

in Formula II (Module A):

R^{2b} is independently CF_3, OR^2 or NH_2;

R^{2c} is H;

R^{2d} is independently O-protecting group or NO_2;

X is a halide or a hydroxyl group, wherein the halide is selected from the group consisting of F, Cl, Br, I, and At; and

2020415711 22 Jan 2025

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or trifluoromethyl;

in Formula III (Module B):

R^{3e} is independently C_1-C_6 alkyl, OR^2, NO_2 or SR^2;

R^{3f} is independently H, O-protecting group, NO_2 or $COOR^2$;

R^{3g} is independently H, C_1-C_6 alkyl, OH or OR^2;

no more than one of R^{3f} or R^{3g} can be H;

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or trifluoromethyl;

or R^{3e} and R^{3f} form a five-membered heterocyclic ring containing a carbonyl group when R^{3e} is OH, NH_2 or NHMe and R^{3f} is NH_2, such that the nitrogen of R^{3f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{3e} and R^{3g} is H;in Formula IV (Module C):

R^{4b} is independently CF_3, OR^2 or NH_2;

R^{4c} is H;

R^{4d} is independently O-protecting group or NO_2;

R^{4e} is independently C_1-C_6 alkyl, OR^2, NO_2 or SR^2;

R^{4f} is independently H, O-protecting group, NO_2 or COOH;

R^{4g} is independently H, C_1-C_6 alkyl, OH or OR^2;

no more than one of R^{4f} or R^{4g} can be H;

or R^{4e} and R^{4f} form a five -membered heterocyclic ring containing a carbonyl group when R^{4e} is OH, NH_2 or NHMe and R^{4f} is NH_2, such that the nitrogen of R^{4f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{4e} and R^{4g} is H;

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or trifluoromethyl;

X is a halide or a hydroxyl group, wherein the halide is selected from the group consisting of F, Cl, Br, I, and At;

2020415711 22 Jan 2025

wherein the protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxymethyl (SEM), $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$.

In a second aspect, there is disclosed a compound according to formula (I), wherein:

R^{1a} is allyl, crotyl, prenyl, benzyl or 2-alkenyl;

R^{1b} is CF_3, OR^2 or NHR^3;

R^{1c} is H;

R^{1d} is OH, O-protecting group, NHR^3 or NO_2;

R^{1b} and R^{1d} are not the same;

R^{1e} is C_1-C_6 alkyl, OH, OR^2, NO_2, NHR^3, $NMeR^3$ or SR^2;

R^{1f} is H, OH, O-protecting group, NO_2, NHR^3, NHC=NH(NH_2), COOH or $N(OH)(CO)CH_3$;

R^{1g} is H, C_1-C_6 alkyl or OH;

no more than one of R^{1f} or R^{1g} can be H;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or a O-protecting group;

protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxymethyl (SEM), $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$; and

R^3 is H, CH_3, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $CO(CH_2)_nNH_2$, $CONH_2$, $CO(CH_2)_nCOOH$ or $COCOOR^4$ (where n = 0, 1 or 2);

R^4 is C_1-C_6 alkyl;

or R^{1e} and R^{1f} form a five-membered heterocyclic ring containing a carbonyl group when R^{1e} is independently OH, NH_2 or NHMe and R^{1f} is NH_2, such that the nitrogen of R^{1f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{1e}; and R^{1g} is H;

when prepared by the process described in the first aspect.

In a third aspect, there is disclosed a compound according to formula (I), wherein:

R^{1a} is allyl, crotyl, prenyl, benzyl or 2-alkenyl;

2020415711 22 Jan 2025

R^{1b} is CF_3, OR^2 or NHR^3;

R^{1c} is H;

R^{1d} is OH, O-protecting group, NO_2 or NHR^3;

R^{1e} is C_1-C_6 alkyl, OH, OR^2, NO_2, NHR^3, $NMeR^3$ or SR^2;

R^{1f} is H, OH, O-protecting group, NO_2, NHR^3, $NHC{=}NH(NH_2)$, $COOR^2$, COOH or $N(OH)(CO)CH_3$;

R^{1g} is H, C_1-C_6 alkyl, or OH;

only one of R^{1f} or R^{1g} can be H;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or O-protecting group;

protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxymethyl (SEM), $CH(OEt)CH_3$, tetrahydropyranyl or $C(OEt)(CH_3)_2$;

R^3 is H, CH_3, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $CO(CH_2)_nNH_2$, $CONH_2$, $CO(CH_2)_nCOOH$ or $COCOOR^4$ (where n = 0, 1 or 2); and

R^4 is C_1-C_6 alkyl;

or R^{1e} and R^{1f} form a five-membered heterocyclic ring containing a carbonyl group when R^{1e} is independently OH, NH_2 or NHMe and R^{1f} is NH_2, such that the nitrogen of R^{1f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{1e}; and R^{1g} is H;

provided that:

i) when R^{1a} is prenyl, R^{1d} is OH or O-protecting group, R^{1f} is OH or O-protecting group, R^{1g} is H and R^{1e} is OH or OR^2, then R^{1b} cannot be OR^2 where R^2 =methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *t*-butyl, or benzyl; and

ii) R^{1b} and R^{1d} are not the same.

In a fourth aspect, there is disclosed a method of treating a cancer comprising administering a therapeutically effective amount of a compound according to formula (I) as described in the third aspect, compound 8 or compound 20, or a pharmaceutically acceptable salt, solvate or pharmaceutical composition including said compounds to a

2020415711 22 Jan 2025

patient in need thereof wherein the cancer is selected from the group consisting of: skin cancer including melanoma; CNS cancer, ovarian cancer, renal cancer, prostate cancer, pancreatic cancer, bladder cancer, kidney cancer, hypo-pharynx cancer, pharynx cancer, tongue cancer, colon cancer, breast cancer, lung cancer, liver cancer, brain cancer, glioblastoma and osteoblastic sarcoma cell cancer, connective tissue sarcoma, Ewing's sarcoma, fibrosarcoma, leiomyosarcoma, liposarcoma, osteosarcoma and rhabdomyosarcoma, pharyngeal cancer, and neuroblastomas.


In a fifth aspect, there is disclosed use of a compound according to formula (I) as described in the third aspect, compound 8 or compound 20, or a pharmaceutically acceptable salt, solvate or pharmaceutical composition including said compounds in the manufacture of a medicament for the treatment of a cancer selected from the group consisting of: skin cancer including melanoma, CNS cancer, ovarian cancer, renal cancer, prostate cancer, pancreatic cancer, bladder cancer, kidney cancer, hypo-pharynx cancer, pharynx cancer, tongue cancer, colon cancer, breast cancer, lung cancer, liver cancer, brain cancer, glioblastoma and osteoblastic sarcoma cell cancer, connective tissue sarcoma, Ewing's sarcoma, fibrosarcoma, leiomyosarcoma, liposarcoma, osteosarcoma and rhabdomyosarcoma, pharyngeal cancer, and neuroblastomas.

In a sixth aspect, there is disclosed a method of treating a skin disease and/or disorder comprising administering a therapeutically effective amount of a compound according to formula (I) as described in the third aspect, compound 8 or compound 20, or a pharmaceutically acceptable salt, solvate or pharmaceutical composition including said compounds to a patient in need thereof.

In seventh aspect, there is disclosed use of a compound according to formula (I) as described in the third aspect, compound 8 or compound 20, or a pharmaceutically acceptable salt, solvate or pharmaceutical composition including said compounds in the manufacture of a medicament for the treatment of a skin disease and/or disorder.

Description of Embodiments

Disclosed herein is a process of synthesising a compound of Formula (I):



Formula (I)

wherein:

R^{1a} is independently allyl, crotyl, prenyl, geranyl, farnesyl, benzyl, 2-alkenyl or 2-alkynyl;

R^{1b} is independently CF_3, OH,OR^2, NO_2, NHEt, NMe_2, NMeEt, NHR^3, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

R^{1c} is independently H, alkyl, alkenyl, alkynyl, alkanedienyl, prenyl, geranyl, farnesyl, or benzyl;

R^{1d} is independently CF_3, OH, OR^2, NHR^3, NO_2, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

R^{1e} is independently H, C_1-C_6 alkyl, OH, OR^2, NO_2, NMe_2, NHR^3 or $NMeR^3$, NHC(O)H, SR^2;

R^{1f} is independently H, OH, OR^2, NO_2, NHR^3, $NHC{=}NH(NH_2)$, $COOR^2$, COOH;

R^{1g} is independently H, alkyl, CF_3,OH or OR^2;

and no more than one of R^{1e}, R^{1f} or R^{1g} can be H;

or R^{1e} and R^{1f} form a five or six-membered heterocyclic ring containing a carbonyl group or $(CO)CH_2$ group when R^{1e} is independently OH, NH_2 or NHMe and R^{1f} is NH_2, such that the nitrogen of R^{1f} is bridged with the carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of R^{1e};

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl, $COCOOR^4$ or O-protecting group when R^2 is attached to an O;


R^3 is independently H, CH_3, OH, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $CO(CH_2)_nNH_2$, $CONH_2$, $CO(CH_2)_nCOOH$ or $COCOOR^4$, where n is 0, 1 or 2; and

R^4 is C_1-C_6 alkyl;


2020415711 20 Jan 2025

the process comprising:

i) a step of coupling a compound of formula (II) (Module A) with a compound of formula (III) (Module B) to afford a compound of formula (IV) (Module C):




Formula (II)



Formula (III)

Module A **Module B**



Formula (IV)

Module C

wherein,

in Formula II (Module A):

R^{2b} is independently CF_3, OH, OR^2, NO_2, NMe_2, NHEt, NMeEt, NHR^3 or $NMeR^3$;

R^{2c} is independently H, alkyl, alkenyl, alkynyl, alkanedienyl, prenyl, geranyl, farnesyl, or benzyl;

R^{2d} is independently CF_3, OH or OR^2, NO_2, NHR^3 , $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

X is a halide or a hydroxyl group, wherein the halide is selected from the group consisting of F, Cl, Br, I, and At;

2020415711 20 Jan 2025

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl, or an O-protecting group;

R^3 is independently H, OH, CH_3, (CO)H, COMe, SO_2Me, $COCH_2NH_2$, or CH_2COOR^2; and

in Formula III (Module B):

R^{3e} is independently H, C_1-C_6 alkyl, OH, OR^2, NO_2, NHMe, NMe_2, NHR^3 or $NMeR^3$, SR^2;

R^{3f} is independently H, OH, OR^2, NO_2, NHR^3, NHC=NH(NH_2), COOH or $COOR^2$;

R^{3g} is independently H, alkyl, CF_3, OH, OR^2;

and no more than one of R^{3e}, R^{3f} or R^{3g} can be H

or R^{3e} and R^{3f} form a five or six-membered heterocyclic ring containing a carbonyl group or $(CO)CH_2$ group when R^{3e} is OH, NH_2 or NHMe and R^{3f} is NH_2, such that the nitrogen of R^{3f} is bridged with the carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of R^{3e};

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or an O-protecting group when R^2 is attached to an O,

R^3 is H, CH_3, OH, (CO)H, COMe, SO_2Me, $COCH_2NH_2$, CH_2COOH and CH_2COOR^2; and

in Formula IV (Module C):

R^{4b} is independently CF_3, OH or OR^2, NO_2, NMe_2, NHEt, NMeEt, NHR^3 or $NMeR^3$;

R^{4c} is independently H, alkyl, alkenyl, alkynyl, alkanedienyl, prenyl, geranyl, farnesyl, or benzyl;

R^{4d} is independently CF_3, OH, OR^2, OR^3, NO_2 or NHR^3, $NMeR^3$, NHC=NH(NH_2) or $COOR^2$;

R^{4e} is independently H, C_1-C_6 alkyl, OH, OR^2, NO_2, NMe_2, NHR^3 or $NMeR^3$, NHC(O)H or SR^2;

2020415711 20 Jan 2025

R^{4f} is independently H, OH, OR^2, NO_2, NHR^3, NHC=NH(NH_2), COOH or $COOR^2$;

R^{4g} is independently H, alkyl, CF_3, OH or OR^2;

or R^{4e} and R^{4f} form a five or six-membered heterocyclic ring containing a carbonyl group or $(CO)CH_2$ group when R^{4e} is OH, NH_2 or NHMe and R^{4f} is NH_2, such that the nitrogen of R^{4f} is bridged with the carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of R^{4e};

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl oran O-protecting group when R^2 is attached to an O;

R^3 is independently H, CH_3, OH, (CO)H, COMe, SO_2Me, $COCH_2NH_2$, CH_2COOH or CH_2COOR^2; and

X is a halide or a hydroxyl group, wherein the halide is selected from the group consisting of F, Cl, Br, I, and At.

The O-protecting group may be selected from those known in the art. Suitable protecting O-protecting groups suitable for use in the present application would be know to a person skilled in the art.

The O-protecting group may be COMe, *t*-BuSi(CH_3)$_2$, 2-(trimethylsilyl)ethoxy]methyl (SEM), $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$.

According to the compounds defined herein by formula (I), formula (III) and formula (IV), $R^{1e, 3e, 4e}$ and $R^{1f, 3f, 4f}$ may form a five or six-membered heterocyclic ring containing a carbonyl group or $(CO)CH_2$ group when $R^{1e, 3e, 4e}$ is OH, NH_2 or NHMe and $R^{1f, 3f, 4f}$ is NH_2, such that the nitrogen of $R^{1f, 3f, 4f}$ is bridged with the carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of $R^{1e, 3e, 4e}$. In one embodiment, the nitrogen of $R^{1f, 3f, 4f}$ is bridged with a carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of $R^{1e, 3e, 4e}$ to form a group selected from any one of the groups: –NH -C(O)- O -, -NH-C(O)-CH_2- O -, - NH -CH_2C(O)-O-, –NH-C(O)-NH-, –NH-C(O) CH_2-NH-, -NH-CH_2C(O)-NH-, –NH -C(O)-N(Me)-, -NH-C(O) CH_2-NMe- or -NH -CH_2C(O)-N(Me)-. In one embodiment $R^{1f, 3f, 4f}$ is NH_2 and $R^{1e, 3e, 4e}$ is NHMe and the nitrogen of $R^{1f, 3f, 4f}$ is bridged with a carbonyl group to the nitrogen of $R^{1e, 3e, 4e}$ to form

2020415711 20 Jan 2025

–NH -C(O)-N(Me)- such that $R^{1e, 3e, 4e}$ and $R^{1f, 3f, 4f}$ form a five membered heterocyclic ring. In another embodiment $R^{1f, 3f, 4f}$ is NH_2 and $R^{1e, 3e, 4e}$ is OH and the nitrogen of $R^{1f, 3f, 4f}$ is bridged with a carbonyl group to the oxygen of $R^{1e, 3e, 4e}$ to form –NH-C(O)-O- such that $R^{1e, 3e, 4e}$ and $R^{1f, 3f, 4f}$ form a five membered heterocyclic ring.

The 2-substituted halo/hydroxy hydroxystilbene compound according to formula (IV) (Module C) undergoes a further reaction to afford the compound of Formula (I) as herein described.

In module A and C, the group X is a halide or hydroxyl group. In one embodiment X is a halide. When X is a halide, formula (II) and (IV) may be referred to as the halide of formula (II) and the halide of formula (IV). In another embodiment X is a hydroxyl group. When X is hydroxyl, formula (II) and (IV) may be referred to as the hydroxyl of formula (II) and the hydroxyl of formula (IV). The hydroxyl of formula (IV) may be activated to the corresponding triflate (trifluoromethylsulfonate) group and may be referred to as the triflate of formula (IV) or the 2-substituted triflate hydroxystilbene of formula (IV).

The conversion of the hydroxyl group to a triflate group may be carried out according to processes known in the art. In one embodiment, when X is hydroxyl, the hydroxyl of formula (IV) is treated with trifluromethansulfonic anhydride in the presence of N-methylmorphine to provide the triflate of formula (IV).

In one embodiment, when X is a halide in formula (IV) (halide of formula (IV)) undergoes a coupling reaction with one of the following:

a) a R^{1a}-substituted boronic acid compound or ester;

b) a R^{1a}-substituted trifluoroborate compound; or

c) a R^{1a}-substituted organostannane compound;

to form the compound of formula (I).

In one embodiment, the 2-substituted halo hydroxystilbene compound according to formula (IV) (Module C) undergoes a further coupling reaction with a 2-alkenyl or

2020415711 20 Jan 2025

benzyl boronic acid or ester, to afford the compound of Formula (I). In one embodiment, a 2-substituted halo hydroxystilbene compound according to formula (IV) (Module C) undergoes a further coupling reaction with a 2-alkenyl or benzyl trifluoroborate compound, to afford a compound of Formula (I). In another embodiment, a 2-substituted halo hydroxystilbene compound according to formula (IV) (Module C) undergoes a further coupling reaction with a 2-alkenyl or benzyl organostannane compound, to afford a compound of Formula (I).

In one embodiment, when X is a hydroxyl in formula (IV) (hydroxyl of formula (IV)), activation of the hydroxyl to a triflate group (OTf, trifluoromethyl sulfonate) is required before coupling can occur. In one embodiment, the hydroxyl group of forumla (IV) is converted to a triflate (trifluromethylsulfonate) group to form a triflate of formula (IV), and the triflate of formula (I)) undergoes a coupling reaction with one of the following:
a) a R^{1a}-substituted boronic acid compound or ester;
b) a R^{1a}-substituted trifluoroborate compound; or
c) a R^{1a}-substituted organostannane compound
to form the compound of formula (I).

In one embodiment, a 2-substituted hydroxy hydroxystilbene compound according to formula (IV) (Module C) is activated to a 2-substituted triflate hydroxystilbene which may then undergoe a coupling reaction with a 2-alkenyl or benzyl boronic acid or ester to afford a compound of Formula (I). In another embodiment, the triflate of Formula (IV) undergoes a further coupling reaction with a 2-alkenyl or benzyl trifluoroborate compound to afford a compound of Formula (I). In onther embodiment, the triflate of Formula (IV) undergoes a further coupling reaction with a 2-alkenyl or benzyl organostannane compound, to afford a compound of Formula (I).

In one embodiment, the halide compound according to formula (IV) or the triflate of formula (IV) as herein described, undergoes a coupling reaction with a R^{1a}-substituted boronic acid compound to form a compound of formula (I), wherein R^{1a} is selected from the group consisting of allyl, crotyl, prenyl, geranyl, farnesyl, benzyl, 2-alkenyl, and 2-alkynyl.

2020415711 20 Jan 2025

In another embodiment, the halide compound according to formula (IV) or the triflate of formula (IV) as herein described, undergoes a coupling reaction with a R^{1a}-substituted organostannane compound to form a compound of formula (I), wherein R^{1a} is selected from the group consisting of allyl, crotyl, prenyl, geranyl, farnesyl, benzyl, 2-alkenyl, and 2-alkynyl.

In another embodiment, the halide compound according to formula (IV) or the triflate of formula (IV),as herein described, undergoes a coupling reaction with a R^{1a}-substituted trifluoroborate to form a compound of formula (I), wherein R^{1a} is selected from the group consisting of allyl, crotyl, prenyl, geranyl, farnesyl, benzyl, 2-alkenyl, and 2-alkynyl.

In another embodiment, the R^{1a} substituent in formula (II) and (IV) is selected from the group consisting of allyl, crotyl, prenyl, , benzyl or 2-alkenyl. In another embodiment, R^{1a} is selected from the group consisting of allyl, crotyl, prenyl or benzyl.

The coupling reaction of a compound of formula (IV) or the triflate of formula (IV) as described herein, with a R^{1a}-substituted boronic acid compound, a R^{1a}-substituted organostannane compound or a R^{1a}-substituted trifluoroborate may be catalysed by a suitable catalyst, including a palladium compound. The palladium catalyst includes but is not limited to tetrakis(triphenylphosphine)palladium(0) and 1,1′-bis(diphenylphosphino) ferrocene]dichloropalladium(II). The coupling reaction described herein may also be carried out in the presence of a base including but not limited to alkali metal carbonates, sauch as potassium carbonate (K_2CO_3), hydrogen carbonates, calcium carbonate, magnesium carbonate and alkylamines including triethylamine.

In one embodiment, the R^{1a}–substituted boronic acid compound is a a allyl, crotyl, prenyl, benzyl, 2-alkenyl boronic pinacol ester. The prenyl boronic pinacol esterincludes but is not limited to 3-methylbut-2-enylboronic acid pinacol ester, crotylboronic pinacol ester, allylboronic pinacol ester, benzylboronic pinacol ester.

2020415711 20 Jan 2025

In one embodiment, the halide compound according to formula (IV) or the or the triflate of formula (IV) as defined herein, undergoes a coupling reaction with a R^{1a}-substituted boronic acid pinacol ester catalysed by a palladium catalyst in the presence of a base. In another embodiment, the halide compound according to formula (IV) undergoes a coupling reaction with a R^{1a}-substituted tributylstannane catalysed by tetrakis(triphenylphosphine)palladium(0).

In aother embodiment, the halide compound according to formula (IV) or the triflate of formula (IV)) as defined herein, undergoes a coupling reaction with a R^{1a}-substituted trifluoroborate. In one specific embodiment, the halide or triflate compound according to formula (IV) undergoes a coupling reaction with potassium allyltrifluoroborate catalysed by 1,1′-bis(diphenylphosphino) ferrocene]dichloropalladium(II) and triethylamine. This coupling method provide an allyl group at R^{1a} position on the A-ring.

In one embodiment, there is provided a process of synthesising a compound of Formula (I)

wherein in Formula (I):

R^{1a} is independently allyl, crotyl, prenyl, benzyl, or 2-alkenyl;
R^{1b} is independently OH, OR^2 or NHC(O)Me;
R^{1c} is H;
R^{1d} is independently OH, NHR^3, NH(CO)H or NO_2;
R^{1e} is independently OH, OR^2, NMe_2, NHR^3, $NMeR^3$, NHC(O)H or SR^2;
R^{1f} is independently H, OH, NO_2, OR^2, NHR^3, NHC=NH(NH_2), or COOH;
R^{1g} is independently H, alkyl, OH or OR^2;
and no more than one of R^{1e}, R^{1f} or R^{1g} can be H;
or R^{1e} and R^{1f} form a five or six-membered heterocyclic ring containing a carbonyl group when R^{1e} is OH, NH_2 or NHMe and R^{1f} is NH_2, such that the nitrogen of R^{1f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{1e};

2020415711 20 Jan 2025

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or an O-protecting group when R^2 is attached to an O, wherein the O-protecting group is selected from the group consisting of COMe, *t*-BuSi$(CH_3)_2$, 2-(trimethylsilyl)ethoxy]methyl (SEM), $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$.;

R^3 is independently H, CH_3, OH, (CO)H, (CO)Me, SO_2Me, $CO(CH_2)_nNH_2$, CH_2COOR^2, $CO(CH_2)_nCOOH$ or $COCOOR^4$, where n is 0, 1 or 2; and

R^4 is C_1-C_6 alkyl;

in Formula II (Module A):

R^{2b} is OH or OR^2;

R^{2c} is H;

R^{2d} is independently OH or OR^2, NO_2, NHR^3 or $COOR^2$;

X is a halide(Hal) or hydroxyl group, wherein the halide is selected from the group consisting of F, Cl, Br, I, and At;

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl, or an O-protecting group;

R^3 is independently H, OH, CH_3, (CO)H, COMe, SO_2Me, $COCH_2NH_2$, or CH_2COOR^2; and

in Formula III (Module B):

R^{3e} is independently OH, OR^2, NO_2, NHMe, NMe_2, NHR^3 $NMeR^3$ or SR^2;

R^{3f} is independently H, OH, OR^2, NO_2, NHR^3, $NHC{=}NH(NH_2)$, COOH, $COOR^2$;

R^{3g} is independently H, alkyl, OH, OR^2;

and no more than one of R^{3e}, R^{3f} or R^{3g} can be H;


or R^{3e} and R^{3f} form a five or six-membered heterocyclic ring containing a carbonyl group or $(CO)CH_2$ group when R^{3e} is OH, NH_2 or NHMe and R^{3f} is NH_2, such that the nitrogen of R^{3f} is bridged with the carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of R^{3e};

2020415711 20 Jan 2025

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or an O-protecting group when R^2 is attached to an O,
R^3 is independently H, CH_3, OH, (CO)H, COMe, SO_2Me, $COCH_2NH_2$, CH_2COOH or CH_2COOR^2; and

in Formula IV (Module C):
R^{4b} is OH or OR^2, NHC(O)Me;
R^{4c} is H;
R^{4d} is independently OH or OR^2, NO_2 or NHR^3, $NMeR^3$;
R^{4e} is independently OH, OR^2, NO_2, NMe_2, NHR^3 or $NMeR^3$, NHC(O)H or SR^2;
R^{4f} is independently H, OH, OR^2, NO_2, NHR^3, NHC=NH(NH_2), COOH or $COOR^2$;
R^{4g} is independently H, alkyl, CF_3, OH or OR^2;
and no more than one of R^{4e}, R^{4f} or R^{4g} can be H;
or R^{4e} and R^{4f} form a five or six-membered heterocyclic ring containing a carbonyl group or $(CO)CH_2$ group when R^{4e} is OH, NH_2 or NHMe and R^{4f} is NH_2, such that the nitrogen of R^{4f} is bridged with the carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of R^{4e};
R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or an O-protecting group when R^2 is attached to an O;
R^3 is independently H,CH_3, OH, (CO)H, COMe, SO_2Me, $COCH_2NH_2$, CH_2COOH or CH_2COOR^2; and
X is a halide or hydroxyl group, wherein the halide is selected from the group consisting of F, Cl, Br, I, and At.

In one embodiment, there is provided a synthesis of a compound of Formula (I):



Formula (I)

wherein in formula (I):

R^{1a} is independently , crotyl, prenyl, benzyl, or 2-alkenyl;

R^{1b} is CF_3, OR^2 or NHC(O)Me;

R^{1c} is H;

R^{1d} is independently OH, NHR^3, or NO_2;

R^{1e} is independently OR^2, NMe_2, NHR^3, or SR^2;

R^{1f} is independently H, OH, NO_2, NHR^3, NHC=NH(NH_2), or COOH;

R^{1g} is independently H, alkyl, OH or OR^2;

or R^{1e} and R^{1f} form a five or six-membered heterocyclic ring containing a carbonyl group when R^{1e} is OH, NH_2 or NHMe and R^{1f} is NH_2, such that the nitrogen of R^{1f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{1e};


R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl;

R^3 is independently H, Me, (CO)H, (CO)Me, SO_2Me, $CO(CH_2)_nNH_2$, $CO(CH_2)_nCOOH$ or $COCOOR^4$ (where n = 0, 1 or 2); and


R^4 is C_1-C_6 alkyl;

wherein the synthesis compries:

i) a step of coupling a compound of formula (II) (Module A) with a compound of formula (III) (Module B) to afford a compound of formula (IV) (Module C):




Formula (II)



Formula (III)

Module A **Module B**



Formula (IV)

Module C

wherein,

in Formula II (Module A):

R^{2b} is CF_3, OH,OR^2, NO_2, NMe_2, NHEt, NMeEt, NHR^3 or $NMeR^3$;

R^{2c} is H;

R^{2d} is CF_3, OH or OR^2, NO_2, NHR^3 , $NMeR^3$, NHC=NH(NH_2) or $COOR^2$;

X is a halide(Hal) or hydroxyl group, wherein the halide is selected from the group consisting of F, Cl, Br, I, and At;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl, or an O-protecting group;

R^3 is H, OH, CH_3, (CO)H, COMe, SO_2Me, $COCH_2NH_2$, or CH_2COOR^2; and

in Formula III (Module B):

R^{3e} isindependently , OH, OR^2, NO_2, NHMe, NMe_2, NHR^3 or $NMeR^3$, (CO)H, NHC(O)H or SR^2;

R^{3f} is independently H, OH, OR^2, NO_2, NHR^3,;

R^{3g} is independently H, alkyl, , OH, OR^2;

and no more that one of R^{3e}, R^{3f} or R^{3g} can be H;

or R^{3e} and R^{3f} form a five or six-membered heterocyclic ring containing a carbonyl group or $(CO)CH_2$ group when R^{3e} is OH, NH_2 or NHMe and R^{3f} is NH_2, such that the nitrogen of R^{3f} is bridged with the carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of R^{3e};

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or an O-protecting group when R^2 is attached to an O,

R^3 is H, CH_3, , (CO)H, COMe, SO_2Me, $COCH_2NH_2$ orCH_2COOR^2; and

in Formula IV (Module C):

R^{4b} is independently CF_3, OH or OR^2,NHC(O)Me ;

R^{4c} is H,;

R^{4d} is OH, NH_2, N(CO)H;

R^{4e} is independently OH, OR^2, NO_2, , NHR^3 or $NMeR^3$, SR^2;

R^{4f} is independently H, OH, OR^2, NO_2, NHR^3;

R^{4g} is independently H, alkyl, CF_3, OH, OR^2;

and only one of R^{4e}, R^{4f} or R^{4g} can be H;


R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or an O-protecting group when R^2 is attached to an O;

R^3 is independently H, (CO)H, COMe, SO_2Me, or CH_2COOR^2; and

X is a halideor a hydroxyl group, wherein the halide is selected from the group consisting of F, Cl, Br, I, and At.

In one embodiment, there is provided a process of synthesising a compound of Formula (I):

2020415711 20 Jan 2025



Formula (I)

wherein in formula (I):

R^{1a} is independently allyl, crotyl, prenyl, benzyl,;

R^{1b} is independently OR^2 or NHC(O)Me;

R^{1c} is H;

R^{1d} is independently OH, NH_2, N(CO)H;

R^{1e} is independently OH, OR^2, NO_2, NHR^3 or $NMeR^3$, (CO)H, SMe;

R^{1f} is independently H, OH, OR^2, NO_2, NHR^3, NHC=NH(NH_2), COOH;


R^{1g} is independently H, alkyl, OH, OR^2;

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or an O-protecting group when R^2 is attached to an O, wherein the O-protecting group is selected from the group consisting of COMe, *t*-BuSi(CH_3)$_2$, 2-(trimethylsilyl)ethoxymethyl (SEM) acetal, CH(OEt)CH_3, tetrahydropyranyl, or C(OEt)(CH_3)$_2$;


R^3 is independently H, CH_3, OH, (CO)H, (CO)Me, SO_2Me, CH_2COOR^2, $COCH_2NH_2$, CO(CH_2)$_n$COOH (where n = 0, 1 or 2);

wherein the synthesis comprises:

i) a step of coupling a compound of formula (II) (Module A) with a compound of formula (III) (Module B) to afford a compound of formula (IV) (Module C):




Formula (II)



Formula (III)

2020415711 20 Jan 2025

Module A **Module B**



Formula (IV)

Module C

wherein

in Formula II:

R^{2b} is CF_3, OH or OR^2;

R^{2c} is H,

R^{2d} is OH or NH_2, N(CO)H;

X is a halide (Hal) or hydroxyl group, wherein the halide is selected from the group consisting of F, Cl, Br, I, and At;

a halide selected from the group consisting of F, Cl, Br, I, and At;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or O-protecting group when R^2 is attached to an O, wherein the O-protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxymethyl (SEM) acetal, $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$; and

in Formula III:

R^{3e} is OH, OR^2, NO_2, NHR^3 or $NMeR^3$, SR^2;

R^{3f} is H, OH, OR^2, NO_2, NHR^3;

R^{3g} is H, alkyl, OH, OR^2;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or O-protecting group when R^2 is protecting an O,wherein the O-protecting group is

2020415711 20 Jan 2025

selected from the group consisting of COMe, *t*-BuSi(CH_3)$_2$, 2-(trimethylsilyl)ethoxymethyl (SEM) acetal, CH(OEt)CH_3, tetrahydropyranyl, or C(OEt)(CH_3)$_2$; and

R^3 is H, CH_3, (CO)H, COMe, SO_2Me or $CH_2COOR^{2,}$, $COCH_2NH_2$; and

in Formula IV:

R^{4b} is CF_3, OH or OR^2;

R^{4c} is H;

R^{4d} is OH, NH_2, N(CO)H;

R^{4e} is OH, OR^2, NO_2, NHR^3 or $NMeR^3$, SR^2;

R^{4f} is H, OH, OR^2, NO_2, NHR^3;

R^{4g} is H, alkyl, OH, OR^2;


R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or O-protecting group when R^2 is attached to an O, wherein the O-protecting group is selected from the group consisting of COMe, *t*-BuSi(CH_3)$_2$, 2-(trimethylsilyl)ethoxymethyl (SEM) acetal, CH(OEt)CH_3, tetrahydropyranyl, or C(OEt)(CH_3)$_2$;

R^3 is H, (CO)H, COMe, SO_2Me, or CH_2COOR^2; and

X is a halide (Hal) or hydroxyl group, wherein the halide is selected from the group consisting of F, Cl, Br, I, and At;

.

[0001] In one embodiment, there is provided a process of synthesising a compound of Formula (I):



Formula (I)

wherein in formula (I):

2020415711 20 Jan 2025

R^{1a} is allyl, crotyl, prenyl, benzyl,;

R^{1b} is OR^2, NHC(O)Me

R^{1c} is H;

R^{1d} is OH,;

R^{1e} is OR^2, NO_2,;

R^{1f} is NO_2, NHR^3, NHC=NH(NH_2),;


R^{1g} is H, alkyl, OH, OR^2;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl,;

R^3 is H, (CO)H, (CO)Me, SO_2Me, CH_2COOR^2, $COCH_2NH_2$, $CO(CH_2)_nCOOH$ (where n = 0, 1 or 2);


wherein the synthesis comprises:

i) a step of coupling a compound of formula (II) (Module A) with a compound of formula (III) (Module B) to afford a compound of formula (IV) (Module C):




Formula (II)

Module A



Formula (III)

Module B



Formula (IV)

Module C

2020415711 20 Jan 2025

wherein

in Formula II:

R^{2b} is CF_3, OH or OR^2;

R^{2c} is H,

R^{2d} is OH or NH_2, N(CO)H;

Hal is a halide selected from the group consisting of F, Cl, Br, I, and At;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or O-protecting group when R^2 is attached to an O, wherein the O-protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxymethyl (SEM) acetal, $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$; and

in Formula III:

R^{3e} is OH, OR^2, NO_2, NHR^3 or $NMeR^3$, SR^2;

R^{3f} is H, OH, OR^2, NO_2, NHR^3;

R^{3g} is H, alkyl, OH, OR^2;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or O-protecting group when R^2 is protecting an O,wherein the O-protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxymethyl (SEM) acetal, $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$; and

R^3 is H, CH_3, (CO)H, COMe, SO_2Me or $CH_2COOR^{2,}$, $COCH_2NH_2$; and

in Formula IV:

R^{4b} is CF_3, OH or OR^2;

R^{4c} is H;

R^{4d} is OH, NH_2, N(CO)H;

R^{4e} is OH, OR^2, NO_2, NHR^3 or $NMeR^3$, SR^2;

R^{4f} is H, OH, OR^2, NO_2, NHR^3;

R^{4g} is H, alkyl, OH, OR^2;

2020415711 20 Jan 2025

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or O-protecting group when R^2 is attached to an O, wherein the O-protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxymethyl (SEM) acetal, $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$;

R^3 is H, (CO)H, COMe, SO_2Me, or CH_2COOR^2; and

Hal is a halide selected from the group consisting of F, Cl, Br, I, and At;

wherein formula IV is coupled with a R^{1a} boronic pinacol ester selected from the group consisting of 3-methylbut-2-enylboronic acid pinacol ester, crotylboronic pinacol ester, allylboronic pinacol ester and benzylboronic pinacol ester, catalysed by a palladium catalyst in the presence of a base, to produce the compound of formula (I).

In one embodiment, there is provided a process of synthesising a compound of Formula (I): wherein

in formula (I):

R^{1a} is crotyl, prenyl;

R^{1b} is OR^2;

R^{1c} is H;

R^{1d} is OH;

R^{1e} is OR^2;

R^{1f} is NO_2, NHR^3, $NHC{=}NH(NH_2)$;

R^{1g} is H;

R^2 is methyl, ethyl;

R^3 is H, (CO)H, (CO)Me, SO_2Me, CH_2COOR^2, $COCH_2NH_2$, $CO(CH_2)_nCOOH$ (where n = 0, 1 or 2); and

in Formula II:

R^{2b} is OH or OR^2;

R^{2c} is H;

R^{2d} is OH, OSEM;

Halide is Br;

R^2 is methyl or ethyl; and

2020415711 20 Jan 2025

in Formula III:

R^{3e} is OH, OR^2;

R^{3f} is, NO_2, NHR^3; NHC=NH(NH_2),

R^{3g} is H;

R^2 is methyl, ethyl, and

R^3 is H, (CO)H, COMe, SO_2Me or $CH_2COOR^{2,}$, $COCH_2NH_2$ or $CO(CH_2)_nCOOH$ where n is 0, 1 or 2; and

in Formula IV:

R^{4b} is, OR^2;

R^{4c} is H;

R^{4d} is OH;

R^{4e} is OR^2;

R^{4f} is, NO_2, NHR^3, NHC=NH(NH_2),;

R^{4g} is H;

R^2 is methyl, ethyl,

R^3 is H, (CO)H, COMe, SO_2Me, or CH_2COOR^2, $COCH_2NH_2$, $CO(CH_2)_nCOOH$ and

Halide is, Br;

wherein formula IV is coupled with a R^{1a} boronic pinacol ester selected from the group consisting of 3-methylbut-2-enylboronic acid pinacol ester, crotylboronic pinacol ester, allylboronic pinacol ester and benzylboronic pinacol ester, catalysed by a palladium catalyst in the presence of a base, to produce the compound of formula (I).

In one embodiment of the above process, R^{1f} in formula (I) is NO_2. The compound of formula (I) may be further reacted with a reducing agent to convert the NO_2 group to an NH_2 group. This allows for the formation of amine compounds such as compounds **23** and **24**. In one embodiment the compound of formula (I) where R^{1f} is NH_2, is further reacted with methane sulfonyl chloride in the presence of a base, such as triethylamine,

2020415711 20 Jan 2025

to form a compound of formula (I) where R^{1f} is $NHSO_2Me$. This allows for the formation of amine compounds such as compounds **25** and **24**. In another embodiment, the compound of formula (I) where R^{1f} is NH_2, is further reacted with ethyl formate to form a compound of formula (I) where R^{1f} is NH(CO)H. This allows for the formation of amine compounds such as compounds **27** and **28**. Preliminary results have indicated that compounds **27** and **28** are potential lead candidates for therapeutic use in treating atopic dermatitis and psoriasis.

In one embodiment, there is provided a process of synthesising a compound of Formula (I): wherein

in formula (I):

R^{1a} is crotyl, prenyl;

R^{1b} is OR^2,

R^{1c} is H;

R^{1d} is OH;

R^{4e} and R^{4f} form a five or six-membered heterocyclic ring containing a carbonyl group when R^{4e} is OH or NH_2 and R^{4f} is NH_2, such that the nitrogen of R^{4f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{4e};

R^{1g} is H;

R^2 is methyl, ethyl;

R^3 is H, (CO)H, (CO)Me, SO_2Me, CH_2COOR^2, $COCH_2NH_2$ or $CO(CH_2)_nCOOH$ (where n = 0, 1 or 2);

in Formula II:

R^{2b} is OR^2;

R^{2c} is H;

R^{2d} is OSEM;

Hal is Br;

R^2 is methyl or ethyl, and

in Formula III:

2020415711 20 Jan 2025

R^{3e} and R^{3f} form a five or six-membered heterocyclic ring containing a carbonyl group when R^{3e} is OH or NH_2 and R^{3f} is NH_2, such that the nitrogen of R^{3f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{3e};

R^{3g} is H; and

in Formula IV:

R^{4b} is, OR^2;

R^{4c} is H;

R^{4d} is OSEM;

R^{4e} and R^{4f} form a five or six-membered heterocyclic ring containing a carbonyl group when R^{4e} is OH or NH_2 and R^{4f} is NH_2, such that the nitrogen of R^{4f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{4e};

R^{4g} is H;

R^2 is methyl, ethyl;


and

Halide is Br;


wherein formula (IV) is coupled with a R^{1a} boronic pinacol ester selected from the group consisting of 3-methylbut-2-enylboronic acid pinacol ester, crotylboronic pinacol ester, allylboronic pinacol ester and benzylboronic pinacol ester, catalysed by a palladium catalyst in the presence of a base, to produce the compound of formula (I).

In one specific embodiment of the above process, formula (IV) is coupled with 3-methylbut-2-enylboronic acid pinacol ester and catalysed by tetrakis(triphenylphosphine)palladium(0) in the presence of potassium carbobnate. In one embodiment, the compound of formula (I) is selected from compounds **51** and **52**.


In one embodiment of the process of synthesising a compound of Formula (I), the compound according to formula (I) is selected from the group consisting of:




1 [KYN-001]



2 [KYN-138]




3 [KYN-139]




4 [KYN-140]




5 [KYN-153]




6 [KYN-134]




7 [KYN-136]




8 [KYN-119]




9 [KYN-130] R = n-propyl
10 [KYN-131] R = iso-propyl
11 [KYN-132] R = CF_3




12 [KYN-133]




13 [KYN-114]




14 [KYN-118]




15 [KYN-158]




16 [KYN-157]




17 [KYN-120]




18 [KYN-156]




19 [KYN-160]




20 [KYN-146]




21 [KYN-154]




22 [KYN-124]




23 [KYN-125]




24 [KYN-141]




25 [KYN-137]




26 [KYN-129]




27 [KYN-149]




28 [KYN-143]




29 [KYN-128]




30 [KYN-142]




31 [KYN-151]




32 [KYN-148]




33 [KYN-126]




34 [KYN-147]




35 [KYN-152]




36 [KYN-150]




37 [KYN-144]




38 [KYN-155]




39 [KYN-165]




40 [KYN-159]




41 [KYN-161]




42 [KYN-162]




43 [KYN-163]




44 [KYN-164]




45 [KYN-112]




46 [KYN-145]




47 [KYN-167]




48 [KYN-168]




49 [KYN-169]



50 [KYN-170]



51 [KYN-166]



52 [KYN-171]

2020415711 20 Jan 2025

In one embodiment of the process of synthesising a compound of Formula (I), the compound according to formula (I) is selected from the group consisting of:

compounds 22, 23, 24, 25, 26 27, 28 , 29, 30, 31, 36, 24, 33, 34, 35, 36, 37, 38, 39, 40,

The compound of formula (IV) or (I) may optionally undergo one or more further reactions, including but not limited to reaction with one or more $–NH_2$, NO_2 and/or -OH substituents on formula (IV) or formula (I). In one embodiment, this further reaction occurs at the R^{1f} substiuent of formula (I). In one embodiment, one or more $–NH_2$ substituents of formula (IV) or formula (I).may be converted to methoxyoxoacetamido (-NHC(O)C(O)OCH_3) substituents by reaction of the compound containing the NH_2substituent with methyl chlorooxoacetate in the presence of a base, such as triethylamine. In one embodiment, this further reaction occurs at the R^{1f} substiuent of formula (I).

In one embodiment, one or more –OH substituents may be converted to methyl oxalate substituents by reaction of the compound containing the OH substituent with methyl chlorooxoacetate in the presence of a base, such as triethylamine. In one embodiment, this further reaction occurs at the R^{1f} substiuent of formula (I).

In one embodiment, one or more methoxyoxoacetamido substituents are hydrolysed to -NHC(O)C(O)OH substituents by reaction of the compound containing the N methoxyoxoacetamido substituent with a base, for example LiOH. In one embodiment, this further reaction occurs at the R^{1f} substiuent of formula (I).

In one embodiment, one or more methyl oxalate substituents may be hydrolysed to -OH substituents by reaction of the compound containing the methyl oxalate substituent

2020415711 20 Jan 2025

with a base, for example LiOH. In one embodiment, this further reaction occurs at the R^{1f} substiuent of formula (I).

In one embodiment, one or more $-NH_2$ substituents may be converted to guanidine (-$NHC(NH)NH_2$) substituents by reaction of the compound containing the NH_2 substituent with cyanamide in the presence of an acid, such as p-toluenesulfonic acid. In one embodiment, this further reaction occurs at the R^{1f} substituent of formula (I).

In one embodiment, one or more $-NH_2$ substituents may be converted to formamide (-NHC(O)H) substituents by reaction of the compound containing the NH_2 substituent with ethyl formate. In one embodiment, this further reaction occurs at the R^{1f} substituent of formula (I).

In one embodiment, one or more $-NH_2$ substituents may be converted to an acetamido (-$NHC(O)CH_3$) substituents by reaction of the compound containing the NH_2 substituent with acetic anhydride in the presence of a base such as DIPEA (diisopropylethylamine). In one embodiment, this further reaction occurs at the R^{1f} substiuent of formula (I).

In one embodiment, one or more $-NH_2$ substituents may be converted to an amide derivative (-$NHC(O)CH_2CH_2C(O)OH$) substituents by reaction of the compound containing the NH_2 substituent with succinic anhydride in the presence of a base such as DIPEA (diisopropylethylamine). In one embodiment, this further reaction occurs at the R^{1f} substiuent of formula (I).

In one embodiment, one or more $-NH_2$ substituents may be converted to methyl amine substituents (-NHMe) by reaction of the compound containing the NH_2 substituent with formaldehyde in the presence of triacetoxyborohydride. In one embodiment, this further reaction occurs at the R^{1f} substituent of formula (I).

In one embodiment, one or more –OH substituents may be converted to acetate (-$OC(O)CH_3$) substituents by reaction of the compound containing the -OH substituent

2020415711 20 Jan 2025


with acetic anhydride in the presence of a base such as DIPEA (diisopropylethylamine). In one embodiment, this further reaction occurs at the R^{1f} substiuent of formula (I).

In one embodiment, one or more acetate substituents may be hydrolysed to form - OH substituents by reaction of the compound containing the acetate substituent with a base, for example, LiOH. In one embodiment, this further reaction occurs at the R^{1f} substiuent of formula (I).

In one embodiment, one or more $–NO_2$ substituents may be reduced to amine substituents by, for example, reaction of the compound containing the NO_2 substituent with Zn in the presence of ammonium chloride. In one embodiment, this further reaction occurs at the R^{1f} substiuent of formula (I).

Module A

In one embodiment of the process disclosed herein, the compound according to formula (II) is



Formula (II)

Module A

wherein

R^{2b}= OMe


R^{2d}=OH or OSEM

R^{2c}=H

Hal is Br

In one embodiment of the process disclosed herein, the compound according to formula (II) may be prepared according to the steps comprising i) bromination of a mono- or di-hydroxyl substituted toluene compound; ii) protection of one hydroxyl group and/or

alkylation of the the other hydroxyl group; iii) removal of protecting group; iv) acylation of a hydroxyl group; v) dibromination of the aromatic methyl; vi) hydrolysis of the dibromomethyl to form an aldehyde; and vii) protection of the hydroxyl. In one embodiment, there is provided in step i) bromination of a di-hydroxyl substituted toluene compound. In one embodiment of the process disclosed herein, the compound according to formula (II) may be prepared according to the steps comprising i) bromination of a di-hydroxyl substituted toluene compound at a position adjacent to the C-bonded substituent with a brominating agent; ii) protection of a hydroxyl group with an O-protecting group followed by alkylation with an a C1-C3alkyl halogen; iii) removal of the O-protecting group in the presence of a base; iv) acylation of hydroxyl group using acetic anhydride in the presence of a base; v) dibromination of the aromatic methyl group using a brominating agent to form a dibromomethyl group; vi) hydrolysis of the dibromomethyl group to form an aldehyde; and vii) protection of the hydroxyl group by reaction with a suitable compound able to provide an O-protecting group including but not limited to COMe, *t*-BuSi(CH_3)$_2$, 2-(trimethylsilyl)ethoxymethyl (SEM), CH(OEt)CH_3, tetrahydropyranyl, or C(OEt)(CH_3). In one embodiment, there is provided in step vii), protection of the hydroxyl group by reaction with 2-(trimethylsilyl)ethoxymethyl (SEM) chloride to provide a 2-(trimethylsilyl)ethoxymethyl (SEM) acetal protecting group. In one specific embodiment, the compound according to formula (II) is Module A and is prepared according to the following process:




2020415711 20 Jan 2025

Module B

In one embodiment of the process disclosed herein, the compound according to formula (III) may be prepared starting with a di-, or tri-substituted hydroxyl and/or alkoxyl substituted benzaldehyde compound, according to the steps comprising i) protection of the hydroxyl group; ii) reduction of the aromatic aldehyde to a benzyl alcohol; iii) coupling of the benzyl alcohol with a trialkylphosphonate and zinc (II) iodide to form a dialkylbenzylphosphonate.

In one embodiment, the compound according to formula (III) is Module B:



Formula (III)

Module B

wherein

R^{3g}=H


R^{3f}=OSEM

R^{3e}=OMe

R4=Et


In one embodiment of the process disclosed herein, the compound according to formula (III) is Module B and is prepared according to the following process:

2020415711 20 Jan 2025



Module C

In one embodiment, the compound according to formula (IV) is Module C:



Module C

Wherein

R^{4b}=OMe

R^{4c}=H

R^{4d}=OSEM, OH


R^{4g}=H

R^{4e}=OMe

R^{4f}=OSEM


Hal =Br

In one embodiment of the process disclosed herein, the compound according to formula (IV) is prepared according to the following process:



wherein the base can be, but is not limited to, NaH and wherein the formula (II) (III) and (IV) are as defined herein.

In one embodiment of the process disclosed herein, formula(II) is Module A, formula (III) is Module B and formula (IV) is Module C according to the following:




Cross coupling alkylation of the aryl halide, Module C, can be achieved with for, example, an alkyl boronic acid. As an example of the process disclosed herein, there is provided the following embodiment:

i) Module C is coupled with 3-methylbut-2-enylboronic acid pinacol ester in the presence of tetrakis(triphenylphosphine)palladium(0) and potassium carbonate to afford compound 1.1;


2020415711 20 Jan 2025

ii) compound 1.1 is treated with tetrabutylammonium fluoride to afford compound 1, according to the following:



Compounds and Compositions

Disclosed herein is a compound according to formula (I)



Formula (I)

prepared by a process disclosed herein, wherein:

R^{1a} is Hal, allyl, crotyl, prenyl, geranyl, farnesyl, benzyl, 2-alkenyl, 2-alkynyl;

R^{1b} is CF_3, OH or OR^2, NO_2, NHEt, NMe_2, NMeEt, NHR^3, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

R^{1c} is H, alkyl, alkenyl, alkynyl, alkanedienyl, prenyl, geranyl, farnesyl, or benzyl;

2020415711 20 Jan 2025

R^{1d} is CF_3, OH or OR^2, NHR^3, NO_2, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

R^{1e} is H, C_1-C_6 alkyl, OH, OR^2, NO_2, NMe_2, NHR^3 or $NMeR^3$, SR^2;

R^{1f} is H, OH, OR^2, NO_2, NHR^3, $NHC{=}NH(NH_2)$, $COOR^2$, COOH;

R^{1g} is H, alkyl, CF_3, OH or OR^2;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl, $COCOOR^4$ or O-protecting group when attached to an O, wherein the O-protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxy]methyl (SEM) acetal, $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$;

R^3 is H, CH_3, OH, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $CO(CH_2)_nNH_2$, $CONH_2$, $CO(CH_2)_nCOOH$ or $COCOOR^4$ (where n = 0, 1 or 2);


R^4 is C_1-C_6 alkyl; and

Hal is a halide selected from the group consisting of F, Cl, Br, I, and At;

only one of R^{1e}, R^{1f} or R^{1g} can be H; and

when R^{1e} is OH, NH_2 or NHMe and R^{1f} is NH_2, the nitrogen of R^{1f} is bridged with a carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of R^{1e} to form a five or six-membered heterocyclic ring.

Also disclosed herein is a compound according to formula (I):



Formula (I)

wherein:

R^{1a} is Hal, allyl, crotyl, prenyl, geranyl, farnesyl, benzyl, 2-alkenyl, 2-alkynyl;

R^{1b} is CF_3, OH or OR^2, NO_2, NHEt, NMe_2, NMeEt, NHR^3, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

R^{1c} is H, alkyl, alkenyl, alkynyl, alkanedienyl, prenyl, geranyl, farnesyl, or benzyl;

2020415711 20 Jan 2025

R^{1d} is CF_3, OH or OR^2, NO_2, NHR^3, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

R^{1e} is H, C_1-C_6 alkyl, OH, OR^2, NO_2, NMe_2, NHR^3 or $NMeR^3$, SR^2;

R^{1f} is H, OH, OR^2, NO_2, NHR^3, $NHC{=}NH(NH_2)$, $COOR^2$, COOH;

R^{1g} is H, alkyl, CF_3, OH or OR^2;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl, $COCOOR^4$or O-protecting group when attached to an O, wherein the O-protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxy]methyl (SEM) acetal, $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$;

R^3 is H, CH_3, OH, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $CO(CH_2)_nNH_2$, $CONH_2$, $CO(CH_2)_nCOOH$ or $COCOOR^4$ (where n = 0, 1 or 2);

R^4 is C_1-C_6 alkyl; and

Hal is a halide selected from the group consisting of F, Cl, Br, I, and At;

only one of R^{1e}, R^{1f} or R^{1g} can be H,

when R^{1e} is OH, NH_2 or NHMe and R^{1f} is NH_2, the nitrogen of R^{1f} is bridged with a carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of R^{1e} to form a five or six-membered heterocyclic ring;

provided that

when R^{1a} and/or R^{1c} is prenyl, R^{1d} is OH, R^{1f} is OH, R^{1g} is H and R^{1e} is OH, OMe or OEt, then R^{1b} cannot be OH, OR where R =methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *t*-butyl, or benzyl.

In one specific embodiment, there is provided a compound of formula (I) wherein:

R^{1a} is allyl, prenyl, benzyl, 2-alkenyl;

R^{1b} is CF_3, OH or OR^2;

R^{1c} is H;

R^{1d} is OH, NH_2, N(CO)H;

R^{1e} is OH, OR^2, NO_2, NHR^3 or $NMeR^3$, (CO)H, SMe;

R^{1f} is H, OH, OR^2, NO_2, NHR^3, $NHC{=}NH(NH_2)$, COOH;


R^{1g} is H, alkyl, OH;

2020415711 20 Jan 2025

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl;
R^3 is H, CH_3, OH, (CO)H, (CO)Me, SO_2Me, CH_2COOR^2, $COCH_2NH_2$, $CO(CH_2)_nCOOH$ (where n = 0, 1 or 2).
provided that
when R^{1a} or R^{1c} is prenyl, R^{1d} is OH, R^{1f} is OH, R^{1g} is H and R^{1e} is OH, OMe or OEt, then R^{1b} cannot be OR where R =methyl, ethyl, isopropyl,propyl, butyl, isobutyl, *t*-butyl, or benzyl.

In one embodiment, formula (I) is a compound selected from the group consisting of compounds **2** to **7**, **11**, **13** to **19**, **21** to **44**, **46** to **49**, **50**, **51, 52** [KYN 138, 139, 140, 153, 134, 136, 132, 114, 118, 158, 157, 120, 156, 160, 154, 124, 125, 141, 137, 129, 149, 143, 128, 142, 151, 148, 126, 147, 152, 150, 144, 155, 165, 159, 161, 162, 163, 164, 145, 167, 168, 169, 166, 171, KYN-170] as disclosed herein.

Also disclosed herein are embodiments wherein one of R^{1b} and R^{1d} of Formula (I) are a substituent other than OH or OR^2. In one embodiment, at least one of R^{1b} or R^{1d} is CF_3, NO_2, NHR^3, $NMeR^3$, $NHC{=}NH(NH_2)$ or COOR. Accordingly, there is also provided a compound according to formula (I):



Formula (I)

wherein:

R^{1a} is Hal, allyl, crotyl, prenyl, geranyl, farnesyl, benzyl, 2-alkenyl, 2-alkynyl;
R^{1b} is CF_3, OH or OR^2, NO_2, NHEt, NMe_2, NMeEt, NHR^3, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

2020415711 20 Jan 2025

R^{1c} is H, alkyl, alkenyl, alkynyl, alkanedienyl, prenyl, geranyl, farnesyl, or benzyl;

R^{1d} is CF_3, OH or OR^2, NO_2, NHR^3, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

R^{1e} is H, C_1-C_6 alkyl, OH, OR^2, NO_2, NMe_2, NHR^3 or $NMeR^3$, SR^2;

R^{1f} is H, OH, OR^2, NO_2, NHR^3, $NHC{=}NH(NH_2)$, $COOR^2$, COOH;

R^{1g} is H, alkyl, CF_3, OH or OR^2;

wherein at least one of R^{1b} or R^{1d} is CF_3, NO_2, NHR^3, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl, $COCOOR^4$or O-protecting group, wherein the O-protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxy]methyl (SEM) acetal, $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$;

R^3 is H, CH_3, OH, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $CO(CH_2)_nNH_2$, $CONH_2$, $CO(CH_2)_nCOOH$ or $COCOOR^4$ (where n = 0, 1 or 2);

R^4 is C_1-C_6 alkyl; and

Hal is a halide selected from the group consisting of F, Cl, Br, I, and At;


only one of R^{1e}, R^{1f} or R^{1g} can be H,

when R^{1e} is OH, NH_2 or NHMe and R^{1f} is NH_2, the nitrogen of R^{1f} is bridged with a carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of R^{1e} to form a five or six-membered heterocyclic ring.

In one embodiment, Formula (I) is a compound selected from compounds **11**, **43**, **44**, **46**, **47**, **48**, **49**, **50** [KYN-132, 163, 164, 145, 167, 168, 169 [KYN-170] as disclosed herein.

Also disclosed herein are embodiments where the substituent R^{1f} on the B-ring is not H, OH or OR^2 and R^{1e} is not H. In one embodiment, there is provided a compound of formula (I)

2020415711 20 Jan 2025



Formula (I)

wherein:

R^{1a} is Hal, allyl, crotyl, prenyl, geranyl, farnesyl, benzyl, 2-alkenyl, 2-alkynyl;

R^{1b} is CF_3, OH or OR^2, NO_2, NHMe, NHEt, NMe_2, NMeEt, NHR^3, $NMeR^3$, $NHC{=}NH(NH_2)$ or COOR2, NHR3, $NMeR^3$, $NHC{=}NH(NH_2)$ or $COOR^2$;

R^{1c} is H, alkyl, alkenyl, alkynyl, alkanedienyl, prenyl, geranyl, farnesyl, or benzyl;

R^{1d} is CF_3, OH or OR^2, NHR^3, NO_2, NH_2, NHMe, $NHC{=}NH(NH_2)$ or $COOR^2$;

R^{1e} is OH, OR^2;

R^{1f} is NO_2, NHR^3, $NHC{=}NH(NH_2)$, $COOR^2$, COOH, $NHSO_2Me$, $NHC(O)(CH_2)COOH$, NHC(O)COOH, $NHC(O)(CH_2)NNH_2$, $NHC(O)CH_2NH_2$, $NHCH_2COOMe$, ;NHC(O)H, $NHC(O)CH_3$, $NHC(O)(CH_2)_2COOH$, $NHC(NH)NH_2$;

R^{1g} is H;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or O-protecting group, wherein the O-protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxy]methyl (SEM) acetal, $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$;

R^3 is H, CH_3, OH, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $COCH_2NH_2$, $CONH_2$, $CO(CH_2)_nCOOH$, $CO(CH_2)_nCOOR^4$ (where n = 0, 1 or 2);

R^4 is C1-C6 alkyl;

Hal is a halide selected from the group consisting of F, Cl, Br, I, and At;


only one of R^{1e}, R^{1f} or R^{1g} can be H, and

2020415711 20 Jan 2025

when R^{1e} is OH, NH_2 or NHMe and R^{1f} is NH_2, the nitrogen of R^{1f} is bridged with a carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of R^{1e} to form a five or six-membered heterocyclic ring.

In one embodiment, Formula (I) is a compound selected from compounds **21** to **40**, **50, 51, 52** [KYN-154, 124, 125, 141, 137, 129, 149, 143, 128, 142, 151, 148, 126, 147, 152, 150, 144, 155, 165, 159, 166, 170, 171] as disclosed herein.

Also disclosed herein are embodiments where the substituent R^{1e} on the B-ring is not H, OH or OR^2 and R^{1fe} is not H. In one embodiment, there is provided a compound of formula (I):



Formula (I)

wherein:

R^{1a} is Hal, allyl, crotyl, prenyl, geranyl, farnesyl, benzyl, 2-alkenyl, 2-alkynyl;
R^{1b} is CF_3, OH or OR^2, NO_2, NHMe, NHEt, NMe_2, NMeEt, NHR^3, $NMeR^3$, NHC=NH(NH_2) or COOR2, NHR3, $NMeR^3$, NHC=NH(NH_2) or $COOR^2$;
R^{1c} is H, alkyl, alkenyl, alkynyl, alkanedienyl, prenyl, geranyl, farnesyl, or benzyl;
R^{1d} is CF_3, OH or OR^2, NHR^3, NO_2, NH_2, NHMe, NHC=NH(NH_2) or $COOR^2$;
R^{1e} is C_1-C_6 alkyl, NO_2, NH_2, NHMe, NMe_2, NHR^3 or $NMeR^3$, SR^2;
R^{1f} is OH, OR^2;
R^{1g} is H;
R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or O-protecting group, wherein the O-protecting group is selected from the group consisting

2020415711 20 Jan 2025

of COMe, *t*-BuSi(CH_3)$_2$, 2-(trimethylsilyl)ethoxy]methyl (SEM) acetal, CH(OEt)CH_3, tetrahydropyranyl, or C(OEt)(CH_3)$_2$;

R^3 is H, CH_3, OH, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $COCH_2NH_2$, $CONH_2$, $CO(CH_2)_nCOOH$ (where n = 0, 1 or 2); and


Hal is a halide selected from the group consisting of F, Cl, Br, I, and At;

only one of R^{1e}, R^{1f} or R^{1g} can be H,

when R^{1e} is OH, NH_2 or NHMe and R^{1f} is NH_2, the nitrogen of R^{1f} is bridged with a carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of R^{1e} to form a five or six-membered heterocyclic ring.

In one embodiment, Formula (I) is a compound selected from compound **13** to **16**, **41** [KYN-114, 118, 158, 157, 161] as disclosed herein.

Also disclosed herein are embodiments where there is no prenyl group on the A or B–ring. In one embodiment, there is provided a compound of formula (I):



Formula (I)

wherein:

R^{1a} is Hal, allyl, crotyl, geranyl, farnesyl, benzyl, 2-alkenyl, 2-alkynyl;

R^{1b} is CF_3, OH or OR^2, NO_2, NHMe, NHEt, NMe_2, NMeEt, NHR^3, $NMeR^3$, NHC=NH(NH_2) or $COOR^2$;

R^{1c} is H, alkyl, alkenyl, alkynyl, alkanedienyl, geranyl, farnesyl, or benzyl;

R^{1d} is CF_3, OH or OR^2, NHR^3, NO_2, NH_2, NHMe, NHC=NH(NH_2) or $COOR^2$;

R^{1e} is H, OH, OR^2, NO_2, NH_2, NHMe, NMe_2, NHR^3 or $NMeR^3$, SR^2;

R^{1f} is H, OH, OR^2, NO_2, NH_2, NHMe, NHR^3, NHC=NH(NH_2), $COOR^2$, COOH;

2020415711 20 Jan 2025

R^{1g} is H, alkyl, CF_3, OH or OR^2;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl, $C(O)C(O)OR^4$ or O-protecting group, wherein the O-protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxy]methyl (SEM) acetal, $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$;

R^3 is H, CH_3, OH, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $COCH_2NH_2$, $CONH_2$, $CO(CH_2)_nCOOH$ (where n = 0, 1 or 2);

R^4 is C1-C6 alkyl; and

Hal is a halide selected from the group consisting of F, Cl, Br, I, and At;

only one of R^{1e}, R^{1f} or R^{1g} can be H, and

when R^{1e} is OH, NH_2 or NHMe and R^{1f} is NH_2, the nitrogen of R^{1f} is bridged with a carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of R^{1e} to form a five or six-membered heterocyclic ring.

In a specific embodiment, there is provided a compound according to Formula (I), wherein:

R^{1a} is allyl, crotyl, geranyl, farnesyl, benzyl, 2-alkenyl, 2-alkynyl;

R^{1b} is CF_3, OH , OR^2;

R^{1c} is H;

R^{1d} is OH or OR^2, NH_2, NH(CO)H;

R^{1e} is OR^2, R^4, NO_2, NH_2, NHMe, NMe_2, SR^2;

R^{1f} is OH, OR^2, NO_2, NH_2, NHMe, NHR^3, $NHC{=}NH(NH_2)$, $COOR^2$, COOH;

R^{1g} is H;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl, $C(O)C(O)OR^4$ or O-protecting group, wherein the protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxymethyl (SEM) acetal, $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$;

R^3 is H, CH_3, OH, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $COCH_2NH_2$, $CONH_2$, $CO(CH_2)_nCOOH$ (where n = 0, 1 or 2);

R^4 is C1-C6 alkyl;

2020415711 20 Jan 2025

and

Hal is a halide selected from the group consisting of F, Cl, Br, I, and At;

only one of R^{1e}, R^{1f} or R^{1g} can be H,

when R^{1e} is OH, NH_2 or NHMe and R^{1f} is NH_2, the nitrogen of R^{1f} is bridged with a carbonyl group or $(CO)CH_2$ group to the oxygen or nitrogen of R^{1e} to form a five or six-membered heterocyclic ring.

In one embodiment, Formula (I) is a compound selected from compound **2**, **3**, **4**, **5**, **6**, **7** [KYN-138, 139, 140, 153, 134, 136] as disclosed herein.

In another embodiment, there is provided a compound of formula (I) wherein:

R^{1a} is prenyl;

R^{1b} is OR^2;

R^{1c} is H;

R^{1d} is OH;

R^{1e} is OR^2;

R^{1f} is NHR^3, $NHC{=}NH(NH_2)$;

R^{1g} is H;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl; and

R^3 is H, CH_3, OH, (CO)H, (CO)Me, SO_2Me, CH_2COOR^2, $COCH_2NH_2$, $CO(CH_2)_nCOOH$ (where n = 0, 1 or 2).

In yet another embodiment, there is provided a compound of formula (I) wherein:

R^{1a} is prenyl;

R^{1b} is OR^2;

R^{1c} is H;

R^{1d} is OH:

R^{1e} is OR^2;

R^{1f} is OH,;

R^{1g} is alkyl, OH;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl; and

alkyl is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl.

2020415711 20 Jan 2025

Also disclosed herein is a compound according to formula (I) having at least one formamide group and/or ethoxide group on the A and/or B ring. In one embodiment, the A-ring has at least one ethoxide substituent. The ethoxide substituent may be at the R^{1b} or R^{1d} position on the A-ring. In another embodiment, the A-ring has a formamide sunstituent. In another embodiment the B-ring has a formamide substituent. In another embodiment, the A-ring has at least one ethoxide substituent and the B-ring has a formamide substituent. In a specifc embodiment, the compound of formula (I) may be selected from compounds **8**, **20**, **24**, **27**, **28**, **30**, **32**, **34**, **35**, **37** to **41**, **50** , **51** [KYN-119, 146, 141, 149, 143, 142, 148, 147, 152, 144, 155, 165, 159, 161, 170].

Methods of treatment

There is provided a method for treating cancer comprising administering a therapeutically effective amount of a compound of formula (I) as disclosed herein or a pharmaceutically acceptable salt, solvate or pharmaceutical composition including said compounds to a patient in need.

Preliminary Results

Discussion

WO2012/149608 discloses the anticancer activity of specific prenylated polyhydroxystilbene derivatives. In particular, compound **1** [KYN-001], as disclosed herein, was found to have potent activity in the inhibition of cancerous cells. The activity of the compounds of the present disclosure have been compared to compound **1**.

Preliminary studies indicate that compounds where R^{1b}= OEt and/or at least one phenolic OH is replaced by a formamide group are very effective cancer inhibitors. From Table 6, IC_{50} values for 42 cancer cell lines (average activity), the order of potency is **28** > **27** >**8** >**20** > **1**. Compound **28** with formamide and OEt was most active followed by **27** with R^{1b}=OMe and formamide.

Brief Description of Drawings

2020415711 20 Jan 2025

Figure 1 is a chromatogram of LM-6-44 (mixture of compounds **2**, **3** and **4**), before separation.

Figure 2 is a chromatogram of LM-6-44-P1 (compound **4**), after separation.

Figure 3 is a chromatogram of LM-6-44-P2 (compound **2**), after separation

Figure 4 is a chromatogram of LM-6-44-P3 (compound **3**), after separation

Figure 5 is a chromatogram LM-6-85 (mixture of compound **5**, **E-5-4** and **E-5-5**), before separation.

Figure 6 is a chromatogram LM-6-85-P2 (compound **5**), after separation.

Figure 7 is a chromatogram LM-6-85-P1 (compound **5-5**), after separation.

Figure 8 is a chromatogram LM-6-85-P3 (compound **5-4**), after separation.

Figure 9 shows the % effect of varying concentrations of compound **28** on inhibition of CCL2 release and inhibition of cell viability.

Figure 10 shows the % effect of varying concentrations of compound **28** on inhibition of IL-8 release and inhibition of cell viability.

Figure 11 shows the % effect of varying concentrations of compound **28** for inhibition of IL-17A release and inhibition of cell viability.

Figure 12 shows the % effect of varying concentrations of compound **28** for inhibition of IL-2 and IL-4 release and inhibition of cell viability.

Figure 13 shows Concentration-response graphs for compounds **1, 8, 20, 27, 28, 31** and **35.**

Figure 13.1 shows the effect fo compound **1** on: **A.** CCL2 release from inflammation induced by IL-4, IL-13, IL-22 and IFN-γ in human keratinocytes, **B**. IL-8 release from inflammation induced by IL-17and TNF-α in human keratinocytes, **C**. IL-17A release from inflammation induced by CD3, CD28 and IL-23 in human PBMC, **D.** IL-4 and IL-2 release from inflammation induced by CD2, CD3 and CD28 in T-cells. Effects of the compound 1 on cell viability in each assay were parallelly assessed.

Figure 13.2 shows the effect of compound **8** on: **A.** CCL2 release from inflammation induced by IL-4, IL-13, IL-22 and IFN-γ in human keratinocytes, **B**. IL-8 release from inflammation induced by IL-17and TNF-α in human keratinocytes, **C**. IL-17A release from inflammation induced by CD3, CD28 and IL-23 in human PBMC, **D.** IL-4 and

2020415711 20 Jan 2025

IL-2 release from inflammation induced by CD2, CD3 and CD28 in T-cells. Effects of the compound 8 on cell viability in each assay were parallelly assessed.

Figure 13.3 shows the effect of Compound **20** on: **A.** CCL2 release from inflammation induced by IL-4, IL-13, IL-22 and IFN-γ in human keratinocytes, **B**. IL-8 release from inflammation induced by IL-17and TNF-α in human keratinocytes, **C**. IL-17A release from inflammation induced by CD3, CD28 and IL-23 in human PBMC, **D.** IL-4 and IL-2 release from inflammation induced by CD2, CD3 and CD28 in T-cells. Effects of the compound 20 on cell viability in each assay were parallelly assessed.

Figure 13.4 shows the effect of Compound **27** on: **A.** CCL2 release from inflammation induced by IL-4, IL-13, IL-22 and IFN-γ in human keratinocytes, **B**. IL-8 release from inflammation induced by IL-17and TNF-α in human keratinocytes, **C**. IL-17A release from inflammation induced by CD3, CD28 and IL-23 in human PBMC, **D.** IL-4 and IL-2 release from inflammation induced by CD2, CD3 and CD28 in T-cells. Effects of the compound 27 on cell viability in each assay were parallelly assessed.

Figure 13.5 shows the effect of Compound **28** on: **A.** CCL2 release from inflammation induced by IL-4, IL-13, IL-22 and IFN-γ in human keratinocytes, **B**. IL-8 release from inflammation induced by IL-17and TNF-α in human keratinocytes, **C**. IL-17A release from inflammation induced by CD3, CD28 and IL-23 in human PBMC, **D.** IL-4 and IL-2 release from inflammation induced by CD2, CD3 and CD28 in T-cells. Effects of the compound 28 on cell viability in each assay were parallelly assessed.

Figure 13.6 shows the effect of Compound **31** on: **A.** CCL2 release from inflammation induced by IL-4, IL-13, IL-22 and IFN-γ in human keratinocytes, **B**. IL-8 release from inflammation induced by IL-17and TNF-α in human keratinocytes, **C**. IL-17A release from inflammation induced by CD3, CD28 and IL-23 in human PBMC, **D.** IL-4 and IL-2 release from inflammation induced by CD2, CD3 and CD28 in T-cells. Effects of the compound 31 on cell viability in each assay were parallelly assessed.

Figure 13.7 shows the effect of Compound 35 on: **A.** CCL2 release from inflammation induced by IL-4, IL-13, IL-22 and IFN-γ in human keratinocytes, **B**. IL-8 release from inflammation induced by IL-17and TNF-α in human keratinocytes, **C**. IL-17A release from inflammation induced by CD3, CD28 and IL-23 in human PBMC, **D.** IL-4 and

2020415711 20 Jan 2025

IL-2 release from inflammation induced by CD2, CD3 and CD28 in T-cells. Effects of the compound 35 on cell viability in each assay were parallelly assessed.

Figure 14. Concentration dependent inhibition of compound **1** [KYN-001], **20** [KYN-146] and **27** [KYN-149] towards three patients derived glioblastoma multiforme (GBM) cell samples designated as **A.** BNA99; **B**. BNB04 and **C**. BNB18.

Figure 15. Concentrations of compound **27** in different tissue samples isolated from treated mice.

Figure 16. Histochemical analysis of tumor samples from treated 1 and 2 mice

Figure 17. Histochemical analysis of samples from treated 3, 4 and 5 mice

Figure 18. Effect of compound **27** on melanoma B16F10 xenografted in BALB/c mice

Definition

2020415711 20 Jan 2025

Unless specifically defined otherwise, all technical and scientific terms used herein shall be taken to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., chemistry, biochemistry, medicinal chemistry, microbiology and the like). Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

As used herein, the term “and/or”, e.g., “X and/or Y” shall be understood to mean either "X and Y" or "X or Y" and shall be taken to provide explicit support for both meanings or for either meaning, e.g. A and/or B includes the options i) A, ii) B or iii) A and B..

As used herein, the term about, unless stated to the contrary, refers to +/- 20%, typically +/- 10%, typically +/- 5%, of the designated value.

As used herein, the terms “a”, “an” and “the” include both singular and plural aspects, unless the context clearly indicates otherwise.

It is to be appreciated that certain features that are, for clarity, described herein in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any sub-combination.

Throughout the present specification, various aspects and components of the invention can be presented in a range format. The range format is included for convenience and should not be interpreted as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range, unless specifically indicated. For example, description of a range such as from 1 to 5 should be considered to have specifically disclosed sub-ranges such as from 1 to 3,

2020415711 20 Jan 2025

from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 5, from 3 to 5 etc., as well as individual and partial numbers within the recited range, for example, 1, 2, 3, 4, 5, 5.5 and 6, unless where integers are required or implicit from context. This applies regardless of the breadth of the disclosed range. Where specific values are required, these will be indicated in the specification.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

As used herein, the term “halogen” means fluorine, chlorine, bromine, iodine or astatine.

As used herein, the term “hydrocarbon” encompass a chemical compound composed of hydrogen and carbon atoms.

As used herein, the term “alkyl” encompasses both straight-chain (i.e., linear) and branched-chain hydrocarbon groups. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, i-butyl, sec-butyl, pentyl, and hexyl groups. In one example, the alkyl group is of one to six carbon atoms (i.e. $C_{1\text{-}6}$alkyl).

As used herein, the term “alkoxy” refers to the group -O-alkyl, where “alkyl” is as described above. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, and butoxy groups. In one example, the alkoxy group is of one to six carbon atoms (i.e. -O-$C_{1\text{-}6}$alkyl).

As used herein, the term “alkenyl” refers to both straight and branched chain unsaturated hydrocarbon groups with at least one carbon-carbon double bond. Examples of alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, and hexenyl groups. In one example, the alkenyl group is of two to six carbon

2020415711 20 Jan 2025

atoms (i.e. C_{2-6}alkenyl). The term "2-alkenyl" refers to an alkene substituent that has a double bond at the 2 position from its attachment point. It includes allyl, crotyl, prenyl, geranyl, and farnesyl groups

As used herein, the term "alkynyl" refers to both straight and branched chain unsaturated hydrocarbon groups with at least one carbon-carbon triple bond. Examples of alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, and hexynyl groups. In one example, the alkynyl group is of two to six carbon atoms (i.e. C_{2-6}alkynyl).

As used herein, the term "haloalkyl" refers to an alkyl group having at least one halogen substituent, where "alkyl" and "halogen" are as described above. Similarly, the term "dihaloalkyl" means an alkyl group having two halogen substituents, and the term "trihaloalkyl" means an alkyl group having three halogen substituents. Examples of haloalkyl groups include fluoromethyl, chloromethyl, bromomethyl, iodomethyl, fluoropropyl, and fluorobutyl groups. Examples of dihaloalkyl groups include difluoromethyl and difluoroethyl groups. Examples of trihaloalkyl groups include trifluoromethyl and trifluoroethyl groups. In one example, the haloalkyl group is of one to six carbon atoms (i.e. C_{1-6}haloalkyl).

As used herein, the term "heterocyclyl" refers to an aromatic or non-aromatic cyclic group which is analogous to a carbocyclic group, but in which from one to three of the carbon atoms is/are replaced by one or more heteroatoms independently selected from nitrogen, oxygen, or sulfur. A heterocyclyl group may, for example, be monocyclic or polycyclic (e.g. bicyclic). A heteroatom may be N, O, or S.

While it is possible that, for use in therapy a therapeutically effective amount of the compounds as defined herein, or a pharmaceutically acceptable salt or solvate thereof, may be administered as the raw chemical; in one aspect of the present invention the active ingredient is presented as a pharmaceutical composition. Thus, in a further embodiment the invention provides a pharmaceutical composition comprising a compound of formula (I) as disclosed herein, or a pharmaceutically acceptable salt or

2020415711 20 Jan 2025

solvate thereof, in admixture with one or more pharmaceutically acceptable carriers, diluents, or excipients. The carrier(s), diluent(s) or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

When applicable, the compounds of the present invention, including the compounds of formula (I) may be in the form of and/or may be administered as a pharmaceutically acceptable salt.

As used herein the term "pharmaceutically acceptable salt" refers to salts which are toxicologically safe for systemic administration. The pharmaceutically acceptable salts may be selected from alkali or alkaline earth metal salts, including, sodium, lithium, potassium, calcium, magnesium and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, triethanolamine and the like.

As used herein the term "pharmaceutically acceptable excipient" refers to a solid or liquid filler, diluent or encapsulating substance that may be safely used in systemic administration. Depending upon the particular route of administration, a variety of carriers, well known in the art may be used. These carriers or excipients may be selected from a group including sugars, starches, cellulose and its derivatives, malt, gelatine, talc, calcium sulfate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffered solutions, emulsifiers, isotonic saline, and pyrogen-free water.

As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or (Ia) or a salt or physiologically functional derivative thereof) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, methanol, ethanol and acetic acid. In particular the solvent used is a pharmaceutically acceptable solvent. Examples of suitable pharmaceutically acceptable solvents include, without limitation,

2020415711 20 Jan 2025

water, ethanol, acetic acid, glycerol, liquid polyethylene glycols and mixtures thereof. A particular solvent is water.

Administration of compounds of the formula (I) may be in the form of a "prodrug". A prodrug is an inactive form of a compound which is transformed *in vivo* to the active form. Suitable prodrugs include esters, phosphonate esters etc, of the active form of the compound.

It should be understood that in addition to the ingredients particularly mentioned above, the formulations may include other agents conventional in the art having regard to the type of formulation in question.

The compounds of the present disclosure may be suitable for the treatment of diseases in a human or animal patient. In one embodiment, the patient is a mammal including a human, horse, dog, cat, sheep, cow, or primate. In one embodiment the patient is a human. In a further embodiment, the patient is not a human.

As used herein, the term "effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician. Furthermore, the term "therapeutically effective amount" means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function.

As used herein the term "treatment" refers to defending against or inhibiting a symptom, treating a symptom, delaying the appearance of a symptom, reducing the severity of the development of a symptom, and/or reducing the number or type of symptoms suffered by an individual, as compared to not administering a pharmaceutical composition comprising a compound of the invention. The term treatment encompasses the use in a palliative setting

2020415711 20 Jan 2025

Those skilled in the art will appreciate that in the preparation of the compounds of the invention it may be necessary and/or desirable to protect one or more sensitive groups in the molecule to prevent undesirable side reactions. Suitable protecting groups for use according to the present invention are well known to those skilled in the art and may be used in a conventional manner. See, for example, "Protective groups in organic synthesis" by T. W. Greene and P. G. M. Wuts (John Wiley & sons 1991) or "Protecting Groups" by PJ. Kocienski (Georg Thieme Verlag 1994). Examples of suitable amino protecting groups include acyl type protecting groups (e.g. formyl, trifluoroacetyl, acetyl), aromatic urethane type protecting groups (e.g. benzyloxycarbonyl (Cbz) and substituted Cbz), aliphatic urethane protecting groups (e.g. 9-fluorenylmethoxycarbonyl (Fmoc), t-butyloxycarbonyl (Boc), isopropyloxycarbonyl, cyclohexyloxycarbonyl) and alkyl type protecting groups (e.g. benzyl, trityl, chlorotrityl).

According to the fourth aspect of the disclosure, the compounds according to formula (I) are suitable for use in the treatment of cancer. The cancers to be treated include leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer or breast cancer. Most preferably, the cancer to be treated is leukemia or melanoma.

The antitumor effect of the compounds of the present invention may be applied as a sole therapy or may involve, in addition, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. In the field of medical oncology it is normal practice to use a combination of different forms of treatment to treat each patient with cancer such as a combination of surgery, radiotherapy and/or chemotherapy. In particular, it is known that irradiation or treatment with antiangiogenic and/or vascular permeability reducing agents can enhance the amount of hypoxic tissue within a tumour. Therefore the effectiveness of the compounds of the present invention may be improved by conjoint treatment with radiotherapy and/or with an antiangiogenic agent.

2020415711 20 Jan 2025

The individual components of such combinations can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms. The present invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly. It will be understood that the scope of combinations of the compounds of this invention with other anti-neoplastic agents includes in principle any combination with any pharmaceutical composition useful for treating cancer.

When combined in the same formulation it will be appreciated that the two compounds must be stable and compatible with each other and the other components of the formulation and may be formulated for administration. When formulated separately they may be provided in any convenient formulation, conveniently in such a manner as are known for such compounds in the art.

Pharmaceutical compositions of the invention may be formulated for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route. Therefore, the pharmaceutical compositions of the invention may be formulated, for example, as tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions. Such pharmaceutical formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s). Such pharmaceutical formulations may be prepared as enterically coated granules, tablets or capsules suitable for oral administration and delayed release formulations.

When a compound is used in combination with a second therapeutic agent active against the same disease, the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.


Modes for Carrying Out the Invention

In order to better understand the nature of the invention a number of examples will now be described as follows:

Preparation of Module A

Module A is represented by formula (II) of the present disclosure as herein described.

In one embodiment, Module A is represented by A7 and A8 and is prepared according to the following process:



4-Bromo-5-methylbenzene-1,3-diol (A2):

Tetrabutylammonium tribromide (120 g, 248 mmol, 1.0 equiv) in a 3 to 2 mixture of dichloromethane and methanol (300 mL) was added dropwise to a solution of compound **A1** (30 g, 242 mmol, 1.0 equiv) in 3 to 2 mixture of dichloromethane and methanol (200 mL) at 15°C over 3 hours. The resulting mixture was slowly warmed up to room temperature and stirred for 16 hours. The solvents were removed under reduced pressure. Water (200 mL) was added to the residue. The mixture was extracted with ethyl acetate (2 x 250 mL) and methyl tert-butyl ether (500 mL). The combined organic layers was washed with 2.5% sodium bicarbonate (3 x 500 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified over silica gel (2.5 kg), eluting with a gradit of 0 to 50% ethyl acetate in heptanes to give compound **A2** (36.83 g, 75% yield) as an off-white solid. (LM-1-96).

2020415711 20 Jan 2025

Additional compound **A1** (270 g, 2175 mmol, 1.0 equiv) was processed in the same manner. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in dichloromethane (3 L) and purified over silica gel (6 kg), eluting with a gradient of 0 to 100% ethyl acetate in heptanes to give partially purified compound **A2** (407 g, ~70% purity). This crude product was recrystallized twice in 1 to 3 mixture of in methanol and water (1.2 L). The solid was filtered, rinsed with water (500 mL) and dried under high-vacuum at 45°C for 16 hours to give compound **A2** (163.78 g 37% yield) as an off-white solid. (LM-1-100).

4-Bromo-3-methoxy-5-methylphenyl 4-methylbenzenesulfonate (A3):

Potassium carbonate (886 g, 6402 mmol, 6.5 equiv) was added to a solution of compound **A2** (200 g, 985 mmol, 1.0 equiv) in acetone (15 L). After stirring for 30 minutes, *p*-toluenesulfonyl chloride (187.8 g, 985 mmol, 1.0 equiv) was added and the resulting mixture was refluxed for 16 hours. Methyl iodide (166 mL, 2660 mmol, 2.7 equiv) was added to the reaction and refluxing was continued for an additional 24 hours. The reaction mixture was cooled to room temperature, filtered and the solids were rinsed with acetone (4 L). The filtrate was concentrated under reduced pressure. The residue was dissolved in dichloromethane (2 L) and passed through silica gel (6 kg), eluting with a gradient of 0 to 15% ethyl acetate in heptanes (16 L) to give compound **A3** (350 g, ~60% purity), which was used subsequently. (LM-6-1).

4-Bromo-3-methoxy-5-methylphenol (A4):

6M Sodium hydroxide (108 mL, 8.0 equiv) was added to a solution of crude compound **A3** (30 g, 1.0 equiv) in 1 to 1 mixture of tetrahydrofuran and methanol (400 mL). After refluxing for 16 hours. LCMS indicated the reaction was complete. Another batch of crude compound **A3** (300 g) was processed in the same manner and both batches were combined for work-up. After the mixture was cooled to room temperature, acetonitrile (4 L) was added and the mixture was washed with heptanes (2 x 4 L). The heptane layers were discarded. The tetrahydrofuran/methanol/acetonitrile/water mixture was acidify with 1N hydrochloride acid (~6.2 L) to pH = 7, saturated with sodium chloride

2020415711 20 Jan 2025

(3 kg) and extracted with ethyl acetate (2 x 4L). The combined organic layers was concentrated under reduced pressure. The residue was diluted in water (500 mL) and extracted with ethyl acetate (3 x 1 L). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was diluted with acetonitrile (1 L) and heptanes (500 mL).and the layers were separated. The heptanes layer was discarded. The acetonitrile layer was passed through a pad of silica gel (300 g), which was.eluted with ethyl acetate (2 L). The filtrate was concentrated under reduced.pressure. The resulting solid was triturated with 10% ethyl acetate in heptanes.(1.1 L) to give compound **A4** (96.6 g, 45% yield over 2 steps) as an off-white solid. (LM-6-12, LM-6-14)

4-Bromo-3-methoxy-5-methylphenyl acetate (A5):

Acetic anhydride (63.1 mL, 668 mmol, 1.5 equiv) was added to a solution of compound **A4** (96.6 g, 445 mmol, 1.0 equiv) in a mixture of pyridine (377 ml) and dichloromethane (1000 mL) at room temperature. The resulting mixture was stirred for 16 hours. Ice water (500 mL) was added to quench the reaction. The organic layer was washed with icecold 1N HCl (3 x 500 mL), saturated sodium bicarbonate (500 mL), saturated brine (500 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was further dried under high-vacuum at 45°C for 16 hours to give compound **A5** (114.53 g, 99% yield) as an off-white solid, which was used subsequently. (LM-6-15).

4-Bromo-3-(dibromomethyl)-5-methoxyphenyl acetate (A6):

N-Bromosuccinimide (82.6 g, 464 mmol, 2.1 equiv) and benzoyl peroxide (5.35 g, 22.1 mmol, 0.1 equiv) were sequentially added to a solution of compound **A5** (57.27 g, 221 mmol, 1.0 equiv) in carbon tetrachloride (1 L). The resulting mixture was refluxed for 24 hours, at which time LCMS analysis indicated the reaction was complete. Another batch of compound **A5** (57.27 g) was processed in the same manner and both batches were combined for work-up. After the mixture was cooled to room temperature, sodium bisulfite (250 g) was added and the reaction mixture was stirred for 24 hours at

2020415711 20 Jan 2025

room temperature (test on wet starch paper showed no peroxide). The resulting mixture was filtered through Celite (200 g), which was rinsed with dichloromethane (2 L). The filtrate was concentrated under reduced pressure to give crude compound **A6** as a yellow solid, which was used subsequently. (LM-6-17)

2-Bromo-5-hydroxy-3-methoxybenzaldehyde (A7):

Ammonium formate (153 g, 2431 mmol, 5.5 equiv) and a 1 to 1 mixture of ethanol and water (600 mL) was added to a solution of compound **A6** (~442 mmol, 1.0 equiv) in ethanol (800 mL) at 50°C. The resulting mixture was refluxed for 70 hours. LCMS analysis indicated the reaction was complete. The reaction mixture was cooled to room temperature and concentrated hydrochloric acid (15 mL) was added. Solvents were removed under reduced pressure. The residue was diluted in water (500 mL), extracted with ethyl acetate (2 x 1 L) and methyl tert-butyl ether (2 x 1 L). The aqueous layer was filtered through a pad of Celite (50 g), which was rinsed with ethyl acetate (2 L). The organic layer was separated. All organic layers were combined, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was passed through a pad of silica gel (300 g), which was eluted with tetrahydrofuran (3 L) and ethyl acetate (4 L). The filtrate was concentrated under reduced pressure to give crude compound **A7** (141 g) as a black oil, which was used subsequently. (LM-6-18)

2-Bromo-3-methoxy-5-((2-(trimethylsilyl)ethoxy)methoxy)benzaldehyde (A8 representative of Module A):

Diisopropylethylamine (16.5 mL, 94.7 mmol, 1.5 equiv) and 2-(trimethylsilyl)ethoxymethyl chloride (13.4 mL, 75.6 mmol, 1.2 equiv) were added sequentially to a solution of crude compound **A7** (20 g, ~63 mmol, 1.0 equiv) in 1 to 1 mixture of anhydrous tetrahydrofuran and dichloromethane (200 mL) at room temperature. After stirring at room temperature for 16 hours, LCMS analysis indicated ~65% conversion of the reaction. Additional diisopropylethylamine (16.5 mL, 94.7 mmol, 1.5 equiv) and 2-(trimethylsilyl)ethoxymethyl chloride (13.4 mL, 75.6 mmol, 1.2 equiv) were added and the mixture was stirred for additional 24 hours. Saturated


2020415711 20 Jan 2025

sodium bicarbonate (250 mL) was added to quench the reaction and the organic solvent was removed under reduced pressure. The remaining aqueous layer was extracted with methyl tert-butyl ether (500 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated system (330 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give A8 (representative of **Module A)** (8.44 g) as a white solid. (LM-6-20) Additional crude compound **7** (120 g) was processed in the same manner. Saturated sodium bicarbonate (250 mL) was added to quench the reaction and the solvent was removed under reduced pressure. The remaining aqueous layer was diluted with water (250 mL), saturated brine (250 mL) and was extracted with methyl tert-butyl ether (2 x 1 L). The combined organic layers was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was filtered through a pad of silica gel (1 kg), which was eluted with 20% ethyl acetate in heptanes. The filtrate was concentrated under reduced pressure. The residue was equally divided in to 6 portions. Each portion was purified on an Interchim automated system (330 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes. All isolated compound Intermediate A was further purified by trituration with 5% dichloromethane in hexanes (300 mL) to give A8 (representative of **Module A)** (26.73 g, 99% purity and 42.72 g, ~90% purity) as a white solid after drying under vacuum at 45°C for 16 hours. The combined yield was 43% over 3 steps. (LM-6-21)

White Solid, Melting Point 58.3 – 59.1°C; HPLC Analysis: 99.6% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 10.80 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=378.0 $(M+H_2O)^+$; $C_{14}H_{21}BrO_4Si$; ^1H NMR (400 MHz, $CDCl_3$) δ = 10.40 (s,1H), 7.20 (d, J = 2.8 Hz,1H), 6.84 (d, J = 2.7 Hz, 1H), 5.25 (s, 2H), 3.92 (s, 3H), 3.78 – 3.73 (m, 2H), 0.97 – 0.93 (m, 2H), 0.00 (s, 9H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 191.82, 157.76, 157.12, 134.85, 109.31, 107.49, 106.62, 93.06, 66.72, 56.65, 18.02, -1.43.

In another embodiment, Module A is represented by A9 which is prepared according to the following process:.

20 Jan 2025 2020415711



3-Hydroxy-5-((2-(trimethylsilyl)ethoxy)methoxy)benzaldehyde (A11):

N,*N*-Diisopropylethylamine (122 mL, 700 mmol, 1.4 equiv) was added to a solution of compound **A10** (69.06 g, 500 mmol, 1.0 equiv) in anhydrous dimethylformamide (400 mL) at room temperature. 2-(Trimethylsilyl)ethoxymethyl chloride (106.2 mL, 600 mmol, 1.2 equiv) was added dropwise over 30 minutes. The resulting mixture was stirred at room temperature for 70 hours. Water (1.5 L) was added and the mixture was extracted with methyl tert-butyl ether (2 x 2.5 L). The combined organic layers was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was divided into 3 equal 3 portions. Each portion was purified on an Interchim automated system (330 g column), eluting with a gradient of 0 to 50% ethyl acetate in heptanes to give compound **A11** (49.64 g, 26% yield, 71% purity by QNMR) as a yellow oil. (LM-6-84)

2-Bromo-3-hydroxy-5-((2-(trimethylsilyl)ethoxy)methoxy)benzaldehyde (A12):

Compound A11 (49.64 g, 71% purity by QNMR, 131.3 mmol, 1.0 equiv) was put under high vacuum (0.5 Torr) at 50°C for 2 hours to remove residual 2-(trimethylsilyl)ethanol. After cooling to room temperature, anhydrous dichloromethane (700 mL) was added and the mixture was cooled to -17°C. *N*-Bromosuccinimide (25.12 g, 141.1 mmol, 1.07 equiv) in anhydrous dichloromethane (1 L) was added dropwise over 1 hour while keeping the temperature between -15°C and -20°C. After the addition, NMR analysis indicated the reaction was not complete (16% compound A11 remained). Additional *N*-bromosuccinimide (4.62 g, 26 mmol, 0.2 equiv) in anhydrous dichloromethane (200 mL) was added dropwise over 10 minutes. The resulting mixture was stirred at -17°C for another 30 minutes. Water (800 mL) was added and the mixture was warmed up to room temperature. The organic layer was washed with

2020415711 20 Jan 2025

saturated brine (1 L), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was divided into 5 equal portions. Each portion was purified on an Interchim automated system (2 x 120 g column stack), eluting with a gradient of 0 to 12% ethyl acetate in heptanes to give compound A12 (35.84 g, 79% yield) as a yellow oil. (LM-6-87)

2-Bromo-3-ethoxy-5-((2-(trimethylsilyl)ethoxy)methoxy)benzaldehyde (A9, Module A):


Triphenylphosphine (40.6 g, 154.8 mmol, 1.5 equiv) and ethanol (9 mL, 154.8 mmol, 1.5 equiv) were added to a solution of compound A12 (35.84 g, 103.2 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (1 L). After cooling to 0°C for 10 minutes, diisopropyl azodicarboxylate (31 mL, 154.8 mmol, 1.5 equiv) was added dropwise over 15 minutes. The resulting mixture was slowly warmed up to room temperature and stirred for 16 hours. The solvent was removed under reduced pressure. The residue was divided into 5 equal portions. Each portion was purified on an Interchim automated system (2 x 120 g column stack), eluting with 5% ethyl acetate in heptanes to give **A9** (17.5 g, 45% yield) as a yellow solid. (LM-6-88)

Preparation of Module B

Module B is represented by formula (III) of the present disclosure as herein described.

In one embodiment, Module B isrepresented by B4 which is prepared according to the below process:

2020415711 20 Jan 2025



3-Methoxy-4-((2-(trimethylsilyl)ethoxy)methoxy)benzaldehyde (B2):

N,*N*-Diisopropylethylamine (1224 g, 9.47 mol, 1.2 equiv) and 2-(trimethylsilyl)-ethoxymethyl chloride (1315 g, 7.89 mol, 1.0 equiv) were sequentially added to a solution of compound **B1** (1200 g, 7.84 mol, 1.0 equiv) in anhydrous dichloromethane (12 L). After stirring at room temperature overnight, the mixture was poured into a separatory funnel containing saturated sodium bicarbonate (20 L). The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 5 L). The combined organic layers were concentrated under reduced pressure. The residue was combined with 2 other reactions of equal scale and purified over silica gel (2 kg), eluting with a gradient of 0 to 50% MTBE in heptanes to give compound **B2** (2200 g, 99% yield) as a pale-yellow oil. (EK-22-137)

(3-Methoxy-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)methanol (B3):

Sodium borohydride (250 g, 6.61 mol) was added portion-wise over 20 minutes while keeping the temp below 20 ºC to a solution of compound **B2** (2000 g, 7.10 mol) in methanol (8L). After stirring overnight, water (1 L) was added slowly over 20 minutes. The mixture was combined with a reaction of equal scale and concentrated under reduced pressure to remove most of the methanol. The slurry was poured into a separatory funnel and diluted with MTBE (8 L). The layers were separated and the aqueous layer was back extracted with MTBE (2 x 4 L). The combined organic layers

2020415711 20 Jan 2025

were washed with saturated brine (4 L), dried over sodium sulfate (200 g) and concentrated under reduced pressure to give compound **B3** (1970g, 98 % yield) as a yellow oil which was used subsequently. (EK-22-153)

Diethyl (3-methoxy-4-((2-(trimethylsilyl)ethoxy)methoxy)benzyl) phosphonate (B4, Module B):

A 22 L flask was charged with THF (7 L) and zinc(II) iodide (2.24 kg, 2.03 mol, 2 equiv), the addition exothermed to 40°C. Triethyl phosphite (1.17 kg, 7.03 mol, 2 equiv) and compound **B3** (1000 g, 3.52 mol, 1 equiv) in THF (1 L) were sequentially added. After heating at 65°C for 16 hours, the reaction was cooled to room temperature and diluted with water (5 L). Potassium carbonate (1.2 kg, 8.68 mol, 2.47 equiv) was added in portions over 5 minutes adjusting the pH to 9. There was no foaming observed during the addition. The salts were filtered and the filter cake was washed with MTBE (2 x 4 L). The combined filtrates were washed with saturated brine (4 L), dried over sodium sulfate (500 g) and concentrated under reduced pressure. The resulting oil was purified over silica gel (2.0 kg), eluting with a gradient of 25 to 100% ethyl acetate in heptanes to give **B4** (1035 g, 72% yield) as a yellow oil. (EK-22-154) **$C_{18}H_{33}PSiO_6$**


^{1}H NMR (400 MHz, $CDCl_3$) δ = 7.11 (d, J = 8.2 Hz, 1H), 6.89 (m, 1H), 6.80 (dm, J = 8.2 Hz, 1H), 5.26 (s, 2H), 4.08 – 3.98 (m, 4H), 3.88 (s, 3H), 3.82 (m, 2H), 3.10 (d, J = 21.1 Hz, 2H), 1.26 (t, J = 7.1 Hz, 6H), 0.98 – 0.93 (m, 2H), 0.00 (s, 9H).

Preparation of Module C

Module C is represented by formula (IV) of the present disclosure as herein described.

In one embodiment, Module C is represented by C1 which is prepared according to the below process:

2020415711 20 Jan 2025




(*E*)-(2-((4-(2-bromo-3-methoxy-5-((2-(trimethylsilyl) ethoxy) methoxy)styryl)-2-methoxyphenoxy)methoxy)ethyl)trimethylsilane (C1):

A 60% dispersion of sodium hydride in mineral oil (1.07 g, 26.7 mmol, 2 equiv) was added in one portion to a solution of **B4** (5.4 g, 13.4 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (120 mL) at 0°C. The mixture was warmed to room temperature and stirred 30 minutes. A solution of **A8** (4.82 g, 13.4 mmol, 1 equiv) in anhydrous tetrahydrofuran (30 mL) was then added dropwise and the mixture was stirred at room temperature for 16 hours at which time LCMS analysis indicated that ~30% conversion to Module C. Additional 60% dispersion of sodium hydride in mineral oil (1.07 g, 26.7 mmol, 2 equiv) was added, resulting in ~50% conversion after 8 hours by LCMS analysis. Additional 60% dispersion of sodium hydride in mineral oil (2.14 g, 53.4 mmol, 4 equiv) was added, resulting in complete conversion after 16 hours by LCMS analysis. The reaction was carefully quenched with saturated brine (100 mL, 1 drop per minute for the first 5 mL brine) at 0°C. The mixture was extracted with ethyl acetate (2 x 500 mL).The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (220 column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give **C1** (5.2 g, 64% yield) as a yellow oil. (LM-6-27)

$C_{28}H_{43}BrSiO_6$ ^1H NMR (400 MHz, $CDCl_3$) δ = 7.39 (d, J = 16.1 Hz, 1H), 7.17 (d, J = 8.3 Hz, 1H), 7.09 (d, J = 1.7 Hz, 1H), 7.07 (dd, J = 2.0, 8.6 Hz, 1H), 6.99 (d, J = 2.4 Hz, 1H), 6.96 (d, J = 16.2 Hz, 1H), 6.56 (d, J = 2.7 Hz, 1H), 5.29 (s, 2H), 5.25 (s, 2H), 3.94 (s, 3H), 3.88 (s, 3H), 3.83 – 3.77 (m, 4H), 1.00 – 0.94 (m, 4H), 0.02 (s, 9H), 0.00 (s,

2020415711 20 Jan 2025


9H).In another embodiment, Module C is represented by C2 which is prepared according to the below process:



(*E*)-(2-((4-(2-Bromo-3-ethoxy-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-2-methoxyphenoxy)methoxy)ethyl)trimethylsilane (C2):

A 60% dispersion of sodium hydride in mineral oil (750 Mg, 18.8 mmol, 2 equiv) was added in one portion to a solution of compound **B4** (3.8 g, 9.4 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (150 mL) at 0°C. The mixture was warmed up to room temperature and stirred 30 minutes. A solution of **D4** (3.52 g, 9.4 mmol, 1 equiv) in anhydrous tetrahydrofuran (50 mL) was then added dropwise and the mixture was stirred at room temperature for 16 hours. The reaction was carefully quenched with saturated brine (150 mL, 1 drop per minute for the first 5 mL) at 0°C. The mixture was extracted with methyl tert-butyl ether (2 x 150 mL). The combined organic layers was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (120 column), eluting with a gradient of 0 to 15% ethyl acetate in heptanes to give **C2** (1.69 g, 29% yield) as a yellow oil. (LM-6-80).

Preparation of Compound 1 [KYN-001]



(*E*)-(2-((2-methoxy-4-(3-methoxy-2-(3-methylbut-2-en-1-yl)-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)phenoxy)methoxy)ethyl)trimethylsilane (1-1):

Tetrakis(triphenylphosphine)palladium(0) (29 mg, 0.025 mmol, 0.05 equiv), potassium carbonate (138 mg, 1 mmol, 2 equiv), 3-methylbut-2-enylboronic acid pinacol ester (147 mg, 0.75 mmol, 1.5 equiv) and water (5 mL) were added sequentially to a solution of **C1** (306 mg, 0.5 mmol, 1 equiv) in tetrahydrofuran (5 mL). After sparging with nitrogen for 10 minutes, the reaction was heated at 50°C for 20 hours. After cooling to room temperature, the mixture was extracted with ethyl acetate (15 mL) and the organic layer was concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (40 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **1-1** (190 mg, 63% yield) as a yellow oil. (LM-6-29)

(*E*)-3-(4-hydroxy-3-methoxystyryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (1):

1M Tetrabutylammonium fluoride in tetrahydrofuran (4.43 mL, 4.43 mmol, 14 equiv) was added to compound **1-1** (190 mg, 0.32 mmol, 1 equiv) at room temperature. After

2020415711 20 Jan 2025

heating at 67°C for 16 hours, the mixture was cooled to room temperature and diluted with water (4 mL). The mixture was extracted with ethyl acetate (15 mL) and the organic layer was concentrated under reduced pressure. The residue was purified twice on an Interchim automated chromatography system (2 x 25 columns), eluting each time with a gradient of 0 to 60% ethyl acetate in heptanes to give compound **1** (60 mg, 56% yield) as an off-white solid after drying under vacuum at 40°C for 16 hours. (LM-6-30)


White solid, melting point 132.3 – 134.0°C; HPLC Analysis: 96.3% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 8.4 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=341.2 $(M+H)^+$; $C_{21}H_{24}O_4$; ^1H NMR (400 MHz, $CDCl_3$) δ = 7.15 (d, J = 16.0 Hz, 1H), 7.00 (br s, 1H), 6.99 (dd, J = 2.0, 8.2 Hz, 1H), 6.90 (d, J = 8.2 Hz, 1H), 6.85 (d, J = 16.1 Hz, 1H), 6.66 (d, J = 2.6 Hz, 1H), 6.36 (d, J = 2.4 Hz, 1H), 5.12 (tm, J = 6.8 Hz, 1H), 3.94 (s, 3H), 3.80 (s, 3H), 3.41 (br d, J = 6.7 Hz, 2H), 1.81 (s, 3H), 1.68 (d, J = 1.1 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 158.52, 154.37, 146.65, 145.54, 138.13, 130.59, 130.40, 130.24, 124.24, 123.63, 120.65, 120.55, 114.53, 108.22, 103.85, 98.17, 55.86, 55.69, 25.78, 24.45, 17.97.

Preparation of Compound 2, 3 and 4:

4-((*E*)-but-2-en-1-yl)-3-((*E*)-4-hydroxy-3-methoxystyryl)-5-methoxyphenol (2) [KYN-138]

4-((*Z*)-but-2-en-1-yl)-3-((*E*)-4-hydroxy-3-methoxystyryl)-5-methoxyphenol (3) [KYN-139]

(*E*)-4-(but-3-en-2-yl)-3-(4-hydroxy-3-methoxystyryl)-5-methoxyphenol (4) [KYN-140]



(2-((4-((*E*)-2-((*E*)-but-2-en-1-yl)-3-methoxy-5-((2-(trimethylsilyl)ethoxy) methoxy)styryl)-2-methoxyphenoxy)methoxy)ethyl)trimethylsilane (2-1) /

(2-((4-((*E*)-2-((*Z*)-but-2-en-1-yl)-3-methoxy-5-((2-(trimethylsilyl)ethoxy) methoxy)styryl)-2-methoxyphenoxy)methoxy)ethyl)trimethylsilane (3-1)

(*E*)-(2-((4-(2-(but-3-en-2-yl)-3-methoxy-5-((2-(trimethylsilyl)ethoxy) methoxy)styryl)-2-methoxyphenoxy)methoxy)ethyl)trimethylsilane (4-1):

2020415711 20 Jan 2025

Tetrakis(triphenylphosphine)palladium(0) (116 mg, 0.1 mmol, 0.05 equiv), potassium carbonate (553 mg, 4 mmol, 2 equiv), *trans*-crotylboronic acid pinacol ester (728 mg, 4 mmol, 2 equiv) and water (10 mL) were added sequentially to a solution of **C1** (1.22 g, 2 mmol, 1 equiv) in tetrahydrofuran (10 mL). After sparging with nitrogen for 10 minutes, the reaction was heated at 77°C for 20 hours. Another batch of **C1** (1.22 g) with *cis*-crotylboronic acid pinacol ester (2 equiv) was processed in the same manner and both batches were combined for work-up. After cooling to room temperature, the mixture was extracted with ethyl acetate (2 x 50 mL) and the organic layer was concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (80 column), eluting with a gradient of 0 to 15% ethyl acetate in heptanes to give a mixture of compound **2-1**, **3-1** and **4-1** (2.2 g, 94% yield) as a yellow oil. (LM-6-42, LM-6-43)

4-((*E*)-but-2-en-1-yl)-3-((*E*)-4-hydroxy-3-methoxystyryl)-5-methoxyphenol (2) / 4-((*Z*)-but-2-en-1-yl)-3-((*E*)-4-hydroxy-3-methoxystyryl)-5-methoxyphenol 3) / (*E*)-4-(but-3-en-2-yl)-3-(4-hydroxy-3-methoxystyryl)-5-methoxyphenol (4):

1M Tetrabutylammonium fluoride in tetrahydrofuran (52.5 mL, 52.5 mmol, 14 equiv) was added to a mixture of compounds **2**, **3** and **4** (2.2 g, 3.75 mmol, 1 equiv) at room temperature. After heating at 67°C for 16 hours, the mixture was cooled to room temperature and diluted with water (50 mL). The mixture was extracted with dichloromethane (2 x 150 mL) and the organic layer was concentrated under reduced pressure. The residue was purified three times on an Interchim automated chromatography system (3 x 80 columns), eluting each time with a gradient of 0 to 60% ethyl acetate in heptanes to a mixture of compounds **2**, **3** and **4** (760 mg) as a yellow oil. This mixture of oil was subjected to supercritical fluid chromatography (Lotus Separations) to give three compounds, which were appeared as black residue oils. These residues were individually re-purified on an InterChim automated chromatography system (25 column), eluting with a gradient of 0 to 60% ethyl acetate in heptanes to give compounds **2** (90 mg, 7% yield), **3** (60 mg, 5% yield) and **4** (290 mg, 24% yield), respectively, as off-white solids after drying under vacuum at 40°C for 16 hours. (LM-6-44)

2020415711 20 Jan 2025

The following SFC separation (conditions listed below) yielded 400 mg of peak-1 (**4**, LM-6-44-P1), 108 mg of peak-2 (**2**, LM-6-44-P2), and 110 mg of peak-3 (**3**, LM-6-44-P3). Chromatograms are included in this report.

Preparative Method:	**Analytical Method:**
SFC-B (2 x 25 cm)	SFC-B(15 x 0.46 cm)
40% methanol (no additive)/CO_2, 100 bar	40% methanol (no additive)/CO_2, 100 bar
65 mL/min, 220 nm	3.5 mL/min, 220, 254 and 280 nm
inj vol.: 0.5 mL, 15 mg/mL ethanol	

Figure 1 shows LM-6-44 (mixture of compounds **2**, **3** and **4**), before separation

Figure 2 shoes LM-6-44-P1 (compound **4**), after separation.Figure 3 shows LM-6-44-P2 (compound **2**), after separation.

Figure 4 shows LM-6-44-P3 (compound **3**), after separation:

Structure Data:

4-((*E*)-but-2-en-1-yl)-3-((*E*)-4-hydroxy-3-methoxystyryl)-5-methoxyphenol (compound 2) [KYN-138]:

Off-white solid; HPLC Analysis: 96.3% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 8.1 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=327.2 $(M+H)^+$; $C_{20}H_{22}O_4$; ^1H NMR (400 MHz, $CDCl_3$) δ = 7.17 (d, J = 16.1 Hz, 1H), 7.03 – 6.98 (m, 2H), 6.93 – 6.89 (m, 1H), 6.86 (d, J = 16.1 Hz, 1H), 6.67 (d, J = 2.3 Hz, 1H), 6.36 (d, J = 2.4 Hz, 1H), 5.67 (s, 1H), 5.59 – 5.49 (m, 1H), 5.47 – 5.36 (m, 1H), 4.73 (s, 1H), 3.94 (s, 3H), 3.80 (s, 3H), 3.41 (td, J = 1.3, 5.9 Hz, 2H), 1.63 (qd, J = 1.4, 6.2 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 158.63, 154.50, 146.67, 145.59, 138.42, 130.41, 130.31, 129.67, 124.93, 124.34, 120.35, 119.57, 114.59, 108.56, 103.91, 98.24, 55.89, 55.78, 28.29, 17.91.

2020415711 20 Jan 2025


4-((*Z*)-but-2-en-1-yl)-3-((*E*)-4-hydroxy-3-methoxystyryl)-5-methoxyphenol (compound 3) [KYN-139]:

Off-white solid; HPLC Analysis: 98.8% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 8.2 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=327.2 $(M+H)^+$; $C_{20}H_{22}O_4$; ^1H NMR (400 MHz, $CDCl_3$) δ = 7.15 (d, J = 16.0 Hz, 1H), 7.01 – 6.97 (m, 2H), 6.90 (d, J = 7.9 Hz, 1H), 6.85 (d, J = 16.0 Hz, 1H), 6.66 (d, J = 2.3 Hz, 1H), 6.36 (d, J = 2.4 Hz, 1H), 5.68 (s, 1H), 5.53 – 5.32 (m, 2H), 4.87 (s, 1H), 3.93 (s, 3H), 3.80 (s, 3H), 3.48 (d, J = 6.7 Hz, 2H), 1.81 (qd, J = 1.2, 6.4 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 158.60, 154.49, 146.68, 145.58, 138.29, 130.56, 130.24, 129.71, 124.20, 122.99, 120.59, 120.16, 114.56, 108.29, 104.00, 98.23, 55.86, 55.69, 23.37, 12.99.

(*E*)-4-(but-3-en-2-yl)-3-(4-hydroxy-3-methoxystyryl)-5-methoxyphenol (compound 4) [KYN-140]:

Off-white solid; HPLC Analysis: 96.1% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 8.2 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=327.2 $(M+H)^+$; $C_{20}H_{22}O_4$; ^1H NMR (400 MHz, $CDCl_3$) δ = 7.32 (d, J = 16.0 Hz, 1H), 6.99 – 6.95 (m, 2H), 6.92 – 6.89 (m, 1H), 6.74 (d, J = 16.0 Hz, 1H), 6.61 (d, J = 2.4 Hz, 1H), 6.37 (d, J = 2.4 Hz, 1H), 6.22 (ddd, J = 4.8, 10.5, 17.4 Hz, 1H), 5.67 (s, 1H), 5.10 – 5.03 (m, 2H), 4.85 (s, 1H), 4.15 (tdq, J = 2.1, 4.6, 7.0 Hz, 1H), 3.94 (s, 3H), 3.78 (s, 3H), 1.39 (d, J = 7.1 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 158.72, 154.52, 146.69, 145.51, 143.90, 138.85, 130.37, 130.14, 125.60, 124.11, 120.38, 114.56, 111.76, 108.30, 105.18, 98.73, 55.86, 55.70, 34.49, 18.55.

4-((*E*)-But-2-en-1-yl)-3-ethoxy-5-((*E*)-4-hydroxy-3-methoxystyryl)phenol (compound **5) [KYN-153]**



(2-((4-((*E*)-2-((*E*)-But-2-en-1-yl)-3-ethoxy-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-2-methoxyphenoxy)methoxy)ethyl)trimethylsilane (5-1):

Tetrakis(triphenylphosphine)palladium(0) (156 mg, 0.14 mmol, 0.05 equiv), potassium carbonate (1.12 g, 8.1 mmol, 3 equiv), *trans*-crotylboronic acid pinacol ester (1.48 g, 8.1 mmol, 3 equiv) and water (10 mL) were added sequentially to a solution of **C2** (1.69 g, 2.7 mmol, 1 equiv) in 1,4-dioxane (15 mL). After sparging with nitrogen for 10 minutes, the reaction was heated at 95°C for 16 hours. After cooling to room temperature, the mixture was extracted with methyl tert-butyl ether (2 x 20 mL) and the combined organic layers was-concentrated under reduced pressure. The residue was

2020415711 20 Jan 2025

purified on an Interchim-automated chromatography system (40 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give a mixture of compound **5-1**, **5-2** and **5-3** (1.54 g, 89% yield) as a yellow oil. (LM-6-82)

4-((*E*)-But-2-en-1-yl)-3-ethoxy-5-((*E*)-4-hydroxy-3-methoxystyryl)phenol (5):

1M Tetrabutylammonium fluoride in tetrahydrofuran (33.5 mL, 33.5 mmol, 14 equiv) was added to a mixture of compound **5-1**, **5-2** and **5-3** (1.44 g, 2.4 mmol, 1 equiv) in tetrahydrofuran (50 mL) at room temperature. After heating at 67°C for 16 hours, the mixture was cooled to room temperature and diluted with ethyl acetate (200 mL). The mixture was washed with saturated brine (50 mL) and the organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified twice on an Interchim automated chromatography system (2 x 40 g column stack, 2 x 25 g column stack), eluting each time with a gradient of 0 to 100% ethyl acetate in heptanes to a mixture of compound **5**, **5-4** and **5-5** (610 mg) as a yellow oil. This mixture of oil was subjected to supercritical fluid chromatography (Lotus Separations) to give three compounds, which were appeared as black residue oils. The **LM-6-85-P2** residue was re-purified on an InterChim automated chromatography system (25 column), eluting with a gradient of 0 to 60% ethyl acetate in hexanes to give **compound 5** (60 mg, 7% yield) as an off-white solid after drying under vacuum at 40°C for 16 hours. (LM-6-85) The following SFC separation (conditions listed below) yielded 425 mg of peak-1 (**5-5**, LM-6-85-P1), 88 mg of peak-2 (**5**, LM-6-85-P2), and 70mg of peak-3 (**5-4**, LM-6-85-P3). Peak-2 was reworked to enhance the purity.

Chromatograms are included in this report.

Preparative Method:	**Analytical Method:**
SFC-B (2 x 25 cm) 45% methanol/CO_2, 100 bar 80 mL/min, 220 nm inj vol.: 0.5 mL, 20 mg/mL ethanol	SFC-B(15 x 0.46 cm) 40% methanol/CO_2, 120 bar 3 mL/min, 220, 254 and 280 nm

l

Figure 5 shows LM-6-85 (mixture of compound **5**, **E-5-4** and **E-5-5**), before separation.

2020415711 20 Jan 2025

Figure 6 shows LM-6-85-P2 (compound **5**), after separation.

Figure 7 shows LM-6-85-P1 (compound **5-5**), after separation.

Fiugure 8 shows LM-6-85-P3 (compound **5-4**), after separation.


Structure Data:

Compound 5 [KYN-153]

Off-white solid; HPLC Analysis: 97.7% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 μm; Retention Time: 8.6 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=341.2 $(M+H)^+$; $C_{21}H_{24}O_4$; NMR (400 MHz, $CDCl_3$) δ = 7.19 (d, J = 16.1 Hz, 1H), 7.03 – 6.98 (m, 2H), 6.92 (d, J = 8.2 Hz, 1H), 6.85 (d, J = 16.1 Hz, 1H), 6.65 (d, J = 2.4 Hz, 1H), 6.34 (d, J = 2.4 Hz, 1H), 5.66 (s, 1H), 5.59 – 5.40 (m, 2H), 4.70 (s, 1H), 4.00 (q, J = 7.0 Hz, 2H), 3.95 (s, 3H), 3.42 (br d, J = 5.9 Hz, 2H), 1.65 – 1.61 (m, 3H), 1.41 (t, J = 7.0 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 157.95, 154.40, 146.68, 145.57, 138.31, 130.35, 130.29, 129.79, 124.88, 124.43, 120.34, 119.89, 114.59, 108.54, 103.84, 99.17, 63.99, 55.89, 28.49, 17.90, 14.87.

Preparation of (*E*)-4-allyl-3-(4-hydroxy-3-methoxystyryl)-5-methoxyphenol (6) [KYN-134]

2020415711 20 Jan 2025



(*E*)-(2-((4-(2-allyl-3-methoxy-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-2-methoxyphenoxy)methoxy)ethyl)trimethylsilane (6-1):

[1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (46 mg, 0.063 mmol, 0.25 equiv) and allyltributylstannane (248 mg, 0.75 mmol, 3 equiv) were added to a solution of compound **C1** (Module C)(153 mg, 0.25 mmol, 1 equiv) in anhydrous dimethylformamide (3 mL). After sparging with nitrogen for 10 minutes, the reaction was heated at 100°C for 16 hours. The reaction mixture was cooled to room temperature, loaded to a 12 g dry-load cartridge with silica gel (10 g) and purified on an Interchim automated chromatography system (25 column), eluting with a gradient of 0 to 40% ethyl acetate in heptanes to give compound **6-1** (140 mg, 98% yield) as a yellow oil. (LM-6-33)

(*E*)-4-allyl-3-(4-hydroxy-3-methoxystyryl)-5-methoxyphenol (6) [KYN-134]:

1M Tetrabutylammonium fluoride in tetrahydrofuran (3.5 mL, 3.5 mmol, 14 equiv) was added to compound **6-1** (140 mg, 0.25 mmol, 1 equiv) at room temperature, and the mixture was heated at 67°C for 16 hours. After the mixture was cooled to room temperature, water (4 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (15 mL) and the organic layer was concentrated under

2020415711 20 Jan 2025

reduced pressure. The residue was purified twice on an Interchim automated chromatography system (2 x 25 columns), eluting each time with a gradient of 0 to 60% ethyl acetate in heptanes to give compound **6** (34 mg, 45% yield) as an off-white solid after drying under vacuum at 35°C for 16 hours. (LM-6-34)


White solid; HPLC Analysis: 96.3% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 μm; Retention Time: 7.48 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=313.1 $(M+H)^+$; $C_{19}H_{20}O_4$

^{1}H NMR (400 MHz, $CDCl_3$) δ = 7.14 (d, J = 16.2 Hz, 1H), 7.00 (dd, J = 1.5, 7.7 Hz, 1H), 6.98 (s, 1H), 6.90 (d, J = 7.8 Hz, 1H), 6.85 (d, J = 16.1 Hz, 1H), 6.67 (d, J = 2.5 Hz, 1H), 6.36 (d, J = 2.2 Hz, 1H), 5.94 (ddt, J = 5.9, 10.2, 17.0 Hz, 1H), 5.66 (br s, 1H), 4.99 (dq, J = 1.7, 8.5 Hz, 1H), 4.96 (dq, J = 1.7, 17.1 Hz, 1H), 4.76 (br s, 1H), 3.93 (s, 3H), 3.79 (s, 3H), 3.48 (dt, J = 1.7, 5.8 Hz, 2H).

^{13}C NMR (100 MHz, $CDCl_3$) δ = 158.73, 154.70, 146.70, 145.64, 138.71, 137.25, 130.63, 130.26, 124.22, 120.43, 118.57, 114.61, 114.40, 108.56, 104.03, 98.25, 55.92, 55.80, 29.50.

Preparation of (*E*)-4-benzyl-3-(4-hydroxy-3-methoxystyryl)-5-methoxyphenol (7) [KYN-136]

2020415711 20 Jan 2025



(*E*)-(2-((4-(2-benzyl-3-methoxy-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-2-methoxyphenoxy)methoxy)ethyl)trimethylsilane (Compound 7-1):

Tetrakis(triphenylphosphine)palladium(0) (16 mg, 0.014 mmol, 0.05 equiv), potassium carbonate (77 mg, 0.56 mmol, 2 equiv), benzylboronic acid pinacol ester (122 mg, 0.56 mmol, 2 equiv) and water (5 mL) were added sequentially to a solution of **compound C1** (170 mg, 0.28 mmol, 1 equiv) in tetrahydrofuran (5 mL). After sparging with nitrogen for 10 minutes, the reaction was heated at 77°C for 16 hours. After cooling to room temperature, the mixture was extracted with ethyl acetate (15 mL) and the organic layer was concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (40 g column), eluting with a gradient of 0 to 50% ethyl acetate in heptanes to give compound **7-1** (172 mg, 99% yield) as a yellow oil. (LM-6-35)

(*E*)-4-benzyl-3-(4-hydroxy-3-methoxystyryl)-5-methoxyphenol (7) [KYN-136]:

1M Tetrabutylammonium fluoride in tetrahydrofuran (3.92 mL, 3.92 mmol, 14 equiv) was added to compound **7-1** (172 mg, 0.28 mmol, 1 equiv) at room temperature. After heating at 67°C for 16 hours, the mixture was cooled to room temperature and diluted with water (4 mL). The mixture was extracted with ethyl acetate (15 mL) and the

2020415711 20 Jan 2025

organic layer was concentrated under reduced pressure. The residue was purified twice on an Interchim automated chromatography system (40 & 25 columns), eluting each time with a gradient of 0 to 60% ethyl acetate in heptanes to give compound **7** (37 mg, 37% yield) as an off-white solid after drying under vacuum at 35°C for 16 hours. (LM-6-36)


Off-white solid; HPLC Analysis: 96.4% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 8.09 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=363.1 $(M+H)^+$; $C_{23}H_{22}O_4$;

^{1}H NMR (400 MHz, $CDCl_3$) δ = 7.24 – 7.00 (m, 2H), 7.18 – 7.10 (m, 3H), 7.09 (d, J = 16.1 Hz, 1H), 6.89 (dd, J = 1.7, 8.6 Hz, 1H), 6.85 (d, J = 8.1 Hz, 1H), 6.85 (d, J= 1.7 Hz), 6.82 (d, J = 15.9 Hz), 6.68 (d, J = 2.5 Hz, 1H), 6.39 (d, J = 2.5 Hz, 1H), 5.65 (br s, 1H), 4.87 (br s, 1H), 4.10 (s, 2H), 3.87 (s, 3H), 3.77 (s, 3H).

^{13}C NMR (100 MHz, $CDCl_3$) δ = 159.03, 154.85, 146.63, 145.58, 141.66, 138.83, 130.62, 130.12, 128.22, 128.16, 125.55, 124.31, 120.60, 119.60, 114.48, 108.23, 104.06, 98.21, 55.83, 55.72, 30.92.

Preparation of (E)-3-Ethoxy-5-(4-hydroxy-3-methoxystyryl)-4-(3-methylbut-2-en-1-yl)phenol (8) [KYN-119]

2020415711 20 Jan 2025



3-Bromo-5-ethoxyphenol (8-2):

A 60% dispersion of sodium hydride (2.9 g, 73.62mmol, 1.1 equiv) in mineral oil was added in several portions to a solution of compound **8-1** (12.65 g, 66.93 mmol, 1 equiv) in anhydrous tetrahydrofuran (700 mL) at room temperature. After stirring at room temperature for 15 minutes, ethyl iodide (5.38 mL, 66.93 mmol, 1 equiv) was added. The resulting solution was heated at 50°C for 8 hours. The reaction was cooled to room temperature and transferred to a separatory funnel containing saturated ammonium chloride solution (500 mL). Ethyl acetate (1L) was added and the organic layer separated. The aqueous layer was extracted with ethyl acetate (3 x 400 mL) and the combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (Sorbtech 120 g column), eluting with a gradient of 0 to 50% ethyl acetate in heptanes to give compound **8-2** (4.37 g, 31% yield) as a yellow oil. (TA-1-107)

1-Bromo-3-ethoxy-5-((3-methylbut-2-en-1-yl)oxy)benzene (8-3):

A 60% dispersion of sodium hydride (1.1 g, 28.64 mmol, 1.1 equiv) in mineral oil and 3,3-dimethylallyl bromide (4.27 g, 28.6 mmol, 1.1 equiv) were sequentially added to a solution of compound **8-2** (5.65 g, 26.03 mmol, 1 equiv) in anhydrous THF (500 mL).

2020415711 20 Jan 2025

The reaction mixture was heated at 50°C and stirred overnight. The reaction was cooled to room temperature and transferred to a separatory funnel containing saturated ammonium chloride solution (400 mL). Ethyl acetate (700 mL) was added and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (3 x 200 mL) and the combined organic layers were dried with sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (Sorbtech 120 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **8-3** (6.8 g, 88% yield) as a yellow oil. (TA-1-102).

(2-((2-Methoxy-4-vinylphenoxy)methoxy)ethyl)trimethylsilane (8-5):

N,NDiisopropylethylamine (8.8 mL, 50 mmol, 1.5 equiv) and 2-(trimethylsilyl)ethoxymethyl chloride (7.1 mL, 40 mmol, 1.2 equiv) were sequentially added to a solution of compound **8-4** (5 g, 33.33 mmol, 1.0 equiv) in anhydrous dichloromethane (50 mL) at room temperature. After stirring at room temperature overnight, saturated ammonium chloride (50 mL) was added to quench the reaction. The aqueous layer was extracted with dichloromethane (2 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 10% ethyl acetate in heptanes to give compound **8-5** (6.5g, 70% yield) as a clear oil. (NK-1-45)

(E)-(2-((4-(3-Ethoxy-5-((3-methylbut-2-en-1-yl)oxy)styryl)-2-methoxyphenoxy)methoxy)ethyl)trimethylsilane (8-6):

Compound **8-5** (1.49 g, 5.32 mmol, 1.2 equiv), triphenylphosphine (110 mg, 0.443 mmol, 0.1 equiv), potassium acetate (868 mg, 8.86 mmol, 2 equiv) and palladium acetate (50 mg, 0.221 mmol, 0.05 equiv) were added to a solution of compound **8-3** (1.26 g, 4.43 mmol, 1.0 equiv) in anhydrous toluene (30 mL). The reaction mixture was sparged with nitrogen for 15 minutes. After refluxing (110°C) for 16 hours, the reaction mixture was cooled to room temperature and filtered through celite (~ 5 g). The filtrate

2020415711 20 Jan 2025

was transferred to a separatory funnel containing saturated sodium bicarbonate (30 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (2 X 20 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. Another batch using compound 3 (1.26 g) was processed in a similar way. The combined residue was purified on an Interchim automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **8-6** (960 mg, 22% yield) as a pale yellow oil. (NK-1-49)

(E)-4-(3-Ethoxy-5-((3-methylbut-2-en-1-yl)oxy)styryl)-2-methoxyphenol (8-7):

1M tetrabutylammonium fluoride in THF (14.0 mL, 13.88 mmol, 7 equiv) was added to a solution of compound **8-6** (960 mg, 1.98 mmol, 1 equiv) in anhydrous THF (40 mL) at room temperature. The mixture was refluxed overnight (66°C), at which point LCMS indicated that the reaction was complete. After the mixture was cooled to room temperature, water (10 mL) was added to quench the reaction. The volatiles were removed under reduced pressure followed by the addition of ethyl acetate (15 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (2 x 15 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (Sorbtech 12 g column), eluting with a gradient of 0 to 50% ethyl acetate in heptanes to give compound **8-7** (503 mg, 71 % yield) as a yellow oil. (NK-1-44)

(E)-3-Ethoxy-5-(4-hydroxy-3-methoxystyryl)-4-(3-methylbut-2-en-1-yl)phenol (8) [KYN-119]:

Montmorillonite K30 powder (500 mg) was added to a solution of compound **8-7** (500 mg, 1.41 mmol) in anhydrous dichloromethane (20 mL) at room temperature and the mixture was stirred at room temperature overnight. No product formation was observed by LCMS. The mixture was filtered and fresh Montmorillonite K30 powder (500 mg) was added and the mixture was stirred at room temperature overnight, at which point

2020415711 20 Jan 2025


LCMS indicated that 30-40% of desired compound 8 was formed, along with two regio-isomers and unreacted starting compound 7 as byproducts. The mixture was filtered and the solid was washed with dichloromethane (2 x 15 mL). The filtrate was concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 50% ethyl acetate in heptanes. Trituration with 30% dichloromethane in heptanes (10 mL) gave pure compound **8 [KYN-119]** (60 mg, 12 % yield) as a white solid. (NK-1-52-C)

Beige solid, melting point 133.9 – 134.7°C; HPLC Analysis: 96.7% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 9.10 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=355.2 $(M+H)^+$; $C_{22}H_{26}O_4$; ^1H NMR (400 MHz, $CDCl_3$) δ = 7.16 (d, J = 16.1 Hz, 1H), 7.00 (br s, 1H), 6.99 (dd, J = 1.9, 9.0 Hz, 1H), 6.90 (d, J = 8.4 Hz, 1H), 6.84 (d, J = 16.1 Hz, 1H), 6.64 (d, J = 2.4 Hz, 1H), 6.33 (d, J = 2.4 Hz, 1H), 5.13 (tm, J = 1.4, 7.0 Hz, 1H), 3.98 (q, J = 7.0 Hz, 2H), 3.93 (s, 3H), 3.43 (d, J = 7.0 Hz, 2H), 1.81 (d, J = 1.0 Hz, 3H), 1.67 (d, J = 1.2 Hz, 3H), 1.41 (t, J = 7.0 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 157.88, 154.27, 146.68, 145.53, 138.12, 130.40, 130.34, 130.32, 124.39, 123.74, 120.89, 120.55, 114.56, 108.32, 103.86, 99.12, 63.94, 55.88, 25.78, 24.54, 18.01, 14.89.

Compound 8 (KYN-119) can also be synthesised by the modular methodology of the present disclosure using equivalents to Module A, B and C and subsequernt cross coupling alkylation of the aryl halide.

Preparation (E)-3-(4-Hydroxy-3-methoxystyryl)-4-(3-methylbut-2-en-1-yl)-5-propoxyphenol (9) [KYN-130]

2020415711 20 Jan 2025



3-Bromo-5-propoxyphenol (9-2):

Potassium carbonate (21.9 g, 158.73 mmol, 1.2 equiv) and propyl iodide (15 mL, 158.73 mmol, 1.2 equiv) were added sequentially to a solution of compound **9-1** (10.0 g, 52.91 mmol, 1 equiv) in acetonitrile (300 mL) at room temperature. The resulting suspension was refluxed (80°C) for 16 hours. After cooling to room temperature the reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was dissolved in ethyl acetate (150 mL) and transferred to a separatory funnel containing 1M hydrochloric acid solution (100 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 40 g column), eluting with a gradient of 0 to 30% ethyl acetate in heptanes to obtain compound **9-2** (11.3 g, 37% yield) as a light brown oil (NRK-1-89).

1-Bromo-3-((3-methylbut-2-en-1-yl)oxy)-5-propoxybenzene (9-3):

Potassium carbonate (10.1 g, 73.36 mmol, 1.5 equiv) and 3,3-dimethylallyl bromide (6.8 mL, 58.70 mmol, 1.2 equiv) were added sequentially to a solution of compound **9-2** (11.3 g, 48.91 mmol, 1 equiv) in acetonitrile (200 mL) at room temperature. The resulting suspension was refluxed (80°C) for 16 hours. After cooling to room

2020415711 20 Jan 2025

temperature the reaction mixture was filtered and the filtrate was concentrated under reduced pressure to obtain compound **9-3** (16.0 g, 99% yield) as a light brown oil (NRK-1-90) which was used subsequently,

(E)-(2-((2-methoxy-4-(3-((3-methylbut-2-en-1-yl)oxy)-5-propoxystyryl)phenoxy)methoxy)ethyl)trimethylsilane (9-6):

(2-((2-Methoxy-4-vinylphenoxy)methoxy)ethyl)trimethylsilane (9-5, see 8-5 for prep) (12.3 g, 4.15 mmol, 1.1 equiv), triphenylphosphine (2.1 g, 8.02 mmol, 0.2 equiv), potassium carbonate (11 g, 80.26 mmol, 2 equiv) and palladium acetate (910 mg, 4.01 mmol, 0.1 equiv) were added to a solution of compound **9-3** (12.0 g, 40.13 mmol, 1.0 equiv) in anhydrous toluene (300 mL) at room temperature. The reaction mixture was sparged with nitrogen for 15 minutes. After refluxing (110°C) for 16 hours, the reaction mixture was cooled to room temperature and filtered through celite (~ 30 g). The filtrate was transferred to a separatory funnel containing saturated sodium bicarbonate solution (200 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (2 X 100 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 80 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **9-6** (6.25 g, 31% yield) as a light brown oil. (NRK-1-91)

(E)-2-methoxy-4-(3-((3-methylbut-2-en-1-yl)oxy)-5-propoxystyryl)phenol (8-7):

1M Tetrabutylammonium fluoride in THF (139 mL, 138.59 mmol, 7 equiv) was added to a solution of compound **9-6** (9.86 g, 19.8 mmol, 1 equiv) in anhydrous THF (200 mL) at room temperature. The mixture was refluxed (66°C) for 16 hours, at which point LCMS indicated that the reaction was complete. After the mixture was cooled to room temperature, water (20 mL) was added. The volatiles were removed under reduced pressure followed by the addition of ethyl acetate (150 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated

2020415711 20 Jan 2025

under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 80 g column), eluting with a gradient of 0 to 50% ethyl acetate in heptanes to give compound **9-7** (6.66 g, 92% yield) as a yellow solid. (NRK-1-92)

(E)-3-(4-hydroxy-3-methoxystyryl)-4-(3-methylbut-2-en-1-yl)-5-propoxyphenol (9) [KYN-130]:


Montmorillonite K30 powder (6.66 g) was added to a solution of compound **8-7** (6.66 g, 18.09 mmol) in anhydrous dichloromethane (200 mL) at room temperature. After stirring at room temperature overnight, LCMS indicated that 30-40% of desired compound **9** had formed, along with two regioisomers and unreacted starting compound **9-7** as by-products. The mixture was filtered through celite, which was washed with dichloromethane (2 x 50 mL). The filtrate was concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 80 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes. The product was triturated with 30% dichloromethane in heptanes (20 mL) to give pure compound **9 [KYN-130]** (1.02 g, 15% yield) as a white solid. (NRK-1-95-C)

White solid, melting point 141.6 – 142.8°C; HPLC Analysis: 99.48% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 9.4 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (negative mode) m/z=367.2 $(M-H)^-$; $C_{23}H_{28}O_4$; ^1H NMR (400 MHz, $CDCl_3$) δ = 7.16 (d, J = 16.1 Hz, 1H), 7.00 (br s, 1H), 6.99 (dd, J = 2.0, 8.2 Hz, 1H), 6.90 (d, J = 8.3 Hz, 1H), 6.84 (d, J = 15.9 Hz, 1H), 6.64 (d, J = 2.5 Hz, 1H), 6.33 (d, J = 2.4 Hz, 1H), 5.14 (tm, J = 7.0 Hz, 1H), 3.93 (s, 3H), 3.88 (t, 6.4 Hz, 2H), 3.43 (d, J = 6.8 Hz, 2H), 1.83 (m, J = 6.4, 7.6 Hz, 2H), 1.81 (d, J = 1.0 Hz, 3H), 1.67 (d, J = 1.2 Hz, 3H), 1.04 (t, J = 7.5 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 158.02, 154.27, 146.68, 145.57, 138.14, 130.36, 130.33, 130.31, 124.42, 123.84, 120.88, 120.55, 114.56, 108.32, 103.75, 98.97, 69.90, 55.90, 25.78, 24.57, 22.68, 18.01, 10.68.

2020415711 20 Jan 2025

Compound **9** (KYN-130) can also be synthesised by the modular methodology of the present disclosure using equivalents to Module A, B and C and subsequernt cross coupling alkylation of the aryl halide.

Preparation of 3-(4-Hydroxy-3-methoxystyryl)-5-isopropoxy-4-(3-methylbut-2-en-1-yl)phenol (10) [KYN-131]



3-Hydroxy-5-isopropoxybenzaldehyde (10-2):

A mixture of compound **10-1** (3 g, 21.7 mmol, 1 equiv), potassium carbonate (4.5 g, 32.6 mmol, 1.5 equiv) and isopropyl iodide (2.1 mL, 21.7 mmol, 1 equiv) in N,N'-dimethylformamide (60 mL) was heated at 70°C for 16 hours. Additional \ isopropyl iodide (1.05 Ml, 10.9 mmol, 0.5 equiv) was added and the reaction was continued for 2 hours. After cooling to room temperature, the pH was adjusted to 4 with 6 N HCl. The remaining solid was removed by filtration. The filtrate was extracted with ethyl acetate

2020415711 20 Jan 2025

(4 x 50 mL). The combined organic layers were washed with saturated brine (50 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on an InterChim automated chromatography system (40 g SorbTech column), eluting with a gradient of 0 to 70% ethyl acetate in heptanes to give compound **10-2** (1.13 g, 29% yield) as a brown solid. (QZH-RCI-4).

3-Isopropoxy-5-((3-methylbut-2-en-1-yl)oxy)benzaldehyde (10-3):

A mixture of compound **10-2** (1.13 g, 6.27 mmol, 1 equiv), potassium carbonate (1.73 g, 12.5 mmol, 2 equiv) and 1-bromo-3-methylbut-2-ene (0.87 mL, 7.53 mmol, 1.2 equiv) in acetone (35 mL) was refluxed for 16 hours. After cooling to room temperature, the reaction was diluted with water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with saturated brine (30 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on a Büchi automated chromatography system (24 g SorbTech column), eluting with a gradient of 0 to 50% ethyl acetate in heptanes to give compound **10-3** (1.33, 86% yield) as a yellow oil. (QZH-RCI-6).

2-((4-(3-Isopropoxy-5-((3-methylbut-2-en-1-yl)oxy)styryl)-2-methoxyphenoxy)methoxy)ethyl)trimethylsilane (10-4):

A solution of **Module B** (2.17 g, 5.36 mmol, 1 equiv) in tetrahydrofuran (10 mL) was added to a suspension of a 60% dispersion of sodium hydride in mineral oil (0.43 g, 10.7 mmol, 2 equiv) in tetrahydrofuran (30 mL) at 0°C. The reaction was stirred at 0°C for 1 hour. A solution of compound **10-3** (1.33 g, 5.36 mmol, 1 equiv) in tetrahydrofuran (10 mL) was added and the reaction was allowed to warm to room temperature overnight. The reaction was diluted with water (50 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with saturated brine (50 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on a Büchi automated chromatography system (24 g RediSep column), eluting with a gradient of 0 to 10% ethyl acetate in heptanes to give compound **10-4** (1.65 g, 62% yield) as a yellow oil. (QZH-RCI-9).

2020415711 20 Jan 2025

4-(3-Isopropoxy-5-((3-methylbut-2-en-1-yl)oxy)styryl)-2-methoxyphenol (10-5):

A solution of compound **10-4** (1.65 g, 3.3 mmol, 1 equiv) and 1.0 M tetrabutylammonium fluoride in tetrahydrofuran (16.5 mL, 16.5 mmol, 5 equiv) in tetrahydrofuran (20 mL) was refluxed overnight. After cooling to room temperature, the reaction was diluted with water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with saturated brine (50 mL), dried over sodium sulfate and concentrated under reduced pressure. The residue was purified on a Büchi automated chromatography system (12 g RediSep column), eluting with a gradient of 0 to 30% ethyl acetate in heptanes to give **Compound 10-5** (0.85 g, 70% yield) as a brown oil. (QZH-RCI-10)

3-(4-Hydroxy-3-methoxystyryl)-5-isopropoxy-4-(3-methylbut-2-en-1-yl)phenol (10) [KYN-131]:


Montmorillonite K10 powder (1 g, Sigma-Aldrich, catalog # 69866) was added to a solution of compound **10-5** (0.85 g, 2.3 mmol, 1 equiv) in anhydrous dichloromethane (10 mL). The reaction was stirred at room temperature for 16 hours, at which point the LC/MS indicates >90% conversion of the starting material. The solid was removed by filtration and the filter cake was rinsed with dichloromethane (100 mL). The filtrate was concentrated under reduced pressure. The residue was initially purified on a Büchi automated chromatography system (25 g SorbTech column), eluting with a gradient of 0 to 30% ethyl acetate in heptanes. The fractions that contains product (>85% purity by LC/MS) were collected and again purified on an InterChim automated chromatography system (25 g InterChim 20 to 45 microns silica gel column), eluting with a gradient of 0 to 30% ethyl acetate in heptanes to give **Compound 10** [KYN-131] (75 mg, 9% yield, 99.2% purity by HPLC) as an off-white solid. (QZH-RCI-12).

Off-white solid; HPLC Analysis: 99.2% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 9.2 min; Mobile Phase: ACN/formic acid/water; $C_{23}H_{28}O_4$; ^{1}H NMR (400 MHz, $CDCl_3$) δ = 7.15 (d, J = 16.1 Hz, 1H), 7.00 (br s, 1H), 6.99 (dd, J = 2.0, 8.0 Hz, 1H), 6.90 (d, J = 8.3 Hz, 1H),

6.85 (d, J = 16.1 Hz, 1H), 6.64 (d, J = 2.4 Hz, 1H), 6.35 (d, J = 2.2 Hz, 1H), 5.12 (tm, J = 1.4, 7.0 Hz, 1H), 4.49 (septet, J = 6.0 Hz, 1H), 3.94 (s, 3H), 3.41 (d, J = 6.9 Hz, 2H), 1.82 (d, J = 1.0 Hz, 3H), 1.67 (d, J = 1.2 Hz, 3H), 1.34 (d, J = 6.1 Hz, 6H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 156.75, 154.19, 146.68, 145.57, 138.37, 130.34, 130.27, 130.23, 124.52, 123.87, 121.87, 120.55, 114.55, 108.32, 103.95, 100.46, 70.35, 55.90, 25.78, 24.69, 22.17, 18.10.

Compound **10** (KYN-131) can also be synthesised by the modular methodology of the present disclosure using equivalents to Module A, B and C and subsequernt cross coupling alkylation of the aryl halide.

Preparation of (*E*)-3-(4-Hydroxy-3-methoxystyryl)-4-(3-methylbut-2-en-1-yl)-5-(trifluoromethoxy)phenol (11) [KYN-132]



1-Bromo-3-((3-methylbut-2-en-1-yl)oxy)-5-(trifluoromethoxy)benzene (11-2):

Potassium carbonate (5.36 g, 38.9 mmol, 2 equiv) and 3,3-dimethylallyl bromide (2.9 mL, 23.34 mmol, 1.2 equiv) were added sequentially to a solution of compound **11-1** (5.0 g, 19.45 mmol, 1 equiv) in acetonitrile (100 mL) at room temperature. The resulting suspension was heated to reflux (80°C) for 16 hours. After cooling to room

2020415711 20 Jan 2025

temperature, the reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The crude residue was dissolved in ethyl acetate (100 mL) and washed with 1M hydrochloric acid solution (2 x 50 mL). The organic layer was dried over sodium sulfate and evaporated under reduced pressure to obtain compound **11-2** (5.0 g, 79% yield) as a pale yellow oil (NRK-1-96) which was used subsequently.

(*E*)-(2-((2-methoxy-4-(3-((3-methylbut-2-en-1-yl)oxy)-5-(trifluoromethoxy)styryl)phenoxy)methoxy)ethyl)trimethylsilane (11-5):

(2-((2-Methoxy-4-vinylphenoxy)methoxy)ethyl)trimethylsilane (11-4, see 8-5 for prep) (4.30 g, 15.38 mmol, 1.0 equiv), triphenylphosphine (800 mg, 3.07 mmol, 0.2 equiv), potassium carbonate (4.25 g, 30.76 mmol, 2 equiv) and palladium acetate (350 mg, 1.6 mmol, 0.1 equiv) were added to a solution of compound **11-2** (5.0 g, 15.38 mmol, 1.0 equiv) in anhydrous toluene (150 mL) at room temperature. The reaction mixture was sparged with nitrogen for 15 minutes. After refluxing (110°C) for 16 hours, the reaction mixture was cooled to room temperature and filtered through celite (~ 20 g). The filtrate was transferred to a separatory funnel containing saturated sodium bicarbonate (100 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 80 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **11-5** (4.89 g, 61% yield) as a light brown oil. (NRK-1-97)

(*E*)-2-methoxy-4-(3-((3-methylbut-2-en-1-yl)oxy)-5-(trifluoromethoxy)styryl)phenol (11-6):

1M Tetrabutylammonium fluoride solution in THF (66 mL, 65.24 mmol, 7 equiv) was added to a solution of compound **11-5** (4.89 g, 9.32 mmol, 1 equiv) in anhydrous THF (200 mL) at room temperature. After refluxing (66°C) for 16 hours. LCMS analysis indicated that the reaction was complete. The mixture was cooled to room temperature and diluted with water (20 mL). The volatiles were removed under reduced pressure

2020415711 20 Jan 2025

and the residue was diluted with ethyl acetate (150 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 80 g column), eluting with a gradient of 0 to 50% ethyl acetate in heptanes to give compound **11-6** (3.2 g, 87 % yield) as a pale yellow oil. (NRK-1-98)

(*E*)-3-(4-hydroxy-3-methoxystyryl)-4-(3-methylbut-2-en-1-yl)-5-(trifluoromethoxy)phenol (11) [KYN-132]:

Montmorillonite K30 powder (3.2 g) was added to a solution of **Compound 11-6** (3.2 g, 8.89 mmol) in anhydrous dichloromethane (100 mL) at room temperature and the mixture was stirred at room temperature overnight. LCMS indicated that 10-15% of desired compound **11** was formed, along with two regio-isomers and unreacted starting compound **11-6** as by-products. The mixture was filtered and treated with fresh montmorillonite K30 powder (3.2 g) at room temperature for an additional 24 hours. The reaction mixtrure was filtered and solid was washed with dichloromethane (2 x 50 mL). The combined filtrate was concentrated under reduced pressure. The residue was first purified on a Reveleris automated chromatography system (Sorbtech 80 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give several mixed fractions containing compound **11**. The fractions were pooled together and the resulting material was purified on a Reveleris automated chromatography system (Redisep Rf Gold HP C18, 100 g column), eluting with a gradient of 0 to 80% acetonitrile in water. The product was triturated with 30% dichloromethane in heptanes (10 mL) to give pure compound **11** (60 mg, 1.7% yield) as a white solid. (NRK-1-99-C)


White solid, melting point 141.6 – 142.6°C; HPLC Analysis: 98.81% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 9.8 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (negative mode) m/z=393.0 $(M-H)^-$; $C_{21}H_{21}F_3O_4$; ^1H NMR (400 MHz, $CDCl_3$) δ = 7.09 (d, J = 15.9 Hz, 1H), 7.00 (dd, J = 1.8, 7.1 Hz, 1H), 6.99 (br s, 1H), 6.99 (m, 1H), 6.92

2020415711 20 Jan 2025

(d, J = 8.9 Hz, 1H), 6.87 (d, J = 16.1 Hz, 1H), 6.69 (m, 1H), 5.07 (tm, J = 6.9 Hz, 1H), 3.94 (s, 3H), 3.42 (d, J = 6.9 Hz, 2H), 1.80 (s, 3H), 1.69 (s, 3H); ^{19}F NMR (376 MHz, $CDCl_3$) δ = -56.88 (s, 3F); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 153.95, 148.13, 146.73, 145.92, 139.81, 131.69, 131.66, 129.80, 124.31, 123.25, 122.29, 120.77, 114.64, 110.74, 108.43, 106.97, 55.90, 25.68, 25.02, 17.93.

Compound 11 (KYN-132) can also be synthesised by the modular methodology of the present disclosure using equivalents to Module A, B and C and subsequemt cross coupling alkylation of the aryl halide.

Preparation of 3-(3-Ethoxy-4-hydroxystyryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (12) [KYN-133]:



3-Bromo-5-methoxyphenol (12-2):

2020415711 20 Jan 2025

A mixture of 2-(diethylamino)ethanethiol hydrochloride (46.92 g, 276.5 mmol, 1.2 equiv) in DMF (1000 mL) was cooled in an ice-bath, and sodium *t*-butoxide (55.3 g, 576 mmol, 2.5 equiv) was added in portions while keeping the temperature below 25°C. After stirring for 5 minutes, the reaction was warmed to room temperature. After 5 minutes, **Compound 12-1** (50 g, 230.4 mmol, 1.0 equiv) was added, and the mixture was refluxed (138°C) for 3 hours at which time LCMS analysis indicated that the reaction was complete. The reaction mixture was cooled to 0°C and adjusted to pH 1 with of 1M HCl (~1000 mL), while maintaining the temperature below 20°C. The mixture was extracted with ethyl acetate (4 x 1 L) and the combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. Additional compound 1 (25 g) was processed in a similar way and combined with the above residue. The combined residue was purified on an Interchim automated chromatography system (Sorbtech 330 g column), eluting with a gradient of 10 to 20% ethyl acetate in heptanes to give **Compound 12-2** (60 g, 86% yield) as a light brown solid. (NK-1-5)

1-Bromo-3-methoxy-5-((3-methylbut-2-en-1-yl)oxy)benzene (12-3):

Potassium carbonate powder (82 g, 594.20 mmol, 2 equiv) and 3,3-dimethylallyl bromide (53 g, 355.7 mmol, 1.2 equiv) were added sequentially to a solution of **Compound 12-2** (60 g, 297.02 mmol, 1.0 equiv) in acetone (500 mL) at room temperature. After refluxing (55°C) overnight, the reaction was cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure and the residue was purified on an Interchim automated chromatography system (Sorbtech 220 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give **Compound 12-3** (60 g, 75% yield) as a light brown oil. (NK-1-8)

3-Ethoxy-4-((2-(trimethylsilyl)ethoxy)methoxy)benzaldehyde (12-5):

2-(Trimethylsilyl)ethoxymethyl chloride (3.4 mL, 19 mmol, 1.05 equiv) was added to a solution of **Compound 12-4** (3 g, 18.1 mmol, 1 equiv) and *N,N'*-diisopropylethylamine (9.5 mL, 54.3 mmol, 3 equiv) in dichloromethane (60 mL) at room temperature. The

2020415711 20 Jan 2025

reaction was stirred for 16 hours, at which point LC/MS analysis indicates the reaction was completed. The reaction mixture was washed sequentially with water (100 mL), saturated ammonium chloride (100 mL) and saturated brine (50 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to give **Compound 12-5** (6 g, >theory) as an orange oil, which was used subsequently. (QZH-RCI-34).

(2-((2-Ethoxy-4-vinylphenoxy)methoxy)ethyl)trimethylsilane (12-6):

2.5 M *n*-Butyllithium in hexane (8 mL, 20 mmol, 1.1 equiv) was added to a mixture of methyltriphenylphosphonium bromide (7.1 g, 20 mmol, 1.1 equiv) in tetrahydrofuran (90 mL) at 0°C. After stirring for 30 minutes, a solution of **Compound 12-5** (6 g, 18.1 mmol, 1 equiv) in tetrahydrofuran (20 mL) was added while at such a rate as to maintain the internal temperature of the reaction below 5°C. Hexane (150 mL) was added and the solid resulting solid was filtered. The filtrate was concentrated under reduced pressure. The residue was purified on a Büchi automated chromatography system (80 g column), eluting with a gradient of 0 to 30% ethyl acetate in heptanes to give **Compound 12-6** (4.43 g, 84% yield) as a clear oil. (QZH-RCI-35).

((2-((2-Ethoxy-4-(3-methoxy-5-((3-methylbut-2-en-1-yl)oxy)styryl)phenoxy)methoxy)ethyl)trimethylsilane (12-7):

A mixture of Compound **12-6** (4.43 g, 15 mmol, 1 equiv), 1-bromo-3-methoxy-5-((3-methylbut-2-en-1-yl)oxy)benzene (**12-3**) (4.3 g, 15.8 mmol, 1.05 equiv), palladium(II) acetate (0.34 g, 1.5 mmol, 0.1 equiv), triphenylphosphine (0.79 g, 3 mmol, 0.2 equiv) and potassium carbonate (4.14 g, 30 mmol, 2 equiv) in toluene (130 mL) was sparged with nitrogen for ten minutes. After refluxing for 16 hours, the reaction was cooled to room temperature and diluted with heptanes (150 mL). The solids were removed by filtration and discarded. The filtrate was concentrated under reduced pressure and the residue was purified on a Büchi automated chromatography system (120 g column), eluting with a gradient of 0 to 25% ethyl acetate in heptanes to give Compound **12-7** (3.18 g, 44% yield) as a brown oil. (QZH-RCI-37).

2020415711 20 Jan 2025

2-Ethoxy-4-(3-methoxy-5-((3-methylbut-2-en-1-yl)oxy)styryl)phenol (12-8):

A solution of **Compound 12-7** (3.18 g, 6.56 mmol, 1 equiv) and 1.0 M tetrabutylammonium fluoride in tetrahydrofuran (45.9 mL, 45.9 mmol, 7 equiv) in tetrahydrofuran (32 mL) was refluxed overnight. After cooling to room temperature, water (100 mL) and saturated ammonium chloride (200 mL) was added. The reaction mixture was extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with saturated brine (50 mL), dried over sodium sulfate and concentrated under reduced pressure. The residue was purified on a Büchi automated chromatography system (24 g column), eluting with a gradient of 0 to 35% ethyl acetate in heptanes to give **Compound 12-8** (1.76 g, 76% yield) as a yellow oil. (QZH-RCI-38).

3-(3-Ethoxy-4-hydroxystyryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (12) (KYN-133):

Montmorillonite K10 powder (1.76 g, Sigma-Aldrich, catalog # 69866) was added to a solution of **Compound 12-8** (1.76 g, 4.96 mmol, 1 equiv) in anhydrous dichloromethane (10 mL). The reaction was stirred at room temperature for 24 hours, at which point the LC/MS analysis indicates >90% conversion of the starting material. The reaction mixture was directly absorbed on Celite (25 g) and purified on a Büchi automated chromatography system (80 g column), eluting with a gradient of 0 to 35% ethyl acetate in heptanes to give **Compound 12 [KYN-133]** (0.17 g, 10% yield, 99.4% purity by HPLC%) as an off-white solid.(QZH-RCI-38).


Off-white solid, melting point 126.6 – 129.1°C; HPLC Analysis: 99.4% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 9.1 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=355.2 $(M+H)^+$; $C_{22}H_{26}O_4$; ^1H NMR (400 MHz, $CDCl_3$) δ = 7.12 (d, J = 16.2 Hz, 1H), 6.98 (s, 1H), 6.97 (dd, J = 2.0, 8.5 Hz, 1H), 6.90 (dm, J = 8.6 Hz, 1H), 6.82 (d, J = 15.9 Hz, 1H), 6.64 (d, J = 2.4 Hz, 1H), 6.34 (d, J = 2.4 Hz, 1H), 5.74 (s, 1H), 5.13 (tm, J = 1.4, 6.9 Hz, 1H), 4.85 (s, 1H), 4.14 (q, J = 6.9 Hz, 2H), 3.78 (s,

20 Jan 2025 2020415711

3H), 3.40 (d, J = 6.9 Hz, 2H), 1.80 (d, J = 0.8 Hz, 3H), 1.67 (d, J = 1.2 Hz, 3H), 1.46 (t, J = 7.1 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 158.54, 154.34, 145.93, 145.65, 138.17, 130.58, 130.46, 130.24, 124.19, 123.66, 120.71, 120.44, 114.50, 109.28, 103.94, 98.23, 64.49, 55.68, 25.74, 24.45, 17.93, 14.87.

The compound **12** (KYN-133) can also be synthesised by the modular methodology of the present disclosure using equivalents to Module A, B and C and subsequernt cross coupling alkylation of the aryl halide.

Preparation of (E)-3-(3-Ethyl-4-hydroxystyryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (13) [KYN-114]



3-Bromo-5-methoxyphenol (13-2):

Sodium *t*-butoxide (332.05 g, 3455.3 mmol, 2.5 equiv) was added in portions while keeping the temperature below 25°C to a mixture of 2-(diethylamino)ethanethiol hydrochloride (281.48 g, 1658.5 mmol, 1.2 equiv) in DMF (3000 mL) in an ice-bath.

2020415711 20 Jan 2025

After 5 minutes, the reaction was warmed to room temperature and stirred an additional 5 minutes. Compound **13-1** (300 g, 1382.1 mmol, 1.0 equiv) was added and the mixture was refluxed (138°C) for 3 hours, at which time LCMS indicated that the reaction was complete. After cooling to room temperature, the mixture was cooled in an ice-bath and 1M HCl (~3000 mL) was added adjusting to pH 1. The mixture was extracted with ethyl acetate (3 x 5 L) and the combined organic layers were washed with saturated brine (4 L), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified over silica gel (2.6 kg), eluting with a gradient of 0 to 25% ethyl acetate in heptanes to give compound **13-2** (257.1 g, 92% yield) as a brown solid. (GB-27-172)

1-Bromo-3-methoxy-5-((3-methylbut-2-en-1-yl)oxy)benzene (13-3):

Powdered potassium carbonate \ (350.0 g, 2532.5 mmol, 2 equiv) and 3,3-dimethylallyl bromide (226.45 g, 1519.5 mmol, 1.2 equiv) were added sequentially to a solution of compound **13-2** (257.1 g, 1266.2 mmol, 1.0 equiv) in acetone (7500 mL) at room temperature. After refluxing overnight, the reaction was cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure and the residue was purified on a Biotage-150 column, eluting with a gradient of 0 to 10% ethyl acetate in heptanes to give compound **13-3** (358.0 g, >100% yield) as a brown oil. (GB-27-174)

3-Methoxy-5-((3-methylbut-2-en-1-yl)oxy)benzaldehyde (13-4): 2.5M *n*-Butyllithium in hexanes (557 mL, 1392.6 mmol, 1.1 equiv) was added dropwise, while keeping the temperature below -70°C, to a solution of compound **13-3** (358.0 g, ~1266.2 mmol, 1.0 equiv) in anhydrous THF (7000 mL) at -75°C. After stirring at -75°C for 30 minutes, anhydrous DMF (147 mL, 1899.0 mmol, 1.5 equiv) was added dropwise while keeping the temperature below -70°C. The resulting mixture was allowed to slowly warm to room temperature overnight. Ice-cold water (500 mL) was added to quench the reaction. The mixture was diluted with ethyl acetate (5 L) and the layers were separated. The organic layer was washed with saturated brine (500 mL). The combined aqueous layers were extracted with ethyl acetate (2 x 500 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated

2020415711 20 Jan 2025

under reduced pressure. The residue was purified on a Biotage-150 column, eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **13-4** (221.5 g, 79% overall yield for two steps) as a yellow oil. (GB-27-175)

(3-Methoxy-5-((3-methylbut-2-en-1-yl)oxy)phenyl)methanol (13-5):

Sodium borohydride (38.04 g, 1005.6 mmol, 1.0 equiv) was added in portions, while keeping the temperature below 10°C, to a solution of compound **13-4** (221.5 g, 1005.6 mmol, 1.0 equiv) in methanol (3500 mL) at 0°C. After stirring at 5-10°C for 1 hour, water (200 mL) was added to quench the reaction. The mixture was concentrated under reduced pressure to remove most of methanol. The residue was diluted with ethyl acetate (2.5 L) and washed with saturated brine (600 mL). The aqueous layer was extracted with ethyl acetate (2 x 500 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give compound **13-5** (218.61 g, 98% yield) as a yellow oil, which was used subsequently. (GB-27-178)

1-(Bromomethyl)-3-methoxy-5-((3-methylbut-2-en-1-yl)oxy)benzene (13-6):

Carbon tetrabromide (358.76 g, 1081.84 mmol, 1.1 equiv) was added to a solution of compound **13-5** (218.61 g, 983.49 mmol, 1.0 equiv) in dichloromethane (4400 mL) at room temperature. The resulting mixture was cooled to 0°C, and triphenylphosphine (283.76 g, 1081.84 mmol, 1.1 equiv) was added in portions. After stirring at room temperature for 4 hours, the mixture was concentrated under reduced pressure. The residue was purified on a Biotage-150 column, eluting with a gradient of 0 to 10% ethyl acetate in heptanes to give compound **13-6** (273.76 g, 97% yield) as a yellow oil. (GB-27-181) **Note:** Compound **13-6** appears unstable when purified on some prepacked silica gel columns.

Diethyl (3-methoxy-5-((3-methylbut-2-en-1-yl)oxy)benzyl)phosphonate (13-7):

1M lithium hexamethyldisilylazide in THF (6.57 mL, 6.57 mmol, 1.8 equiv) was added to a solution of diethyl phosphite (0.94 mL, 7.3 mmol, 2.0 equiv) in anhydrous THF

2020415711 20 Jan 2025

(20 mL) at 0°C. After stirring at 0°C for 30 minutes, a solution of compound **13-6** (1.04 g, 3.65 mmol, 1.0 equiv) in anhydrous THF (10 mL) was added and the mixture was stirred at room temperature overnight. The reaction was quenched with water (30 mL) and the mixture was washed with saturated brine (30 mL). The aqueous layer was extracted with ethyl acetate (2 x 60 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (400 g column), eluting with a gradient of 0 to 10% methanol in dichloromethane to give compound **13-7** (1.10 g, 88% yield) as a brown oil. (LM-1-41)

3-Ethyl-4-hydroxybenzaldehyde (13-9): [1,1′-Bis(diphenylphosphino)ferrocene] dichloropalladium(II) (2.18 g, 2.98 mmol, 0.05 equiv) and cesium carbonate (38.9 g, 119.4 mmol, 2 equiv) were added to a solution of 3-bromo-4-hydroxylbenzaldehyde (**13-8**) (12 g, 59.7 mmol, 1 equiv) in anhydrous THF (150 mL). 1M Triethylborane solution in THF (119.4 mL, 119.4 mmol, 1.8 equiv) was added and the mixture was refluxed (66°C) overnight. After cooling room temperature, the reaction was diluted with water (100 mL) and extracted with ethyl acetate (2 x 250 mL). The combined organic layers were washed with saturated brine (200 mL), dried over sodium sulfate, and concentrated under reduced pressure. Crude residue was purified initially on an InterChim Automated Chromatography System (220 g column), eluting with a gradient of 0 to 40% ethyl acetate in heptanes. A second purification on an InterChim Automated Chromatography System (80 g column), eluting with a gradient of 0 to 40% ethyl acetate in heptanes to give compound **13-9** (5.21 g, 58% yield) as a brown oil. (LM-1-2)

3-Ethyl-4-((2-(trimethylsilyl)ethoxy)methoxy)benzaldehyde (13-10): 2-(Trimethylsilyl)ethoxymethylchloride (6.1 mL, 34.52 mmol, 1.1 equiv) was added to a solution of compound **13-9** (4.71 g, 31.38 mmol, 1 equiv) in anhydrous dichloromethane (120 mL). Diisopropylethylamine (8.2 mL, 47.07 mmol, 1.5 equiv) was added and the mixture was stirred for 2 hours at room temperature. The reaction mixture was quenched with saturated sodium bicarbonate (50 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over sodium

2020415711 20 Jan 2025

sulfate and concentrated under reduced pressure. The crude residue was purified initially on an InterChim Automated Chromatography System (220 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes. A second purification on an InterChim Automated Chromatography System (120 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **13-10** (6.77 g, 77% yield) as a clear oil. (LM-1-4)

(E)-(2-((2-Ethyl-4-(3-methoxy-5-((3-methylbut-2-en-1-yl)oxy)styryl)phenoxy)methoxy)ethyl)trimethylsilane (13-11):

1.0M Potassium t-butoxide solution in THF (11.7 mL, 11.68 mmol, 2 equiv) was added dropwise to a cooled solution of diethyl (3-methoxy-5-((3-methylbut-2-en-1-yl)oxy)benzyl)phosphonate (**13-7**) (2 g, 5.84 mmol, 1 equiv) in anhydrous THF (20 mL) at 0°C. After stirring for 15 minutes at room temperature, a solution of compound 9 (2.5 g, 8.76 mmol, 1.5 equiv) in anhydrous THF (5 mL) was added dropwise. The reaction mixture was stirred overnight at room temperature then quenched with saturated brine (50 mL) and extracted with ethyl acetate (200 mL). The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude residue was purified on an Interchim Automated Chromatography System (80 g column), eluting with a gradient of 0 to 30% ethyl acetate in heptanes to give compound **13-11** (1.32 g, 48% yield) as a clear oil. (CSK-2-97)

(E)-2-Ethyl-4-(3-methoxy-5-((3-methylbut-2-en-1-yl)oxy)styryl)phenol (13-12):

1.0M Tetrabutylammonium fluoride in THF (19.7 mL, 19.7 mmol, 7 equiv) was added to a solution of compound **13-11** (1.32 g, 2.81 mmol, 1 equiv) in anhydrous THF (20 mL) and resulting mixture was refluxed overnight. Reaction mixture was cooled to room temperature and diluted with water (25 mL). The mixture was extracted with ethyl acetate (100 mL). The organic layer was washed with saturated brine (25 mL), dried over sodium sulfate, and concentrated under reduced pressure. The crude residue was purified initially on an InterChim Automated Chromatography System (80 g column), eluting with a gradient of 0 to 100% ethyl acetate in heptanes. A second

2020415711 20 Jan 2025

purification on an InterChim Automated Chromatography System (40 g column), eluting with a gradient of 0 to 30% ethyl acetate in heptanes gave compound **13-12** (770 mg, 80% yield) as a thick clear oil. (CSK-2-98)

(E)-3-(3-Ethyl-4-hydroxystyryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (13) [KYN-114]:


Montmorillonite K30 (620 mg) was added to a solution of compound **13-12** (620 mg, 1.83 mmol, 1 equiv) in anhydrous dichloromethane (12 mL) and resulting mixture was stirred at room temperature overnight. Mixture was filtered through a Celite pad, which was rinsed with dichloromethane (50 mL). The filtrate was concentrated under reduced pressure. The crude residue was purified on an Interchim Automated Chromatography System (25 g column) eluting with a gradient of 0 to 30% ethyl acetate in heptanes to give compound **13 [KYN-114]** (120 mg, 19% yield) as an off-white solid. (CSK-2-99)

^{1}H NMR (400 MHz, Methanol-d_3) δ = 7.22 (d, J = 2.2 Hz, 1H), 7.13 (dd, J = 2.0, 8.3 Hz, 1H), 7.11 (d, J = 16.1 Hz, 1H), 6.83 (d, J = 16.1 Hz, 1H), 6.72 (d, J = 8.3 Hz, 1H), 6.63 (d, J = 2.2 Hz, 1H), 6.33 (d, J = 2.2 Hz, 1H), 5.06 (septett, J = 1.4, 6.8 Hz, 1H), 3.77 (s, 3H), 3.37 (br d, J = 6.6 Hz, 2H), 2.62 (q, J = 7.5 Hz, 2H), 1.80 (d, J = 1.0 Hz, 3H), 1.67 (d, J = 1.2 Hz, 3H), 1.21 (t, J = 7.5 Hz, 3H); ^{13}C NMR (100 MHz, Methanol-d_3) δ = 159.69, 157.12, 156.09, 139,51, 131.92, 131.12, 130.70, 128.30, 126.20, 125.49, 124.54, 115.95, 104.67, 98.95, 55.96, 25.87, 25.09, 24.26, 18.06, 14.68.

The compound of KYN-114 can also be synthesised by the modular methodology of the present disclosure using equivalents to Module A, B and C and subsequernt cross coupling alkylation of the aryl halide.

[0002] Preparation of (E)-3-(4-hydroxy-3-(methylthio)styryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (14) [KYN-118]

2020415711 20 Jan 2025



3-(Methylthio)-4-((2-(trimethylsilyl)ethoxy)methoxy)benzaldehyde (14-2):

N,*N*-Diisopropylethylamine (0.78 mL, 4.46 mmol, 1.5 equiv) and 2-(trimethylsilyl)ethoxymethyl chloride (0.63 mL, 3.57 mmol, 1.2 equiv) were added sequentially to a solution of compound **14-1** (0.50 g, 2.97 mmol, 1.0 equiv) in anhydrous dichloromethane (30 mL) at room temperature and stirred at room temperature overnight. Another reaction of equal scale was combined and quenched with saturated sodium bicarbonate (50 mL). The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (80 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **14-2** (1.67 g, 94% yield) as a pale yellow oil. (LM-1-39 and LM-1-40)

(*E*)-(2-((4-(3-Methoxy-5-((3-methylbut-2-en-1-yl)oxy)styryl)-2-(methylthio)phenoxy)methoxy)ethyl)trimethylsilane (14-3):

A solution of compound **13-7** (1.1 g, 3.2 mmol, 1.0 equiv) in anhydrous THF (10 mL) was added dropwise to 60% dispersion of sodium hydride in mineral oil (257 mg, 6.4

2020415711 20 Jan 2025

mmol, 2.0 equiv) in anhydrous THF (20 mL) at 0°C. The mixture was warmed to room temperature and stirred for 30 minutes. A solution of compound **14.2** (0.955 g, 3.2 mmol, 1.0 equiv) in anhydrous THF (10 mL) was then added dropwise and the mixture was stirred at room temperature overnight. The reaction was quenched with water (30 mL) and the mixture was washed with saturated brine (70 mL).

The aqueous layer was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (40 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **14-3** (1.01 g, 79% yield based on 0.17 g recovered starting material compound **14.2**) as a yellow oil. (LM-1-42)

(*E*)-4-(3-Methoxy-5-((3-methylbut-2-en-1-yl)oxy)styryl)-2-(methylthio)phenol (14.4):

1M Tetrabutylammonium fluoride in THF (7 mL, 7 mmol, 7 equiv) was added to a solution of compound **14.3** (0.486 g, 1.0 mmol, 1.0 equiv) in anhydrous THF (10 mL) at room temperature. After refluxing overnight, the mixture was cooled to room temperature and diluted with water (20 mL) and ethyl acetate (50 mL). The layers were separated and the organic layer was washed with saturated brine (30 mL). The combined aqueous layers were extracted with ethyl acetate (2 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (25 g column), eluting with a gradient of 0 to 30% ethyl acetate in heptanes to give compound **14.4** (0.25 g, 70% yield) as a brown oil. (LM-1-43)

(*E*)-3-(4-Hydroxy-3-(methylthio)styryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (14): Montmorillonite K30 powder (Aldrich# 69866, 0.25 g) was added to a solution of compound **14.4** (0.25 g, 0.7 mmol) in anhydrous dichloromethane (15 mL) at room temperature, and the mixture was stirred at room temperature overnight, at which point LCMS indicated that the reaction was complete. The mixture was filtered

2020415711 20 Jan 2025

and the solid rinsed with dichloromethane (2 x 15 mL). The combined filtrate was concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (25 g column, 20-45 um), eluting with a gradient of 0 to 40% ethyl acetate in heptanes to give a mixture of compounds **14A**, **14B** and **14** (0.18 g, 70% combined yield). (LM-1-44)

Additional compound **14-4** (0.27 g) of **11** used) was processed in same manner, and to give a mixture of compounds **14A**, **14B** and **14** (0.22 g, 81% combined yield). (LM-1-46)

Crude compounds **14A**, **14B** and **14** (LM-1-44 and LM-1-46) were further purified on an Interchim automated chromatography system (25 g column, 20-45 um), eluting with a gradient of 0 to 40% ethyl acetate in heptanes to give compound **14B** (50 mg, 10% yield) as a pale-yellow solid, compound **14B** (100 mg, 19% yield) as a pale-yellow solid and compound **14** (170 mg, 33% yield) as a white solid. (LM-1-54A, LM-1-54B and LM-1-54C). ***Note:*** *The three compounds structures were determined at the University of Florida by NMR.*

Compound **14** can also be synthesised by the modular methodology of the present disclosure using equivalents to Module A, B and C and subsequernt cross coupling alkylation of the aryl halide.


(*E*)-3-(4-Hydroxy-3-(methylthio)styryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (14) [KYN-118]:

White solid, melting point 124.5 – 125.2°C; HPLC Analysis: 98.9% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 9.00 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=357.1 $(M+H)^+$; $C_{21}H_{24}O_3S$; ^1H NMR (400 MHz, $CDCl_3$) δ = 7.60 (d, J = 2.2 Hz, 1H), 7.37 (dd, J = 2.2, 8.3 Hz, 1H), 7.17 (d, J = 16.2 Hz, 1H), 6.98 (d, J = 8.3 Hz, 1H), 6.82 (d, J = 16.1 Hz, 1H), 6.66 (s, 1H), 6.65 (d, J = 2.5 Hz, 1H), 6.36 (d, J = 2.5 Hz, 1H), 5.11 (septett, J = 1.3, 6.8 Hz, 1H), 4.71 (br s, 1H), 3.80 (s, 3H), 3.41

20 Jan 2025 2020415711

(br d, J = 6.8 Hz, 2H), 2.36 (s, 3H), 1.81 (d, J = 1.0 Hz, 3H), 1.68 (d, J = 1.2 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 158.61, 155.89, 154.39, 138.04, 132.98, 131.00, 130.83, 129.29, 128.98, 125.01, 123.58, 121.37, 120.92, 115.13, 103.93, 98.39, 55.74, 25.79, 24.47, 19.90, 17.98.

(*E*)-3-(4-Hydroxy-3-(methylamino)styryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (15) [KYN-158]



3-Nitro-4-((2-(trimethylsilyl)ethoxy)methoxy)benzaldehyde (15-2):

2-(Trimethylsilyl)ethoxymethyl chloride (17.9 g,166.70 mmol, 1.2 equiv) and *N*,*N*-diisopropylethylamine (24.0 mL, 134.73 mmol, 1.5 equiv) were sequentially added to a solution of compound **15-1** (15.0 g, 89.82 mmol, 1.0 equiv) in dichloromethane (150 mL) at room temperature. After stirring for 16 hours, the reaction mixture was diluted with saturated sodium bicarbonate (150 mL).The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 100 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 80 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **15-2** (23.5 g, 88% yield) as a yellow oil (NRK-1-179).

2020415711 20 Jan 2025

(3-Nitro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)methanol (15-3):

Sodium borohydride (2.92 g, 79.12 mmol, 1.0 equiv) was added in two portions to a solution of compound **15-2** (23.5 g, 79.12 mmol, 1.0 equiv) in methanol at 0°C. The resulting solution was stirred at room temperature for 1 hour. The reaction mixture was quenched with water (20 mL). The volatiles were removed under reduced pressure and the resulting crude residue was dissolved in ethyl acetate (150 mL) and washed with saturated ammonium chloride (100 mL). The aqueous layer was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over sodium sulfate and evaporated under reduced pressure to give compound **15-3** (23.7 g, 99% yield) as an orange oil, which was used subsequently. (NRK-1-120)

Diethyl (4-hydroxy-3-nitrobenzyl)phosphonate (15-4):

Zinc iodide (21.31 g, 66.80 mmol, 2.0 equiv) was added to triethylphosphite (11.5 mL, 66.80 mmol, 2.0 equiv). After stirring for 15 minutes at room temperature a solution of compound **15-3** (10.0 g, 33.40 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (100 mL) was added. The resulting solution was refluxed (66°C) for 4 hours. After cooling to room temperature, the volatiles were removed under reduced pressure. The crude residue was dissolved in ethyl acetate (150 mL) and washed with 1M sodium hydroxide (150 mL). The aqueous layer was neutralized with 1M HCL (250 mL). The resulting aqueous layer was extracted with ethyl acetate (3 x 200 mL). The combined organic layers were dried over sodium sulfate and evaporated under reduced pressure to give compound **15-4** (7.12 g, 76% yield) as a yellow oil, which was used subsequently. (NRK-1-187)

Diethyl (3-nitro-4-((2-(trimethylsilyl)ethoxy)methoxy)benzyl)phosphonate (15-5):

2-(Trimethylsilyl)ethoxymethyl chloride (4.1 g,24.63 mmol, 1.0 equiv) and *N*,*N*-diisopropylethylamine (6.5 mL, 36.94 mmol, 1.5 equiv) were sequentially added to a solution of compound **15-4** (7.12 g, 24.63 mmol, 1.0 equiv) in dichloromethane (100 mL) at room temperature. After stirring for 20 hours, the reaction mixture was diluted

2020415711 20 Jan 2025

with saturated sodium bicarbonate (100 mL).The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 50 mL). -The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give compound **15-5** (9.45 g, 92% yield) as a yellow oil, which was used subsequently. (NRK-1-189)

(*E*)-(2-((4-(2-Bromo-3-methoxy-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-2-nitrophenoxy)methoxy)ethyl)trimethylsilane (15-6):

A 60% dispersion of sodium hydride in mineral oil (3.6 g, 90.24 mmol, 4 equiv) was added in 5 portions to a solution of compound **15-5** (9.45 g, 22.56 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (100 mL) at 0°C. The mixture was warmed up to room temperature and stirred for 30 minutes. A solution of **A8 (Module A)** (8.15 g, 22.56 mmol, 1 equiv) in anhydrous tetrahydrofuran (20 mL) was added dropwise and the mixture was stirred at room temperature for 16 hours. The reaction was carefully quenched with saturated brine (20 mL, 1 drop per minute for the first 5 mL brine) at 0 oC. The volatiles were removed under reduced pressure. Saturated ammonium chloride (100 mL) was added. The mixture was extracted with ethyl acetate (2 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was first purified on a Reveleris automated chromatography system (Sorbtech 330 g column), eluting with a gradient of 0 to 10% ethyl acetate in heptanes. The product was further purified on a Reveleris automated chromatography system (Sorbtech 330 g column) eluting with a gradient of 0 to 10% ethyl acetate in heptanes to give compound **15-6** (1.63 g, 12% yield) as a yellow oil. (NRK-1-190)

(*E*)-(2-((4-(3-Methoxy-2-(3-methylbut-2-en-1-yl)-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-2-nitrophenoxy)methoxy)ethyl)trimethylsilane (15-7):

Tetrakis(triphenylphosphine)palladium(0) (300 mg, 0.26 mmol, 0.1 equiv), potassium carbonate (710 mg, 5.2 mmol, 2 equiv), 3-methylbut-2-enylboronic acid pinacol ester

2020415711 20 Jan 2025

(1.01 g, 5.2 mmol, 2 equiv) and water (2 mL) were added sequentially to a solution of compound **15-6** (1.6 g, 2.60 mmol, 1 equiv) in 1,4-dioxane (20 mL) in a sealed tube. After sparging with nitrogen for 10 minutes, the reaction was heated at 100°C for 16 hours. After cooling to room temperature, the reaction mixture was filtered through Celite. The filtrate was evaporated under reduced pressure. The residue was suspended in saturated sodium bicarbonate (100 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 80 g column), eluting with a gradient of 0 to 10% ethyl acetate in heptanes to give compound **15-7** (1.8 g, >100% yield) as an orange oil. (NRK-6-25)

(*E*)-3-(4-Hydroxy-3-nitrostyryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (15-8):

1M Tetrabutylammonium fluoride in tetrahydrofuran (41 mL, 40.92 mmol, 14 equiv) was added to a solution of compound **15-7** (1.8 g, 2.92 mmol, 1 equiv) in tetrahydrofuran (20 mL) at room temperature. After heating at 67°C for 16 hours, the mixture was cooled to room temperature and diluted with water (20 mL) and saturated ammonium chloride (100 mL). The volatiles were removed under reduced pressure and the remaining aqueous layer was extracted with ethyl acetate (2 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 80 g column), eluting with a gradient of 0 to 80% ethyl acetate in heptanes to give compound **15-8** (370 mg, 36% yield) as a yellow solid. (NRK-6-26)

(*E*)-3-(3-Amino-4-hydroxystyryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (15-9):

Activated zinc powder (680 mg, 10.4 mmol, 10.0 equiv), ammonium chloride (560 mg, 10.4 mmol, 10.0 equiv) and water (6 mL) were added sequentially to a solution of

2020415711 20 Jan 2025

compound **15-8** (370 mg, 1.04 mmol, 1.0 equiv) in tetrahydrofuran (20 mL) at room temperature. The resulting suspension was stirred at room temperature for 16 hours. The suspension was filtered through Celite and the solids were washed with ethyl acetate (20 mL). The filtrate was evaporated to dryness under reduced pressure. The residue was suspended in saturated ammonium chloride (50 mL) and extracted with ethyl acetate (2 x 30 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give compound **15-9** (270 mg, 81% yield) as an off white solid, which was used subsequently. (NRK-6-32)


(*E*)-3-(4-Hydroxy-3-(methylamino)styryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (15):

37%wt% Aqueous formaldehyde (52µL, 0.62 mmol. 2.0 equiv) and sodium triacetoxyborohydride (262 mg, 1.24 mmol, 4.0 equiv) were sequentially added to a solution of compound **15-9** (100 mg, 0.31 mmol, 1.0 equiv) in dichloromethane (10 mL). The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with dichloromethane (20 mL) and washed with saturated sodium bicarbonate (15 mL). The aqueous layer was extracted with dichloromethane (2 x 10 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was initially purified on a Reveleris automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 100% ethyl acetate in heptanes to give compound **15 [KYN-158]** (52 mg, 52% yield) as an off white solid. (NRK-6-40)

NOTE: *In a trial run, compound **15-9** (50 mg) was converted to compound **15** using conditions as described above. Purification of crude **15** obtained from this reaction on a Reveleris automated chromatography system (Redisep Rf Gold HP C18, 50 g column), eluting with a gradient of 0 to 80% acetonitrile in water, resulted in the formation of an impurity (with mass m/z = 2M-1). LCMS analysis indicated that the ratio of this impurity over **15**, increased over a period of time. A similar result was obtained when a solution of compound **15** was allowed to stand in methanol for 16 hours, thus suggesting that compound **15** might be unstable in solution.*

2020415711 20 Jan 2025

(*E*)-3-(3-(Dimethylamino)-4-hydroxystyryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (16) [KYN-157]



(*E*)-5-(3-Methoxy-2-(3-methylbut-2-en-1-yl)-5-((2-(trimethylsilyl) ethoxy)methoxy)styryl)-2-((2-(trimethylsilyl)ethoxy)methoxy)aniline) (16-1):

Activated zinc powder (1.89 g, 29.1 mmol, 10.0 equiv), ammonium chloride (1.57 g, 29.1 mmol, 10.0 equiv) and water (3 mL) were added sequentially to a solution of compound **15-7** (1.79 g, 2.91 mmol, 1.0 equiv) in tetrahydrofuran (50 mL) at room temperature. The resulting suspension was stirred at room temperature for 16 hours. The suspension was filtered and the solids were washed with ethyl acetate (20 mL). The filtrate was evaporated to dryness under reduced pressure. The residue was suspended in saturated ammonium chloride (30 mL), and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give compound **16-1** (1.7 g, 99% yield) as a light yellow oil, which was used subsequently. (NRK-1-199)

(*E*)-5-(3-Methoxy-2-(3-methylbut-2-en-1-yl)-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-*N*,*N*-dimethyl-2-((2-(trimethylsilyl)ethoxy)methoxy)aniline (16-2):

2020415711 20 Jan 2025

37%wt% Aqueous formaldehyde (37 µL, 0.46 mmol. 1.0 equiv) and sodium triacetoxyborohydride (196 mg, 0.92 mmol, 2.0 equiv) were sequentially added to a solution of compound **16-1** (267 mg, 0.46 mmol, 1.0 equiv) in dichloromethane (10 mL). The reaction mixture was stirred at room temperature for 30 minutes. LCMS analysis indicated the formation of both mono and di *N*-methylated products. Additional formaldehyde solution (0.5 mL, excess) was added to the reaction mixture and stirred at room temperature for 16 hours. The reaction mixture was diluted with dichloromethane (20 mL) and washed with saturated sodium bicarbonate (20 mL). The aqueous layer was extracted with dichloromethane (2 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was initially purified on a Reveleris automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 15% ethyl acetate in heptanes. The resulting product was further purified on a Reveleris automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 15% ethyl acetate in heptanes to give compound **16-2** (194 mg, 69% yield) as a light yellow oil. (NRK-1-198)

(*E*)-3-(3-(Dimethylamino)-4-hydroxystyryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (16) [KYN-157]: 1M Tetrabutylammonium fluoride in tetrahydrofuran (4.5 mL, 4.42 mmol, 14 equiv) was added to a solution of compound **16-2** (194 mg, 0.32 mmol, 1 equiv) in tetrahydrofuran (10 mL) at room temperature. After heating at 67°C for 8 hours, the mixture was cooled to room temperature and diluted with water (20 mL) and saturated ammonium chloride (20 mL). The volatiles were removed under reduced pressure and the remaining aqueous layer was extracted with ethyl acetate (3 x 30 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Redisep Rf Gold HP C18, 50 g column), eluting with a gradient of 0 to 60% acetonitrile in water to give compound **16 [KYN-157]** (40 mg, 36% yield) as a pale yellow solid. (NRK-1-201)


Pale yellow solid, melting point 45 – 53°C; HPLC Analysis: 97.0% purity; Wavelength 210 nm, bandwidth 4; Column: Water Atlantis T3, 2.1 x 50 mm, 3 µm; Retention

2020415711 20 Jan 2025

Time: 5.75 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=354.2 $(M+H)^+$; $C_{22}H_{27}NO_3$; ^1H NMR (400 MHz, $CDCl_3$) δ = 7.31 (d, J = 2.0 Hz, 1H), 7.17 (dd, J = 2.0, 8.3 Hz, 1H), 7.14 (d, J = 16.1 Hz, 1H), 6.92 (d, J = 8.3 Hz, 1H), 6.84 (d, J = 16.0 Hz, 1H), 6.67 (d, J = 2.3 Hz, 1H), 6.37 (d, J = 2.3 Hz, 1H), 5.12 (septett, J = 1.3, 6.8 Hz, 1H), 3.79 (s, 3H), 3.41 (br d, J = 6.8 Hz, 2H), 2.69 (s, 6H), 1.82 (s, 3H), 1.69 (d, J = 1.0 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 158.55, 154.55, 151.23, 140.76, 138.25, 130.52, 130.27, 130.07, 124.75, 124.06, 123.76, 120.54, 118.70, 114.21, 103.93, 98.24, 55.69. 45.14 (2C), 25.77, 24.47, 17.98.

Preparation of Compound 17 [KYN-120]

(E)-4-(5-Hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxy-6-methylphenol (17)



2020415711 20 Jan 2025

4-Bromo-2-methoxy-6-methylphenol (17-5):

N-Bromosuccinimide (5.15 g, 28.98 mmol, 1 equiv) was added to a solution of compound **17-4** (4 g, 28.98 mmol, 1.0 equiv) in acetic acid (60 mL) at room temperature. After stirring at room temperature overnight, the volatiles were removed under reduced pressure. The residue was diluted with water (200 mL) and extracted with ethyl acetate (3 X 60 mL). The combined organic layer was washed with saturated sodium bicarbonate (100 mL) dried over sodium sulfate filtered, and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (Sorbtech 12 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **17-5** (7 g, 99% yield) as a colorless oil. (NK-1-35)

(2-((4-Bromo-2-methoxy-6-methylphenoxy)methoxy)ethyl)trimethylsilane (17-6):

N,N-Diisopropylethylamine (3.6 mL, 20.73 mmol, 1.5 equiv) and 2-(trimethylsilyl)ethoxymethyl chloride (2.9 mL, 16.58 mmol, 1.2 equiv) were sequentially added to a solution of compound **17-5** (3 g, 13.82 mmol, 1.0 equiv) in anhydrous dichloromethane (60 mL) at room temperature. After stirring overnight, saturated ammonium chloride (100 mL) was added. The aqueous layer was extracted with dichloromethane (3 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (Sorbtech 12 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **17-6** (2.37 g, 88% yield) as a pale-yellow oil. (NK-1-29)

(2-((2-Methoxy-6-methyl-4-vinylphenoxy)methoxy)ethyl)trimethylsilane (17-7):

Potassium vinyltrifluoroborate (1.08 g, 8.06 mmol, 1.4 equiv), triethylamine (1.3 mL, 9.2 mmol, 1.6 equiv) and $Pd(dppf)Cl_2$ (210 mg, 0.029 mmol, 0.05 equiv) were added to

2020415711 20 Jan 2025

a solution of compound **17-6** (2.0 g, 5.75 mmol, 1.0 equiv) in 2-propanol (40 mL). After sparging with nitrogen for 10 minutes, the mixture was refluxed (80°C) for 16 hours. The reaction was cooled to room temperature and filtered through celite (~ 5 g). The filtrate was concentrated under reduced pressure, diluted with saturated sodium bicarbonate (20 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **17-7** (1.06 g, 65% yield) as a colorless oil. (NK-1-34)

(E)-(2-((2-Methoxy-4-(3-methoxy-5-((3-methylbut-2-en-1-yl)oxy)styryl)-6-methylphenoxy)methoxy)ethyl)trimethylsilane (17-8):

1-Bromo-3-methoxy-5-((3-methylbut-2-en-1-yl)oxy)benzene (17-3) (1.49 g, 5.26 mmol, 1.2 equiv), triphenylphosphine (114 mg, 0.438 mmol, 0.1 equiv), potassium acetate (850 mg, 8.76 mmol, 2 equiv) and palladium acetate (50 mg, 0.219 mmol, 0.05 equiv) were added to a solution of compound **17-7** (1.29 g, 4.38 mmol, 1.0 equiv) in anhydrous toluene (60 mL). After sparging with nitrogen for 15 minutes, the mixture was refluxed (110°C) for 16 hours. The reaction mixture was cooled to room temperature and filtered through celite (~ 5 g). The filtrate was transferred to a separatory funnel containing saturated sodium bicarbonate 20 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (2x20 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 30% ethyl acetate in heptanes to give compound **17-8** (420 mg, 20% yield) as a colorless oil. (NK-1-40)

1M Tetrabutylammonium fluoride in THF (6.1 mL, 6.06 mmol, 7 equiv) was added to a solution of compound **17-8** (420 mg, 0.86 mmol, 1 equiv) in anhydrous THF (40 mL) at room temperature. After refluxing overnight (66°C), LCMS indicated that the reaction was complete. The mixture was cooled to room temperature and diluted with

2020415711 20 Jan 2025

water (10 mL). The organic volatiles were removed under reduced pressure and diluted with ethyl acetate (20 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (Sorbtech 14 g column), eluting with a gradient of 0 to 50% ethyl acetate in heptanes to give **Compound 17-9** (220 mg, 73% yield) as a yellow oil. (NK-1-41)

(E)-4-(5-Hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxy-6-methylphenol (17) [KYN-120]:

Montmorillonite K30 powder (220 mg) was added to a solution of **Compound 17-9** (220 mg, 0.45 mmol) in anhydrous dichloromethane (20 mL) at room temperature. After stirring at room temperature overnight, LCMS indicated that 30-40% of desired compound 10 was formed, along with two regioisomers and unreacted starting compound 9. The mixture was filtered, washed with dichloromethane (2 x 15 mL) and the filtrate was concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (Sorbtech 12 g column), eluting with a gradient of 0 to 50% ethyl acetate in heptanes. Trituration with 30% dichloromethane in heptanes (10 mL) gave pure compound **17 [KYN-120]** (38 mg, 17% yield) as a white solid. (NK-1-42-S3)


White solid, melting point 140.3 – 140.4°C; HPLC Analysis: 97.6% purity; Wavelength 210 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 9.29 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=355 $(M+H)^+$; $C_{22}H_{26}O_4$; ^1H NMR (400 MHz, $CDCl_3$) δ = 7.14 (d, J = 16.1 Hz, 1H), 6.88 (m, 1H), 6.87 (m, 1H), 6.83 (d, J = 16.1 Hz, 1H), 6.65 (d, J = 2.5 Hz, 1H), 6.35 (d, J = 2.5 Hz, 1H), 5.72 (d, J = 0.5 Hz, 1H), 5.13 (tm, J = 1.4, 6.9 Hz, 1H), 4.60 (s, 1H), 3.92 (s, 3H), 3.80 (s, 3H), 3.42 (br d, J = 6.9 Hz, 2H), 2.27 (s, 3H), 1.82 (d, J = 1.0 Hz, 3H), 1.69 (d, J = 1.2 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 158.58, 154.34, 146.37, 143.77, 138.32, 130.62, 130.53, 129.17, 124.00, 123.87,

2020415711 20 Jan 2025

123.73, 122.35, 120.71, 105.96, 103.87, 98.13, 56.00, 55.71, 25.78, 24.49, 17.97, 15.45.

Compound **17** can also be synthesised by the modular methodology of the present disclosure using equivalents to Module A, B and C and subsequernt cross coupling alkylation of the aryl halide.

(*E*)-5-(5-Hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-3-methoxybenzene-1,2-diol (18) [KYN-156]



3-Methoxy-4,5-bis((2-(trimethylsilyl)ethoxy)methoxy)benzaldehyde (18-2):

N,*N*-Diisopropylethylamine (3.14 mL, 18 mmol, 3.0 equiv) and 2-(trimethylsilyl)ethoxymethyl chloride (2.53 mL, 14.3 mmol, 2.4 equiv) were added sequentially to a solution of compound **18-1** (1.0 g, 6 mmol, 1.0 equiv) in a 1:1:2 mixture of anhydrous tetrahydrofuran/dimethylformamide/dichloromethane (80 mL) at room temperature. After stirring at room temperature for 16 hours, a saturated sodium bicarbonate (100 mL) was added to quench the reaction. The layers were separated and the aqueous layer was extracted with methyl *tert*-butyl ether (2 x 250 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (80 g column), eluting with a gradient of 0 to 35% ethyl

2020415711 20 Jan 2025

acetate in heptanes to give compound **18-2** (2 g, 78% yield) as a colorless oil. (LM-6-96)

(3-Methoxy-4,5-bis((2-(trimethylsilyl)ethoxy)methoxy)phenyl)methanol (18-3):

Sodium borohydride (176 mg, 4.66 mmol, 1.0 equiv) was added in one portion solution of compound **18-2** (2 g, 4.66 mmol, 1.0 equiv) in methanol (50 mL) at 0°C. After stirring at 0°C for 1 hour, water (50 mL) was added to quench the reaction. The mixture was concentrated under reduced pressure to remove most of methanol. The residue was diluted with saturated brine (50 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers was dried over sodium sulfate, filtered and concentrated under reduced pressure to give compound **18-3** (2 g) as a colorless oil, which was used subsequently. (LM-6-104).

Diethyl (3-methoxy-4,5-bis((2-(trimethylsilyl)ethoxy)methoxy)benzyl)phosphonate (18-4):

Zinc iodide (2.97 g, 9.32 mmol, 2.0 equiv) and triethyl phosphite (1.6 mL, 9.32 mmol, 2.0 equiv) were added sequentially to a solution of compound **18-3** (2 g, 4.66 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (100 mL) at room temperature. The mixture was refluxed (68°C) for 16 hours. After cooling to room temperature, water (50 mL), potassium carbonate (1.61 g, 2.5 equiv) and methyl *tert*-butyl ether (200 mL) were added sequentially. The mixture was filtered through a pad of Celite (20 g), which was rinsed with ethyl acetate (300 mL). The layers were separated and the organic layer was washed with saturated brine (100 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (80 g column), eluting with a gradient of 0 to 100% ethyl acetate in heptanes, to give mixture of compound **4A** and **4B** (1 g).
N,*N*Diisopropylethylamine (2.52 mL, 14.4 mmol, 6 equiv) and 2-(trimethylsilyl)ethoxymethyl chloride (2.04 mL, 11.2 mmol, 4.8 equiv) were added successively to a solution of compounds **4A** and **4B** (1 g, 2.4 mmol, 1.0 equiv) in anhydrous dichloromethane (100 mL) at room temperature. After stirring at room

2020415711 20 Jan 2025

temperature for 16 hours, saturated sodium bicarbonate (100 mL) was added to quench the reaction. The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 100 mL). The combined organic layers was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (80 g column), eluting with a gradient of 0 to 100% ethyl acetate in heptanes to give compound **18-4** (1.15 g, 45% yield over three steps) as a colorless oil. (LM-8-4, LM-8-5)

(*E*)-(((((5-(2-Bromo-3-methoxy-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-3-methoxy-1,2-phenylene)bis(oxy))bis(methylene))bis(oxy))bis(ethane-2,1-diyl))bis(trimethylsilane) (18-5):

A 60% dispersion of sodium hydride in mineral oil (168 mg, 4.2 mmol, 2 equiv) was added in one portion to a solution of compound **18-4** (1.15 g, 2.1 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (50 mL) at 0°C. The mixture was warmed up to room temperature and stirred 30 minutes. A solution of Intermediate A (754 mg, 2.1 mmol, 1 equiv) in anhydrous tetrahydrofuran (20 mL) was added dropwise and the mixture was stirred at room temperature for 16 hours. The reaction was carefully quenched with saturated brine (20 mL, 1 drop per minute for the first 5 mL brine) at 0°C. The mixture was extracted with methyl *tert*-butyl ether (2 x 150 mL). The combined organic layers was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (80 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **18-5** (1.18 g, 75% yield) as a colorless oil. (LM-8-6)

(*E*)-(((((3-Methoxy-5-(3-methoxy-2-(3-methylbut-2-en-1-yl)-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-1,2-phenylene)bis(oxy))bis(methylene))bis(oxy))bis(ethane-2,1-diyl))bis(trimethylsilane) (18-6):

2020415711 20 Jan 2025

Tetrakis(triphenylphosphine)palladium(0) (90 mg, 0.078 mmol, 0.05 equiv), potassium carbonate (428 mg, 3.1 mmol, 2 equiv), 3-methylbut-2-enylboronic acid pinacol ester (611 mg, 3.1 mmol, 2 equiv) and water (4 mL) were added sequentially to a solution of compound **18-5** (1.18 g, 1.56 mmol, 1 equiv) in 1,4-dioxane (12 mL). After sparging with nitrogen for 10 minutes, the reaction was heated at 95°C for 16 hours. After cooling to room temperature, the mixture was extracted with methyl *tert*-butyl ether (2 x 20 mL). The combined organic layers was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (80 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **18-6** (1 g, 86% yield) as a colorless oil. (LM-8-7)


(*E*)-5-(5-Hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-3-methoxybenzene-1,2-diol (18) [KYN-156]:

1M Tetrabutylammonium fluoride in tetrahydrofuran (25.3 mL, 25.3 mmol, 21 equiv) was added to a solution of compound **18-6** (900 mg, 1.2 mmol, 1 equiv) in tetrahydrofuran (25 mL) at room temperature. After heating at 67°C for 16 hours, the mixture was cooled to room temperature and diluted with water (20 mL) and saturated brine (20 mL). The mixture was extracted with ethyl acetate (300 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified three times on an Interchim automated chromatography system (80 g column, 2 x 40 g column stacked, 2 x 25 g column stacked), eluting each time with a gradient of 0 to 100% ethyl acetate in heptanes to give compound **18** (70 mg, ~85% purity). This crude compound **18** was equally divided in to 7 portions. Each portion was purified on a reverse ACCQPrep HP125 automated chromatography system (SunFire Prep C18 OBD 5µm 19x250mm column), eluting with a gradient of 0 to 100% acetonitrile in water to give compound **18** (50 mg). This material was further purified on an Interchim automated chromatography system (25 g column), eluting with a gradient of 0 to 100% ethyl acetate in hexanes to give compound **18 [KYN-156]** (27 mg, 6.3% yield) as an off-white solid after drying under vacuum at 40°C for 16 hours. (LM-8-9).

2020415711 20 Jan 2025

Off white solid; HPLC Analysis: 96.0% purity; Wavelength 254 nm, bandwidth 4; Column: Luna C18(2), 2.0 x 20 mm, 3 µm; Retention Time: 7.7 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=357.1 $(M+H)^+$; $C_{21}H_{24}O_5$; ^1H NMR (400 MHz, Acetone-d_6) δ = 8.08 (s, 1H), 7.72 – 7.41 (m, 2H), 7.19 (d, J = 16.1 Hz, 1H), 6.84 (d, J = 16.0 Hz, 1H), 6.75 – 6.72 (m, 2H), 6.72 (d, J = 2.3 Hz, 1H), 6.40 (d, J = 2.2 Hz, 1H), 5.09 (septett, J = 1.3, 7.0 Hz, 1H), 3.86 (s, 3H), 3.78 (s, 3H), 3.41 (br d, J = 7.0 Hz, 2H), 1.82 (d, J = 0.7 Hz, 3H), 1.64 (d, J = 1.1 Hz, 3H); ^{13}C NMR (100 MHz, Acetone-d_6) δ = 158.88, 156.66, 148.63, 145.92, 138.33, 134.46, 130.72, 129.84, 129.52, 124.69, 124.46, 119.36, 107.91, 104.14, 102.28, 98.62, 55.95. 55.38, 25.38, 24.37, 17.58.

(*E*)-3-(3-Hydroxy-5-methoxystyryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (19) [KYN-160]



3-(Hydroxymethyl)-5-methoxyphenol (19-2):

Sodium borohydride (263 mg, 4.66 mmol, 1.0 equiv) was added in one portion to a solution of compound **19-1** (1.06 g, 7 mmol, 1.0 equiv) in methanol (70 mL) at 0°C. After stirring at 0°C for 1 hour, water (50 mL) was added to quench the reaction. The mixture was concentrated under reduced pressure to remove most of methanol. The

2020415711 20 Jan 2025

residue was diluted with saturated brine (50 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an InterChim automated chromatography system (40 g column), eluting with a gradient of 0 to 100% ethyl acetate in heptanes to give compound **19-2** (1.07 g, 99% yield) as a white solid. (LM-8-17)

3-(Bromomethyl)-5-methoxyphenol (19-3):

Carbon tetrabromide (2.55 g, 7.7 mmol, 1.1 equiv) was added to a solution of compound **19-2** (1.06 g, 7 mmol, 1.0 equiv) in a 1 to 2 mixture of anhydrous tetrahydrofuran and dichloromethane (75 mL) at room temperature. The mixture cooled in an ice-bath, and triphenylphosphine (2.02 g, 7.7 mmol, 1.1 equiv) was added in one portion. The mixture was then warmed up to room temperature and stirred for 2 hours. The solvent was removed under reduced pressure. The residue was purified on an InterChim automated chromatography system (80 g column), eluting with a gradient of 0 to 50% ethyl acetate in heptanes to give compound **19-3** (1.18 g, 79% yield) as an off-white solid. (LM-8-18)

Diethyl (3-hydroxy-5-methoxybenzyl)phosphonate (19-4):

Triethylphosphite (2.8 mL, 16.3 mmol, 3 equiv) were added to a solution of compound **19-3** (1.18 g, 5.4 mmol, 1.0 equiv) in anhydrous toluene (100 mL) at room temperature. After refluxing (110°C) for 16 hours, the reaction was cooled to room temperature and the solvent was removed under reduced pressure. The residue was purified on an InterChim automated chromatography system (80 g column), eluting with a gradient of 0 to 100% ethyl acetate in heptanes to give compound **19-4** (1.32 g, 89% yield) as a colorless oil. (LM-8-19)

Diethyl (3-methoxy-5-((2-(trimethylsilyl)ethoxy)methoxy)benzyl) phosphonate (19-5):

2020415711 20 Jan 2025

N,*N*-Diisopropylethylamine (3.1 mL, 24 mmol, 5 equiv) and 2-(trimethylsilyl)ethoxymethyl chloride (3.4 mL, 19.3 mmol, 4 equiv) were added sequentially to a solution of compound **19-4** (1.32 g, 4.8 mmol, 1.0 equiv) in anhydrous dichloromethane (50 mL) at room temperature. After stirring at room temperature for 16 hours, saturated sodium bicarbonate (50 mL) was added to quench the reaction. The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 200 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an InterChim automated chromatography system (80 g column), eluting with a gradient of 0 to 100% ethyl acetate in heptanes to give compound **19-5** (1.27 g, 65% yield) as a colorless oil. (LM-8-20)

(*E*)-(2-((3-(2-Bromo-3-methoxy-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-5-methoxyphenoxy)methoxy)ethyl)trimethylsilane (19-6):

A 60% dispersion of sodium hydride in mineral oil (204 mg, 5.1 mmol, 2 equiv) was added in one portion to a solution of compound **19-5** (1.03 g, 2.55 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (50 mL) at 0°C. The mixture was warmed up to room temperature and stirred 30 minutes. A solution of **A8 (Module A)** (0.92 mg, 2.55 mmol, 1 equiv) in anhydrous tetrahydrofuran (20 mL) was added dropwise and the mixture was stirred at room temperature for 16 hours. The reaction was carefully quenched with saturated brine (20 mL, 1 drop per minute for the first 5 mL brine) at 0 oC. The mixture was extracted with methyl *tert*-butyl ether (2 x 150 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an InterChim automated chromatography system (80 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **19-6** (1.23 g, 79% yield) as a colorless oil. (LM-8-21)

(*E*)-(2-((3-Methoxy-5-(3-methoxy-2-(3-methylbut-2-en-1-yl)-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)phenoxy)methoxy)ethyl)trimethylsilane (19-7):

2020415711 20 Jan 2025


Tetrakis(triphenylphosphine)palladium(0) (116 mg, 0.1 mmol, 0.05 equiv), potassium carbonate (553 mg, 4 mmol, 2 equiv), 3-methylbut-2-enylboronic acid pinacol ester (785 mg, 4 mmol, 2 equiv) and water (5 mL) were added sequentially to a solution of compound **19-6** (1.23 g, 2 mmol, 1 equiv) in 1,4-dioxane (15 mL). After sparging with nitrogen for 10 minutes, the reaction was heated at 95°C for 16 hours. After cooling to room temperature, the mixture was extracted with methyl *tert*-butyl ether (2 x 20 mL) and the combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an InterChim automated chromatography system (80 g column), eluting with a gradient of 0 to 15% ethyl acetate in heptanes to give compound **19-7** (1.1 g, 91% yield) as a colorless oil. (LM-8-22)

(*E*)-3-(3-Hydroxy-5-methoxystyryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (19) [KYN-160]:

1M Tetrabutylammonium fluoride in tetrahydrofuran (25.6 mL, 25.6 mmol, 14 equiv) was added to a solution of compound **19-7** (1.1 g, 1.83 mmol, 1 equiv) in tetrahydrofuran (25 mL) at room temperature. After heating at 67°C for 16 hours, the mixture was cooled to room temperature and diluted with water (20 mL) and saturated brine (20 mL). The mixture was extracted with ethyl acetate (300 mL) and the organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified twice on an InterChim automated chromatography system (120 g column, 2 x 25 g column stacked), eluting each time with a gradient of 0 to 100% ethyl acetate in heptanes to give compound **19** (110 mg, 17% yield) as an off-white solid after drying under vacuum at 40°C for 16 hours. (LM-8-23).

***E*)-4-(3-Ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)benzene-1,2-diol (20) [KYN-146]**

2020415711 20 Jan 2025



3,4-Bis((2-(trimethylsilyl)ethoxy)methoxy)benzaldehyde (20-2): *N*,*N*-Diisopropylethylamine (37.8 mL, 217.2 mmol, 3.0 equiv) and 2-(trimethylsilyl)ethoxymethyl chloride (29.0 g, 173.8 mmol, 2.4 equiv) were added sequentially to a solution of compound **20-1** (10.0 g, 72.4 mmol, 1.0 equiv) in anhydrous dichloromethane (200 mL) at room temperature. After stirring at room temperature for 16 hours, saturated sodium bicarbonate solution (150 mL) was added. The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 150 mL). The combined organic layers was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (120 g column), eluting with a gradient of 0 to 50% ethyl acetate in heptanes to give compound **20-2** (28.03 g, 97% yield) as a yellow oil. (LM-1-75)

(3,4-Bis((2-(trimethylsilyl)ethoxy)methoxy)phenyl)methanol (20-3): Sodium borohydride (2.66 g, 70.3 mmol, 1.0 equiv) was added in one portion to a solution of compound **20-2** (28.03 g, 70.3 mmol, 1.0 equiv) in methanol (200 mL) at 0°C. After stirring at 0°C for 1 hour, water (75 mL) was added to quench the reaction. The mixture was concentrated under reduced pressure to remove most of methanol. The residue was diluted with saturated brine (75 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic layers was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (120 g column), eluting with a gradient of 0 to 100% ethyl acetate in heptanes to give compound **20-3** (26.84 g, 95% yield) as a yellow oil. (LM-1-80)

2020415711 20 Jan 2025

Diethyl (3,4-bis((2-(trimethylsilyl)ethoxy)methoxy)benzyl)phosphonate (20-4):

Zinc iodide (42.77 g, 134.0 mmol, 2.0 equiv) and triethyl phosphite (23 mL, 134.0 mmol, 2.0 equiv) were added sequentially to a solution of compound **20-3** (26.84 g, 67.0 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (400 mL) at room temperature. The mixture was refluxed (68°C) for 4 hours, at which time LCMS analysis indicated that the reaction was complete. After cooling to room temperature, the mixture was concentrated under reduced pressure to remove most of tetrahydrofuran. The residue was diluted with saturated sodium bicarbonate (150 mL) and extracted with methyl tert-butyl ether (2 x 400 mL). The combined organic layers was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (220 g column), eluting with a gradient of 0 to 100% ethyl acetate in heptanes to give compound **20-4** (24.18 g, 69% yield) as a yellow oil. (LM-1-82)

(*E*)-(((((4-(2-Bromo-3-ethoxy-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-1,2-phenylene)bis(oxy))bis(methylene))bis(oxy))bis(ethane-2,1-diyl))bis(trimethylsilane) (20-5):

A 60% dispersion of sodium hydride in mineral oil (2.43 g, 60.6 mmol, 2 equiv) was added in one portion to a solution of compound **20-4** (15.76 g, 30.3 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (300 mL) at 0°C. The mixture was warmed to room temperature and stirred 30 minutes. A solution containing compound **A9 (Module A)** (11.36 g, 30.3 mmol, 1 equiv) in anhydrous tetrahydrofuran (100 mL) was added dropwise and the mixture was stirred at room temperature for 16 hours. The reaction was carefully quenched with saturated brine (250 mL, 1 drop per minute for the first 5 mL brine) at 0°C. The mixture was extracted with methyl tert-butyl ether (2 x 500 mL). The combined organic layers was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (330 column), eluting with a gradient of 0 to 15% ethyl acetate in heptanes to give compound **20-5** (15.5 g, 69% yield) as a yellow oil. (LM-6-89)

2020415711 20 Jan 2025

(*E*)-(((((4-(3-ethoxy-2-(3-methylbut-2-en-1-yl)-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-1,2-phenylene)bis(oxy))bis(methylene))bis(oxy))bis(ethane-2,1-diyl))bis(trimethylsilane) (20-6):

Tetrakis(triphenylphosphine)palladium(0) (1.21 g, 1.05 mmol, 0.05 equiv), potassium carbonate (5.78 g, 41.8 mmol, 2 equiv), 3-methylbut-2-enylboronic acid pinacol ester (8.2 g, 41.8 mmol, 2 equiv) and water (50 mL) were added sequentially to a solution of compound **20-5** (15.5 g, 20.9 mmol, 1 equiv) in 1,4-dioxane (150 mL). After sparging with nitrogen for 10 minutes, the reaction was heated at 95°C for 16 hours. After cooling to room temperature, the mixture was extracted with methyl tert-butyl ether (2 x 300 mL). The combined organic layers was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (330 column), eluting with a gradient of 0 to 15% ethyl acetate in heptanes to give a compound **20-6** (15.28 g, 99% yield) as a yellow oil. (LM-6-90)

(*E*)-4-(3-Ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)benzene-1,2-diol (20) [KYN-146]:

1M Tetrabutylammonium fluoride in tetrahydrofuran (513 mL, 513 mmol, 21 equiv) was added to a mixture of compound **20-6** (17.86 g, 24.4 mmol, 1 equiv) in tetrahydrofuran (500 mL) at room temperature. After heating at 67°C for 16 hours, the mixture was cooled to room temperature and diluted with water (350 mL) and saturated brine (350 mL). The mixture was extracted with methyl tertbutyl ether (1.5 L) and ethyl acetate (1.5 L). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified three times on an Interchim automated chromatography system (2 x 40 g column stacked, 2 x 80 g column stacked, 2 x 40 g column stacked), eluting each time with a gradient of 0 to 100% ethyl acetate in heptanes, to give a mixture of SEM protected compounds (3.94 g) and compound **20** (1.5 g, ~70% purity). This crude compound **20** was further purified on a reverse Interchim automated chromatography system (300 g column),

2020415711 20 Jan 2025

eluting with a gradient of 0 to 100% acetonitrile in water to give compound **20** (480 mg). The mixture of SEM –protected compounds (3.94 g) was treated with 1M tetrabutylammonium fluoride in tetrahydrofuran (58.7 mL, 58.7 mmol, 7.0 equiv) and processed in the same manner to give compound **20** (450 mg). All SEM-protected material was combined (480 mg, 450 mg and 130 mg, LM-6-69) and purified on an Interchim automated chromatography system (40 g column), eluting with a gradient of 0 to 55% ethyl acetate in hexanes to give compound **20 [KYN-146]** (1.0 g, 10% yield in total) as an off-white solid after drying under vacuum at 40°C for 16 hours. (LM-6-91).


Structure Data:

Compound 20 [KYN-146]

Off-white solid; HPLC Analysis: 96.3% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 μm; Retention Time: 8.3 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=341.2 $(M+H)^+$; $C_{21}H_{24}O_4$; ^{1}H NMR (400 MHz, Acetone-d_6) δ = 7.98 (br s, 2H), 7.18 (d, J = 16.1 Hz, 1H), 7.08 (d, J = 2.1 Hz, 1H), 6.90 (ddd, J = 0.4, 2.1, 8.1 Hz, 1H), 6.87 – 6.80 (m, 2H), 6.70 (d, J = 2.3 Hz, 1H), 6.37 (d, J = 2.3 Hz, 1H), 5.11 (septett, J = 1.3, 7.0 Hz, 1H), 3.99 (q, J = 7.0 Hz, 2H), 3.42 (d, J = 7.0 Hz, 2H), 1.81 (d, J = 0.9 Hz, 3H), 1.64 (d, J = 1.1 Hz, 3H), 1.38 (t, J = 7.0 Hz, 3H); ^{13}C NMR (100 MHz, Acetone-d_6) δ = 158.18, 156.56, 145.65, 145.59, 138.34, 130.60, 130.33, 129.87, 124.65, 124.23, 119.52, 119.50, 115.75, 113.29, 104.08, 99.43, 63.86, 25.40, 24.44, 17.65, 14.75.

(*E*)-4-(5-Hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxybenzoic acid (21) [KYN-154]

2020415711 20 Jan 2025



Methyl 4-((diethoxyphosphoryl)methyl)-2-methoxybenzoate (21-2):

1M Lithium bis(trimethylsilyl)amide in tetrahydrofuran (7 mL, 7 mmol, 1.8 equiv) was added to a solution of diethyl phosphite (1 mL, 7.7 mmol, 2.0 equiv) in anhydrous tetrahydrofuran (30 mL) at 0°C. After stirring at 0°C for 30 minutes, a solution of compound **21-1** (1 g, 3.9 mmol, 1 equiv) in anhydrous tetrahydrofuran (10 mL) was added dropwise and the mixture was stirred at room temperature for 16 hours. The reaction was diluted with saturated brine (50 mL) and extracted with ethyl acetate (2 x 300 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (40 column), eluting with a gradient of 0 to 100% ethyl acetate in heptanes to give compound **21-2** (1.22 g, 99% yield) as a colorless oil. (LM-6-92)

(*E*)-4-(2-Bromo-3-methoxy-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-2-methoxybenzoic acid (21-3):

A 60% dispersion of sodium hydride in mineral oil (160 mg, 4 mmol, 2 equiv) was added in one portion to a solution of compound **21-2** (0.63 g, 2 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (30 mL) at 0°C. The mixture was warmed up to room temperature and stirred 30 minutes. A solution of A8 (**Module A)** (0.72 g, 2 mmol, 1 equiv) in anhydrous tetrahydrofuran (10 mL) was added dropwise and the mixture was stirred at room temperature for 16 hours. The reaction was diluted with saturated brine

2020415711 20 Jan 2025

(20 mL, 1 drop per minute for the first 5 mL brine) at 0°C. The mixture was extracted with methyl tert-butyl ether (2 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (40 column), eluting with a gradient of 0 to 100% ethyl acetate in heptanes to give compound **21-3** (0.55 g, 55% yield) as a yellow solid. (LM-6-93)

(*E*)-2-Methoxy-4-(3-methoxy-2-(3-methylbut-2-en-1-yl)-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)benzoic acid (21-4):

Tetrakis (triphenylphosphine)palladium(0) (58 mg, 0.05 mmol, 0.05 equiv), potassium carbonate (415 mg, 3 mmol, 3 equiv), 3-methylbut-2-enylboronic acid pinacol ester (392 mg, 2 mmol, 2 equiv) and water (4 mL) were added sequentially to a solution of compound **21-3** (509 mg, 1 mmol, 1 equiv) in 1,4-dioxane (12 mL). After sparging with nitrogen for 10 minutes, the reaction was heated at 95 oC for 16 hours. After cooling to room temperature, the mixture was extracted with ethyl acetate (2 x 20 mL) and the combined organic layers was concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (25 g column), eluting with a gradient of 0 to 80% ethyl acetate in heptanes to give compound **21-4** (490 mg, 98% yield) as a yellow oil. (LM-6-94)

(*E*)-4-(5-Hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxybenzoic acid (21) [KYN-154]:

1M Tetrabutylammonium fluoride in tetrahydrofuran (7 mL, 7 mmol, 7 equiv) was added to a mixture of compound **21-4** (490 mg, 1 mmol, 1 equiv) in tetrahydrofuran (20 mL) at room temperature. After heating at 67°C for 16 hours, the mixture was cooled to room temperature and diluted with ethyl acetate (200 mL). The mixture was washed with saturated brine (50 mL) and the organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified twice on an Interchim automated chromatography system (2 x 25 g column stacked), eluting each time with a gradient of 0 to 100% ethyl acetate in heptanes and twice on a reverse


2020415711 20 Jan 2025

Interchim automated chromatography system (50 g column), eluting each time with a gradient of 0 to 100% acetonitrile in water to give compound **S10** (70 mg, ~70% purity). This material was equally divided in to 8 portions. Each portion was purified on a reverse ACCQPrep HP125 automated chromatography system (SunFire Prep C18 OBD 5 µm 19 x 250 mm column), eluting with a gradient of 0 to 100% acetonitrile in water to give compound **21 [KYN-154]** (30 mg, 8% yield) as an off-white solid after lyophilization for 16 hours. (LM-6-95).

Off-white solid; HPLC Analysis: 98.8% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 8.4 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=369.2 $(M+H)^+$; $C_{22}H_{24}O_5$; ^1H NMR (400 MHz, Acetone-d_6) δ = 7.92 (d, J = 8.1 Hz, 1H), 7.58 (d, J = 16.1 Hz, 1H), 7.38 (d, J = 1.1 Hz, 1H), 7.30 (dd, J = 1.2, 8.2 Hz, 1H), 7.05 (d, J = 16.3 Hz, 1H), 6.78 (d, J = 2.3 Hz, 1H), 6.48 (d, J = 2.2 Hz, 1H), 5.08 (septett, J = 1.3, 7.0 Hz, 1H), 4.09 (s, 3H), 3.80 (s, 3H), 3.45 (br d, J = 6.8 Hz, 2H), 1.81 (s, 3H), 1.64 (d, J = 1.0 Hz, 3H); ^{13}C NMR (100 MHz, Acetone-d_6) δ = 165.55, 159.48, 158.97, 156.82, 144.29, 137.40, 133.08, 130.20, 130.14, 129.15, 124.52, 120.27, 119.38, 118.33, 110.57, 104.49, 99.64, 56.36. 55.46, 25.36, 24.36, 17.57.

Preparation of Compound 22 [KYN-124] and Compound 23 [KYN-125]

2020415711 20 Jan 2025



4-(Bromomethyl)-2-methoxy-1-nitrobenzene (22-1):

Carbon tetrabromide (21.7 g, 65.5 mmol, 1.2 equiv) was added in 5 portions to a solution of 3-methoxy-4-nitrobenzyl alcohol (10 g, 54.5 mmol, 1.0 equiv) and triphenylphosphine (17.2 g, 65.5 mmol, 1.2 equiv) in dichloromethane (300 mL) at 0°C. After stirring at room temperature for 16 hours, the reaction mixture was concentrated under reduced pressure. The residue was purified on an InterChim automated chromatography system (330 g column), eluting with a gradient of 0 to 50% ethyl acetate in heptanes, to give compound **22-1** (12.8 g, 95% yield) as a yellow solid (CH-LM-02-26)

Diethyl (3-methoxy-4-nitrobenzyl)phosphonate (22-2):

Triethyl phosphite (26.8 mL, 156 mmol, 3.0 equiv) was added to a solution of compound **22-1** (12.8 g, 52 mmol, 1.0 equiv) in toluene (400 mL). After refluxing (110°C) for 40 hours, NMR analysis indicated the reaction was complete. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified on an InterChim automated chromatography system (330 g

2020415711 20 Jan 2025

column), eluting with a gradient of 0 to 100% ethyl acetate in heptanes followed by 10% methanol in dichloromethane to give compound **22-2** (15.5 g, 98% yield) a pale yellow oil (CH-LM-02-27).

(E)-(2-((4-Bromo-3-methoxy-5-(3-methoxy-4-nitrostyryl)phenoxy)methoxy)ethyl)trimethylsilane (22-3):

A 60% dispersion of sodium hydride in mineral oil (6.1 g, 153.3 mmol, 3.0 equiv) was added in 3 portions to a solution of compound **22-2** (15.5 g, 51.1 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (450 mL) at 0°C. The mixture was warmed up to room temperature and stirred for 30 minutes. A solution of Intermediate A (18.5 g, 51.1 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (150 mL) was added dropwise and the mixture was stirred at room temperature for 16 hours. The reaction was carefully quenched with water (500 mL, 1 drop per minute for the first 5 mL water) at 0°C and extracted with methyl tert-butyl ether (1.5 L) and ethyl acetate (1 L). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified in three equal portions on an InterChim automated chromatography system (3 x 330 g column), eluting with a gradient of 10 to 50% ethyl acetate in heptanes, to give compound **22-3** (9.9 g, 38% yield) as a yellow solid. (CH-LM-02-28)

(E)-(2-((3-Methoxy-5-(3-methoxy-4-nitrostyryl)-4-(3-methylbut-2-en-1-yl) phenoxy)methoxy)ethyl)trimethylsilane (22-4):

Tetrakis(triphenylphosphine) palladium(0) (2.1 g, 1.8 mmol, 0.05 equiv), potassium carbonate (10 g, 72 mmol, 2.0 equiv), 3-methylbut-2-enylboronic acid pinacol ester (14.1 g, 72 mmol, 2.0 equiv) and water (90 mL) were added sequentially to a solution of compound **22-3** (18.3 g, 36 mmol, 1.0 equiv) in 1,4-dioxane (270 mL) in a sealed tube. After sparging with nitrogen for 10 minutes, the reaction was heated at 100°C for 16 hours. After cooling to room temperature, the reaction mixture was extracted with methyl tert-butyl ether (500 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified in two equal portions on an InterChim automated chromatography system (2 x 220 g column),

2020415711 20 Jan 2025

eluting with a gradient of 0 to 12% ethyl acetate in heptanes to give compound **22-4** (15.1 g, 84% yield) as a yellow solid. (CH-LM-02-29)

(E)-3-Methoxy-5-(3-methoxy-4-nitrostyryl)-4-(3-methylbut-2-en-1-yl)phenol (22): 1M Tetrabutylammonium fluoride in tetrahydrofuran (366 mL, 366 mmol, 7.0 equiv) was added to a solution of compound **22-4** (26.1 g, 52.3 mmol, 1.0 equiv) in tetrahydrofuran (400 mL) at room temperature. After heating at 68°C for 16 hours, the mixture was cooled to room temperature and diluted with water (100 mL). The volatiles were removed under reduced pressure. The residue was diluted with saturated ammonium chloride (250 mL) and extracted with ethyl acetate (2 x 500 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified in three equal portions on an InterChim automated chromatography system (3 x 330 g column), eluting with a gradient of 30 to 100% ethyl acetate in heptanes to give compound **22** (17.1 g, 89% yield) as a yellow solid. (CH-LM-02-30) Yellow solid, melting point 167.1 – 169.0°C; HPLC Analysis: 99.2% purity; Wavelength 210 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 μm; Retention Time: 9.77 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=370.1 $(M+H)^+$; $C_{21}H_{23}NO_5$; ^1H NMR (400 MHz, $CDCl_3$) δ = 7.91 (d, J = 8.3 Hz, 1H), 7.43 (d, J = 16.1 Hz, 1H), 7.12 (ddd, J = 0.5, 1.7, 8.3 Hz, 1H), 7.11 (br d, J = 1.5 Hz, 1H), 6.91 (d, J = 16.1 Hz, 1H), 6.68 (d, J = 2.4 Hz, 1H), 6.42 (d, J = 2.4 Hz, 1H), 5.09 (tm, J = 6.8 Hz, 1H), 4.76 (s, 1H), 4.01 (s, 3H), 3.82 (s, 3H), 3.43 (d, J = 6.8 Hz, 2H), 1.80 (d, J = 0.7 Hz, 3H), 1.68 (d, J = 1.2 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 158.67, 154.55, 153.70, 144.15, 138.12, 136.81, 130.97, 130.89, 128.38, 126.57, 123.42, 121.71, 118.09, 111.20, 104.15, 99.44, 56.45, 55.76, 25.74, 24.46, 17.99.


(E)-3-(4-Amino-3-methoxystyryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (23) [KYN-125]:

Zinc powder (30.3 g, 463 mmol, 10.0 equiv), ammonium chloride (25 g, 463 mmol, 10.0 equiv) and water (70 mL) were added sequentially to a solution of compound **22** (17.1 g, 46.3 mmol, 1.0 equiv) in tetrahydrofuran (700 mL) at room temperature. The

2020415711 20 Jan 2025

resulting suspension was stirred at room temperature for 4 hours. The suspension was filtered and the solids were washed with ethyl acetate (1 L). The filtrate was evaporated to dryness under reduced pressure. The residue was purified in five equal portions on an InterChim automated chromatography system (5 x 120 g column), eluting each time with a gradient of 0 to 40% ethyl acetate in heptanes to give compound **23** (10.5 g, 67% yield) as an off-white solid. (CH-LM-02-31). Melting point 159.3 – 163.3°C; HPLC Analysis: 94.8% purity; Wavelength 210 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 7.80 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=340.2 $(M+H)^+$; $C_{21}H_{25}NO_3$; ^1H NMR (400 MHz, $CDCl_3$) δ = 7.10 (d, J = 16.1 Hz, 1H), 6.95 (d, J = 1.7 Hz, 1H), 6.92 (dd, J = 1.9, 7.9 Hz, 1H), 6.81 (d, J = 15.9 Hz, 1H), 6.69 (d, J = 7.8 Hz, 1H), 6.62 (d, J = 2.5 Hz, 1H), 6.34 (d, J = 2.4 Hz, 1H), 5.12 (tm, J = 1.5, 6.9 Hz, 1H), 3.89 (s, 3H), 3.80 (s, 3H), 3.41 (d, J = 6.6 Hz, 2H), 1.81 (d, J = 1.0 Hz, 3H), 1.67 (d, J = 0.9 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 158.56, 154.40, 147.42, 138.48, 136.08, 130.88, 130.49, 128.67, 123.77, 122.88, 120.54, 120.50, 114.86, 108.07, 103.83, 97.97, 55.69. 55.45, 25.77, 24.48, 17.97.

(*E*)-3-(4-Amino-3-methoxystyryl)-5-ethoxy-4-(3-methylbut-2-en-1-yl)phenol (24) [KYN-141]



(*E*)-(2-((4-Bromo-3-ethoxy-5-(3-methoxy-4-nitrostyryl)phenoxy)methoxy)ethyl)trimethylsilane (24-1):

2020415711 20 Jan 2025

A 60% dispersion of sodium hydride in mineral oil (2.7 g, 67.3 mmol, 3.0 equiv) was added in 3 portions to a solution of compound **22-2** (6.8 g, 22.4 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (200 mL) at 0°C. The mixture was warmed up to room temperature and stirred for 30 minutes. A solution of compound **A9** (Module A) (8.4 g, 22.4 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (50 mL) was added dropwise and the mixture was stirred at room temperature for 16 hours. The reaction was carefully quenched with water (200 mL, 1 drop per minute for the first 5 mL water) at 0°C and extracted with methyl *tert*-butyl ether (1 L) and ethyl acetate (500 mL). The combined organic layers was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an InterChim automated chromatography system (220 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **24-1** (9.04 g, 77% yield) as a yellow solid. (LM-8-98).

(*E*)-(2-((3-Ethoxy-5-(3-methoxy-4-nitrostyryl)-4-(3-methylbut-2-en-1-yl)phenoxy)methoxy)ethyl)trimethylsilane (24-2):

Tetrakis (triphenylphosphine) palladium(0) (1 g, 0.86 mmol, 0.05 equiv), potassium carbonate (4.76 g, 34.47 mmol, 2.0 equiv), 3-methylbut-2-enylboronic acid pinacol ester (6.76 g, 34.47 mmol, 2.0 equiv) and water (30 mL) were added sequentially to a solution of compound **24-1** (9.04 g, 17.24 mmol, 1.0 equiv) in 1,4-dioxane (120 mL) in a sealed tube. After sparging with nitrogen for 10 minutes, the reaction was heated at 100°C for 16 hours. After cooling to room temperature, the reaction mixture was extracted with methyl *tert*-butyl ether (200 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an InterChim automated chromatography system (2 x 200 g column stacked), eluting with a gradient of 0 to 7% ethyl acetate in heptanes to give compound **24-2** (8.84 g, 99% yield) as a yellow oil. (LM-8-99).

(*E*)-3-Ethoxy-5-(3-methoxy-4-nitrostyryl)-4-(3-methylbut-2-en-1-yl)phenol (24-3):

1M Tetrabutylammonium fluoride in tetrahydrofuran (130 mL, 130 mmol, 7.0 equiv) was added to a solution of compound **24-2** (9.53 g, 18.55 mmol, 1.0 equiv) in tetrahydrofuran (200 mL) at room temperature. After heating at 68°C for 16 hours, the

2020415711 20 Jan 2025


mixture was cooled to room temperature and diluted with water (50 mL). The volatiles were removed under reduced pressure. The residue was diluted with saturated ammonium chloride (250 mL) and extracted with ethyl acetate (2 x 400 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an InterChim automated chromatography system (330 g column), eluting with a gradient of 0 to 60% ethyl acetate in heptanes to give compound **24-3** (5.05 g, 71% yield) as a yellow solid. (LM-8-100).

(*E*)-3-(4-Amino-3-methoxystyryl)-5-ethoxy-4-(3-methylbut-2-en-1-yl)phenol (24): Zinc powder (8.61 g, 131.7 mmol, 10.0 equiv), ammonium chloride (7.1 g, 131.7 mmol, 10.0 equiv) and water (20 mL) were added sequentially to a solution of compound **24-3** (5.05 g, 13.17 mmol, 1.0 equiv) in tetrahydrofuran (200 mL) at room temperature. The resulting suspension was stirred at room temperature for 16 hours. The suspension was filtered through a pad of Celite (50 g), which was rinsed with ethyl acetate (400 mL). The filtrate was evaporated to dryness under reduced pressure. The residue was purified twice on an InterChim automated chromatography system (2 x 120 g column stacked), eluting each time with a gradient of 0 to 100% ethyl acetate in heptanes to give compound **24** (4.56 g, 98% yield) as an off white solid. (LM-8-101). Off white solid, melting point 187 – 196°C; HPLC Analysis: 97.9% purity; Wavelength 210 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 8.3 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=354.2 $(M+H)^+$; $C_{22}H_{27}NO_3$; ^1H NMR (400 MHz, $CDCl_3$) δ = 7.11 (br d, J = 16.0 Hz, 1H), 6.95 (br s, 1H), 6.92 (br d, J = 7.7 Hz, 1H), 6.80 (br d, J = 16.0 Hz, 1H), 6.70 (br d, J = 7.9 Hz, 1H), 6.59 (br s, 1H), 6.31 (br s, 1H), 5.14 (br t, J = 5.9 Hz, 1H), 4.90 (br s, 1H), 3.99 (q, J = 6.6 Hz, 2H), 3.90 (s, 5H), 3.42 (br d, J = 6.1 Hz, 2H), 1.91 – 1.74 (m, 3H), 1.74 – 1.61 (m, 3H), 1.41 (br t, J = 6.8 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 157.88, 154.28, 147.40, 138.44, 136.10, 130.80, 130.30, 128.66, 123.84, 122.96, 120.67, 120.51, 114.83, 108.10, 103.74, 98.82, 63.90, 55.46, 25.79, 24.55, 18.03, 14.93.

2020415711 20 Jan 2025

(*E*)-N-(4-(5-hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)methanesulfonamide (25) [KYN-137] and (*Z*)-N-(4-(5-hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)methanesulfonamide (26) [KYN-129]

(*E*Z)-3-methoxy-5-(3-methoxy-4-(methylsulfonamido)styryl)-4-(3-methylbut-2-en-1-yl)phenyl methane sulfonate (25 and 26):**



Triethylamine (0.15 mL, 1.08 mmol, 3 equiv) and methane sulfonyl chloride (0.1 mL, 0.70 mmol, 2 equiv) were sequentially added to a solution of compound **23** (120 mg, 0.36 mmol, 1.0 equiv) in anhydrous THF (10 mL) at room temperature. After refluxing (66°C) for 16 hours, the reaction mixture was cooled to room temperature and the volatiles were removed under reduced pressure. The residue was dissolved in ethyl acetate (20 mL) and washed with saturated sodium bicarbonate (20 mL). The aqueous layer was extracted with ethyl acetate (2 X 15 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 30% ethyl acetate in heptanes to give compounds **25-1** and **26-1** (100 mg, 66 % yield) as a white solid. (NRK-1-74)

1M Tetrabutylammonium fluoride solution in THF (2 mL, 1.63 mmol, 7 equiv) was added to a solution of compounds **25-1** and **26-1** (100 mg, 0.234 mmol, 1 equiv) in

2020415711 20 Jan 2025

anhydrous THF (10 mL) at room temperature. After refluxing (66°C) for 16 hours, LCMS analysis indicated that the reaction was complete. After the mixture was cooled to room temperature and diluted with saturated ammonium chloride (10 mL). The volatiles were removed under reduced pressure and the residue was diluted with ethyl acetate (20 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 15 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (RediSep Rf Gold HP C18, 50 g column), eluting with a gradient of 0 to 40% acetonitrile in water to give compound **25 [KYN-137]** (15.0 mg) as an off white solid and compound **26 [KYN-129]** (19 mg, 22 % yield) as a light brown oil.

(*E*)-N-(4-(5-hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)methanesulfonamide (25) [KYN-137]

Off white solid; melting point 170.7 – 173.5°C; HPLC Analysis: 92.4% purity; Wavelength 210 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 8.4 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=418.1 $(M+H)^+$; $C_{22}H_{27}NO_5S$; ^1H NMR (400 MHz, $CDCl_3$) δ = 7.50 (d, J = 8.2 Hz, 1H), 7.27 (s, 1H), 7.26 (s, 1H), 7.25 – 7.22 (m, 1H), 7.02 (d, J = 1.6 Hz, 1H), 6.88 (d, J = 16.0 Hz, 1H), 6.68 (d, J = 2.3 Hz, 1H), 6.39 (d, J = 2.3 Hz, 1H), 5.11 (tseptets, J = 1.3, 6.8 Hz, 1H), 4.92 (br s, 1H), 3.93 (s, 3H), 3.81 (s, 3H), 3.42 (br d, J = 6.7 Hz, 2H), 2.97 (s, 3H), 1.81 (s, 3H), 1.68 (d, J = 1.0 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 158.60, 154.52, 149.51, 137.63, 135.35, 130.67, 129.64, 126.58, 125.48, 123.62, 120.99, 120.75, 120.06, 108.33, 104.01, 98.68, 55.77, 55.72, 39.14, 25.76, 24.47, 17.99.


(*Z*)-N-(4-(5-hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)methanesulfonamide (26) [KYN-129]

Light brown oil; HPLC Analysis: 97.8% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 9.2 min; Mobile

2020415711 20 Jan 2025

Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=418.1 $(M+H)^+$; $C_{22}H_{27}NO_5S$; ^1H NMR (400 MHz, $CDCl_3$) δ = 7.31 (d, J = 8.3 Hz, 1H), 6.77 (dd, J = 1.7, 8.4 Hz, 1H), 6.66 (d, J = 1.7 Hz, 1H), 6.63 (d, J = 12.3 Hz, 1H), 6.50 (d, J = 12.2 Hz, 1H), 6.35 (d, J = 2.5 Hz, 1H), 6.19 (d, J = 2.2 Hz, 1H), 5.08 (tm, J = 1.4, 6.9 Hz, 1H), 3.79 (s, 3H), 3.50 (s, 3H), 3.27 (br d, J = 7.1 Hz, 2H), 2.90 (s, 3H), 1.68 (s, 3H), 1.58 (d, J = 0.9 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 158.87, 154.74, 148.69, 138.86, 134.39, 130.97, 129.90, 129.71, 124.78, 122.90, 122.67, 120.75, 120.01, 111.24, 107.31, 98.13, 55.65, 55.32, 39.14, 25.75, 25.66, 17.87.

(*E*)-*N*-(4-(5-Hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)formamide (27) [KYN-149]




Compound **23 [KYN-125]** (120 mg, 0.35 mmol, 1.0 equiv) was added to ethyl formate (15 mL) to obtain a cloudy solution, which was heated at 55°C for 20 hours (clear solution on heating). The reaction mixture was cooled to room temperature and evaporated to dryness under reduced pressure. The residue was dissolved in ethyl acetate (20 mL) and washed with saturated ammonium chloride (20 mL). The aqueous layer was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was initially purified on a Reveleris automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 60% ethyl acetate in heptanes. The product was triturated with 10% ethyl acetate in heptanes (10 mL) to afford compound **27** (50 mg, 38% yield) as an off-white solid. (NRK-1-159).

2020415711 20 Jan 2025

(E)-N-(4-(5-hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)formamide (27) [KYN-149]

White solid, melting point 181.2 – 181.7°C; HPLC Analysis: 99.6% purity; Wavelength 210 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 8.4 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (negative mode) m/z=733.3 $(2M-H)^-$; $C_{22}H_{25}NO_4$; ^1H NMR (400 MHz, DMSO-d_6) δ = 9.69 (s, 1H), 9.24 (s, 1H), 8.30 (d, J = 1.8 Hz, 1H), 8.16 (d, J = 8.2 Hz, 1H) 7.31 – 7.22 m, 2H), 7.09 (d, J = 8.6 Hz, 1H), 6.90 (d, J = 16.1 Hz, 1H), 6.64 (d, J = 2.1 Hz, 1H), 6.35 (d, J = 2.2 Hz, 1H), 5.00 (septt, J = 1.4, 6.8 Hz, 1H), 3.91 (s, 3H), 3.73 (s, 3H), 3.36 (br d, J = 6.7 Hz, 2H), 1.76 (s, 3H), 1.60 (s, 3H); ^{13}C NMR (100 MHz, DMSO-d_6) δ = 160.45, 158.45, 156.69, 149.10, 137.43, 133.78, 129.85, 127.03, 125.99, 124.50, 120.63, 119.75, 118.74, 109.00, 104.13, 99.16, 56.25. 55.91, 25.96, 24.28, 18.21.

***E*)-*N*-(4-(3-Ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)formamide (28) [KYN-143]**



(*E*)-*N*-(4-(3-Ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)formamide (28) [KYN-143]:


Compound **24** (100 mg, 0.29 mmol, 1.0 equiv) was added to ethyl formate (10 mL) to obtain a cloudy solution, which was heated at 55°C for 20 hours (clear solution on heating). The reaction mixture was cooled to room temperature and evaporated to dryness under reduced pressure. The residue was dissolved in ethyl acetate (20 mL) and washed with saturated ammonium chloride (20 mL). The aqueous layer was extracted

2020415711 20 Jan 2025

with ethyl acetate (2 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was initially purified on a Reveleris automated chromatography system (Sorbtech 12 g column), eluting with a gradient of 0 to 50% ethyl acetate in heptanes. The product was triturated with 10% ethyl acetate in heptanes (10 mL) to afford compound **28 [KYN-143]** (45 mg, 64% yield) as an off-white solid. (NRK-1-145).

Off white solid, melting point 173 – 176°C; HPLC Analysis: 98.9% purity; Wavelength 210 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 9.0 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (negative mode) m/z=761.3 $(M-H)^-$; $C_{23}H_{27}NO_4$; ^1H NMR (400 MHz, DMSO-d_6) δ = 9.69 (s, 1H), 9.20 (s, 1H), 8.30 (d, J = 1.7 Hz, 1H), 8.16 (d, J = 8.3 Hz, 1H), 7.29 (d, J = 16.1 Hz, 1H), 7.25 (d, J = 1.1 Hz, 1H), 7.10 (br d, J = 8.3 Hz, 1H), 6.90 (d, J = 16.0 Hz, 1H), 6.62 (d, J = 2.1 Hz, 1H), 6.32 (d, J = 2.0 Hz, 1H), 5.01 (br t, J = 7.0 Hz, 1H), 3.95 (q, J = 7.0 Hz, 2H), 3.91 (s, 3H), 3.37 (br d, J = 6.7 Hz, 2H), 1.76 (s, 3H), 1.60 (s, 3H), 1.33 (t, J = 6.9 Hz, 3H); ^{13}C NMR (100 MHz, DMSO-d_6) δ = 160.44, 157.71, 156.59, 149.09, 137.40, 133.79, 129.74 (2C), 127.01, 126.04, 124.52, 120.62, 119.72, 118.90, 109.03, 104.1, 99.96, 63.74, 56.27, 25.99, 24.34, 18.25, 15.25.

(*E*)-N-(4-(5-hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)acetamide (29) [KYN-128]:




N,*N*-Diisopropylethylamine (0.1 mL, 0.38 mmol, 2 equiv) and acetic anhydride (0.1 mL, 0.38 mmol, 2 equiv) were sequentially added to a solution of **Compound 23 [KYN-125]** (65 mg, 0.19 mmol, 1.0 equiv) in anhydrous THF (10 mL) at room temperature. After refluxing (66°C) for 16 hours, the reaction mixture was cooled to

2020415711 20 Jan 2025

room temperature and the volatiles were removed under reduced pressure. The residue was dissolved in ethyl acetate (20 mL) and washed with saturated sodium bicarbonate (20 mL). The aqueous layer was extracted with ethyl acetate (2 X 10 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (RediSep Rf Gold HP C18, 50 g column), eluting with a gradient of 0 to 80% acetonitrile in water to give relatively pure **Compound 29,** which was further purified by trituration with 30% dichloromethane in heptanes (10 mL) to give pure **Compound 29 [KYN-128]** (17 mg, 23 % yield) as a white solid. (NRK-1-66)

Off white grey solid, melting point 205.7 – 205.9°C; HPLC Analysis: 97.4% purity; Wavelength 210 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 8.4 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=382.2 $(M+H)^+$; $C_{23}H_{27}NO_4$; ^{1}H NMR (400 MHz, $CDCl_3$) δ = 8.40 (d, J = 8.8 Hz, 1H), 7.84 (s, 1H), 7.23 (d, J = 16.1 Hz, 1H), 7.04 (d, J = 1.8 Hz, 1H), 7.03 (dd, J = 1.7, 6.0 Hz, 1H), 6.88 (d, J = 16.1 Hz, 1H), 6.79 (d, J = 2.3 Hz, 1H), 6.39 (d, J = 2.3 Hz, 1H), 6.24 (s, 1H), 5.12 (tm, J = 1.4, 6.8 Hz, 1H), 3.93 (s, 3H), 3.81 (s, 3H), 3.42 (d, J = 6.7 Hz, 2H), 2.24 (s, 3H), 1.81 (d, J = 0.6 Hz, 3H), 1.67 (d, J = 1.0 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 168.65, 158.58, 155.07, 147.91, 137.68, 133.65, 130.42, 129.84, 127.11, 125.77, 123.86, 120.71, 120.44, 119.67, 106.87, 103.98, 98.62, 55.68, 55.65, 25.75, 24.88, 24.45, 17.98.

(E)-*N*-(4-(3-Ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)acetamide (30) [KYN-142]



(*E*)-3-(4-Acetamido-3-methoxystyryl)-5-ethoxy-4-(3-methylbut-2-en-1-yl)phenyl acetate (30-1):

2020415711 20 Jan 2025

N,*N*-Diisopropylethylamine (0.25 mL, 1.36 mmol, 4 equiv) and acetic anhydride (0.1 mL, 0.75 mmol, 2.2 equiv) were sequentially added to a solution of compound **24** (120 mg, 0.34 mmol, 1.0 equiv) in anhydrous THF (20 mL) at room temperature. After refluxing (66□C) for 16 hours, the reaction mixture was cooled to room temperature and the volatiles were removed under reduced pressure. The residue was dissolved in ethyl acetate (20 mL) and washed with saturated sodium bicarbonate (20 mL). The aqueous layer was extracted with ethyl acetate (2 x 10 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give compound **30-1** (136 mg, 92% yield) as a pale yellow solid, which was used subsequently. (NRK-1-133)

(*E*)-N-(4-(3-ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)acetamide (30) [KYN-142]:


1M Lithium hydroxide (1.6 mL, 1.55 mmol, 5.0 equiv) was added to a solution of compound **30-1** (136 mg, 0.31 mmol, 1.0 equiv) in tetrahydrofuran (10 mL) at room temperature. The resulting solution was stirred at room temperature for 4 hours. The volatiles were removed under reduced pressure. The residue was dissolved in ethyl acetate (20 mL) and washed with saturated ammonium chloride (10 mL). The aqueous layer was extracted with ethyl acetate (2 x 10 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 12 g column), eluting with a gradient of 0 to 50% ethyl acetate in heptanes. The product was triturated with diethyl ether (5 mL) to give pure compound **30 [KYN-142]**(20 mg, 17% yield) as a white solid. (NRK-1-135)

Off white solid, melting point 188 – 189°C; HPLC Analysis: 99.3% purity; Wavelength 210 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 9.0 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=396.2 $(M+H)^+$; $C_{24}H_{29}NO_4$; ^1H NMR (400 MHz, $CDCl_3$) δ = 8.41 (d, J = 8.1 Hz, 1H), 7.85 (s, 1H), 7.26 – 7.22 (m, 1H), 7.06 – 7.00 m, 2H), 6.88 (d, J = 16.0 Hz, 1H), 6.79 (d, J = 2.1 Hz, 1H), 6.42 – 6.31 (m, 2H), 5.14 (septett, J = 1.2, 6.8 Hz, 1H), 4.00

20 Jan 2025 2020415711

(q, J = 6.9 Hz, 2H), 3.93 (s, 3H), 3.44 (br d, J = 6.7 Hz, 2H), 2.24 (s, 3H), 1.82 (s, 3H), 1.68 (s, 3H), 1.42 (t, J = 7.0 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 168.71, 157.91, 155.05, 147.92, 137.60, 133.73, 130.22, 129.71, 127.06, 125.90, 123.96, 120.78, 120.55, 119.67, 106.82, 103.91, 99.52, 63.88, 55.68, 25.79, 24.88, 24.53, 18.04, 14.93.

(*E*)-2-Amino-*N*-(4-(5-hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)acetamide (31) [KYN-151]



(9H-Fluoren-9-yl)methyl (E)-(2-((4-(5-hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)amino)-2-oxoethyl)carbamate:

Fmocglycine (520 mg, 1.76 mmol, 3.0 equiv), *N*,*N*-Diisopropylethylamine (0.5 mL, 2.95 mmol, 5.0 equiv) and 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (HATU) (900 mg, 2.36 mmol, 4.0 equiv) were sequentially added to a solution of (*E*)-3-(4-amino-3-methoxystyryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (compound **23**) [KYN-125] (200 mg, 0.59 mmol, 1.0 equiv) in dichloromethane (10 mL). The resulting solution was stirred at room temperature for 16 hours. LC-MS analysis indicated the formation of compound 11 and compound 12. The reaction mixture was diluted with dichloromethane (20 mL) and washed with saturated sodium bicarbonate (30 mL). The aqueous layer was extracted with dichloromethane (2 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 24 g column),

2020415711 20 Jan 2025

eluting with a gradient of 0 to 60% ethyl acetate in heptanes to give a mixture of compound **31-1** and compound **31-2** (330 mg) as an off white solid (NRK-1-161).


(*E*)-2-amino-*N*-(4-(5-hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)acetamide (31): 1M lithium hydroxide (5 mL) was added to a solution of compound **31-1** and compound **31-2** (330 mg) in tetrahydrofuran at room temperature. After stirring for 16 hours, the volatiles were removed under reduced pressure. The residue was dissolved in ethyl acetate (30 mL) and washed with saturated ammonium chloride (30 mL). The aqueous layer was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 5% methanol in dichloromethane containing 1% of 7M ammonia in methanol to give compound **31** (25.0 mg, 23 % yield over 2 steps) as an off white solid (NRK-1-164).

(E)-2-amino-N-(4-(5-hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)acetamide (31) [KYN-151]

Off white solid, melting point 196.0 – 201.9°C; HPLC Analysis: 98.7% purity; Wavelength 210 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 5.78 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=397.2 $(M+H)^+$; $C_{23}H_{28}N_2O_4$; ^{1}H NMR (400 MHz, DMSO-d_6) δ = 10.10 (br s, 1H), 9.24 (s, 1H), 8.29 (d, J = 8.3 Hz, 1H), 7.30 – 7.23 (m, 2H), 7.10 (dd, J = 1.7, 8.4 Hz, 1H), 6.90 (d, J = 16.0 Hz, 1H), 6.63 (d, J = 2.2 Hz, 1H), 6.35 (d, J = 2.2 Hz, 1H), 5.00 (septt, J = 1.2, 7.0 Hz, 1H), 3.92 (s, 3H), 3.73 (s, 3H), 3.38 – 3.33 (m, 2H), 3.28 – 3.24 (m, 2H), 2.33 (br s, 2H), 1.76 (s, 3H), 1.60 (s, 3H); ^{13}C NMR (100 MHz, DMSO-d_6) δ = 171.88, 158.45, 156.68, 148.71, 137.47, 133.12, 129.92, 129.83, 127.42, 125.67, 124.51, 119.96, 118.87, 118.69, 108.71, 104.09, 99.11, 56.30. 55.91, 45.67, 25.95, 24.28, 18.20.

(*E*)-2-Amino-*N*-(4-(3-ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)acetamide (32) [KYN-148]

2020415711 20 Jan 2025



(9*H*-Fluoren-9-yl)methyl (*E*)-(2-((4-(3-ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)amino)-2-oxoethyl)carbamate (12):

Fmocglycine (500 mg, 1.71 mmol, 3.0 equiv), *N*,*N*-Diisopropylethylamine (0.5 mL, 2.85 mmol, 5.0 equiv) and 1-[Bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (HATU) (860 mg, 2.28 mmol, 4.0 equiv) were sequentially added to a solution of compound **24** (200 mg, 0.57 mmol, 1.0 equiv) in dichloromethane (10 mL). The resulting solution was stirred at room temperature for 16 hours. LC-MS analysis indicated the formation of compound **32-1** and compound **32-2**. The reaction mixture was diluted with dichloromethane (20 mL) and washed with saturated sodium bicarbonate (30 mL). The aqueous layer was extracted with dichloromethane (2 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 60% ethyl acetate in heptanes to give a mixture of compound **32-1** and compound **32-2** (550 mg) as an off white solid (NRK-1-158).

(*E*)-2-Amino-*N*-(4-(3-ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)acetamide (32) [KYN-148]:


1M lithium hydroxide solution (5 mL) was added to a solution of compound **32-1** and compound **32-2** (550 mg) in tetrahydrofuran (20 mL) at room temperature. After stirring for 16 hours, the volatiles were removed under reduced pressure. The crude was dissolved in ethyl acetate (30 mL) and washed with saturated ammonium chloride (30

2020415711 20 Jan 2025

mL). The aqueous layer was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was first triturated with 30 % ethyl acetate in heptanes (30 mL) to afford a beige solid, which was further purified on a Reveleris automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 5% methanol in dichloromethane containing 1% of 7M ammonia in methanol to give compound **32 [KYN-148]** (30.0 mg, 13% yield over 2 steps) as an off white solid (NRK-1-162).

Off white solid, melting point 200.0 – 203.7°C; HPLC Analysis: 99.5% purity; Wavelength 210 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 8.25 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=411.2 $(M+H)^+$; $C_{24}H_{30}N_2O_4$; ^{1}H NMR (400 MHz, DMSO-d_6) δ = 10.08 (br s, 1H), 9.20 (s, 1H), 8.29 (d, J = 8.3 Hz, 1H), 7.32 – 7.23 (m, 2H), 7.11 (dd, J = 1.5, 8.4 Hz, 1H), 6.90 (d, J = 16.0 Hz, 1H), 6.63 (d, J = 2.1 Hz, 1H), 6.32 (d, J = 2.1 Hz, 1H), 5.01 (br t, J = 7.0 Hz, 1H), 3.95 (q, J = 6.8 Hz, 2H), 3.92 (s, 3H), 3.40 – 3.34 (m, 2H), 3.29 – 3.24 (m, 2H), 2.33 (br s, 2H), 1.77 (s, 3H), 1.61 (s, 3H), 1.33 (t, J = 6.9 Hz, 3H); ^{13}C NMR (100 MHz, DMSO-d_6) δ = 171.88, 157.72, 156.59, 148.71, 137.46, 133.14, 129.87, 129.73, 127.41, 125.74, 124.54, 119.93, 118.86, 108.74, 104.08, 99.92, 63.74, 56.32, 45.67, 25.99, 24.35, 18.25, 15.25.

Methyl (*E*)-(4-(5-hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)glycinate (33) [KYN-126]:



N,*N*-Diisopropylethylamine (0.5 mL, 2.92 mmol, 4 equiv) and methyl bromoacetate (0.2 mL, 2.21 mmol, 3 equiv) were sequentially added to a solution of compound **23**


2020415711 20 Jan 2025

[KYN-125] in anhydrous THF (10 mL) at room temperature. After refluxing (66°C) for 16 hours, the reaction was cooled to room temperature and the volatiles were removed under reduced pressure. The residue was dissolved in ethyl acetate (30 mL) and washed with saturated sodium bicarbonate (20 mL). The aqueous layer was extracted with ethyl acetate (2 X 30 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (RediSep Rf Gold HP C18, 50 g column), eluting with a gradient of 0 to 70% acetonitrile in water to give compound **33 [KYN-126]** (180 mg, 59% yield) as an off white solid. (NRK-1-65-1).

Off white grey solid, melting point 147.3 – 160.2°C; HPLC Analysis: 98.1% purity; Wavelength 210 nm, bandwidth 4; Column: Luna C18(2), 2.0 x 20 mm, 3 µm; Retention Time: 3.84 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=412.2 $(M+H)^+$; $C_{24}H_{29}NO_5$; ^{1}H NMR (400 MHz, $CDCl_3$) δ = 7.10 (d, J = 16.2 Hz, 1H), 6.97 (dd, J = 1.6, 6.7 Hz, 1H), 6.96 (br s, 1H), 6.84 (d, J = 15.8 Hz, 1H), 6.65 (d, J = 2.4 Hz, 1H), 6.45 (d, J = 8.6 Hz, 1H), 6.34 (d, J = 2.4 Hz, 1H), 5.13 (tm, J = 1.5, 6.9 Hz, 1H), 4.92 (br t, J= 4.3 Hz, 1H), 4.75 (br s, 1H), 3.98 (d, J = 5.1 Hz, 2H), 3.91 (s, 3H), 3.80 (s, 3H), 3.79 (s, 3H), 3.41 (d, J = 6.6 Hz, 2H), 1.82 (d, J = 0.7 Hz, 3H), 1.68 (d, J = 1.2 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 171.44, 158.55, 154.37, 147.19, 138.52, 137.00, 130.88, 130.47, 127.54, 123.79, 122.63, 120.85, 120.50, 109.64, 107.10, 103.78, 97.92, 55.69, 55.47, 52.26, 45.43, 25.76, 24.47, 17.98.

Methyl (*E*)-(4-(3-ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)glycinate (34) [KYN-147]

2020415711 20 Jan 2025



Methyl (*E*)-(4-(3-ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)glycinate (34) [KYN-147]:


N,*N*-Diisopropylethylamine (0.4 mL, 2.24mmol, 4 equiv) and methyl bromoacetate (0.21 mL, 1.68 mmol, 3 equiv) were sequentially added to a solution of compound **24** (200 mg, 0.56 mmol, 1.0 equiv) in anhydrous THF (20 mL) at room temperature. After refluxing (66°C) for 16 hours, the reaction mixture was cooled to room temperature and the volatiles were removed under reduced pressure. The residue was dissolved in ethyl acetate (30 mL) and transferred to a separatory funnel containing saturated sodium bicarbonate solution (20 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 30 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was initially purified on a Reveleris automated chromatography system (Redisep Rf Gold HP C18, 50 g column), eluting with a gradient of 0 to 60% acetonitrile in water. The product was triturated with 10% ethyl acetate in heptanes (10 mL) to give compound **34 [KYN-147]** (40 mg, 17% yield) as an off white solid. (NRK-1-151)

Off white solid, melting point 144 – 169°C; HPLC Analysis: 97.3% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 10.06 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=426.2 $(M+H)^+$; $C_{25}H_{31}NO_5$; ^1H NMR (400 MHz, $CDCl_3$) δ = 7.11 (d, J = 16.0 Hz, 1H), 6.99 – 6.94 (m, 2H), 6.84 (br d, J = 16.0 Hz, 1H), 6.63 (d, J = 2.3 Hz, 1H), 6.45 (d, J = 8.6 Hz, 1H), 6.31 (d, J = 2.4 Hz, 1H), 5.14 (septett, J = 1.3, 7.0 Hz, 1H), 4.92 (br s, 1H), 4.73 (br s, 1H), 3.99 (q, J = 7.0 Hz, 2H), 3.97 (s, 2H), 3.91 (s, 3H), 3.79 (s, 3H), 3.43 (br d, J = 6.8 Hz, 2H), 1.82 (s, 3H), 1.68 (d, J = 0.9 Hz, 3H), 1.41 (t, J = 7.0 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 171.44, 157.88, 154.27, 147.20,

2020415711 20 Jan 2025

138.45, 136.96, 130.77, 130.28, 127.59, 123.86, 122.74, 120.82, 120.65, 109.66, 107.14, 103.69, 98.79, 63.91, 55.48, 52.25, 45.44, 25.79, 24.54, 18.04, 14.92.

(*E*)-2-((4-(3-Ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)amino)-2-oxoacetic acid (35) [KYN-152]



(*E*)-3-Ethoxy-5-(3-methoxy-4-(2-methoxy-2-oxoacetamido)styryl)-4-(3-methylbut-2-en-1-yl)phenyl methyl oxalate (35-1):

Methyl chlorooxoacetate (0.1 mL, 0.85 mmol, 2.5 equiv) was added to a solution of triethylamine (0.25 mL, 1.7 mmol, 5.0 equiv) and compound **24 [KYN-141]** (120 mg, 0.34 mmol, 1.0 equiv) in tetrahydrofuran (20 mL) at 5°C. The reaction mixture was warmed to room temperature and stirred for 16 hours. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was dissolved in ethyl acetate (20 mL) and washed with saturated ammonium chloride (20 mL). The aqueous layer was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 60% ethyl acetate in heptanes to give compound **35-1** (130.0 mg, 73%) as a beige solid (NRK-1-168).

(*E*)-2-((4-(3-Ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)amino)-2-oxoacetic acid (35) [KYN-152]:


1M lithium hydroxide (0.75 mL, 0.75 mmol, 3.0 equiv) was added to a solution of compound **35-1** (130 mg, 0.25 mmol, 1.0 equiv) in tetrahydrofuran (20 mL) at room

2020415711 20 Jan 2025

temperature. After stirring for 16 hours, the volatiles were removed under reduced pressure. The residue was dissolved in ethyl acetate (30 mL) and washed with 1M HCl (10 mL). The aqueous layer was extracted with ethyl acetate (2 x 30 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was triturated with 10% ethyl acetate in heptanes (20 mL) to give compound **35 [KYN-152]** (42.0 mg, 38% yield) as an off white solid (NRK-1-170).

Off white solid, melting point 207.8 – 207.9°C; HPLC Analysis: 99.1% purity; Wavelength 210 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 8.24 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (negative mode) m/z=424.1 $(M-H)^-$; $C_{24}H_{27}NO_6$; ^1H NMR (400 MHz, DMSO-d_6) δ = 9.63 (s, 1H), 9.21 (br s, 1H), 8.10 (d, J = 8.3 Hz, 1H), 7.38 – 7.29 (m, 2H), 7.18 (br d, J = 8.4 Hz, 1H), 6.93 (d, J = 16.1 Hz, 1H), 6.63 (d, J = 2.0 Hz, 1H), 6.33 (d, J = 2.1 Hz, 1H), 5.01 (br t, J = 7.0 Hz, 1H), 4.06 – 3.91 (m, 5H), 3.38 (br d, J = 6.8 Hz, 2H), 1.76 (s, 3H), 1.60 (s, 3H), 1.33 (t, J = 6.9 Hz, 3H); ^{13}C NMR (100 MHz, DMSO-d_6) δ = 162.25, 157.73, 156.61,156.08, 149.59, 137.30, 135.11, 129.78, 129.62, 126.77, 125.77, 124.51, 120.32, 119.82, 119.04, 109.14, 104.17, 100.10, 63.75, 56.53, 25.99, 24.35, 18.26, 15.25.

(*E*)-4-((4-(5-Hydroxy-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)amino)-4-oxobutanoic acid (compound 36) [KYN-150]



Succinic anhydride (140 mg, 1.4 mmol, 4.0 equiv) and *N*,*N*-diisopropylethylamine (0.36 mL, 2.1 mmol. 6.0 equiv) were sequentially added to a solution of **(*E*)-3-(4-amino-3-methoxystyryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenol (compound**

2020415711 20 Jan 2025


23) [KYN-125] (120 mg, 0.35 mmol, 1.0 equiv) in toluene (20 mL). The resulting cloudy solution was refluxed (110°C) for 16 hours (clear solution on heating). The reaction mixture was cooled to room temperature and diluted with ethyl acetate (20 mL). The organic layer was washed with saturated ammonium chloride (20 mL). The aqueous layer was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give a mixture of compound **36-1** and compound **36** (210 mg) as a light brown oil. The residue was dissolved in tetrahydrofuran (10 mL) and treated with 1M lithium hydroxide (1.0 mL) at room temperature for 16 hours. The reaction mixture was evaporated to dryness and the resulting residue was dissolved in ethyl acetate (20 mL). The organic layer was washed with saturated ammonium chloride (20 mL). The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The residue was triturated with 10% ethyl acetate in heptanes (10 mL). The product was suspended in diethyl ether (10 mL) and stirred at room temperature for 16 hours. The suspension was filtered to afford compound **36** (60 mg, 40% yield over 2 steps) as a light grey solid. (NRK-1-163).

(E)-N-((4-(3-methoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2methoxyphenyl)amino)-4-oxobutanoic acid (compound 36) [KYN-150]

Light grey solid, melting point 169.4 – 175.7°C; HPLC Analysis: 97.8% purity; Wavelength 210 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 7.98 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (negative mode) m/z=438.2 $(M-H)^-$; $C_{25}H_{29}NO_6$; ^1H NMR (400 MHz, Acetonitrile-d_3) δ = 8.25 (br s, 1H), 8.21 (br d, J = 8.3 Hz, 1H), 7.28 (d, J = 16.1 Hz, 1H), 7.17 (d, J = 1.7 Hz, 1H), 7.07 (dd, J = 1.8, 8.4 Hz, 1H), 6.94 (d, J = 16.1 Hz, 1H), 6.68 (d, J = 2.3 Hz, 1H), 6.39 (d, J = 2.3 Hz, 1H), 5.05 (septt, J = 1.4, 6.8 Hz, 1H), 3.92 (s, 3H), 3.77 (s, 3H), 3.41 (br d, J = 6.8 Hz, 2H), 2.70 – 2.65 (m, 2H), 2.64 – 2.60 (m, 2H), 1.80 (d, J = 0.7 Hz, 3H), 1.64 (d, J = 1.1 Hz, 3H); ^{13}C NMR (100 MHz, Acetonitrile-d_3) δ = 174.42, 171.50, 159.61, 156.96, 138.79, 131.50, 130.93, 128.74, 126.52, 124.90, 120.85, 120.77, 120.69, 109.17, 104.80, 99.68, 56.67. 56.39, 32.51, 29.64, 25.88, 24.99, 18.23.

2020415711 20 Jan 2025

(*E*)-4-((4-(3-Ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)amino)-4-oxobutanoic acid (37) [KYN-144]




(*E*)-4-((4-(3-Ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)amino)-4-oxobutanoic acid (compound 37) [KYN-144]:

Succinic anhydride (58 mg, 0.58 mmol, 2.0 equiv) and *N*,*N*-diisopropylethylamine (0.15 mL, 0.87 mmol. 3.0 equiv) were sequentially added to a solution of compound **24** (100 mg, 0.29 mmol, 1.0 equiv) in toluene (20 mL). The resulting cloudy solution was refluxed (110°C) for 16 hours (clear solution on heating). The reaction mixture was cooled to room temperature and diluted with ethyl acetate (20 mL). The organic layer was washed with saturated ammonium chloride (20 mL). The aqueous layer was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give a mixture of compound **37-1** and compound **37** (165 mg) as a light brown solid. The residue was dissolved in tetrahydrofuran (10 mL) and treated with 1M lithium hydroxide solution (1.0 mL) at room temperature for 16 hours. The reaction mixture was evaporated to dryness and the resulting residue was dissolved in ethyl acetate (20 mL). The organic layer was washed with saturated ammonium chloride (20 mL). The organic layer was collected, dried over sodium sulfate and concentrated under reduced pressure. The residue was triturated with 10% ethyl acetate in heptanes (10 mL). The product was suspended in diethyl ether (10 mL) and stirred at room temperature for 16 hours. The suspension was filtered to afford compound **37 [KYN-144]** (40 mg, 31% yield over 2 steps) as a light grey solid. (NRK-1-148)

2020415711 20 Jan 2025

Light grey solid, melting point 173 – 180°C; HPLC Analysis: 96.4% purity; Wavelength 254 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 8.52 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (negative mode) m/z=452.2 $(M-H)^-$; $C_{26}H_{31}NO_6$; ^1H NMR (400 MHz, Acetonitrile-d_3) δ = 8.25 (br s, 1H), 8.21 (br d, J = 8.3 Hz, 1H), 7.29 (d, J = 16.1 Hz, 1H), 7.17 (d, J = 1.7 Hz, 1H), 7.07 (dd, J = 1.7, 8.3 Hz, 1H), 6.94 (d, J = 16.1 Hz, 1H), 6.67 (d, J = 2.3 Hz, 1H), 6.36 (d, J = 2.3 Hz, 1H), 5.07 (septett, J = 1.5, 7.0 Hz, 1H), 3.99 (q, J = 7.0 Hz, 2H), 3.92 (s, 3H), 3.43 (br d, J = 7.0 Hz, 2H), 2.70 – 2.65 (m, 2H), 2.64 – 2.60 (m, 2H), 1.80 (s, 3H), 1.64 (d, J = 1.0 Hz, 3H), 1.37 (t, J = 7.0 Hz, 3H); ^{13}C NMR (100 MHz, Acetonitrile-d_3) δ = 174.41, 171.48, 158.91, 156.86, 149.80, 138.77, 134.49, 131.38, 130.85, 128.72, 126.61, 124.95, 120.95, 120.84, 120.68, 109.18, 104.74, 100.55, 64.93, 55.67, 32.52, 29.64, 25.90, 25.07, 18.32, 15.30.

(*E*)-1-(4-(3-Ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)guanidine (38) [KYN-155]



(*E*)-1-(4-(3-ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)guanidine (38) [KYN-155]:

Cyanamide (237 mg, 5.66 mmol, 20.0 equiv) and *p*-toluenesulfonic acid (1.07 g, 5.66 mmol, 20.0 equiv) were added to a solution of compound **24** (100 mg, 0.28 mmol, 1.0 equiv) in ethanol (50 mL).

After refluxing (79°C) for 16 hours, additional cyanamide (237 mg, 5.66 mmol, 20.0 equiv) and *p*-toluenesulfonic acid (1.07 g, 5.66 mmol, 20.0 equiv) were added to the

2020415711 20 Jan 2025

reaction mixture, which was refluxed an additional16 hours. The reaction mixture was cooled to room temperature and the volatiles were removed under reduced pressure. The residue was dissolved in ethyl acetate (50 mL) and washed with saturated sodium bicarbonate (50 mL). The aqueous layer was extracted with ethyl acetate (2 x 30 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. Additional compound **24** (100 mg) was converted to compound **38** in a similar manner. The combined residue was first purified on a Reveleris automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 15% methanol in dichloromethane containing 5% of 7M ammonia in methanol to afford relatively pure **38**. The product was further purified on a Reveleris automated chromatography system (Redisep Rf Gold HP C18, 50 g column), eluting with a gradient of 0 to 45% acetonitrile in water containing 10 mM ammonium bicarbonate and 5% methanol to afford compound **38 [KYN-155]** (37.0 mg, 16% yield) as a white solid (NRK-1-177).

White solid, melting point 130.5 – 130.6°C; HPLC Analysis: 99.7% purity; Wavelength 210 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 6.45 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=396.2 $(M+H)^+$; $C_{23}H_{29}N_3O_3$; ^{1}H NMR (400 MHz, DMSO-d_6) δ = 7.20 (d, J = 16.0 Hz, 1H), 7.11 (s, 1H), 7.01 (d, J = 7.5 Hz, 1H), 6.96 – 6.80 (m, 2H), 6.62 (d, J = 2.2 Hz, 1H), 6.30 (d, J = 2.2 Hz, 1H), 5.06 – 4.98 (m, 1H), 3.94 (q, J = 6.9 Hz, 2H), 3.82 – 3.72 (m, 3H), 3.35 (br d, J = 6.8 Hz, 2H), 1.77 (s, 3H), 1.61 (s, 3H), 1.33 (t, J = 6.9 Hz, 3H); ^{13}C NMR (100 MHz, DMSO-d_6) δ = 157.70, 156.60, 153.04, 137.68, 130.36, 129.71, 124.83, 124.59, 124.37, 120.26, 118.60, 110.05, 103.97, 99.72, 63.74, 55.76, 25.99, 24.34, 18.27, 15.27.

(*E*)-*N*-(4-(3-ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenyl)-N-hydroxyacetamide (compound 39) [KYN-165]

2020415711 20 Jan 2025




5% Rhodium on activated charcoal (5 mg, 0.672 µmol, 0.003 equiv) and hydrazine monohydrate (27 mg, 0.27 mmol, 1.2 equiv) were added to a solution of compound **24-3** (86 mg, 0.224 mmol, 1.0 equiv) in tetrahydrofuran (8 mL) at 0°C. After stirring at 0°C for 1 hour, sodium bicarbonate (75 mg, 0.896 mmol, 4 equiv) and acetyl chloride (53 mg, 0.672 mmol, 3 equiv) were sequentially added to the reaction. The mixture was warmed to room temperature and stirred for 1 hour. The suspension was diluted with ethyl acetate (30 mL) and washed with saturated ammonium chloride (10 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an InterChim automated chromatography system (25 g column), eluting with a gradient of 0 to 100% ethyl acetate in heptanes, to give compound **39** (44 mg, 44% yield) as an off-white oil. (LM-8-65)

HPLC Analysis: 97.2% purity; Wavelength 254 nm, bandwidth 4; Column: Waters Atlantis T3, 2.1 x 50 mm, 3 µm; Retention Time: 8.3 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=412.2 $(M+H)^+$; $C_{24}H_{29}NO_5$; ^1H NMR (400 MHz, $CDCl_3$) δ = 9.69 – 7.44 (m, 1H), 7.40 – 7.28 (m, 2H), 7.08 (br d, J = 6.6 Hz, 1H), 7.02 (s, 1H), 6.87 (br d, J = 15.4 Hz, 1H), 6.70 (br s, 1H), 6.41 (br s, 1H), 5.12 (br t, J = 6.7 Hz, 1H), 3.98 (q, J = 6.9 Hz, 2H), 3.86 (s, 3H), 3.43 (br d, J = 6.5 Hz, 2H), 1.97 (br s, 3H), 1.80 (s, 3H), 1.67 (s, 3H), 1.40 (t, J = 6.9 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 167.75, 157.86, 155.23, 154.91, 141.36, 136.98, 130.47, 130.07, 128.96, 126.01, 123.73, 120.97, 119.27, 109.83, 104.13, 100.11, 63.93, 55.75, 25.75, 24.48, 19.41, 18.01, 14.87.

(E)-N-(4-(3-Ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-hydroxyphenyl)formamide (40) [KYN-159]

2020415711 20 Jan 2025



5-(hydroxymethyl)-2-nitrophenol (40-2): Sodium borohydride (2.27 g, 59.88 mmol, 1.0 equiv) was added in two portions to a solution of compound **40-1** (10.0 g, 59.88 mmol, 1.0 equiv) in methanol at 0 °C. The resulting solution was stirred at room temperature for 1 hour. The reaction mixture was quenched by the addition of water (20 mL). The volatiles were removed under reduced pressure and the resulting crude residue was dissolved in ethyl acetate (150 mL) and washed with 1M HCl (100 mL). The aqueous layer was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over sodium sulfate and evaporated under reduced pressure to give compound **40-2** (9.98 g, 98% yield) as a yellow solid (NRK-1-202), which was used subsequently.

5-(Bromomethyl)-2-nitrophenol (40-3): Carbon tetrabromide (4.05 g, 12.18 mmol, 2.0 equiv) was added in 4 portions to a solution of compound **40-2** (1.0 g, 6.09 mmol, 1.0 equiv) and triphenylphosphine (3.19 g, 12.18 mmol, 2.0 equiv) in dichloromethane (50 mL) at 0°C. The resulting solution was stirred at room temperature for 16 hours. The reaction mixture was quenched by the addition of 1M HCl (40 mL). The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 20 mL). The combined organic layers were dried over sodium sulfate and evaporated under reduced pressure. The residue was purified on a Reveleris automated chromatography

2020415711 20 Jan 2025

system (Sorbtech 40 g column), eluting with a gradient of 0 to 40% ethyl acetate in heptanes to give compound **40-3** (1.5 g, 92% yield) as a yellow solid (NRK-6-23).

Diethyl (3-hydroxy-4-nitrobenzyl)phosphonate (40-4): Triethylphosphite (3.3 mL, 19.39 mmol, 3.0 equiv) was added to a solution of compound **40-3** (1.5 g, 6.46 mmol, 1.0 equiv) in toluene (30 mL). The resulting solution was refluxed (110°C) for 20 hours. After cooling to room temperature, the volatiles were removed under reduced pressure. The crude residue was dissolved in dichloromethane (50 mL) and washed with 1M sodium hydroxide (100 mL). The aqueous layer was neutralized with 1M hydrochloric acid (150 mL). The resulting aqueous layer was extracted with ethyl acetate (3 x 100 mL). The combined organic layers were dried over sodium sulfate and evaporated under reduced pressure to give compound **40-4** (1.0 g, 56% yield) as a yellow solid, which was used subsequently. (NRK-6-24)

Diethyl (4-nitro-3-((2-(trimethylsilyl)ethoxy)methoxy)benzyl)phosphonate (40-5): 2-(Trimethylsilyl)ethoxymethyl chloride (0.6 mL,3.46 mmol, 1.0 equiv) and *N*,*N*-diisopropylethylamine (0.9 mL, 5.19 mmol, 1.5 equiv) were sequentially added to a solution of compound **40-4** (1.0 g, 3.46 mmol, 1.0 equiv) in dichloromethane (50 mL) at room temperature. After stirring for 20 hours, the reaction mixture was diluted with saturated sodium bicarbonate (30 mL).The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give compound **5** (1.02 g, 71% yield) as a yellow oil, which was used subsequently. (NRK-6-29)

(*E*)-(2-((5-(2-Bromo-3-ethoxy-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-2-nitrophenoxy)methoxy)ethyl)trimethylsilane (40-6): Potassium *tert*-butoxide (800 mg, 7.06 mmol, 2 equiv) was added in 3 portions to a solution of compound **5** (1.02 g, 3.53 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (50 mL) at 0°C. The mixture was warmed up to room temperature and stirred for 30 minutes. A solution of **Module D** (1.32 g, 3.53 mmol, 1 equiv) in anhydrous tetrahydrofuran (20 mL) was added dropwise and the mixture was stirred at room temperature for 16 hours. The reaction

2020415711 20 Jan 2025

was carefully quenched with saturated brine (20 mL, 1 drop per minute for the first 5 mL brine) at 0°C. The volatiles were removed under reduced pressure. Saturated ammonium chloride (50 mL) was added and the mixture was extracted with ethyl acetate (2 x 60 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 40 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **40-6** (867 mg, 39% yield) as a yellow oil. (NRK-6-31)

(*E*)-(2-((5-(3-Ethoxy-2-(3-methylbut-2-en-1-yl)-5-((2-(trimethylsilyl)ethoxy) methoxy)styryl)-2-nitrophenoxy)methoxy)ethyl)trimethylsilane (40-7): Tetrakis (triphenylphosphine)palladium(0) (156 mg, 0.14 mmol, 0.1 equiv), potassium carbonate (373 mg, 2.7 mmol, 2 equiv), 3-methylbut-2-enylboronic acid pinacol ester (530 mg, 2.7 mmol, 2 equiv) and water (3 mL) were added sequentially to a solution of compound **40-6** (867 mg, 1.4 mmol, 1 equiv) in 1,4-dioxane (30 mL) in a sealed tube. After sparging with nitrogen for 10 minutes, the reaction was heated at 100°C for 16 hours. LCMS analysis indicated formation of the desired compound **40-7** (70 % conversion). Additional 3-methylbut-2-enylboronic acid pinacol ester (530 mg, 2.7 mmol, 2 equiv) was added, and the reaction mixture was heated at 100°C for 16 hours. After cooling to room temperature, the reaction mixture was filtered through Celite and the filtrate evaporated under reduced pressure. The residue was suspended in saturated ammonium chloride (20 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 40 g column), eluting with a gradient of 0 to 30% ethyl acetate in heptanes to give compound **40-7** (852 mg, 99% yield) as a yellow oil. (NRK-6-37)

(*E*)-3-Ethoxy-5-(3-hydroxy-4-nitrostyryl)-4-(3-methylbut-2-en-1-yl)phenol (40-8): 1M Tetrabutylammonium fluoride in tetrahydrofuran (19 mL, 18.90 mmol, 14 equiv) was added to a solution of compound **40-7** (852 mg, 1.36 mmol, 1 equiv) in tetrahydrofuran (20 mL) at room temperature. After heating at 67°C for 16 hours, the

2020415711 20 Jan 2025

mixture was cooled to room temperature and diluted with water (10 mL) and saturated ammonium chloride (30 mL). The volatiles were removed under reduced pressure and the remaining aqueous layer was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 40 g column), eluting with a gradient of 0 to 80% ethyl acetate in heptanes to give compound **40-8** (410 mg, 83% yield) as a yellow solid. (NRK-6-26)

(*E*)-3-(4-Amino-3-hydroxystyryl)-5-ethoxy-4-(3-methylbut-2-en-1-yl)phenol (40-9): Activated zinc powder (730 mg, 11.1 mmol, 10.0 equiv), ammonium chloride (590 mg, 11.1 mmol, 10.0 equiv) and water (5 mL) were added sequentially to a solution of compound **40-8** (410 mg, 1.11 mmol, 1.0 equiv) in tetrahydrofuran (20 mL) at room temperature. The resulting suspension was stirred at room temperature for 16 hours. The suspension was filtered and the solids were washed with ethyl acetate (20 mL). The filtrate was evaporated to dryness under reduced pressure. The residue was suspended in saturated ammonium chloride (20 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 80% ethyl acetate in heptanes to give compound **40-9** (234 mg, 63% yield) as a pale yellow solid. (NRK-6-39)


(*E*)-*N*-(4-(3-Ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-hydroxyphenyl)formamide (40) [KYN-159]: Compound **40-9** (100 mg, 0.3 mmol, 1.0 equiv) was added to ethyl formate (10 mL) and the reaction was heated at 55°C for 20 hours. The reaction mixture was cooled to room temperature and evaporated to dryness under reduced pressure. The residue was dissolved in ethyl acetate (20 mL) and washed with saturated ammonium chloride (20 mL). The aqueous layer was extracted with ethyl acetate (2 x 15 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 24 g column), eluting with a

2020415711 20 Jan 2025

gradient of 0 to 80% ethyl acetate in heptanes. The product was triturated with 10% ethyl acetate in heptanes (10 mL) to afford compound **40** (74 mg, 69% yield) as an off-white solid. (NRK-6-41).

Off-white solid; melting point 157.9 – 162.9°; HPLC Analysis: 97.0% purity; Wavelength 210 nm, bandwidth 4; Column: Waters Atlantis T3, 2.1 x 50 mm, 3 µm; Retention Time: 8.4 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=368.2 $(M+H)^+$; $C_{22}H_{25}NO_4$; ^1H NMR (400 MHz, DMSO-d_6) δ = 10.04 (br s, 1H), 9.63 (s, 1H), 9.19 (br s, 1H), 8.28 (d, J = 1.7 Hz, 1H), 8.04 (d, J = 8.3 Hz, 1H), 7.16 (d, J = 16.1 Hz, 1H), 7.05 (d, J = 1.7 Hz, 1H), 6.97(dd, J = 1.7, 8.3 Hz, 1H), 6.83 (d, J = 16.1 Hz, 1H), 6.62 (d, J = 2.2 Hz, 1H), 6.31 (d, J = 2.1 Hz, 1H), 5.02 (br t, J = 7.0 Hz, 1H), 3.94 (q, J = 6.9 Hz, 2H), 3.34 (br s, 2H), 1.75 (s, 3H), 1.62 (s, 3H), 1.33 (t, J = 6.9 Hz, 3H); ^{13}C NMR (100 MHz, DMSO-d_6) δ = 160.41, 157.69, 156.59, 147.23, 137.32, 133.69, 130.08, 129.78, 126.32, 125.48, 124.32, 121.06, 118.76, 118.45, 112.80, 104.10, 99.93, 63.75, 25.99, 24.29, 18.28, 15.25.

(*E*)-*N*-(5-(3-Ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-hydroxyphenyl)formamide (41) [KYN-161]



(*E*)-(2-((4-(2-Bromo-3-ethoxy-5-((2-(trimethylsilyl)ethoxy) methoxy)styryl)-2-nitrophenoxy)methoxy)ethyl)trimethylsilane (41-1):

2020415711 20 Jan 2025

A 60% dispersion of sodium hydride in mineral oil (1.09 g, 45.52 mmol, 4 equiv) was added in 2 portions to a solution of compound **15-5** (3.29 g, 11.38 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (60 mL) at 0°C. The mixture was warmed to room temperature and stirred for 30 minutes. A solution of **Module D** (4.3 g, 11.38 mmol, 1 equiv) in anhydrous tetrahydrofuran (20 mL) was added dropwise and the mixture was stirred at room temperature for 16 hours. The reaction was carefully quenched with saturated brine (20 mL, 1 drop per minute for the first 5 mL brine) at 0°C. The volatiles were removed under reduced pressure. Saturated ammonium chloride (60 mL) was added and the mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 80 g column), eluting with a gradient of 0 to 10% ethyl acetate in heptanes to give compound **41-1** (740 mg, 16% yield) as a yellow oil. (NRK-6-48)

(*E*)-(2-((4-(3-Ethoxy-2-(3-methylbut-2-en-1-yl)-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-2-nitrophenoxy) methoxy)ethyl)trimethylsilane (41-2):

Tetrakis(triphenylphosphine)palladium(0) (120 mg, 0.1 mmol, 0.1 equiv), potassium carbonate (276 mg, 2.0 mmol, 2 equiv), 3-methylbut-2-enylboronic acid pinacol ester (400 mg, 2.0 mmol, 2 equiv) and water (2 mL) were added sequentially to a solution of compound **41-1** (640 mg, 1.0 mmol, 1 equiv) in 1,4-dioxane (10 mL) in a sealed tube. After sparging with nitrogen for 10 minutes, the reaction was heated at 100°C for 16 hours. After cooling to room temperature, the reaction mixture was filtered through Celite. The filtrate was concentrated under reduced pressure. The residue was suspended in saturated sodium bicarbonate (30 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 40 g column), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **41-2** (525 mg, 71% yield) as a yellow oil. (NRK-6-53)

2020415711 20 Jan 2025

(*E*)-3-Ethoxy-5-(4-hydroxy-3-nitrostyryl)-4-(3-methylbut-2-en-1-yl)phenol (41-3):

1M Tetrabutylammonium fluoride in tetrahydrofuran (12 mL, 11.68 mmol, 14 equiv) was added to a solution of compound **41-2** (525 mg, 0.84 mmol, 1 equiv) in tetrahydrofuran (12 mL) at room temperature. After heating at 67°C for 16 hours, the mixture was cooled to room temperature and diluted with water (20 mL) and 1M HCL (30 mL). The volatiles were removed under reduced pressure and the remaining aqueous layer was extracted with ethyl acetate (3 x 30 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 80 g column), eluting with a gradient of 0 to 60% ethyl acetate in heptanes to give compound **41-3** (120 mg, 40% yield) as a yellow solid. (NRK-6-54)

(*E*)-3-(3-Amino-4-hydroxystyryl)-5-ethoxy-4-(3-methylbut-2-en-1-yl)phenol (41-4):

Activated zinc powder (210 mg, 3.26 mmol, 10.0 equiv), ammonium chloride (176 mg, 3.26 mmol, 10.0 equiv) and water (2 mL) were added sequentially to a solution of compound **41-3** (120 mg, 0.326 mmol, 1.0 equiv) in tetrahydrofuran (10 mL) at room temperature. The resulting suspension was stirred at room temperature for 16 hours. The suspension was filtered through Celite, which was washed with ethyl acetate (20 mL). The filtrate was concentrated to dryness under reduced pressure. The residue was suspended in saturated ammonium chloride (20 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 60% ethyl acetate in heptanes to give compound **41-4** (100 mg, 91% yield) as a pale yellow solid. (NRK-6-55)

(*E*)-*N*-(5-(3-Ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-2-hydroxyphenyl)formamide (41) [KYN-161]:

2020415711 20 Jan 2025

A solution of compound **41-4** (100 mg, 0.3 mmol, 1.0 equiv) in ethyl formate (10 mL) was heated at 55°C for 20 hours. The reaction mixture was cooled to room temperature and concentrated to dryness under reduced pressure. The residue was dissolved in ethyl acetate (30 mL) and washed with saturated ammonium chloride (30 mL). The aqueous layer was extracted with ethyl acetate (2 x 30 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 60% ethyl acetate in heptanes to afford compound **41** (80 mg, 73% yield) as a pale yellow solid. (NRK-6-57).


Pale yellow solid; HPLC Analysis: 97.5% purity; Wavelength 254 nm, bandwidth 4; Column: Waters Atlantis T3, 2.1 x 50 mm, 3 μm; Retention Time: 8.3 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=368.2 $(M+H)^+$; $C_{22}H_{25}NO_4$; ^1H NMR (400 MHz, DMSO-d_6) δ = 10.08 (br s, 1H), 9.58 (s, 1H), 9.16 (br s, 1H), 8.31 (d, J = 1.7 Hz, 1H), 8.28 (d, J = 2.1 Hz, 1H), 7.20 – 7.02 (m, 2H), 6.91 – 6.78 (m, 2H), 6.63 – 6.58 (m, 1H), 6.30 (d, J = 2.2 Hz, 1H), 5.00 (br t, J = 7.0 Hz, 1H), 3.94 (q, J = 6.9 Hz, 2H), 3.35 (br s, 1H), 3.31 – 3.28 (m, 1H), 1.77 – 1.70 (m, 3H), 1.67 – 1.47 (m, 3H), 1.33 (t, J = 7.0 Hz, 3H); ^{13}C NMR (100 MHz, DMSO-d_6) δ = 160.55, 157.67, 156.57, 147.20, 137.62, 130.08, 128.90, 126.77, 124.51, 124.29, 123.97, 123.49, 118.83, 118.52, 115.61, 103.97, 99.69, 63.74, 25.96, 24.34, 18.24, 15.26.

(*E*)-2-Methoxy-4-(3-methoxy-2-(3-methylbut-2-en-1-yl)-5-nitrostyryl)phenol (42) [KYN-162]

(*E*)-4-(5-Amino-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenol (S16) (43) [KYN-163]

(*E*)-*N*-(3-(4-Hydroxy-3-methoxystyryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenyl)formamide (S17) (44) [KYN-164]

2020415711 20 Jan 2025



(*E*)-2-Methoxy-6-(3-methoxy-4-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-4-nitrophenol (42-2): A 60% dispersion of sodium hydride in mineral oil (14.2 g, 356 mmol, 9 equiv) was added in one portion to a solution of B4 (**Module B)** (16 g, 39.5 mmol, 1 equiv) in anhydrous tetrahydrofuran (400 mL) at 0°C. The mixture was warmed up to room temperature and stirred 30 minutes. A solution of compound **42-1** (11.7 g, 59.3 mmol, 1.5 equiv) in anhydrous tetrahydrofuran (100 mL) was added dropwise and the mixture was refluxed (68°C) for 16 hours. LCMS analysis indicated ~15% conversion to the product. Additional 60% dispersion of sodium hydride in mineral oil (4.7 g, 119 mmol, 3 equiv) was added and the mixture was refluxed (68°C) for an additional 24 hours. The reaction was cooled to 0°C and carefully quenched with water (40 mL, 1 drop per minute for the first 10 mL and then diluted with saturated ammonium chloride solution (2 L). The mixture was extracted with methyl *tert*-butyl ether (2 L) and ethyl acetate (3 L). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified twice on an Interchim automated chromatography system (2 x 120 g column, stacked), eluting each time with a gradient of 0 to 100% ethyl acetate in heptanes to give compound **42-2** (2.8 g, 16% yield) as a yellow solid. (LM-8-46)

(*E*)-2-(4-Hydroxy-3-methoxystyryl)-6-methoxy-4-nitrophenyl trifluoromethanesulfonate (42-3): Trifluoromethanesulfonic anhydride (1.9 g, 6.7 mmol, 1.07 equiv) was added dropwise over 5 minutes, maintaining the reaction

2020415711 20 Jan 2025

temperature at 0°C, to a solution of compound **42-2** (2.8 g, 6.26 mol, 1.0 equiv) and *N*-methylmorpholine (1.03 mL, 9.4 mmol, 1.5 equiv) in dichloromethane (100 mL) at 0°C. After stirring at 0°C for 3 hours, the reaction mixture was quenched by addition of 10% citric acid (100 mL) over 15 minutes maintaining the reaction temperature below 5°C. The layers were separated and the aqueous layer was extracted with dichloromethane (2 x 100 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (80 g column), eluting with a gradient of 0 to 60% ethyl acetate in heptanes to give compound **42-3** (2.26 g, 80% yield) as a yellow solid. (LM-8-47)

(*E*)-2-Methoxy-4-(3-methoxy-2-(3-methylbut-2-en-1-yl)-5-nitrostyryl)phenol (42) [KYN-162]: Tetrakis(triphenylphosphine)palladium(0) (237 mg, 0.2 mmol, 0.05 equiv), potassium carbonate (1.2 g, 8.2 mmol, 2 equiv), 3-methylbut-2-enylboronic acid pinacol ester (1.6 g, 8.2 mmol, 2 equiv) and water (11 mL) were added sequentially to a solution of compound **42-3** (1.83 g, 4.1 mmol, 1 equiv) in 1,4-dioxane (33 mL). After sparging with nitrogen for 10 minutes, the reaction was heated at 95°C for 16 hours. After cooling to room temperature, the mixture was diluted with saturated ammonium chloride solution (30 mL) and extracted with methyl *tert*-butyl ether (2 x 100 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (120 g column), eluting with a gradient of 0 to 60% ethyl acetate in heptanes to give compound **42** (0.82 g, 54% yield) as a yellow oil. . HPLC Analysis: 97.3% purity; Wavelength 254 nm, bandwidth 4; Column: Waters Atlantis T3, 2.1 x 50 mm, 3 μm; Retention Time: 10.7 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=370.2 $(M+H)^+$; $C_{21}H_{23}NO_5$; ^1H NMR (400 MHz, $CDCl_3$) δ = 8.10 (d, J = 2.2 Hz, 1H), 7.59 (d, J = 2.2 Hz, 1H), 7.18 – 7.13 (m, 1H), 7.08 – 7.01 (m, 3H), 6.94 (d, J = 8.2 Hz, 1H), 5.71 (s, 1H), 5.07 (sptt, J = 1.3, 6.8 Hz, 1H), 3.95 (s, 3H), 3.93 (s, 3H), 3.55 (br d, J = 6.8 Hz, 2H), 1.84 (d, J = 0.9 Hz, 3H), 1.70 (d, J = 1.1 Hz, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ = 157.84, 147.03, 146.73,

2020415711 20 Jan 2025

146.17, 138.48, 135.17, 132.87, 132.61, 129.45, 122.31, 121.10, 120.63, 114.73, 113.29, 108.83, 103.38, 56.10, 55.91, 25.75, 25.52, 18.09.

(*E*)-4-(5-Amino-3-methoxy-2-(3-methylbut-2-en-1-yl)styryl)-2-methoxyphenol (43) [KYN-163]: Water (6 mL), ammonium chloride (613 mg, 11.4 mmol, 10 equiv) and zinc powder (743 mg, 11.4 mmol, 10 equiv) were added sequentially to a solution of compound **42** (420 mg, 1.14 mmol, 1 equiv) in tetrahydrofuran (60 mL) at room temperature. The resulting suspension was stirred at room temperature for 3 hours. The suspension was filtered through Celite, which was washed with ethyl acetate (50 mL). The filtrate was evaporated to dryness under reduced pressure. The residue was purified on an Interchim automated chromatography system (80 g column), eluting with a gradient of 0 to 100% ethyl acetate in heptanes to give compound **43** (60 mg, >95% purity and 180 mg, ~90% purity; 62% yield) as an off-white solid after drying under vacuum at 40°C for 16 hours. (LM-8-53).

Off-white solid; HPLC Analysis: 97.6% purity; Wavelength 254 nm, bandwidth 4; Column: Waters Atlantis T3, 2.1 x 50 mm, 3 μm; Retention Time: 6.7 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=340.2 $(M+H)^+$; $C_{21}H_{25}NO_3$; ^{1}H NMR (400 MHz, DMSO-d_6) δ = 9.08 (s, 1H), 7.12 – 7.04 (m, 2H), 6.91 (dd, J = 1.9, 8.3 Hz, 1H), 6.81 – 6.73 (m, 2H), 6.43 (d, J = 2.0 Hz), 6.17 (d, J = 2.0 Hz), 4.99 (sptt, J = 1.3, 6.8 Hz, 1H), 4.88 (s, 2H), 3.81 (s, 3H), 3.69 (s, 3H), 3.28 (br d, J = 7.0 Hz, 2H), 1.75 (d, J = 0.6 Hz, 3H), 1.60 (d, J = 0.7 Hz, 3H); ^{13}C NMR (100 MHz, DMSO-d_6) δ = 158.21, 148.28, 147.79, 146.99, 137.40, 129.49, 129.22, 125.10, 124.35, 120.35, 116.08, 115.59, 110.09, 103.11, 97.74, 55.99, 55.68, 55.36, 25.97, 24.18, 18.18.


(*E*)-*N*-(3-(4-Hydroxy-3-methoxystyryl)-5-methoxy-4-(3-methylbut-2-en-1-yl)phenyl)formamide (44) [KYN-164]: A solution of compound **43** (90 mg, 0.27 mmol, 1.0 equiv) in ethyl formate (10 mL) was heated at 55°C for 20 hours. The reaction mixture was cooled to room temperature and evaporated to dryness under reduced pressure. The residue was purified on an Interchim automated chromatography system (25 g column), eluting with a gradient of 0 to 60% ethyl acetate in heptanes to

2020415711 20 Jan 2025

give compound **44** (80 mg, 82% yield) as an off-white solid after drying under vacuum at 40°C for 16 hours. (LM-8-57).

Off-white solid; HPLC Analysis: 97.3% purity; Wavelength 254 nm, bandwidth 4; Column: Waters Atlantis T3, 2.1 x 50 mm, 3 µm; Retention Time: 6.7 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=368.2 $(M+H)^+$; $C_{22}H_{25}NO_4$; ^1H NMR (400 MHz, DMSO-d_6) δ = 10.08 (s, 1H), 9.98 (d, J = 11.1 Hz, 1H), 9.15 (s, 1H), 8.90 – 8.80 (m, 1H), 8.27 (d, J = 1.8 Hz, 1H), 7.42 (d, J = 1.8 Hz), 7.22 – 7.11 (m, 2H), 7.07 – 6.91 (m, 2H), 6.87 – 6.70 (m, 2H), 5.04 – 4.96 (m, 1H), 3.82 (s, 3H), 3.78 – 3.74 (m, 3H), 3.40 (br d, J = 6.7 Hz, 2H), 1.77 (s, 3H), 1.61 (s, 3H); ^{13}C NMR (100 MHz, DMSO-d_6) δ = 163.17, 159.99, 157.64, 148.30, 147.31, 137.64, 137.56, 137.52, 130.91, 130.48, 129.07, 123.75, 123.72, 123.52, 123.08, 120.66, 120.60, 116.09, 110.38, 108.53, 101.90, 56.19, 56.03, 56.00, 25.94, 24.56, 18.24.

(E)-4-Bromo-3-(4-hydroxy-3-methoxystyryl)-5-methoxyphenol (45) [KYN-112]:



1.0M Tetrabutylammonium fluoride in THF (2.3 mL, 2.29 mmol, 7 equiv) was added to a solution of (E)-(2-((4-(2-Bromo-3-methoxy-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-2-methoxyphenoxy)methoxy)ethyl)trimethylsilane (**C1**) (200 mg, 0.327 mmol, 1 equiv) in anhydrous THF (5 mL) and refluxed overnight. After cooling to room temperature, the reaction mixture was quenched with water (25 mL) and extracted with ethyl acetate (100 mL). Organic layer was washed with saturated brine (25 mL), dried over sodium sulfate and concentrated under reduced pressure. The residue was purified twice on an AnaLogixs automated system (12 g column), eluting each time with a gradient of 0 to


2020415711 20 Jan 2025

100% ethyl acetate in heptanes to give **Compound 45 [KYN-112]** (21 mg, 18% yield) as brown film. (CSK-2-95)

HPLC Analysis: 94.3% purity; Wavelength 210 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 µm; Retention Time: 7.0 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (negative mode) m/z=349/351 $(M-H)^-$; $C_{16}H_{15}BrO_4$; ^1H NMR (400 MHz, Methanol-d_3) δ = 7.31 (d, J = 16.2 Hz, 1H), 7.10 (d, J = 2 Hz, 1H), 7.00 (dd, J = 2.0, 8.1 Hz, 1H), 6.93 (d, J = 16.1 Hz, 1H), 6.79 (d, J = 8.0 Hz, 1H), 6.75 (d, J = 2.7 Hz, 1H), 6.40 (d, J = 2.7 Hz, 1H), 3.90 (s, 3H), 3.82 (s, 3H); ^{13}C NMR (100 MHz, Methanol-d_3) δ = 158.69, 158.32, 149.15, 148.08, 140.14, 132.49, 130.67, 126.01, 121.41, 116.38, 110.75, 105.77, 103.89, 100.20, 56.57, 56.37.

Preparation of Compound 46 [KYN-145] - (E)-3-(4-hydroxy-3-methoxystyryl)-4-(3-methylbut-2-en-1-yl)-5-(trifluoromethyl)phenol (46) [KYN-145]

Proposed modular synthesis




The following key steps for the modular synthesis is proposed as follows. Reaction of 2-bromo-3-trifluoromethyl-5-((2-trimethylsilyl)ethoxy)methoxy)benzaldehyde (Module

2020415711 20 Jan 2025

A) with B4 (Module B) in the presence of sodium hydride to give the Module C product which may be converted to compound 46 in 2 steps.

Preparation by the rearrangement method



1-Bromo-3-((3-methylbut-2-en-1-yl)oxy)-5-(trifluoromethyl)benzene (46-2):

Potassium carbonate (28 g, 206 mmol, 2 equiv) and 3,3-dimethylallyl bromide (18.5 g, 124.48 mmol, 1.2 equiv) were added sequentially to a solution of compound **46-1** (25.0 g, 107.73 mmol, 1 equiv) in acetonitrile (100 mL) at room temperature. The resulting suspension was refluxed (80°C) for 16 hours. After cooling to room temperature, the reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The crude residue was dissolved in ethyl acetate (300 mL) and washed with 1M hydrochloric acid solution (2 x 70 mL). The organic layer was dried over sodium sulfate and evaporated under reduced pressure to obtain compound **46-2** (31.0 g, 99% yield) as a pale yellow oil (NRK-1-106) which was used subsequently.

2020415711 20 Jan 2025

(*E*)-3-(3-methoxy-4-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-5-(trifluoromethyl)phenol (46-3):

(2-((2-Methoxy-4-vinylphenoxy)methoxy)ethyl)trimethylsilane (**8-5**) (3.97 g, 14.20 mmol, 1.0 equiv), triphenylphosphine (750 mg, 2.84 mmol, 0.2 equiv), potassium carbonate (4.25 g, 30.76 mmol, 2 equiv) and palladium acetate (320 mg, 1.42 mmol, 0.1 equiv) were added to a solution of compound **46-2** (5.0 g, 14.20 mmol, 1.0 equiv) in anhydrous toluene (100 mL) at room temperature. The reaction mixture was sparged with nitrogen for 15 minutes. After refluxing (110°C) for 16 hours, the reaction mixture was cooled to room temperature and filtered through celite (~ 20 g). The filtrate was transferred to a separatory funnel containing saturated sodium bicarbonate (150 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (2 X 50 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 40 g column) eluting with a gradient of 0 to 50% ethyl acetate in heptanes to give **Compound 46-3** (5.25 g, 85% yield) as a pale yellow oil. (NRK-1-107)

(*E*)-(2-((2-methoxy-4-(3-((3-methylbut-2-en-1-yl)oxy)-5-(trifluoromethyl)styryl)phenoxy)methoxy)ethyl)trimethylsilane (46-4):

Potassium carbonate (3.36 g, 24.40 mmol, 2 equiv) and 3,3-dimethylallyl bromide (2.18 g, 14.64 mmol, 1.2 equiv) were added successively to a solution of **Compound 46-3** (5.25 g, 12.20 mmol, 1 equiv) in acetonitrile (150 mL) at room temperature. After refluxing (80°C) for 16 hours, the reaction was cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure. The crude residue was dissolved in ethyl acetate (100 mL) and washed with 1M hydrochloric acid solution (2 x 50 mL). The organic layers was dried over sodium sulfate and evaporated under reduced pressure to give **Compound 46-4** (5.0 g, 80% yield) as a pale yellow oil, which was used subsequently. (NRK-1-111)

2020415711 20 Jan 2025

(*E*)-2-methoxy-4-(3-((3-methylbut-2-en-1-yl)oxy)-5-(trifluoromethyl)styryl)phenol (46-5):

1M Tetrabutylammonium fluoride in THF (69 mL, 68.78 mmol, 7 equiv) was added to a solution of **Compound 46-4** (5.0 g, 9.82 mmol, 1 equiv) in anhydrous THF (200 mL) at room temperature. After refluxing (66°C) for 16 hours, analysis LCMS indicated that the reaction was complete. The mixture was cooled to room temperature and diluted with water (20 mL). The volatiles were removed under reduced pressure. The mixture was diluted with ethyl acetate (150 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on a Reveleris automated chromatography system (Sorbtech 80 g column) eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give **Compound 46-5** (3.25 g, 87 % yield) as a pale yellow solid. (NRK-1-113)

(*E*)-3-(4-hydroxy-3-methoxystyryl)-4-(3-methylbut-2-en-1-yl)-5-(trifluoromethyl)phenol (46) [KYN-145]:

Montmorillonite K30 powder (3.25 g) was added to a solution of **Compound 46-7** (3.2 g, 8.89 mmol) in anhydrous dichloromethane (200 mL) at room temperature. After stirring overnight. LCMS analysis indicated that 10-15% of desired **Compound 46** was formed, along with two regio-isomers and unreacted starting **Compound 46-5** as by-products. The mixture was filtered and treated with fresh montmorillonite K30 powder (3.2 g) at room temperature for an additional 24 hours. The reaction mixture was filtered and the solids were washed with dichloromethane (2 x 50 mL). The combined filtrates was concentrated under reduced pressure. The residue was first purified on a Reveleris automated chromatography system (Sorbtech 80 g column), eluting with a gradient of 0 to 50% ethyl acetate in heptanes to give several mixed fractions containing **Compound 46**. The fractions were collected and purified again on a Reveleris automated chromatography system (Sorbtech 24 g column), eluting with a gradient of 0 to 40% ethyl acetate in heptanes. All the fractions that containing **Compound 46** (along with another isomer) were collected and purified again on a

2020415711 20 Jan 2025

Reveleris automated chromatography system (Redisep 100 g C-18 column), eluting with a gradient of 0 to 100% acetonitrile in water to give **Compound 46** (118 mg, 85% purity by HPLC, 3% yield) as a yellow solid. This material was dissolved in ethyl acetate (3 mL) and heptanes (7 mL), and the solution was slowly evaporated to a volume of ~ 3 mL overnight at room temperature to give a layer of crystals in bottom of solution. The solid was collected to give **Compound 46 [KYN-145]** (34 mg, 96.5% purity by HPLC) as an off-white solid. (NRK-1-115) and (QZH-RCI-47).

Off-white solid; HPLC Analysis: 96.5% purity; Wavelength 210 nm, bandwidth 4; Column: SorbTech C18AQ, 2.1 x 50 mm, 3 μm; Retention Time: 11.9 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=379.1 $(M+H)^+$; $C_{21}H_{21}F_3O_3$; ^{1}H NMR (400 MHz, CD_3OD) δ = 7.33 (d, J = 16.1 Hz, 1H), 7.21 (br m, 1H), 7.19 (s, 1H), 7.12 (br m, 1H), 6.88 (d, J = 16.2 Hz, 1H), 6.88 (br m, 1H), 6.64 (s, 1H), 5.21 (tm, J = 1.5, 7.1 Hz, 1H), 3.90 (s, 3H), 3.36 (br d, J = 7.1 Hz, 2H), 1.78 (d, J = 1.0 Hz, 3H), 1.73 (d, J = 0.9 Hz, 3H); ^{19}F NMR (376 MHz, CD_3OD) δ = -64.35 (s, 3F); ^{13}C NMR (100 MHz, CD_3OD) δ = 159.66, 148.18, 147.81, 142.37, 134.79, 133.34, 133.01, 132.66, 129.41, 128.29, 127.12, 126.81, 125.22, 117.72, 117.28, 114.99, 114.95, 111.53, 111.49, 110.19, 56.78, 32.91, 25.99, 18.15.


The compound of 46 KYN-145 can also be synthesised by the modular methodology of the present disclosure using equivalents to Module A, B and C and subsequernt cross coupling alkylation of the aryl halide.

(*E*)-3-Amino-5-(4-hydroxy-3-methoxystyryl)-4-(3-methylbut-2-en-1-yl)phenol (47)

(*E*)-*N*-(5-Hydroxy-3-(4-hydroxy-3-methoxystyryl)-2-(3-methylbut-2-en-1-yl)phenyl)formamide (48)

(*E*)-*N*-(5-Hydroxy-3-(4-hydroxy-3-methoxystyryl)-2-(3-methylbut-2-en-1-yl)phenyl)acetamide (49)

2020415711 20 Jan 2025



Methyl 3-nitro-5-((2-(trimethylsilyl)ethoxy)methoxy)benzoate (47-1): *N,N*-Diisopropylethylamine (10.3 mL, 59 mmol, 3 equiv) and 2-(trimethylsilyl)-ethoxymethyl chloride (5.2 mL, 29.6 mmol, 1.5 equiv) were sequentially added to a solution of methyl 3-nitro-5-hydroxybenzoate (3.88 g, 19.7 mol, 1.0 equiv) in anhydrous dichloromethane (200 mL). After stirring at room temperature for 16 hours, saturated sodium bicarbonate (250 mL) was added. The layers were separated and the aqueous layer was extracted with dichloromethane (250 mL). The combined organic layers were dried over sodium sulfate, filtered, concentrated under reduced pressure. The residue was purified on an InterChim automated chromatography system (120 g column), eluting with a gradient of 0 to 30% ethyl acetate in heptanes to give compound **47-1** (6.12 g, 95% yield) as a colorless oil. (CHLM-02-9).

Methyl 3-amino-5-((2-(trimethylsilyl)ethoxy)methoxy)benzoate (47-2): Zinc powder (18.33 g, 280 mmol, 15.0 equiv), ammonium chloride (15.1 g, 280 mmol, 15.0

2020415711 20 Jan 2025

equiv) and water (20 mL) were added sequentially to a solution of compound **47-1** (6.12 g, 18.7 mmol, 1.0 equiv) in tetrahydrofuran (200 mL) at room temperature. The resulting suspension was refluxed (68°C) for 5 hours. The suspension was cooled to room temperature, diluted with ethyl acetate (500 mL), filtered through Celite, which was washed with ethyl acetate (500 mL). The filtrate was evaporated to dryness under reduced pressure. The residue was purified on an InterChim automated chromatography system (2 x 120 g column stacked), eluting with a gradient of 0 to 60% ethyl acetate in heptanes to give compound **47-2** (4.76 g, 86% yield) as a pale yellow oil. (CH-LM-02-10).

Methyl 3-amino-2-bromo-5-((2-(trimethylsilyl)ethoxy)methoxy)benzoate (47-3): *N*-Bromosuccinimide (2.85 g, 16 mmol, 1.0 equiv) was added portion wise to a solution of compound **47-2** (4.76 g, 16 mmol, 1.0 equiv) in anhydrous dichloromethane (500 mL) at 0°C. After stirring at 0°C for 1 hour, ice-cold water (500 mL) was added and the mixture was warmed to room temperature. The layers were separated and the organic layer was washed with saturated sodium bicarbonate (500 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an InterChim automated chromatography system (2 x 120 g column stacked), eluting with a gradient of 0 to 20% ethyl acetate in heptanes to give compound **47-3** (5.05 g, 84% yield) as a pale yellow oil. (CH-LM-02-14).

3-Amino-2-bromo-5-((2-(trimethylsilyl)ethoxy)methoxy)benzaldehyde (47-4): 1M Diisobutylaluminum hydride in toluene (26.84 mL, 26.84 mmol, 2.0 equiv) was added dropwise to a solution of compound **47-3** (5.05 g, 13.42 mmol, 1.0 equiv) in toluene (250 mL) at -78°C. The resulting mixture was stirred at -78°C for 3 hours. Saturated potassium sodium tartrate (120 mL) was added dropwise and the mixture was slowly warmed to room temperature. After stirring for 16 hours, methyl *tert*-butyl ether (300 mL) was added. The layers were separated and the organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an InterChim automated chromatography system (2 x 120 g column stacked), eluting

2020415711 20 Jan 2025

with a gradient of 0 to 60% ethyl acetate in heptanes to give compound **47-4** (3.25 g, 70% yield) as a yellow oil. (CH-LM-02-16).

(*E*)-2-Bromo-3-(3-methoxy-4-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-5-((2-(trimethylsilyl)ethoxy)methoxy)aniline (47-5): A 60% dispersion of sodium hydride in mineral oil (1.34 g, 33.6 mmol, 4.0 equiv) was added in one portion to a solution of **Module B** (3.4 g, 8.4 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (150 mL) at 0°C. The mixture was warmed up to room temperature and stirred for 30 minutes. A solution of compound **47-4** (3.25 g, 9.4 mmol, 1.12 equiv) in anhydrous tetrahydrofuran (50 mL) was added dropwise and the mixture was stirred at room temperature for 16 hours. The reaction was carefully quenched with water (250 mL, 1 drop per minute for the first 5 mL water) at 0°C and extracted with methyl tert-butyl ether (400 mL) and ethyl acetate (400 mL). The combined organic layers was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an InterChim automated chromatography system (2 x 120 g column stacked), eluting with a gradient of 0 to 30% ethyl acetate in heptanes to give compound **47-5** (2.6 g, 52% yield) as a yellow solid. (CH-LM-02-17)

(*E*)-3-(3-Methoxy-4-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-2-(3-methylbut-2-en-1-yl)-5-((2-(trimethylsilyl)ethoxy)methoxy)aniline (47-6): Tetrakis(triphenylphosphine) palladium(0) (252 mg, 0.22 mmol, 0.05 equiv), potassium carbonate (1.2 g, 8.71 mmol, 2.0 equiv), 3-methylbut-2-enylboronic acid pinacol ester (1.71 g, 8.71 mmol, 2.0 equiv) and water (15 mL) were added sequentially to a solution of compound **47-5** (2.6 g, 4.36 mmol, 1.0 equiv) in 1,4-dioxane (45 mL) in a sealed tube. After sparging with nitrogen for 10 minutes, the reaction was heated at 100°C for 16 hours. After cooling to room temperature, the reaction mixture was extracted with methyl tert-butyl ether (100 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an InterChim automated chromatography system (120 g column), eluting with a gradient of 0 to 35% ethyl acetate in heptanes to give compound **47-6** (2.07 g, 81% yield) as a yellow solid. (CH-LM-02-18)

2020415711 20 Jan 2025

(*E*)-3-Amino-5-(4-hydroxy-3-methoxystyryl)-4-(3-methylbut-2-en-1-yl)phenol (47) [KYN-167]: 1M Tetrabutylammonium fluoride in tetrahydrofuran (35 mL, 35 mmol, 14.0 equiv) was added to a solution of compound **47-6** (1.47 g, 2.51 mmol, 1.0 equiv) in tetrahydrofuran (120 mL) at room temperature. After heating at 68°C for 16 hours, the mixture was cooled to room temperature and diluted with water (50 mL). The volatiles were removed under reduced pressure. The residue was diluted with saturated ammonium chloride (150 mL) and extracted with ethyl acetate (2 x 300 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an InterChim automated chromatography system (80 g column) eluting with a gradient of 0 to 100% ethyl acetate in heptanes. The product fractions were combined, concentrated under reduced pressure and further purified on an InterChim automated chromatography system (RediSep Rf GOLD 100 g HP C18 column), eluting with a gradient of 0 to 100% acetonitrile in water to give compound **47** (148 mg, 18% yield) as an off-white solid. (CH-LM-02-22) Another batch of compound **11** (400 mg) was processed in the same manner to give compound **47** (15 mg, 7% yield) as an off-white solid. (CH-LM-02-19) HPLC Analysis: 99.2% purity; Wavelength 254 nm, bandwidth 4; Column: Waters Atlantis T3, 2.1 x 50 mm, 3 μm; Retention Time: 6.1 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=326.2 $(M+H)^+$; $C_{20}H_{23}NO_3$; ^1H NMR (400 MHz, DMSO-d_6) δ = 9.06 (br s, 1H), 8.72 (br s, 1H), 7.12 – 7.05 (m, 2H), 6.91 (dd, J = 1.9, 8.3 Hz, 1H), 6.77 – 6.70 (m, 2H), 6.27 (d, J = 2.3 Hz), 6.06 (d, J = 2.3 Hz), 4.99 (sptt, J = 1.3, 6.7 Hz, 1H), 4.62 (s, 2H), 3.81 (s, 3H), 3.24 – 3.17 (m, 2H), 1.77 (s, 3H), 1.64 (s, 3H); ^{13}C NMR (100 MHz, DMSO-d_6) δ = 156.14, 148.25, 147.75, 146.90, 137.67, 129.92, 129.60, 129.53, 124.97, 124.23, 120.36, 116.04, 114.60, 110.16, 101.93, 101.72, 56.03, 25.98, 25.57, 18.26.

(*E*)-*N*-(5-Hydroxy-3-(4-hydroxy-3-methoxystyryl)-2-(3-methylbut-2-en-1-yl)phenyl)formamide (48): Compound **47** (49 mg, 0.15 mmol, 1.0 equiv) was added to ethyl formate (10 mL) to obtain a cloudy solution, which was heated at 55°C (clear solution on heating). After 24 hours, the reaction mixture was cooled to room

2020415711 20 Jan 2025

temperature and evaporated to dryness under reduced pressure. The residue was purified on an InterChim automated chromatography system (RediSep Rf GOLD 100 g HP C18 column), eluting with a gradient of 0 to 100% acetonitrile in water to give compound **48** (25 mg, 47% yield) as an off-white solid after lyophilization. (CH-LM-02-23) HPLC Analysis: 99.8% purity; Wavelength 254 nm, bandwidth 4; Column: Waters Atlantis T3, 2.1 x 50 mm, 3 µm; Retention Time: 6.6 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=354.2 $(M+H)^+$; $C_{21}H_{23}NO_4$; ^1H NMR (400 MHz, DMSO-d_6) δ = 9.66 – 9.45 (m, 1H), 9.23 (br s, 2H), 8.26 – 8.19 (m, 1H), 7.17 – 7.06 (m, 3H), 6.99 – 6.85 (m, 2H), 6.83 (d, J = 2.7 Hz, 1H), 6.76 (d, J = 8.1 Hz), 6.49 (d, J = 2.3 Hz, 1H), 4.95 (br s, 1H), 3.81 (s, 3H), 3.39 – 3.33 (m, 2H), 1.78 – 1.73 (m, 3H), 1.64 – 1.59 (m, 3H); ^{13}C NMR (100 MHz, DMSO-d_6) δ = 163.08, 159.42, 155.17, 154.60, 147.22, 146.16, 137.35, 135.29, 130.02, 129.59, 129.53, 129.34, 128.21, 128.11, 122.94, 122.89, 122.79, 122.64, 122.56, 121.68, 119.68, 119.63, 115.00, 110.26, 109.37, 109.21, 108.56, 55.00, 54.96, 24.88, 17.32.

(*E*)-3-Acetamido-5-(4-acetoxy-3-methoxystyryl)-4-(3-methylbut-2-en-1-yl)phenyl acetate (49-1):

N,*N*-Diisopropylethylamine (0.32 mL, 1.8 mmol, 6 equiv) and acetic anhydride (0.1 mL, 1 mmol, 3.3 equiv) were sequentially added to a solution of compound **47** (98 mg, 0.3 mmol, 1.0 equiv) in anhydrous tetrahydrofuran (50 mL) at room temperature. After refluxing (66°C) for 16 hours, the reaction mixture was cooled to room temperature and the volatiles were removed under reduced pressure. The residue was dissolved in ethyl acetate (20 mL) and washed with saturated sodium bicarbonate (20 mL). The aqueous layer was extracted with ethyl acetate (2 x 10 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give compound **49-1** (135 mg, 99% yield) as a pale yellow solid, which was used subsequently. (CH-LM-02-24)


(*E*)-*N*-(5-hydroxy-3-(4-hydroxy-3-methoxystyryl)-2-(3-methylbut-2-en-1-yl)phenyl)acetamide (49) [KYN-169]:

2020415711 20 Jan 2025

1M Lithium hydroxide (1.27 mL, 1.27 mmol, 5.0 equiv) was added to a solution of compound **49-1** (115 mg, 0.255 mmol, 1.0 equiv) in a 5 to 1 mixture of tetrahydrofuran and methanol (30 mL) at room temperature. The resulting solution was stirred at room temperature for 1 hour. Another batch of compound **49-1** (20 mg) was processed in the same manner. Two batches were combined and the volatiles were removed under reduced pressure. The residue was dissolved in ethyl acetate (50 mL) and washed with saturated ammonium chloride (30 mL). The aqueous layer was extracted with ethyl acetate (2 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on an InterChim automated chromatography system (RediSep Rf GOLD 100 g HP C18 column), eluting with a gradient of 0 to 100% acetonitrile in water to give compound **49** (50 mg, 46% yield) as an off-white solid after lyophilization. (CH-LM-02-25) Off-white solid melting point 87.3 – 193.8°C (decomp.); HPLC Analysis: 99.3% purity; Wavelength 254 nm, bandwidth 4; Column: Waters Atlantis T3, 2.1 x 50 mm, 3 μm; Retention Time: 6.6 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=368.2 $(M+H)^+$; $C_{22}H_{25}NO_4$; ^{1}H NMR (400 MHz, DMSO-d_6) δ = 9.19 (s, 2H), 9.14 (br s, 1H), 7.18 – 7.09 (m, 2H), 6.95 (dd, J = 1.8, 8.2 Hz, 1H), 6.91 – 6.79 (m, 2H), 6.76 (d, J = 8.1 Hz, 1H), 6.70 (d, J = 2.2 Hz, 1H), 4.94 (sptt, J = 1.2, 6.8 Hz, 1H), 3.81 (s, 3H), 3.37 – 3.32 (m, 2H), 2.01 (s, 3H), 1.75 (s, 3H), 1.60 (s, 3H); ^{13}C NMR (100 MHz, DMSO-d_6) δ = 168.82, 155.54, 148.27, 147.17, 138.26, 137.47, 130.43, 129.96, 129.34, 124.94, 124.37, 123.98, 120.64, 116.05, 113.45, 110.34, 109.99, 56.06, 26.29, 25.98, 23.67, 18.29.

(*E*)-*N*-(5-Hydroxy-3-(4-formamido-3-methoxystyryl)-2-(3-methylbut-2-en-1-yl)phenyl)formamide (50) [KYN-170]:

20 Jan 2025 2020415711




Compound **47-4** (3.8 g) was treated with sodium hydride (7.2 equiv) and compound **22-2** (1.8 equiv) at room temperature in tetrahydrofuran for 16 hours to give compound **50-1** (4.6 g, 85% yield).

Compound **50-1** (4.6 g) is being treated with tetrakis (triphenylphosphine)palladium(0) (0.05 equiv), potassium carbonate (2 equiv and 3-methylbut-2-enylboronic acid pinacol ester (2 equiv) in a 3 to1 mixture of dioxane/water at 100°C towards compound **50-2** (3.99 g, 89% yield). Compound **50-2** (0.79 g) was treated with 1M tetra-butylammonium fluoride in tetrahydrofuran (7 equiv) at 68°C for 16 hours towards compound **50-3**.

(*E*)-6-(3-Ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-1-methyl-1,3-dihydro-2*H*-benzo[*d*]imidazol-2-one (**51**) [**KYN-166**]:

2020415711 20 Jan 2025



Methyl 3-methyl-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazole-5-carboxylate (51-2): A mixture of compound **51-1** (10.4 g, 57.7 mmol, 1 equiv), carbonyldiimidazole (14.0 g, 86.5 mmol, 1.5 equiv) in *N*,*N'*-dimethylformamide (104 mL) was heated to 80°C for 2 hours at which time LC/MS analysis indicated the reaction was complete. After cooling to room temperature, the solvent was removed under reduced pressure. 1N HCl (100 mL) and water (80 mL) were added to the residue and the resulting mixture was stirred at room temperature for 1 hour. The solid was filtered and dried under vacuum at 40°C for 16 hours to give compound **51-2** (11.5 g, 97% yield) as a white solid. (YZ-3-165).

6-(Hydroxymethyl)-1-methyl-1,3-dihydro-2*H*-benzo[*d*]imidazol-2-one (51-3): 1M Lithium aluminum hydride in tetrahydrofuran (83.7 mL, 83.7 mmol, 1.5 equiv) was added slowly to a solution of compound **51-2** (11.5 g, 55.8 mmol, 1 equiv) in anhydrous tetrahydrofuran (230 mL) at -79°C. The reaction was gradually warmed to room temperature over 4 hours and stirred overnight, at which point LC/MS analysis indicated the reaction was complete. Water (10 mL), 1N sodium hydroxide aqueous solution (5 mL) were added sequentially to the reaction mixture. The mixture was stirred at room temperature for 30 minutes and filtered. The filtrate was concentrated

2020415711 20 Jan 2025

under reduced pressure. The residue was purified on an Interchim automated chromatography system (330 g Sorbtech silica gel column), eluting with a gradient of 0 to 10% methanol in dichloromethane to give compound **51-3** (7.2 g, 72% yield) as a white solid. (YZ-3-166).

Diethyl ((3-methyl-2-oxo-2,3-dihydro-1*H*-benzo[*d*]imidazol-5-yl)methyl)phosphonate (51-4): Triethyl phosphite (13.8 mL, 13.4 g, 40.4 mmol, 2 equiv) was added to a solution of compound **51-3** (7.2 g, 40.4 mmol, 1 equiv) and zinc iodide (25.8 g, 80.8 mmol, 2 equiv) in anhydrous tetrahydrofuran (72 mL). The reaction mixture was stirred at 70°C for 4 hours. 1H-NMR analysis indicated that the reaction was complete. After cooling to room temperature, the reaction mixture was diluted with methyl *tert*-butyl ether (200 mL) and filtered. The filtrate was concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (330 g Sorbtech silica gel column), eluting with a gradient of 0 to 6% methanol in dichloromethane to give compound **51-4** (2.7 g, 22% yield) as a white solid. (YZ-3-167).

(*E*)-6-(2-Bromo-3-ethoxy-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)-1-methyl-1,3-dihydro-2*H*-benzo[*d*]imidazol-2-one (51-5): Potassium *tert*-butoxide (3.0 g, 27.2 mmol, 3 equiv) was added to a solution of compound **51-4** (2.7 g, 9.0 mmol, 1 equiv) in anhydrous dimethoxyethane (35 mL) at 0°C. After stirring for 30 minutes at 0°C, a solution of **Module D** (3.7 g, 10.0 mmol, 1.1 equiv) was added portionwise. The reaction mixture was gradually warmed up to room temperature and stirred for 20 hours. LC/MS analysis indicated that the reaction was complete. The reaction mixture was diluted with methyl *tert*-butyl ether (200 mL) and saturated ammonium chloride (200 mL). The layers were separated and the aqueous layer was extracted with additional methyl *tert*-butyl ether (200 mL). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified on a Biotage automatic chromatography system (330 g Sorbtech silica gel column), eluting with a gradient of 25 to 60% ethyl acetate in heptane to give compound **51-5** (300 mg, 6% yield) as an off-white solid. (YZ-3-168).

2020415711 20 Jan 2025


(*E*)-6-(3-Ethoxy-2-(3-methylbut-2-en-1-yl)-5-((2-(trimethylsilyl) ethoxy)methoxy)styryl)-1-methyl-1,3-dihydro-2*H*-benzo[*d*]imidazol-2-one (51-6): A 3 to 1 mixture of mixture of dioxane and water (16 mL) was sparged with nitrogen for 30 minutes. Compound **51-5** (290 mg, 0.56 mmol, 1 equiv), potassium carbonate (32 mg, 1.12 mmol, 2 equiv), tetrakis(triphenylphosphine)palladium(0) (32 mg, 0.03 mmol, 0.05 equiv) and 4,4,5,5-tetramethyl-2-(3-methylbut-2-en-1- yl)-1,3,2-dioxaborolane (220 g, 1.12 mmol, 2 equiv) were added sequentially. The reaction mixture was stirred at 100°C for 7 hours. LC/MS analysis indicated that the reaction was complete. The reaction mixture was diluted with methyl *tert*-butyl ether (100 mL) and water (100 mL). The layers were separated and the aqueous layer was extracted with additional methyl *tert*-butyl ether (100 mL). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified on a Biotage automatic chromatography system (40 g Sorbtech silica gel column), eluting with a gradient of 10 to 40% ethyl acetate in heptane to give compound **51-6** (160 mg, 56% yield) as an off-white solid. (YZ-3-170).

(*E*)-6-(3-Ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)-1-methyl-1,3-dihydro-2*H*-benzo[*d*]imidazol-2-one (51) [KYN-166]: 1M Tetrabutylammonium fluoride in tetrahydrofuran (2.0 mL, 2.0 mmol, 7 equiv) was added to an solution of compound **51-6** (145 mg, 0.29 mmol, 1 equiv) in tetrahydrofuran (3 mL). After stirring at 70°C for 24 hours. LC/MS analysis indicated that the reaction was complete. The reaction mixture cooled to room temperature and diluted with ethyl acetate (100 mL) and saturated brine (100 mL). The layers were separated and the aqueous layer was extracted with additional ethyl acetate (100 mL). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified on an Interchim automated chromatography system (80 g Sorbtech silica gel column), eluting with a gradient of 0 to 5% methanol in dichloromethane to give compound **51** (29 mg, 27% yield, 98.4% purity) as an off-white solid. (YZ-3-172). HPLC Analysis: 97.3% purity; Wavelength 254 nm, bandwidth 4; Column: Waters Atlantis T3, 2.1 x 50 mm, 3 µm; Retention Time: 8.4 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=379.2 $(M+H)^+$; $C_{23}H_{26}N_2O_3$; ^1H NMR (400 MHz, DMSO-d_6) δ =

2020415711 20 Jan 2025

7.32 (s, 1H), 7.27 (d, J = 16.1 Hz, 1H), 7.16 (d, J = 7.9 Hz, 1H), 6.97 (s, 1H), 6.94 (d, J = 6.6 Hz, 1H), 6.63 (d, J = 2.1 Hz, 1H), 6.31 (d, J = 2.0 Hz, 1H), 5.02 (br t, J = 6.8 Hz, 1H), 4.25 – 3.69 (m, 4H), 3.42 – 3.34 (m, 2H), 1.77 (s, 3H), 1.61 (s, 3H), 1.33 (t, J = 6.9 Hz, 3H); ^{13}C NMR (100 MHz, DMSO-d_6) δ = 157.77, 156.49, 155.02, 137.69, 132.04, 130.90, 130.62, 129.79, 128.52, 124.59, 121.14, 118.77, 109.10, 105.26, 103.95, 99.67, 63.77, 26.89, 26.03, 24.37, 18.27, 18.28.

(*E*)-6-(3-Ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)benzo[*d*]oxazol-2(3*H*)-one (52) [KYN-171]:



Methyl 2-oxo-2,3-dihydrobenzo[*d*]oxazole-6-carboxylate (52-1): A mixture of methyl 4-amino-3-hydroxybenzoate (10 g, 59.8 mmol, 1 equiv), carbonyldiimidazole (14.5 g, 89.7 mmol, 1.5 equiv) in *N*,*N'*-dimethylformamide (100 mL) was heated to 80°C for 2 hours at which time LC/MS analysis indicated the reaction was complete. After cooling to room temperature, the solvent was removed under reduced pressure. 1N HCl (120 mL) was added to the residue and the resulting mixture was stirred for 3 hours at room temperature. The solid was filtered and dried under vacuum at 40°C for 16 hours to give compound **52-1** (11.6 g, 99% yield, 97% purity) as an off-white solid. (CH-QZH-01-17).

2020415711 20 Jan 2025

6-(Hydroxymethyl)benzo[*d*]oxazol-2(3*H*)-one (52-2): 1M lithium aluminum hydride in tetrahydrofuran (39 mL, 39 mmol, 1.5 equiv) was added at a rate maintaining the reaction temperature below 5°C to a mixture of compound **52-1** (5 g, 25.6 mmol, 1 equiv) in tetrahydrofuran (120 mL) at 0°C. The reaction was stirred at room temperature for overnight, at which point LC/MS analysis indicated the reaction was complete. The reaction was cooled to 5°C, water (1.5 mL), 4N sodium hydroxide solution (3 mL) and water (6 mL) was added sequentially. The mixture was stirred at room temperature for 30 minutes and filtered. The filtrate was concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (220 g Sorbtech silica gel column), eluting with a gradient of 0 to 10% methanol in dichloromethane to give compound **52-2** (1.03 g, 24% yield) as a yellow solid. (CH-QZH-01-021).

Diethyl ((2-oxo-2,3-dihydrobenzo[*d*]oxazol-6-yl)methyl)phosphonate (52-3): Triethyl phosphite (3.8 mL, 3.73 g, 22.48 mmol, 2 equiv) was added to a solution of compound **52-2** (1.86 g, 11.24 mmol, 1 equiv) and zinc iodide (7.18 g, 22.48 mmol, 2 equiv) in tetrahydrofuran (55 mL). The reaction mixture was stirred at 70°C for 3 hours. 1H-NMR analysis indicated that the reaction was complete. After cooling to room temperature, the reaction was diluted with methyl *tert*-butyl ether (200 mL) and filtered. The filtrate was concentrated under reduced pressure. The residue was purified on an Interchim automated chromatography system (220 g Sorbtech silica gel column), eluting with a gradient of 0 to 5% methanol in dichloromethane to give compound **52-3** (1.9 g, 59% yield) as an off-white solid. (YZ-3-151).

(*E*)-6-(2-Bromo-3-ethoxy-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)benzo[*d*]oxazol-2(3*H*)-one (52-4): Potassium *tert*-butoxide (2.10 g, 18.96 mmol, 3 equiv) was added to a solution of compound **52-3** (1.8 g, 6.30 mmol, 1 equiv) in anhydrous dimethoxyethane (53 mL) at 0°C. After stirring for 1 hour at 0°C, a solution of **Module D** (2.61 g, 6.96 mmol, 1.1 equiv) in anhydrous dimethoxyethane (10 mL) was added slowly. The reaction mixture was

2020415711 20 Jan 2025

gradually warmed up to room temperature and stirred for 2 days. LC/MS analysis indicated that the reaction was complete. The reaction mixture was diluted with methyl *tert*-butyl ether (200 mL) and saturated ammonium chloride aqueous solution (200 mL). The layers were separated and the aqueous layer was extracted with additional methyl *tert*-butyl ether (200 mL). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified on a Biotage automatic chromatography system (220 g Sorbtech silica gel column), eluting with a gradient of 5 to 30% ethyl acetate in heptane to give compound **52-4** (0.94 g, 29% yield) as an off-white solid. (YZ-3-155).

(*E*)-6-(3-Ethoxy-2-(3-methylbut-2-en-1-yl)-5-((2-(trimethylsilyl)ethoxy)methoxy)styryl)benzo[*d*]oxazol-2(3*H*)-one (52-5): A mixture of dioxane/water (45 mL/15 mL) was sparged with nitrogen for 30 minutes. Compound **52-4** (0.94 g, 1.86 mmol, 1 equiv), potassium carbonate (0.51 g, 3.72 mmol, 2 equiv), tetrakis(triphenylphosphine)palladium(0) (0.11 g, 0.08 mmol, 0.05 equiv) and 4,4,5,5-tetramethyl-2-(3-methylbut-2-en-1-yl)-1,3,2-dioxaborolane (0.73 g, 3.72 mmol, 2 equiv) were added sequentially. The reaction mixture was stirred at 100°C for 20 hours. LC/MS analysis indicated that the reaction was complete. The reaction mixture was diluted with methyl *tert*-butyl ether (200 mL) and water (200 mL). The layers were separated and the aqueous layer was extracted with additional methyl *tert*-butyl ether (200 mL). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified on a Biotage automatic chromatography system (220 g Sorbtech silica gel column), eluting with a gradient of 5 to 30% ethyl acetate in heptane to give compound **52-5** (0.54 g, 59% yield) as a white solid. (YZ-3-156).

(*E*)-6-(3-Ethoxy-5-hydroxy-2-(3-methylbut-2-en-1-yl)styryl)benzo[*d*]oxazol-2(3*H*)-one (52): 1M tetrabutylammonium fluoride in tetrahydrofuran (4.9 mL, 4.94 mmol, 7 equiv) was added to an solution of compound **52-5** (0.35 g, 0.71 mmol, 1 equiv) in anhydrous tetrahydrofuran (5 mL). The reaction mixture was stirred at 70°C for 24 hours. LC/MS analysis indicated that trace product was generated but the majority of

2020415711 20 Jan 2025

starting material remained unreacted. The volume of the reaction mixture was concentrated under reduced pressure to ~ 1mL and stirred at 70°C for another 24 hours. LC/MS analysis indicated that the reaction was complete. The reaction mixture was diluted with ethyl acetate (100 mL) and saturated brine (100 mL). The layers were separated and the aqueous layer was extracted with additional ethyl acetate (100 mL). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified on an Interchim automated chromatography system (80 g Sorbtech silica gel column), eluting with a gradient of 0 to 2% methanol in dichloromethane to give compound **52** (58 mg, >95% purity, and 78 mg, ~70% purity, 53% overall yield) as a white solid. (YZ-3-158). HPLC Analysis: 97.0% purity; Wavelength 254 nm, bandwidth 4; Column: Waters Atlantis T3, 2.1 x 50 mm, 3 μm; Retention Time: 8.9 min; Mobile Phase: ACN/formic acid/water; Mass Spectrum (positive mode) m/z=366.2 $(M+H)^+$; $C_{22}H_{23}NO_4$; ^1H NMR (400 MHz, DMSO-d_6) δ = 11.65 (br s, 1H), 9.20 (br s, 1H), 7.56 (s, 1H), 7.38 – 7.23 (m, 2H), 7.07 (d, J = 8.1 Hz, 1H), 6.95 (d, J = 16.0 Hz, 1H), 6.66 – 6.58 (m, 1H), 6.36 – 6.27 (m, 1H), 5.01 (br t, J = 6.4 Hz, 1H), 3.94 (q, J = 6.8 Hz, 2H), 3.41 – 3.34 (m, 2H), 1.74 (s, 3H), 1.60 (s, 3H), 1.33 (t, J = 6.8 Hz, 3H); ^{13}C NMR (100 MHz, DMSO-d_6) δ = 157.70, 156.57, 154.94, 144.44, 137.36, 132.39, 130.35, 129.81, 129.71, 125.91, 124.51, 123.41, 118.94, 110.22, 107.20, 104.16, 99.96, 63.74, 25.98, 24.27, 18.25, 15.25.

CELLULAR STUDIES

In vitro studies related to Compounds 1 to 15 in human cancer cell lines

Introduction

Compounds **1** to **15** were evaluated and their effect on cancer growth examined in cell viability assays on multiple cancer types (**Tables 1 to 5**). Cancer cells including pancreatic, bladder, kidney, colon, breast, lung, liver and osteosarcomas obtained from ATCC (**American Type Culture Collection**) were authenticated before use by Short Tandem Repeat genomic analysis (Reid Y, Storts D, Riss T and Minor L. Authentication of Human Cell Lines by STR DNA Profiling Analysis. 2013 May 1. In: Markossian S, Sittampalam GS, Grossman A, et al., editors. Assay Guidance Manual. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing

2020415711 20 Jan 2025

Translational Sciences; 2004.). Experimental protocol for each cancer cell line was verified and optimized according to literature reports before use (Tables 1 to 3).

Cell Culture / Molecular Biology Protocols

Cryopreservation of Mammalian Cell Lines

Cancer cells were grown on a 100 mm plate according to the manufacturer specification. After culture media removal, cells were split by washing in PBS (1x), then trypsin (1 mL) was added followed by 2-5 min incubation at 37°C. Cells were resuspended in cell culture media , then transferred into a 15 mL Falcon tube and then centrifuged for 5 min at 1,000 rpm at room temperature (RT). The supernatant was removed, and cell pellet was resuspended in Fetal Bovine Serum (900 µL). The cell suspension (900 µL) was transferred into 1 mL cryovial containing DMSO (100 µL). Care was taken to ensure that cells in freezing media had minimal exposure at RT (<10 min). Cryovials were then transferred into an isopropanol-containing CoolCell and stored at -80°C. The CoolCell ensures that the temperature decreases steadily by 1°C/minute. Cryovials were removed from the CoolCell after 24 h, then transferred into liquid nitrogen for long term storage. A minimum of 4 aliquots were banked in LN2 for each cell line.

Thawing and Passaging Cancer Cells

Cryovial was removed from the LN2 tank and hold in RT until the sides were thawed but center remained frozen. A warm media (9 mL) was added dropwise to the partially frozen cells. The cell suspension is centrifuged for 5 min at 1,000 rpm at RT. Supernatant was removed, and cell pellet resuspended in a 1 mL medium. The suspension was transferred into 100 mm culture plate and incubated at 37°C for 24 h. Upon strong attachment, cells were given fresh medium. Change of media was repeated every 3 days until the cell density reached confluency. Sub-culturing was carried out when cells reached approximately 80% confluent (80% of surface of flask covered by

2020415711 20 Jan 2025

cell monolayer). Split ratios 1:3 up to 1:10 were used to ensure cells readiness for an experiment. Sub-culture was carried out to 10 passages or less.

Cell Viability Assay

1.7*103 cells/well were seeded in quadruplicates in 96-well plate after plating. Drugs were added at 5 μM and 2-fold dilutions over 18 concentrations (0.000038146 - 5 μM concentration range) to generate a dose-response curve. Cell growth was assessed on day 1, 3 and 5 after drug treatments using the CellTiter Glo Luminescence Cell Viability Assay (Promega) according to manufacturer's protocol. Thermo Scientific Varioskan LUX Multimode Microplate instrument was used for plate reading. Data are expressed as mean luminescence (arbitrary units) ± S.D.

IC_{50} Calculation

Cell Viability Assays were employed to determine the concentration of Compound 1 **(KYN-001)** and analogues where the response is reduced by half. For each treatment of cancer cells, 1, 2, 5, 10 and 20 μM solutions of compounds were applied. GraphPad Prism 7 software was used to fit dose response curves. Relative Luminescence Units were plotted against the log values of the doses used and the nonlinear regression model was used for data analysis

Results

Effect of Compound 1 (KYN-001) and analogues on cancer cells' viability

The time- and dose-dependent effect of exogenously added compounds on cancer cell proliferation was assessed using CellTiter Glo Luminescence Cell Viability Assay. The concentration of the drug where the response is reduced by half (IC_{50}) was calculated in all cases. The inhibitory action of Compound **1 (KYN-001)** analogues compared to that of the parent compounds **1 (KYN-001), 8 (KYN-119)** and **27 (KYN-149)** is shown in **Tables 1 to 5**.

2020415711 20 Jan 2025

Compound **8 [KYN-119]** was the most potent (lowest IC_{50}) amongst the compounds evaluated in all cell lines tested in **Tables 1** and **2**. Compounds **17[KYN-120], 23 (KYN-125), 29 (KYN-128)** and **33 (KYN-126)** were marginally less potent than the parent compound **1**. Loss of the anti-proliferative effect was observed in the case of Compound **22 (KYN-124)**.

The protocol for cell proliferation was optimized for Compound **8 (KYN-119)** to enable a more accurate assessment of its low IC_{50} value. In this protocol, 18 dosages (2 fold dilutions ranging from 0.000038146 to 5 μM) were applied to cells seeded in 96-well plates, and Luminescence was measured after 1, 3 and 5 days upon treatments. It is notable that neither **1** nor **8** affect cell viability on Day 1 upon treatment at dosages <1 μM. This observation suggests that at < 1 μM dosages, compounds **1 (KYN-001)** and **8 (KYN-119)** are not toxic to cells.

A comparative study on **1 [KYN-001]** and **8 [KYN-119]** was carried out on 83 cancer cell lines (**Table 3**). Potent activity was shown by **1 [KYN-001]** with IC_{50} values in the range 0.01 to 0.1 μM towards the following cell lines:- Tongue SCC-15, CAL 27, UPCI:SCC090, SCC-4; Leiomyosarcoma SK-UT-1B, SK-LMS-1; Bladder UMUC_3, SCABER, 5637, RT-112; Breast MDA-MB-231; Liver SNU-423, SNU-398, Huh7; Connective Tissue Sarcoma TE 381.T, HT-1080; Osteosarcomas MG3, KHOS_N/P; Lung NCI-H661, NCI-H1299, NCI-H2126, BEAS-2B, NCI-H1048; Hypo-pharynx UPCI:SCC152; Fibrosarcomas SW 684; Liposarcoma 93T449, 94T778; Pharynx FADU; Rhabomyosarcoma SJCRH30, CCL 166; Kidney CCL 166. On the average the activity of **8 [KYN-119]** was 10 fold more potent than **1 [KYN-001]**. Very potent activity was shown by **8 [KYN-119]** with IC_{50} values in the range 0.001 to 0.01 μM towards the following cell lines:- Lung NCI-H2126, NCI-H1299; Bladder RT-112, 5637, UMUC_3; Osteosarcomas T1-73, MG3; Fibrosarcomas SW 684; Rhabomyosarcoma CCL 166; Liver SNU-398; Breast MDA-MB-231; Kidney Caki-1; Pancreatic CAPAN-2. Potent activity was shown by **8 [KYN-119]** with IC_{50} values in the range 0.01 to 0.1 μM towards the following cell lines:- Bladder SCABER, HT-1197, T24, J82; Colon SW_480, HT_116; Connective Tissue Sarcoma HT-1080; Ewing's Sarcoma HTB-166; Hypo-pharynx UPCI:SCC152; Kidney ACHN, SK-NEP-

2020415711 20 Jan 2025

1, 769-P, 786-O; Leiomyosarcoma SK-LMS-1; Liposarcoma 93T449, 94T778; Liver HepG2, Huh7, SNU-475, JHH-6; Lung NCI-H661, NCI-H1048, BEAS-2B, NCI-H1437, NCI-H1563, NCI-H1573, A549; Osteosarcomas KHOS_N/P, SAOS-2, Hs888.T, HOS_CRL_1543, KHOS_312H, U2OS; Pancreatic PANC-1, MIA PaCa-2, CFPAC; Pharynx FADU; Rhabomyosarcoma TE 159.T, A-204, SJCRH30, Hs 729; Tongue SCC-15, SCC-4, UPCI:SCC090, CAL 27, SCC-9.


The analogues of compound **1 [KYN-001]**, including compounds **8 [KYN-129]**, **12 [KYN-130]** and **13 [KYN-131]** were tested for their efficacy on cancer cell viability using the optimized cell proliferation protocol together with Compounds **1 [KYN-001]**and **9 [KYN-119],** and the results are shown in **Table 4**. None of these compounds is more effective than **9 [KYN-119]**. Compounds **12 [KYN-130]** and **13 [KYN-131]** exhibited a similar activity as **1 [KYN-001]**on cancer cell growth inhibition upon 3 Days of treatment. Total loss of the anti-proliferative effect was observed in compound **8 [KYN-129]**.

Comparative assessment of **1 [KYN_001]** and **8 [KYN-119]**, and their analogues, IC50 values (μM) towards A498 and MIA PaCa-2 cancer cell lines was made over 8 experiments (**Table 5A and 5B**).

Activity shown towards A498 cells in the potent range of IC_{50} value less than 0.1 μM was only observed for compound **30 [KYN-142]**. Order of activity (high to low) for compounds in the moderately potent range of 0.1 to 1 μM are as follows:- **2, 3, 4, 7, 8, 9, 10, 11, 12, 17, 20, 23, 27, 28, 29, 33, 34, 38 [KYN-155, 131, 138, 120, 130, 143, 136, 132, 125, 128, 119, 139, 146, 140, 133, 147, 149, 126]**. Activity shown towards MIA PaCa-2 cells in the highly potent range of IC_{50} value, less than 0.001 μM, was only observed for **28 [KYN-143]**. Order of activity for compounds with IC_{50} values in the very potent 0.01 to 0.1 μM range are as following:- **1, 5, 8, 10, 20, 27, 30 [KYN-149, 119, 153, 146, 142, 001, 131]**. Compounds with IC_{50} values in the potent 0.1 to 1 μM range are as following:- **2, 3, 4, 9, 11, 23, 29, 32, 34 [KYN-130, 138, 147, 132, 125, 128, 139, 148, 140]**.

2020415711 20 Jan 2025

Cancer cell viability inhibition Structure-Activity Relationships (SARs) for compounds **1** to **49** and **51 [KYN-001, KYN-119, KYN-120, KYN-124, KYN-125, KYN-126, KYN-128** to **KYN-134, KYN-136** to **KYN-169]** based on IC_{50} values in **Tables 1 to 5**.



Based on the lead compound **1 [KYN-001]** analogues with variations in chemical structure were prepared to vary substituents on the stilbene core to improve and optimise biological activity, bioavailability and solubility properties.

Variation of the prenyl substituent of **1** [**KYN-001]** (R^{1a}=prenyl) was carried out by organic synthesis to give the following analogues:- **45 [KYN-112]** (R^{1a} =Br), **7 [KYN-136]** (R^{1a} =benzyl), **6 [KYN-134]** (R^{1a} =allyl), **2 [KYN-138]** (R^{1a} =E-crotyl ((E)-but-2-en-1-yl)), **3 [KYN-139]** (R^{1a} =Z-crotyl ((Z)-but-2-en-1-yl)), **4 [KYN-140]** (R^{1a} =iso-crotyl (but-3-en-2-yl)). In general, all the variations showed reduced biological activity (**Tables 1, 4 and 5**) except for **2 [KYN-138]** with the E-crotyl group that show biological activity comparable with **1** [**KYN-001]**. **2 [KYN-138]** is calculated to be less lipophilic and about 3 times more water soluble than **1** [**KYN-001]**, indicating that it may have better bioavailability and pharmacokinetic properties.

The following analogues were prepared with variation to the R^{1b} substituent of **1** [**KYN-001]** (R=OMe):- **8 [KYN-119]** (R=OEt), **9 [KYN-130]** (R=propoxy), **10 [KYN-131]** (R=iso-propoxy), **11 [KYN-132]** (R=trifluoromethoxy), **46 [KYN-145]** (R=trifluoromethyl). Replacement of the methoxy group with a trifluoromethyl group resulted in a complete loss of biological activity towards the cell lines tested. **8 [KYN-119]** with the ethoxy group showed an average 10 fold enhancement of cancer cell viability inhibition over the 83 cell lines (**Table 3**). Further extension of the alkyl group

2020415711 20 Jan 2025

size as for **9 [KYN-130]** (R=propoxy) and **10 [KYN-131]** (R=iso-propoxy) resulted in comparable or weaker biological activity and, also, these compounds are calculated to be significantly more lipophilic than **1 [KYN-001]** and much less water soluble.

The **1 [KYN-001]** (R^{1e}=OMe) analogue **12 [KYN-133]** (R^{1e}=OEt), from the cell lines tested, showed an approximately 10 fold reduction in cancer cell viability inhibition. This is in sharp contrast to the 10 fold enhancement seen with **8 [KYN-119]** with the ethoxy group variation from **1 [KYN-001]**. Other **1 [KYN-001]** (R^{1e}=OMe) analogues, **15 [KYN-158]** (R^{1e}=NHMe) , **16 [KYN-157]** (R^{1e}=NHMe) , **41 [KYN-161]** (R^{1e}=NHMe) tested as inactive or weakly active.

1 [KYN-001] analogues were prepared with variation to the R^{1f} substituent of **1 [KYN-001]** (R^{1f}=OH). Replacement of the hydroxyl group with an amino group provides an extra valency for addition of extra chemical structure. The analogue with an amino group **23 [KYN-125]** showed activity similar to but overall reduced on the cell lines tested compared with **1 [KYN-001]**. With extra valency available through the nitrogen a series of amino derivatives of **23 [KYN-125]** were prepared as compounds **25, 26, 27, 29, 31, 33, 36 [KYN-126, 128, 129, 137, 149, 150, 151]**. The acetamide derivative **29 [KYN-128]** (R^{1f}=-(CO)CH_3) showed similar activity to **1 [KYN-001]** and the formamide derivative **27 [KYN-149]** (R^{1f}=-(CO)H) tested on two cell lines showed on IC_{50} value of 0.015 μM towards MIA PaCa-2 cells approximately 5 fold more potent than **1 [KYN-001]**. All amino derivatives larger than acetamide, overall, showed weaker inhibition or were inactive. Replacement of the R^{1f} hydroxy group of **1 [KYN-001]** with a carboxy group gave an analogue **21 [KYN-154]** (R^{1f}=COOH) with IC_{50} greater than 3 μM on two cell lines, A498 and MIA PaCa-2. Replacement of the R^{1g} hydrogen atom of **1 [KYN-001]** with a methyl group to give an analogue **17 [KYN-120]** (R^{1g}=CH_3) resulted in an approximately 3 fold reduction in inhibitory activity towards the six cell lines tested (**Table 2**). A similar loss of activity was observed for analogue **18 [KYN-156]** (R^{1g}=OH) with an additional hydroxyl group ((**Table 5A**). Moving the R^{1f} hydroxy group of **1 [KYN-001]** as in analogue **19 [KYN-160]** (R^{1g}=OH) also strongly weakened activity in the cell lines tested.

2020415711 20 Jan 2025

Where a single change in substituent was made with respect to the **1 [KYN-001]** chemical structure two substituent changes were found to independently enhance cancer cell viability inhibition, R^{1d}=OEt as observed with compound **8 [KYN-119]** (R^{1b}=OEt) and R^{1f}=NH(CO)H as observed with compound **27 [KYN-149]** (R^{1f}=-NH(CO)H). A compound was prepared with both of these substituent changes, **28 [KYN-143]** (R^{1b}=OEt; R^{1f}=NH(CO)H) and found to much enhanced inhibition towards A498 (IC_{50} 0.18 μM) and MIA PaCa-2 (IC_{50} 0.00094 μM) cell lines. These inhibition values compare favourably with compound **8 [KYN-119]** which showed less inhibition towards the A498 (IC_{50} 0.36 μM) and MIA PaCa-2 (IC_{50} 0.025 μM) cell lines. Replacing the R^{1e} methoxy group of **28 [KYN-143]** with a hydroxyl group as in analogue **40 [KYN-159]** (R^{1e}=OH) very strongly weakened activity in the two cell lines tested (**Table 5A**). The N-hydroxy derivative of the hydroxy group of **28 [KYN-143]** as in analogue **39 [KYN-165]** (R^{1f} = N(OH)(CO)H) resulted in the almost complete loss of anticancer activity in the two cell lines tested (**Table 5B**).

Replacement of the R^{1d} hydroxyl group of **1 [KYN-001]** with a nitro group gave an analogue **42 [KYN-162]** (R^{1d}=NO_2) which resulted in almost complete loss of anticancer activity towards two cell lines (**Table 5A**). No significant enhancement of activity was observed when the R^{1d} nitro group was converted to an amino **43 [KYN-163]** (**R^{1d}=NH_2**) and further into a formamide group **44 [KYN-164]** (**R^{1d}=NH(CO)H**) (**Table 5A**).

Replacement of the R^{1b} hydroxyl group of **1 [KYN-001]** with an amino group gave an analogue **47 [KYN-167]** (R^{1b}=NH_2) which gave indeterminate anticancer activity response towards two cell lines (**Table 5B**). Formamide and acetamide derivatives were prepared as **48 [KYN-168]** (R^{1b}=NH(CO)H) and **49 [KYN-169]** (R^{1b}=NH(CO)Me), respectively, which were determined to have anticancer activities comparable to **1 [KYN-001]** for two cancer cell lines (**Table 5A**).

An analogue of **8 [KYN-119]** with a 5-membered heterocyclic ring fused through joining R^{1e} and R^{1f}, compound **51 [KYN-166]** and compound **52** [KYN-171] showed no significant activity towards the two cell lines tested (**Table 5A**).

2020415711 20 Jan 2025

Table 1, IC_{50} values (μM) of Compounds **1, 13, 14, 45 [KYN-001, 112, 114, 118]** on Day 3 upon drug treatment (based on 10 dosages ranging from 0.0001-20 μM [31 October 2018]

	Cancer	Colon	Pancreatic	Breast	Bladder	Kidney
Compound Number	Cell Line / KYN code	SW_480	MIA PaCa-2	MDA-MB-231	RT-112	CRL-1611
1	KYN-001	0.298	0.204	0.0293	0.105	0.0937
13	KYN-114	26.47	3.003	N/A	0.949	2.12
14	KYN-118	N/A	3.47	~ 10.6	1.33	2.96
45	KYN-112	10.8	20.4	~ 10.3	N/A	N/A

Table 2. IC_{50} values (μM) of **Compounds 1, 17, 22, 23, 29, 33** on Day 5 upon drug treatment (based on 10 dosages ranging from 0.0001-20 μM and, for **Compound 8**, 18 dosages ranging from 0.000038146 to 5 μM) [31 October 2018, corrected 9 June 2019]

	Cancer	Bladder	Bladder	Breast	Colon	Kidney	Pancreatic
Comp.	Cell Line	5637	RT-112	MDA-MB-231	HCT_116	ACHN	MIA PaCa-2
1	KYN- 001	0.0306	0.0287	0.0573	0.165	0.0897	0.0507
8	KYN-119	~ 0.00943	~ 0.00565	~ 0.00000253	0.028	~ 0.0000135	~ 0.00047
17	KYN-120	0.104	0.115	0.246	0.353	0.283	0.182
22	KYN-124	N/A	N/A	6.2	N/A	N/A	N/A
23	KYN-125	0.0653	0.0682	0.138	0.474	0.26	0.18
29	KYN-128	0.0674	0.0764	0.155	0.627	0.281	0.185
33	KYN-126	0.0859	0.0955	0.169	0.68	2.84	0.0968

Table 3. Effect of **1 [KYN-001]** and **8 [KYN-119]** compounds on cancer cells' viability as assessed by CellGlow Titer Assay calculated as IC_{50} μM. Cells were treated with 18 (2-fold) dilutions (concentration range: 5 - 0.00003 μM) 24h after plating and luminesence measurements were performed upon 3 Days of treatment. Combined

2020415711 20 Jan 2025

results from 7 experiments reported; 31 Oct 18, 19 Dec 18, 15 May 19, 4 Jun 19, 6 Jun 19, 8 Jun 19, 19 Jun 19.

		Compound 1 [KYN-001]			Compound 8 [KYN-119]			
Cancer	Cell Line	Average IC_{50} µM	STDev	n	Average	STDev	n	Fold IC_{50}
Bladder	5637	0.0347	0.0044	2	0.00391	0.00064	2	8.9
Bladder	HT_1376	N/A		0	0.610		1	
Bladder	HT-1197	0.258		1	0.0115		1	22
Bladder	J82	0.184		1	0.0465		1	4.0
Bladder	RT-112	0.0529	0.045	3	0.00363	0.00066	2	15
Bladder	RT4	N/A		0	1.67		1	
Bladder	SCABER	0.0337		1	0.0101		1	3.3
Bladder	SW780	0.712		1	0.217		1	3.3
Bladder	T24	0.129		1	0.0225		1	5.8
Bladder	TCCSUP	0.294		1	0.112		1	2.6
Bladder	UMUC_3	0.0313		1	0.00548		1	5.7
Bladder	UMUC-14	1.16		1	0.563		1	2.1
Breast	MCF7	0.694	0.19	2	0.136	0.028	2	5.1
Breast	MDA-MB-231	0.0326	0.0046	3	0.00848	0.0050	2	3.8
Colon	HCT_116	0.416	0.077	2	0.0355	0.020	2	12
Colon	SW_480	0.179	0.11	3	0.0179	0.0030	2	10
Connective Tissue Sarcoma	HT-1080	0.0367		1	0.0173		1	2.1
Connective Tissue Sarcoma	TE 381.T	0.0357		1	0.00750		1	4.8
Ewing's Sarcoma	HTB-166	0.257		1	0.0492		1	5.2
Fibrosarcomas	SW 684	0.0552		1	0.00463		1	12
Hypo-pharynx	UPCI:SCC152	0.0463		1	0.0230		1	2.0
Kidney	769-P	N/A		0	0.0337		1	
Kidney	786-O	0.334		1	0.0648		1	5.1
Kidney	A-498	2.81	4.8	5	0.329	0.25	4	8.5
Kidney	ACHN	0.494	0.0027	2	0.0104	0.0011	3	48
Kidney	Caki-1	0.103		1	0.00890		1	12
Kidney	Caki-2	1.12		1	0.281		1	4.0
Kidney	CRL-1611	0.0937		1				
Kidney	HTB-45	1.73		1	0.463		1	3.7
Kidney	SK-NEP-1	0.158		1	0.0178		1	8.9
Leiomyosarcoma	SK-LMS-1	0.0659		1	0.0175		1	3.8
Leiomyosarcoma	SK-UT-1B	0.0226		1	0.00639		1	3.5
Liposarcoma	93T449	0.0555		1	0.0151		1	3.7
Liposarcoma	94T778	0.0845		1	0.0257		1	3.3

20 Jan 2025 2020415711

Liver	HepG2	0.212	0.0030	2	0.0202	0.00005	2	11
Liver	Huh7	0.0789	0.0017	2	0.0206	0.00049	2	3.8
Liver	JHH-5	N/A		0	4.37	3.5	2	
Liver	JHH-6	0.172	0.0008	2	0.0364	0.0022	2	4.7
Liver	JHH-7	0.696	0.87	2	0.519	0.16	2	1.3
Liver	SNU-398	0.0429	0.0002	2	0.00815	0.00014	2	5.3
Liver	SNU-423	0.0338	0.0002	2	0.00623	0.00029	2	5.4
Liver	SNU-475	0.239	0.21	2	0.0324	0.00037	2	7.4
Lung	A549	0.163	0.039	2	0.0309	0.00066	2	5.3
Lung	BEAS-2B	0.0764	0.0017	2	0.0150	0.00054	2	5.1
Lung	NCI-H1048	0.0917		1	0.0145	0.0035	2	6.3
Lung	NCI-H1299	0.0624	0.0026	2	0.00856	0.00001	2	7.3
Lung	NCI-H1437	0.347		1	0.0166		1	21
Lung	NCI-H1563	0.449		1	0.0195		1	23
Lung	NCI-H1573	0.217	0.016	2	0.0205	0.00080	2	11
Lung	NCI-H2126	0.0754		1	0.00173		1	44
Lung	NCI-H596	0.303	0.12	2	0.115	0.034	2	2.6
Lung	NCI-H661	0.0366	0.0025	2	0.0115	0.0011	2	3.2
Osteosarcomas	HOS_CRL_1543	0.358	0.32	3	0.0320	0.0023	3	11
Osteosarcomas	Hs888.T	0.210	0.049	2	0.0261	0.0020	2	8.1
Osteosarcomas	KHOS_312H	0.356	0.25	2	0.0367	0.00071	3	9.7
Osteosarcomas	KHOS_N/P	0.0687	0.0090	3	0.0105	0.00011	3	6.6
Osteosarcomas	MG3	0.0359	0.0041	3	0.00688	0.00039	3	5.2
Osteosarcomas	SAOS-2	0.110	0.046	2	0.0154	0.0020	3	7.2
Osteosarcomas	SJSA_1	2.30		1	9.58	6.7	2	0.2
Osteosarcomas	T1-73	0.804		1	0.00393	0.00022	2	205
Osteosarcomas	U2OS	0.325	0.25	3	0.0368	0.0040	3	8.8
Pancreatic	AsPC-1n	N/A		0	2.00	1.4	3	
Pancreatic	BxPC3	1.06	0.48	2	0.355	0.082	2	3.0
Pancreatic	CAPAN-1	6.22	6.7	2	4.69		1	1.3
Pancreatic	CAPAN-2	0.182	0.12	3	0.00975	0.00062	3	19
Pancreatic	CFPAC	0.492	0.15	3	0.0824	0.013	3	6.0
Pancreatic	HPAC	4.99	5.2	2	1.97	1.4	2	2.5
Pancreatic	HPAFII	1.07	0.63	2	0.403	0.15	3	2.7
Pancreatic	MIA PaCa-2	0.127	0.057	6	0.0181	0.015	4	7.0
Pancreatic	PANC-1	0.107	0.043	2	0.0115	0.0025	2	9.3
Pharynx	DETROIT	1.17		1	0.438		1	2.7
Pharynx	FADU	0.0744		1	0.0371		1	2.0
Rhabomyosarcoma	A-204	N/A		0	0.0307		1	
Rhabomyosarcoma	CCL 166	0.0960		1	0.00605		1	16
Rhabomyosarcoma	Hs 729	0.383		1	0.0649		1	5.9
Rhabomyosarcoma	SJCRH30	0.0823		1	0.0434		1	1.9

2020415711 20 Jan 2025

Rhabomyosarcoma	TE 159.T	0.147		1	0.0196		1	7.5
Tongue	CAL 27	0.0568		1	0.0383		1	1.5
Tongue	SCC-15	0.0170		1	0.0149		1	1.1
Tongue	SCC-25	0.744		1	0.276		1	2.7
Tongue	SCC-4	0.100		1	0.0239		1	4.2
Tongue	SCC-9	0.181		1	0.0755		1	2.4
Tongue	UPCI:SCC090	0.0901		1	0.0260		1	3.5
Average fold								10.0

0.005% - $4.88x10^{-6}$% - $3x10^{-8}$% DMSO concentrations served as negative controls in the assay, as these dilutions correspond to the highest, median and lowest concentration of DMSO in the range of 18 drug concentrations tested)

IC_{50} (μM) values correspond to log(inhibitor) vs. response (four parameters) and dose - response graphs were generated using GraphPad Prism8.

Table 4. Effect of compounds on cancer cells' viability as assessed by CellGlow Titer Assay calculated as IC_{50} μM. Cells were treated with 18 (2-fold) dilutions (concentration range: 5 - 0.00003 μM) 24h after plating and luminesence measurements were performed upon 3 Days of treatment. Combined results from experiments reported; 4 Jun 19, 6 Jun 19, 8 Jun 19.

		Cancer	Bladder	Kidney	Kidney	Pancreatic	Pancreatic	Lung
Cpd	KYN #	Cell Line	RT-112	ACHN	A-498	MIA PaCa-2	CAPAN-1	NCI-H1299
1	KYN-001	Average	0.027	0.496	0.888	0.109	1.46	0.0642
		STDev	0.0029		0.733	0.0437		
		n	2	1	3	3	1	1
8	KYN-119	Average	0.00409	0.0098	0.2099	0.0103	2.45	0.00856
		STDev		0.0004		0.0005	3.17	
		n	1	2	1	2	2	1
2	KYN-138	Exp D			0.119	0.117		
4	KYN-139	Exp D			0.381	0.361		
5	KYN-140	Exp D			0.755	0.667		
6	KYN-134	Exp C	0.862			1.59		
7	KYN-136	Exp C	0.17			0.288		

2020415711 20 Jan 2025

9	KYN-130	Exp A	0.022	0.609		0.019	N/A	
10	KYN-131	Exp A	0.0256	0.0409		0.0371	2.237	
11	KYN-132	Exp B	0.0392		0.665	0.104		0.193
12	KYN-133	Exp B	0.347		N/A	0.822		0.827
25	KYN-137	Exp D			7.74	N/A		
26	KYN-129	Exp A	N/A	N/A		N/A	N/A	
46	KYN-145	Exp C	N/A			N/A		

Table 5A. Effect of compounds on cancer cells' viability as assessed by CellGlow Titer Assay. Comparative assessment of IC_{50}s (μM) of **1 [KYN-001]** and **27 [KYN-149]**, and their analogues. Cells were treated with 11 dilutions (concentration range: 3 - 0.00001 μM) Combined results from seven experiments reported;

Compound		Cancer Cell Line	Kidney A-498	Pancreatic MIA PaCa-2
1	KYN-001	Exp E	0.0522	0.0645
		Exp F	1.354	0.0697
		Exp G	1.596	0.0847
		Exp H	1.271	0.0663
		Exp I	1.612	0.1054
		Exp J	1.557	0.0725
		Exp K	0.5509	0.1012
		average	1.1419	0.0806
		STD Dev	0.6052	0.0169
8	KYN-119	Exp E	0.0404	0.0408
		Exp F	0.414	0.0152
		Exp G	0.604	0.0243
		Exp H	0.37	0.0178
		Exp I	0.721	0.0345
		average	0.43	0.0265
		STD Dev	0.26	0.0109
27	KYN-149	Exp G	0.932	0.0147
		Exp J	0.9844	0.01341
		Exp K	0.2688	0.0168
		average	0.7284	0.0150
		STD Dev	0.3989	0.0017

Compound		Cancer Cell Line	Kidney A-498	Pancreatic MIA PaCa-2
2	KYN-138	Exp E	0.132	0.135
3	KYN-153	Exp G	1.194	0.0275
4	KYN-139	Exp E	0.545	0.52
5	KYN-140	Exp E	0.754	0.746
6	KYN-134	Exp E	1.09	1.28
7	KYN-136	Exp E	0.199	N/A
9	KYN-130	Exp E	0.147	0.115
10	KYN-131	Exp E	0.126	0.0812
11	KYN-132	Exp E	0.202	0.207
12	KYN-133	Exp E	0.91	1.09
15	KYN-158	Exp J	> 3	>3
16	KYN-157	Exp I	> 3	> 3
17	KYN-120	Exp E	0.142	1.15
18	KYN-156	Exp I	~ 3	~ 1
19	KYN-160	Exp J	> 3	0.9213
20	KYN-146	Exp F	0.714	0.0473
21	KYN-154	Exp H	~ 3	> 3
22	KYN-124	Exp E	N/A	N/A
23	KYN-125	Exp E	0.234	0.352
24	KYN-141	Exp E	N/A	N/A
25	KYN-137	Exp E	15	N/A
26	KYN-129	Exp E	N/A	N/A
28	KYN-143	Exp F	0.181	0.000936
29	KYN-128	Exp E	0.27	0.491
30	KYN-142	Exp E	0.0479	0.0608
31	KYN-151	Exp G	> 3	3.18
32	KYN-148	Exp G	1.835	0.54
33	KYN-126	Exp E	0.988	2.04
34	KYN-147	Exp F	0.915	0.173
35	KYN-152	Exp G	> 3	N/A

2020415711 20 Jan 2025

36	KYN-150	Exp G	N/A	N/A
37	KYN-144	Exp F	N/A	> 3
38	KYN-155	Exp H	~ 0.1	> 3
40	KYN-159	Exp J	2.926	> 3
41	KYN-161	Exp J	N/A	> 3
42	KYN-162	Exp K	~ 3	N/A
43	KYN-163	Exp K	~ 3	~ 3
44	KYN-164	Exp K	2.042	1.157
46	KYN-145	Exp E	N/A	N/A

Table 5B. Effect of compounds on cancer cells' viability as assessed by CellGlow Titer Assay. Comparative assessment of IC_{50}s (μM) of **1 [KYN-001]** and **27 [KYN-149]**, and their analogues. Cells were treated with 11 dilutions (concentration range: 3 - 0.00001 μM) Combined results from three experiments reported;

		Cancer	Pancreatic	Brain	Breast
		Cell Line	MIA PaCa-2	U-87 MG	4T1
Compound		Exprmnt	CRL-1420	HTB-14	
1	KYN-001	Exp N	0.07244	0.1867	0.1171
27	KYN-149	Exp N	0.01474	0.03007	0.02923
1	KYN-001	Exp L	0.1432	0.2812	
1	KYN-001	Exp M	0.7713	1.603	
27	KYN-149	Exp L	0.002868	0.00986	
27	KYN-149	Exp M	0.01052	0.02182	
39	KYN-165	Exp L	> 3	~ 3	
47	KYN-167	Exp M	N/A	N/A	
48	KYN-168	Exp M	0.4856	0.555	
49	KYN-169	Exp M	0.5312	1.405	
51	KYN-166	Exp L	N/A	~ 3	

Table 6. Effect of compounds on cancer cells' viability as assessed by CellGlow Titer Assay. Comparative assessment of IC_{50}s (μM) of Compound **1 [KYN-001]** and Compound **8 [KYN-119]**, and their analogues. Cells were treated with 11 dilutions (concentration range: 3 - 0.00001 μM);

Cancer Type	Cancer Cell Line	Compound/IC_{50} (μM)

2020415711 20 Jan 2025

		1	8	20	27	28
SARCOMAS		**KYN-001**	**KYN-119**	**KYN-146**	**KYN-149**	**KYN-143**
Osteosarcoma	MG-63 / CRL-1427	0.0441	0.0182	0.0313	0.0825	0.0048
Osteosarcoma	Saos-2 / HTB-85	0.173	0.0791	0.1291	0.0424	0.0233
Muscle Ewing's Sarcoma	A-673 / CRL-1598	0.471	0.1573	0.3116	0.2291	0.1117
Bone Ewing's Sarcoma	RD-ES / HTB-166	0.3098	0.1629	0.3379	0.133	0.0651
Muscle Rhabdomyosarcoma	A-204 / HTB-82	0.1987	0.0678	0.131	0.0524	0.0253
Rhabdomyosarcoma	TE 159.T / CRL-7752	N/A	N/A	N/A	0.031	N/A
HEAD and NECK CANCERS						
squamous cell carcinoma - hypopharynx	UPCI:SCC152 / CRL-3240	0.1404	0.0549	0.1491	0.0366	0.0205
squamous cell carcinoma -base of the tongue	UPCI:SCC090 / CRL-3239	0.0009	0.0005	0.0478	0.02	0.0561
squamous cell carcinoma - pharynx	Fadu / HTB-43	0.1386	0.0541	0.0801	0.0286	0.0118
pharyngeal carcinoma	Detroit 562 / CCL-138	0.131	0.0766	0.1224	0.0203	0.0114
squamous cell carcinoma - tongue	CAL 27 / CRL-2095	0.0894	0.0309	0.0409	0.015	0.005
squamous cell carcinoma - tongue	SCC-4 / CRL-1624	0.0395	0.0232	0.0313	0.0114	0.0031
NEUROBLASTOMAS						
	CHP-212 / CRL-2273	0.0281	0.0098	0.0261	0.0057	0.003
	BE(2)-C / CRL-2268	0.0671	0.0259	0.0548	0.0136	0.0112
	SK-N-DZ / CRL-2149	0.132	0.0501	0.1401	0.0326	0.0164
	SK-N-FI / CRL-2142	0.1157	0.0266	0.0485	0.0157	0.0097
PANCREATIC CANCER						
	MIA PaCa-2 / CRL-1420	0.1089	0.0234	0.0549	0.0214	0.0129
	PANC-1 / CRL-1469	0.1101	0.0314	0.0416	0.0288	0.0178
	BxPC-3 / CRL-1687	0.9436	0.3873	1.412	0.3021	0.1747
	Capan-1 / HTB-79	2.67	2.319	2.237	0.7918	0.7348
	HPAF-II / CRL-1997	0.417	0.242	0.6378	0.1019	0.1106
LUNG CANCER						
	NCI-H1437 / CRL-5872	0.1428	0.0327	0.0732	0.0322	0.0259
	NCI-H2126 / CCL-256	0.1055	0.0331	0.097	0.031	0.0107
	NCI-H1563 / CRL-5875	0.1838	0.0545	0.0741	0.0598	0.0159
	NCI-H1573 / CRL-5877	0.2728	0.0335	0.0558	0.048	0.0212
LIVER CANCER						
	Hep G2 / HB-8065	0.5773	0.296	0.2345	0.2514	0.0991
	SNU-398 / CRL-2233	0.2077	0.0746	0.1105	0.054	0.0327
	SNU-423 / CRL-2238	0.2033	0.0797	0.1194	0.0535	0.0275

2020415711 20 Jan 2025

	SNU-449 / CRL-2234	0.0818	0.0325	0.064	0.0151	0.0102
KIDNEY CANCER						
	769-P / CRL-1933	0.3627	0.109	0.1737	0.1101	0.0401
	A-498 / HTB-44	1.073	0.4012	0.6204	0.6418	0.198
	ACHN / CRL-1611	0.2412	0.0757	0.0834	0.0267	0.0188
	Caki-1 / HTB-46	0.12	0.0279	0.0963	0.0154	0.0072
	Caki-2 / HTB-47	0.4263	0.5236	0.3023	1.553	0.0698
COLON CANCER						
	SW480 / CCL-228	0.2246	0.1086	0.1577	0.0896	0.03
	SW620 / CCL-227	0.1209	0.0355	0.1027	0.0317	0.018
	HT-29 / HTB-38	1.563	0.9394	1.992	0.4315	0.3248
BLADDER CANCER						
	UM-UC-3 / CRL-1749	0.3327	0.0548	0.1258	0.0302	0.0213
	RT4 / HTB-2	1.384	0.9682	2.012	0.4529	0.463
	T24 / HTB-4	0.1823	0.0611	0.1113	0.0325	0.0221
	HT-1197 / CRL-1473	0.1081	0.0485	0.0617	0.0171	0.0122
	SCaBER / HTB-3	0.065	0.0273	0.0537	0.0109	0.006

Day 3 upon treatment of MIA PaCa_2 pancreatic cancer cells, 24h after plating *(11 dilutions)*, as assessed by CellTiter Glow Assay**.**

IC_{50} (μM) values correspond to log(inhibitor) vs. response (four parameters) and dose - response graphs were generated using GraphPad Prism8.

Compounds **23**, **29** and **33** were prepared to give compounds with improved bioavailability pharmaco-kinetic properties (more optimal logP and water solubility) compared with the lead anticancer compounds **1** and **8**.

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the above-described embodiments, without departing from the broad general scope of the present disclosure. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

Evaluation of compound 1 to treat skin diseases

2020415711 20 Jan 2025

Aim

To evaluate compounds **1, 8, 20, 27, 28, 31** and **35** with skin disease relevant *in vitro* assays. Evaluation was conducted by LEO Pharma Open Innovation, USA.

Specific Objectives

1. Determination of inhibition of CCL2 release from IL-4, IL-13, IL-22 and IFN-γ-stimulated primary human keratinocytes [assay number 1280] and determination of the effect on cell viability [assay number 1243].
2. Determination of inhibition of IL-8 release from IL-17A and TNFα-induced primary human keratinocytes [assay number 1250] and determination of the effect on cell viability [assay number 1244].
3. Determination of inhibition of IL-17A secretion from human PBMC stimulated with antiCD3/antiCD28-coated beads [assay number 1321] and determination of the effect on cell viability [assay number 1322].
4. Determination of inhibition of IL-4 and IL-2 secretion from human CD4-positive T-cells stimulated with antiCD2/antiCD3/antiCD28-coated beads [assay number 1297, 1298] and determination of the effect on cell viability [assay number 1299].

Disease Relevance Summary

1. Compounds which inhibit keratinocyte CCL2 secretion may be expected to have efficacy in atopic dermatitis.
2. Compounds which inhibit keratinocyte IL-8 secretion may be expected to have efficacy in psoriasis.
3. Compounds which inhibit IL-17A secretion may be expected to have efficacy in psoriasis.
4. Compounds which inhibit IL-4 secretion may be expected to have efficacy in atopic dermatitis. Compounds which also inhibit IL-2 secretion have a broader immunosuppressive effect since IL-2 is an autocrine growth factor for T-cells.

Results

Compound 28 [KYN-143] example concentration effect plots:

1. CCL2 release

2020415711 20 Jan 2025

Figure 9 shows the % effect of varying concentrations of compound **28** on inhibition of CCL2 release and inhibition of cell viability.

Discussion: Compound **28** showed medium potency reduction of CCL2 release with a similar reduction of cell viability. Without being bound by theory, the inventors believe that since plateaus at a partial level of cell viability from maximum are probably not due to cytotoxicity, but instead possibly part of the molecule/target MoA.

2. IL-8 release

Figure 10 shows the % effect of varying concentrations of compound 28 on inhibition of IL-8 release and inhibition of cell viability.

Discussion: Compound **28** showed medium potency reduction of IL-8 release, similar to that obtained for reduction of CCL2 release. However, compound **28**, displayed similar effect in both reduction of IL-8 and cell viability in this assay. Without being bound by theory, the inventors believe this possibly indicates a keratinocyte-related mechanism, but with lesser efficacy on IL-8 release, than CCL2 as described above and shown in **Figure 9**.

3. IL-17A release

Figure 11 shows the % effect of varying concentrations of compound 28 for inhibition of IL-17A release and inhibition of cell viability.

Discussion: Compound **28** showed low potency reduction of IL-17A release.

4. IL-2 and IL-4 release

Figure 12 shows the % effect of varying concentrations of complound **28** for inhibition of IL-2 and IL-4 release and inhibition of cell viability.

Discussion: Compound **28** showed medium potency effect specifically on IL-4 release and a lower potency effect on IL-2 and cell proliferation. Without being bound by theory, the inventors believe that there seem to be a specific effect on IL-4 release in the T cells.

2020415711 20 Jan 2025

Figure 13 shows Concentration-response graphs for compounds **1, 8, 20, 27, 28, 31** and **35.**

DiscussionCompounds **1 (KYN-001), 8 (KYN-119), 20 (KYN-146), 27 (KYN-149), 28 (KYN-143), 31 (KYN-151)** and **35 (KYN-152)** share a similar profile where a more pronounced effect with lower EC_{50} values can be noticed in the CCL2-release assay, followed by IL-8 and IL-4; less than 100% reduction of cell viability except compound **8** and compound **31** (Table 7, Figure 13). A general cytotoxic effect is common in tested molecules and may reach 100% but this is not the case for these compounds. This could indicate a specific mode-of-action that is affecting cell viability without being cytotoxic. Furthermore, there seem to be a specific effect on IL-4 release in the T cells, but with less potency.Compounds **28** (KYN-143) and **27** (KYN-149) stand out as the more potent molecules in these assays, closely followed by **8** (KYN-119) (**Table 7**). Compound **28** (KYN-143) inhibited keratinocyte **CCL2** secretion at EC_{50} 40 nM with 100% maximum efficacy and cell viability at EC_{50} 124 nM with 68% maximum reduction of cell viability. Compounds **27** [KYN-149] inhibited keratinocyte CCL2 secretion at EC_{50} 32 nM with 100% maximum efficacy and cell viability at EC_{50} 41 nM with 67% maximum reduction of cell viability.

Compound **28** [KYN-143] inhibited **IL-8** release from IL-17A and TNFα-induced primary human keratinocytes at EC_{50} 44 nM with 85% maximum efficacy and cell viability at EC_{50} 35 nM with 81% maximum reduction of cell viability. Compounds **27** [KYN-149] inhibited IL-8 release from IL-17A and TNFα-induced primary human keratinocytes at EC_{50} 46 nM with 75% maximum efficacy and cell viability at EC_{50} 32 nM with 83% maximum reduction of cell viability.

Compound **28** [KYN-143] inhibited IL-17A secretion from human PBMC stimulated with antiCD3/antiCD28-coated beads at EC_{50} 526 nM with 73% maximum efficacy and cell viability at EC_{50} 659 nM with 54% maximum reduction of cell viability. Compounds **27** [KYN-149] and other candidate compounds were significantly less effective.

For inhibition of IL-2 secretion from human CD4-positive T-cells stimulated with antiCD2/antiCD3/antiCD28-coated beads, none of the candidate compounds were effective in this assay.

2020415711 20 Jan 2025

Compound **28** [KYN-143] inhibited of IL-4 secretion from human CD4-positive T-cells stimulated with antiCD2/antiCD3/antiCD28-coated beads at EC_{50} 278 nM with 80% maximum efficacy and cell viability at EC_{50} 2360 nM with 60% maximum reduction of cell viability. Compounds **27** [KYN-149] inhibited of IL-4 secretion from human CD4-positive T-cells stimulated with antiCD2/antiCD3/antiCD28-coated beads at EC_{50} 507 nM with 79% maximum efficacy and cell viability at EC_{50} 4350 nM with 52% maximum reduction of cell viability.

Overall, the results indicate that compounds **28** [KYN-143] and **27** [KYN-149] are lead candidates for effective treatment of atopic dermatitis and psoriasis.

Table 7. Compounds **1, 8, 20, 27, 28, 31** and **35** assay results for inhibition of release/secretion of CCl2, IL-8, IL-17, IL-2 and IL-4 from cells and effects of the compounds on the viability of the cells.

		CCL2			
		nM	%	nM	%
	Name	Abs EC_{50}: CCL2 (1280)	Max Eff.: CCL2 (1280)	Abs EC_{50}: Viab (1243)	Max Eff.: Viab (1243)
1	KYN-001	123	101	202	77
8	KYN-119	50	102	235	99
20	KYN-146	108	99	442	61
27	KYN-149	32	100	41	67
28	KYN-143	40	100	124	68
31	KYN-151	445	100	431	86
35	KYN-152	1130	79	5000	30
		IL-8			
		nM	%	nM	%
	Name	Abs EC_{50}: IL-8 (1250)	Max Eff.: IL-8 (1250)	Abs EC_{50}: Viab (1244)	Max Eff.: Viab (1244)
1	KYN-001	80	94	90	92
8	KYN-119	37	107	32	101
20	KYN-146	321	93	221	76
27	KYN-149	46	75	32	83
28	KYN-143	44	85	35	81
31	KYN-151	364	105	416	100

2020415711 20 Jan 2025

35	KYN-152	2950	77	5000	72

		IL-17			
		nM	%	nM	%
	Name	Abs EC_{50}: IL-17 (1321)	Max Eff.: IL-17 (1321)	Abs EC_{50}: Viab (1322)	Max Eff.: Viab (1322)
1	KYN-001	4430	54	5000	50
8	KYN-119	1550	69	582	57
20	KYN-146	1650	85	5000	47
27	KYN-149	2120	65	5000	52
28	KYN-143	526	73	659	54
31	KYN-151	4870	53	5000	32
35	KYN-152	5000	19	5000	18

Abs EC_{50}: Half maximal effective concentration (nM) relative to control

Max Eff.: Highest effect of molecule as a percentage of control maximum effect

		IL-2		IL-4			
		nM	%	nM	%	nM	%
	Name	Abs EC_{50}: IL-2 (1297)	Max Eff.: IL-2 (1297)	Abs EC_{50}: IL-4 (1298)	Max Eff.: IL-4 (1298)	Abs EC_{50}: Viab (1299)	Max Eff.: Viab (1299)
1	KYN-001	5000	42	2930	70	5000	35
8	KYN-119	5000	51	503	82	5000	46
20	KYN-146	5000	34	5000	54	5000	15
27	KYN-149	5000	46	507	79	4350	52
28	KYN-143	4260	55	278	80	2360	60
31	KYN-151	5000	36	5000	29	5000	19
35	KYN-152	5000	16	5000	11	5000	7

Abs EC_{50}: Half maximal effective concentration (nM) relative to control

Max Eff.: Highest effect of molecule as a percentage of control maximum effect

Methods

1. Keratinocyte CCL2 release

Inhibition of CCL2 release from IL-4, IL-13, IL-22 and IFN-γ-stimulated primary human keratinocytes LEO Pharma Open Innovation assay number 1280

Disease relevance

2020415711 20 Jan 2025

The inflammatory skin disease atopic dermatitis (AD) is characterized by the T-cell cytokines including IL-4, IL-13, IL-22 and IFN-γ. In the present assay, keratinocytes are stimulated with a mixture of these cytokines, and the release of CCL2 (also called monocyte chemoattractant protein 1 (MCP-1)) is measured in the culture supernatant by proximity homogenous time-resolved fluorescence (HTRF). The purpose of the assay is to measure if test compounds inhibit the levels of CCL2 released by the keratinocytes. Compound which inhibit keratinocyte CCL2 secretion may be expected to have efficacy in atopic dermatitis.

A known steroid, Betamethasone, inhibits CCL2 release in this assay with an EC_{50} of approximately 15 nM, and an Emax (plateau of the fitted curve) of approximately 60%. A high Emax shows that the compound inhibits a large proportion of the secreted CCL2. A low EC_{50} value indicates that the compound is potent and to perform the inhibition at low concentrations.

Key assay parameters	Description
Human primary keratinocytes (HEKa)	Cells are frozen in passage 2. Cells are used in passage 3-6
IL-4, IL-13, IL-22 and IFN-γ	Atopic dermatitis-like stimulation: Recombinant human interleukin (IL) 4, 13 and 22 at 10 ng/mL and Interferon-γ at 1 ng/mL
Effect	Inhibition of AD stimuli induced CCL2 release from HEKa cells
Positive control (~100% effect)	AD-like stimulation + Terfenadine (CAS: 50679-08-8) at 10 microM
Negative control (~0% effect)	AD-like stimulation and 0.1% DMSO
Reference compound	Betamethasone (CAS: 378-44-9)
Incubation time	48h
Capacity, run-time and requirements	The assay takes 3 days to perform.

Method description

Cell culture:

HEKa are human epidermal keratinocytes isolated from adult skin. The cells have been cryopreserved at the end of the primary culture stage in a medium containing 10% DMSO. Sterile cell culture work applies.

2020415711 20 Jan 2025

Initiating Cultures from Cryopreserved HEKa Cells:

- Thaw a vial of the frozen HEKa stock in a 37°C water/bead bath.
- Transfer the cell suspension into 30 ml T75 cell culture flask.
- Take 15 ml out and dispense over into 2xT75 (15 ml each).
- Set up for assay 5-6 days later or pass it on.

Maintenance of Stock Cultures

- Change the culture medium to freshly supplemented medium, 24 to 36 hours after establishing a secondary culture from cryopreserved cells. For subsequent subcultures, change the medium 48-72 hours after establishing the subculture.
- Only passage up to 3-5 in the assay.

Subculture of HEKa

- View and confirm 80% confluence.
- Remove all of the culture medium from the flask.
- Add 3 ml of TrypLE Express solution to the flask. Rock the flask to ensure that the entire surface is covered.
- Immediately remove all 3 ml of TrypLE Express solution from the flask.
- Add 1½ ml (T75) (3 ml T175) of fresh TrypLE Express solution to the flask.
- View the culture under a microscope. Incubate the flask at room temperature until the cells have become completely round, approximately 8-10 minutes.
- Tap the flask very gently to dislodge cells from the surface of the flask.
- Add 3-4 ml (T75) (7 ml T175) of Trypsin Neutralizer solution to the flask and transfer the detached cells to a sterile conical tube.
- Centrifuge the cells at 170 x g for 7-10 minutes. Observe the cell pellet.
- Remove the supernatant from the tube, being careful not to dislodge the cell pellet.
- Resuspend the cell pellet in 15 ml medium with HKGS supplemented (cat no S-001-K) but without hydrocortisone (when use for assay). Pipette the cells up and down with a 10 ml pipette to ensure a homogeneous cell suspension.
- Determine the concentration of cells in the suspension.

2020415711 20 Jan 2025

- Dilute the cells in supplemented medium and seed new culture in a T175 flask. Incubate the cultures in a 37°C, 5% CO_2/95% air, humidified cell culture incubator.

Assay Day 0:

- Trypsinize the cells as described above.
- Resuspend pellet in 10 ml assay medium (EpiLife Medium with HKGS Kit but without hydrocortisone)
- Filter the cells though a 37μm strainer.
- Count cells using a cell counter.
- Seed HEKa cells in 384-well view plates 3500 c/w/40 μL.
- Place the plates with lids on in a humidity chamber with lid (24.5x24.5cm box added H_2O in the bottom).
- Incubate plates over night at 37°C, 5% CO_2/95% air

Assay Day 1:

- Prepare compound-containing source plate, i.e. titrations in DMSO to be transferred to the assay plate.
- Add 80 nL compounds and controls from the source plate to the assay plate (with cells).
- Add 40 μL stimulation (recombinant human interleukin (IL) 4, 13, 22 at 10 ng/mL and Interferon-gamma at 1 ng /mL) in medium with supplement, but without hydrocortisone.
- Incubate plates at 37°C, 5% CO_2/95% air for 2 days.

Assay Day 3:

- Remove plates from incubation and equilibrate to room temperature for 30 minutes.
- Transfer 8 μL supernatant to white proxi 384-well plates for CCL2 detection.
- Add 8 μL media to the detection plate.
- Add 4 μL CCL2 HTRF detection reagent (to the white proxi 384w).
- Seal and incubate for 4 hours and read in a plate reader.

2020415711 20 Jan 2025

Data analysis and calculations

CCL2 concentration in the supernatants is measured using homogeneous time-resolved fluorescence resonance (TR-FRET). The assay is quantified by measuring fluorescence at 665 nm (proportional to CCL2 concentration) and 620 nm (control). A ratio 665/620*1000 is calculated.

% Effect:

The capacity of the test compound to inhibit CCL2 release is normalized to the signal in the control wells with keratinocytes incubated with 0.1% DMSO (0%) and 10 μM Terfenadine (100%), which fully inhibits the CCL2 release.

2. Keratinocyte IL-8 release

Inhibition of IL-8 release from IL-17A and TNFα-induced primary human keratinocytes LEO Pharma Open Innovation assay number 1250 openinnovation.leo-pharma.com

Disease relevance

The inflammatory skin disease psoriasis is characterized by cytokines IL-17A and TNFα. In the present assay, primary human keratinocytes are stimulated with a mixture of these cytokines, and the release of IL-8 (also called CXCL8) is measured in the culture supernatant by proximity homogenous time-resolved fluorescence (HTRF). The purpose of the assay is to measure if the test compound is able to inhibit the levels of IL-8 released by the keratinocytes, indicating that it is able to inhibit part of the inflammation occurring in cells.

Compounds which inhibit keratinocyte IL-8 secretion may be expected to have efficacy in psoriasis.

A known steroid, Betamethasone, inhibits IL-8 release in this assay with an EC_{50} of approximately 10 nM, and an Emax (plateau of the fitted curve) of approximately 50%. A high Emax indicates that the compound inhibits a large proportion of the IL-8

2020415711 20 Jan 2025

secretion. A low EC_{50} value indicates that the compound is potent and performs the inhibition at low concentrations.

Key assay parameters	Description
Human epidermal keratinocytes, adult (HEKa)	Cells are frozen in passage 2. Cells are used in passage 3-5
IL-17A and TNFα	Psoriasis-like stimulation: Recombinant human interleukin (IL) 17A and tumor necrosis factor alpha (TNFα) both at 10 ng/mL
Effect	Inhibition of IL-17A/TNFα-induced IL-8 release from HEKa
Positive control (~100% effect)	No stimulation and 0.1% DMSO
Negative control (~0% effect)	IL-17A/TNFα stimulation and 0.1% DMSO
Reference compound	Betamethasone (CAS: 378-44-9)
Incubation time	72h
Capacity, run-time and requirements	The assay takes 3 days to perform.

Method description

Cell culture:

HEKa are human epidermal keratinocytes isolated from adult skin (See Cell Culture Method described for Keratinocyte CCL2 release above).

Assay Day 0:

- Detach the cells as described above.
- Resuspend pellet in 10 ml EpiLife Medium with HKGS Kit but without hydrocortisone
- Filter the cells though a 37µm strainer.
- Count cells using a cell counter.
- Seed Human Epidermal Keratinocytes, adult (HEKa) cells in 384-well view plates 3500 c/w/40 µL. Use cell media with supplement but without hydrocortisone as assay medium.
- Place the plates with lids on in a humidity chamber with lid (24.5x24.5cm box added H_2O in the bottom).
- Incubate plates over night at 37°C, 5% CO_2/95% air.

Assay Day 1:

2020415711 20 Jan 2025

- Prepare compound-containing source plate, i.e. titrations in DMSO to be transferred to the assay plate.
- Empty the assay plate, and re-add 25 µL assay medium.
- Add 75 nL compounds and controls from the source plate to the assay plate (with cells).
- Add 25 µL assay medium and incubate for 2 hours.
- Add 25 µL stimulation mix in assay medium (recombinant human interleukin 17A and Tumor necrosis factor-alpha) to give a final concentration of 10 ng/mL of both cytokines.
- Incubate plates at 37°C, 5% CO_2/95% air for 3 days.

Assay Day 4:

- Remove plates from incubation and equilibrate to room temperature for 30 minutes.
- Transfer 2 µL supernatant to white proxi 384-well plates for IL-8 detection.
- Add 2 µL assay medium
- Prepare IL-8 HTRF mix (according to manufactory protocol) and add 2 µL pr well.
- Seal and incubate for 3 hours and read fluorescence in a plate reader.

Data analysis and calculations

IL-8 concentration in the supernatant is measured using homogeneous time-resolved fluorescence resonance (TR-FRET). The assay is quantified by measuring fluorescence at 665 nm (proportional to IL8 concentration) and 620 nm (control). A ratio 665/620*1000 is calculated as a representation of the amount of IL-8 in the supernatant.

% Effect:

The capacity of the test compound to inhibit IL-8 release is normalized to the signal in the negative control wells with keratinocytes incubated with 0.1% DMSO (0%) and 10 µM Terfenadine (100%), which fully inhibits the release of IL-8.

2020415711 20 Jan 2025

3. PBMC IL-17 assay

Inhibition of IL-17A secretion from human PBMC stimulated with antiCD3/antiCD28-coated beads. LEO Pharma Open Innovation assay number 1321

Disease relevance

The inflammatory skin disease psoriasis is characterized by cytokines IL-17A and TNFα. In the present assay, human peripheral blood mononuclear cells (PBMC) are stimulated with beads coated with antibodies against CD3 and CD28 to activate the T-cell receptor, and stimulated with IL-23 to promote T-helper17 activity. The cells are incubated for three days, then the secreted level of IL-17A is measured in the culture supernatant using AlphaLISA and the amount of living cells is measured by addition of resazurin (PrestoBlue®) to identify compounds that inhibit cell proliferation or viability. The purpose of the assay is to measure if test compounds inhibit the secretion of IL-17A by the PBMC. Compounds which inhibit IL-17A secretion may be expected to have efficacy in psoriasis.

The reference compound in this assay is the calcineurin inhibitor Tacrolimus and inhibits IL-17A release with an EC_{50} of approximately 0.34 nM, and with an Emax (plateau of the fitted curve) of approximately 90%. A high Emax shows that the compound inhibits a large proportion of the secreted IL-17. A low EC_{50} value indicates that the compound is potent and performs the inhibition at low concentrations.

Key assay parameters

Parameter	Description
Cells	Human PBMC isolated from buffy coats and kept at -150°C until day of assay
Stimulation	Beads coated with antibodies to CD3 and CD28 (T-cell activation/expansion kit Miltenyi Biotec cat no 130-091-441) One bead/cell.
Effect	Inhibition of IL-17A release
0% effect of test compound	Bead stimulation, 0.1% DMSO
100% effect of test compound	Bead stimulation, 0.1% DMSO, Terfenadine 10 uM
Reference compound	Tacrolimus (Cas no 104987-11-3-P)

2020415711 20 Jan 2025

Incubation time	3 days
Capacity, run-time and requirements	The assay takes 3 days to perform.

Method description

PBMC isolation:

- PBMC are isolated from fresh human buffy coats by centrifugation on lymphoprep® following instructions from Sebmate®
- Cells are spun down and resuspended in freezing medium (RPMI1640 + 20% FBS + 5% DMSO)
- Cells are frozen in aliquots of 8 x 10^7 cells/vial matching one 384 plate. Cells are placed in Coolcell box and placed in -80°C freezer for one day. Vials are moved to the -150° C freezer in a prechilled box.

Assay Day 1:

- Prepare assay medium: RPMI1640 + 10% heat inactivated FBS and 1% pen/strep, supplemented with human IL-23, 20 ng/mL (R&D systems, cat no 1290-IL-010)
- Test compounds: Prepare compound-containing source plate, i.e. titrations in DMSO to be transferred to the assay plate.
- Add 70 nL compounds and controls from the source plate to the assay plate.
- Thaw the cells by adding 1 vial to 20 ml warm assay medium
- Centrifuge the cells down at 170G in 10 minutes, remove the supernatant and resuspend in new medium.
- Filter the cells though a 37µm strainer.
- Count the cells in the cell counter.
- Beads (T Cell Activation/Expansion Kit -human, Miltenyi Biotech, cat.no. 130-091-441): Coat beads with antibodies (antiCD3 and antiCD28) according to the kit procedure.
- Add the beads to the cells, one bead per cell, 2.1e+06 cells/ml. Use a pipette to mix the cells and beads carefully.
- Seed the cell/bead mixture into the assay plate, 70µL/well (1.3e+05 cells/well)

2020415711 20 Jan 2025

- Place the plates in a humidity chamber with lid (24.5x24.5cm box added H_2O in the bottom).
- Incubate plates at 37°C, 5% CO_2/95% air for 3 days.

Assay Day 4:

- IL-17A concentration in the supernatants is measured using an alphaLISA kit (Perkin Elmer, cat no. AL219F).
- Pretest to find optima dilution of samples: Test 5 µL supernatant from control wells and run IL-17A alphaLISA assay with only 2 hours of incubation.
- When data are available, remove assay plates from incubation and equilibrate to room temperature for 30 minutes.
- Transfer 5 µL or corrected amounts of supernatant to a 384-proxy plate
- Add 5 µL alphaLISA acceptor beads.
- Incubate 1 hour at room temperature
- Add 5 µL donor beads
- Incubate overnight at room temperature protected from light.
- Add 7 µL PrestoBlue reagent (resazurin) / well to the assay plate and incubated for 2-4 hours at 37 °C / 5 % CO_2. The fluorescence in the wells is measured (Ex615/ Em 535).

Assay day 5:

- Read alphaLISA plate in a plate reader

Data analysis and calculations

IL-17A concentration in the supernatants is measured using an alphaLISA kit (Perkin Elmer, cat no. AL219F).

% Effect IL-17:

The capacity of the test compound to inhibit IL-17A release is normalized to the signal in the negative control wells treated with a toxic compound, Terfenadine.

The level of living cells in the wells is measured by the addition of PrestoBlue ® and the conversion of Resazurin to Resorufin (fluorescent) in living cells is measured.

2020415711 20 Jan 2025

% Effect viability/proliferation:

The effect of the test compounds on viability/proliferation is normalized to the PrestoBlue signal in the negative control wells treated with a toxic compound, Terfenadine.

4 and 5. T-cell IL-2 & IL-4 assay

Inhibition of IL-4 and IL-2 secretion from human CD4-positive T-cells stimulated with antiCD2/antiCD3/antiCD28-coated beads. LEO Pharma Open Innovation assay number 1297, 1298, 1299.

Disease relevance

The inflammatory skin disease atopic dermatitis is characterized by the T-cell cytokines IL-4, IL-13 and IL-22. In the present assay, human T-cells are stimulated with beads coated with antibodies against CD2, CD3 and CD28 to activate the T-cell receptor. Then the level of secreted of IL-4 is measured in the culture supernatant using electrochemiluminescence (MSD kits, Meso Scale Discovery), IL-2 is measured by proximity homogenous time-resolved fluorescence (HTRF) and the amount of living cells is measured by addition of resazurin (PrestoBlue®) to allow identifying compounds that inhibit T-cell proliferation or viability. The purpose of the assay is to measure if a test compound is able to inhibit the secretion of IL-4 by the T-cells, indicating that it is able to inhibit part of the inflammation occurring in the skin.

Compounds which inhibit IL-4 secretion may be expected to have efficacy in atopic dermatitis. Compounds which also inhibit IL-2 secretion have a broader immunosuppressive effect since IL-2 is an autocrine growth factor for T-cells. A known steroid, Betamethasone, inhibits IL-4 release in this assay with an EC_{50} of approximately 15 nM, and with an Emax (plateau of the fitted curve) of approximately 80%. A high Emax shows that the compound is able to inhibit a large proportion of the secreted IL-4. A low EC_{50} value indicates that the compound is potent and is able to perform the inhibition at low concentrations.

2020415711 20 Jan 2025

Key assay parameters

Human CD4-postive T-cells isolated from buffy coats and kept at -150 degree C until day of assay	
Stimulation	Beads coated with antibodies to CD2, CD3 and CD28 (T-cell activation/expansion kit Miltenyi Biotec cat no 130-091- 441) One bead/cell.
Effect	Inhibition of IL-4 release from T-cells
0% effect of test compound	Bead stimulation, 0.1 % DMSO
100% effect of test compound	Unstimulated cells, 0.1% DMSO
Reference compound	Betamethasone (CAS: 378-44-9)
Incubation time	48h
Capacity, run-time and requirements	The assay takes 3 days to perform.

Method description

CD4+ T-cell isolation:

- Peripheral blood mononuclear cells (PBMC) are isolated from fresh human buffy coats by centrifugation on lymphoprep® following instructions from Sebmate ™ (Stemcell).
- The cells are resuspended in 30 ml of PBS+2%Serum and counted.
- CD4 positive T-cells are isolated from freshly isolated PBMC using EasySep™ humane CD4+ T-cell Isolation Kit (Catalog # 17952) and following the manufacturer's protocol.
- Cells are spun down and resuspended in freezing medium (X-vivo 15 + 10% FBS + 5% DMSO)
- Cells are frozen in aliquots of 3 x 10^7 cells/vial matching one 384 plate. Cells are place in Coolcell box and place in -80° C freezer for one day then transferred to the -150°C freezer in a prechilled box.

Assay Day 1:

- Prepare assay medium: 500 ml X-Vivo 15 + 5 ml Glutamax (2mM final) + 5 ml pen/strep (100 U/ml final).
- Add 5 µL medium to the wells of a 384 well plate (Greiner cat. No 788986).

2020415711 20 Jan 2025

- CD4+ Cells: Thaw frozen cells from -150°C freezer in 37°C bath, and pipette the cells into 10 ml medium. Spin 10 min @ 170 g.
- Resuspend pellet in 3.5 ml per $2.5x10^7$cells and add 10 µL per well to the plate (40000 cells/well)
- Test compounds: Prepare compound-containing source plate, i.e. titrations in DMSO to be transferred to the assay plate.
- Add 25 nL compounds and controls from the source plate to the assay plate (with cells).
- Beads (T Cell Activation/Expansion Kit -human, Miltenyi Biotech, cat.no. 130-091-441): Coat beads with antibodies according to the kit procedure.
- Add 10 µL beads to each well except for the negative controls. One bead per cell. Add 10 µL medium to the negative controls.
- Incubate plates at 37°C, 5% CO_2/95% air for 2 days.

Assay Day 3:

- Remove plates from incubation and equilibrate to room temperature for 30 minutes.
- IL-4 concentration in 10 µL supernatant is measured using an MSD IL-4 384-plate kit (Custom made) according to manufacturer protocol.
- IL-2 concentrations in the supernatant is measured by an IL-2 HTRF kit, CisBio, cat. No 62HIL02PEH.
- Add 4 µL medium to white proxi 384-well plates
- Add 1 µL supernatant.
- Add 4 µL mHTRF mix (each diluted 1:300 in 2/3 reconstitution buffer and 1/3 assay medium).
- Spin the plates for 1 minute at 170g
- Seal and incubate overnight and read fluorescence in a plate reader
- The amount of viable cells is measured by PrestoBlue® reagent
- Add 15 µL diluted PrestoBlue® reagent (resazurin) corresponding to 2.5 µL Prestoblue/well to the assay plate.

2020415711 20 Jan 2025

- Incubate overnight at 37°C / 5% CO_2. The fluorescence in the wells is measured (Ex615/ Em 535).

Data analysis and calculations

IL-4 concentration in the supernatants is measured using electrochemiluminescence (MSD kits, Meso Scale Discovery). IL-2 concentration in the supernatants is measured using homogeneous time-resolved fluorescence resonance (TR-FRET). The assay is quantified by measuring fluorescence at 665 nm (proportional to IL-2 concentration) and 620 nm (control). A ratio 665/620*1000 is calculated.

% Effect for IL-2 and IL-4:

The capacity of the test compound to inhibit IL-4 and IL-2 release is normalized to the signal in the negative control wells with un-stimulated T-cells.

The level of living cells in the wells is measured by the addition of PrestoBlue ® and the conversion of Resazurin to Resorufin (fluorescent) in living cells is measured.

% Effect for viability/proliferation:

The effect of the test compounds on viability/proliferation is normalized to the PrestoBlue signal in the negative control wells treated with a toxic compound, Terfenadine.

***Ex vivo* study: Predicting Patient Response to Oncology Drugs**

ROK-DRPS-001 –Drug Response Summary (June 19, 2020)

Glioblastoma multiforme (GBM) Drug Response Pilot

KIYATEC, Inc., Greenville, South Carolina, USA

1. Project Description/Summary

This project involves an *ex vivo* drug response screen for 3 ROKiT Pharma test agents and Temozolomide in 3 previously dissociated and cryopreserved GBM samples.

2. Technical Conduct

2020415711 20 Jan 2025

2.1 Three previously processed GBM patient samples were chosen to be used in this study.

ID	New or Relapse	IDH1 status	MGMT	Grade
BNA99	New	wild type	methylated	high
BNB04	Recurrent	wild type	unknown	high
BNB18	New	wild type	unmethylated	high

IDH1: isocitrate dehydrogenase-1; MGMT: (O[6]-methylguanine-DNA methyltransferase)

2.2 1-2 vials of each sample were thawed, and cells were seeded as 3D spheroids in one 384-well plate per sample.

2.3 24 hours after seeding, images were taken of all wells and drugs/controls were added.

- Test Compounds: KYN-001, KYN-146, KYN-149, 10-point dose curve at 1:3 dilution starting at 100 μM and ending at 0.005 μM
- Vehicles: Media + 0.5% DMSO, Media + 1% DMSO
- Positive controls: 10% DMSO and 2% DMSO
- Wells containing only vehicle and no cells were used as blanks

2.4 Cell viability was measured 4 days post drug treatment with CellTiter-Glo 3D assay.

- Images were taken of all wells prior to addition of CellTiter Glo reagent.

2.5 Following the blanking of raw data and the removal of outliers (defined by software analysis and highlighted in red in raw data files), IC_{50} values were determined using nonlinear regression (normalized to untreated control) in GraphPad Prism.

- The IC_{50} values are expressed in μM and are defined as the concentration of drug where cell viability is reduced by half.

2020415711 20 Jan 2025

3. Summary of Experimental Results

3.1 Drug response to the test compounds and TMZ is listed in the table below:

Drug	IC_{50} (μM)		
	BNA99	BNB04	BNB18
1 [KYN-001]	14.95	10.89	1.329
20 [KYN-146]	19.13	23.67	4.556
27 [KYN-149]	8.867	4.31	0.6343
TMZ	NR	MR	R

3.2 The RLUs (Relative Light Unit) were high for the cells from each GBM sample, indicating proliferation/viability throughout the assay duration.

3.3 Z-factors reflected successful assays for all samples and drugs.

3.4 TMZ Response:

- NR: Non-responder
- MR: Moderate responder
- R: Responder

Discussion

The three GBM cell samples used in this study, namely BNA99, BNB04 and BNB18, displayed three distinct growth characteristics when grown into 3D spheroids as shown in Figure 14. These cells range from resistant (BNA99), to moderately resistant (BNB04) and sensitive (BNB18) to the clinical drug Temozolomide (TMZ). In the presence of the test compounds **1**, **20** and **27** the spheroids of all three cell lines were disrupted causing cell death and dispersion into the culture medium. These events were clearly demonstrated from images (Figure 14) taken prior to addition of CellTiter Glo reagent which was used to quantify the cell viability by measuring the level of ATP of the live cells.

The test compounds showed moderate to potent inhibition of these GBM 3D spheroid cell samples with IC_{50} value of **27** at sub-micromolar range in the sensitive line BNB18 (IC_{50}=0.63 μM). As predicted the test compounds were active towards

20 Jan 2025 2020415711

sensitive GBM line BNB18 but less active towards BNB04 spheroids and much less active towards BNA99 spheroids. Despite this, the test compounds, particularly **27**, were shown to be relatively active towards the TMZ resistant cells (BNA99) with IC_{50} value of 8.86 μM while TMZ showed no response to this cell line.

The results from this study reveal that the test compounds, particularly **27,** are promising candidates for the development of new anticancer drugs.

Summary

- Assay was successful for all drugs and samples based on z-factors and RLU signals
- IC_{50} values indicated varying sensitivities to KYN-001, KYN-146, and KYN-149 for all 3 samples.
- TMZ response varied for all 3 samples across all 3 response categories.
- Bright field images of spheroids match CellTiterGlo Results (data not shown).
- **27** [KYN-149] more effective than **1** [KYN-001] and **20** [KYN-146] towards all three GBM 3D-spheroid sample types (NR, MR and R).

Reference:-

Shuford, S., et al., 2019. Prospective Validation of an *Ex Vivo*, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer, Nature Scientific Reports, *9:11153* | https://doi.org/10.1038/s41598-019-47578-7

Compound 27 [KYN-149] Maximum Tolerable Dose- LD/50 Single Dose Oral Administration Report

Evaluation was conducted by Kynan Pharma, USA

Study Purpose:

To ascertain initial information regarding the toxicity and tolerability of compound **27**.

Study Design:

2020415711 20 Jan 2025

A single administration of orally formulated maximum dose, 2000 mg/kg was given to 5 BalbC mice. Observation was carried out for 5 days.

Experimentalist: Tiziana Palumbo, Matt Kiosea

Dates of testing: June 8-12, 2020

Method:

Compound **27** was weighed out and diluted into the same SEDDS vehicle used for S1. The SEDDS vehicle is composed of the following components:

- Labrasol (30%)
- PEG-400 (20%)
- Kolliphore RH-40 (30%)
- Labrafil (20%)

The concentration of **27** in SEDDS was 200 mg/mL which would translate to a 2000 mg/kg oral dose for a 20g mouse administered 200 ul. Oral administration was administered to 5 mice and the animals were carefully observed for signs of toxicity in the first hour then sporadically over 5 days.

Results:

All five mice survived and showed no immediate signs of distress. During the remaining days of observation, No distress or any other discomfort was recorded.

Conclusions:

The results of the LD/50 study indicate that compound **27** has a high degree of oral tolerability in the given formulation. 2000 mg/kg is the maximum dose recommended for testing toxicological effects per FDA recommendations.

Preliminary investigation of the effect of compound 27 [KYN-149] in B16F10 xenografted mice.

Evaluation was conducted by Kynan Pharma, USA

2020415711 20 Jan 2025

Objectives

- Observe and assess the effect of oral administration of **27** on animal wellbeing.
- Quantify levels of **27** in tissues (plasma, tumor, liver, spleen and brain) to assess the compound bioaccumulation and distribution.

Method

B16F10 cells (25 x 10^5 cells/mouse) were injected subcutaneously into the right flank of female BALB/c mice aged 7-8 weeks. Mice (n =10) were divided into 2 groups and given daily oral suspension of **27** (treated group), or vehicle (control group) for 15 days. The treated group was orally given a suspension of **27** at 900 mg/kg. The control group was given the vehicle suspension (SEDDS). Measurements performed on days 0, 9 and 15 only. Tissues (plasma, tumor, liver, spleen and brain) were harvested within 3 hours of final treatment. Biopsies of tumor tissues for histopathology were obtained subsequently.

Tissue samples from the tumors of both treated and control mice were fixed with formalin. Histopathological examination of these tumor samples was performed by Lore Laboratory, CA, USA.

Concentrations of **27** in different tissues were determined using LC/MS/MS spectrometry.

Results

Mice showed no signs of toxic effect at 900 mg/kg of **27**. Concentration of **27** in different tissues are determined as shown in table 1 and presented graphically as shown in Figure 15 A and B.

Table 8. Measurement of compound 27 in mice tissues using mass spectrometry

	Concentration of compound 27 in tissues				
Animal	Plasma (ng/mL)	Tumor (µg/mg)	Liver (µg/mg)	Spleen (µg/mg)	Brain (µg/mg)
Control 1	0.0	NA	0	0	0
Control 2	0.0	0	0	NA	0
Control 3	0.0	0	0	0	0

2020415711 20 Jan 2025

Treated 1	0.0	0	12.6	2	156
Treated 2	0.0	NA	10.2	0	77
Treated 3	8.4	0	1.0	0	35
Treated 4	0.4	0	0.0	0	170
Treated 5	0.0	11.6	0.0	0	48
P-Value control vs treated	0.22	0.54	0.36	0.65	0.004

NA = not acquired

Figure 15. Concentrations of 27 in different tissue samples isolated from treated mice. Mice were orally administration of 900 mg/kg of **27** in SEDDS suspension or vehicle (control) daily for 15 days.

It was found that concentration of compound **27** was variously distributed in different tissues as shown in Figure 15. Low plasma level of compound **27** can be explained as the compound being bound to plasma proteins such as albumin.

Histochemical analysis of the tumor samples.

Preliminary investigation revealed that two out of five biopsies samples from five mice treated with **27** displayed melanomas as detailed below.

Treated 1.

It was found that the lesion was located deep in the dermis and panniculus. There was a sheet of pleomorphic round cells with occasional pigmented cytoplasm. These cells were predominantly degenerated or necrotic with adjacent areas of lytic necrosis (Figure 16). Mixed inflammatory cells were noticed at the periphery.

Treated 2.

It was found that the lesion was located in the superficial and mid dermis. There was a sheet of pleomorphic round cells with occasional pigmented cytoplasm surrounded by lytic necrosis (Figure 16). Mixed inflammatory cells were noticed at the periphery.

Histochemical analysis of tumor samples from treated 1 and 2 mice.

These two tumors contained melanoma which grew rapidly from day 0 to 9. The tumors were subsequently diminished after day 10 indicating that it is possibly an effect of compound **27** (Figure 16).

2020415711 20 Jan 2025

Histochemical analysis of samples from treated 3, 4 and 5 mice.

Histochemical analysis of these samples revealed predominantly melanocytes which expand subcutaneous and panniculus with mild mononuclear inflammation (Figure 17). These findings consist with the lack of tumor growth as shown in Table 8 and Figure 18.

Table 8. Tumor volume (mm^3) in mice treated with compound **27**

Compound 27	**Day 0 (mm^3)**	**Day 9 (mm^3)**	**Day 15 (mm^3)**
Treated #1	109.29	132.59	5.31
Treated #2	52.18	178.68	19.93
Treated #3	58.45	37.38	35.03
Treated #4	82.97	60.93	42.35
Treated #5	66.82	47.3	39.44

Figure 18. Effect of Compound **27** on melanoma B16F10 xenografted in BALB/c mice.

Histopathology Conclusions

- Except in two drug-administered tumors, (Treated 1 and Treated 2) the other samples were highly pigmented melanocytes with a round elongated nucleus and no mitotic activity.
- It may be that in those samples with no malignancy observed histologically, either there was no malignancy developed from the beginning or malignant tissue was not sampled and collected.
- Although most of the tissues analyzed were composed of melanocytes, two treated tissues contained melanoma that was necrotic and degenerative, possibly indicative of an effect of treatment. The lack of melanoma in control untreated tissues confound these findings.

Overall Conclusion

2020415711 20 Jan 2025


In conclusion, the study showed that the compound **27** had low toxicity when given orally, and had a high tendency to accumulate in the brain. This could be explained by the highly lipophilic property of the compound.

Histochemical analysis of tumor samples revealed that the melanoma cells xenografted in two out of five mice treated with **27** were lysed and/or underwent necrosis indicating the possible effectiveness of compound **27** in treatment of melanoma *in vivo*. However, further studies are required to determine further details of the pharmacokinetics of **27** and to assess anticancer efficacy *in vivo*.

2020415711 29 Jan 2025

CLAIMS:

1. A process of synthesising a compound of formula (I):



Formula (I)

wherein:

R^{1a} is independently allyl, crotyl, prenyl, benzyl or 2-alkenyl;

R^{1b} is independently CF_3, OR^2 or NHR^3;

R^{1c} is H;

R^{1d} is independently OH, O-protecting group, NHR^3 or NO_2;

R^{1e} is independently C_1-C_6 alkyl, OH, OR^2, NO_2, NHR^3, $NMeR^3$ or SR^2;

R^{1f} is independently H, OH, O-protecting group, NO_2, NHR^3, $N(OH)(CO)CH_3$, $NHC{=}NH(NH_2)$ or COOH;

R^{1g} is independently H, C_1-C_6 alkyl or OH;

R^{1b} and R^{1d} are not the same;

no more than one of R^{1f} or R^{1g} can be H;

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or trifluoromethyl;

protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxymethyl (SEM), $CH(OEt)CH_3$, tetrahydropyranyl and $C(OEt)(CH_3)_2$;

R^3 is independently H, CH_3, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $CO(CH_2)_nNH_2$, $CONH_2$, $CO(CH_2)_nCOOH$ or $COCOOR^4$, where n is 0, 1 or 2; and


R^4 is C_1-C_6 alkyl;

2020415711 29 Jan 2025

or R^{1e} and R^{1f} form a five-membered heterocyclic ring containing a carbonyl group when R^{1e} is independently OH, NH_2 or NHMe and R^{1f} is NH_2, such that the nitrogen of R^{1f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{1e} and R^{1g} is H;


the process comprising:

i) a step of coupling a compound of formula (II) (Module A) with a compound of formula (III) (Module B) to afford a compound of formula (IV) (Module C):




Formula (II)

Module A



Formula (III)

Module B



Formula (IV)

Module C

wherein,

in Formula II (Module A):

R^{2b} is independently CF_3, OR^2 or NH_2;

R^{2c} is H;

R^{2d} is independently O-protecting group or NO_2;

X is a halide or a hydroxyl group, wherein the halide is selected from the group consisting of F, Cl, Br, I, and At; and

2020415711 29 Jan 2025

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or trifluoromethyl;

in Formula III (Module B):

R^{3e} is independently C_1-C_6 alkyl, OR^2, NO_2 or SR^2;

R^{3f} is independently H, O-protecting group, NO_2 or $COOR^2$;

R^{3g} is independently H, C_1-C_6 alkyl, OH or OR^2;

no more than one of R^{3f} or R^{3g} can be H;

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or trifluoromethyl; and

R^4 is C_1-C_6 alkyl;

or R^{3e} and R^{3f} form a five-membered heterocyclic ring containing a carbonyl group when R^{3e} is OH, NH_2 or NHMe and R^{3f} is NH_2, such that the nitrogen of R^{3f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{3e} and R^{3g} is H;

in Formula IV (Module C):

R^{4b} is independently CF_3, OR^2 or NH_2;

R^{4c} is H;

R^{4d} is independently O-protecting group or NO_2;

R^{4e} is independently C_1-C_6 alkyl, OR^2, NO_2 or SR^2;

R^{4f} is independently H, O-protecting group, NO_2 or COOH;

R^{4g} is independently H, C_1-C_6 alkyl, OH or OR^2;

no more than one of R^{4f} or R^{4g} can be H;

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or trifluoromethyl; and

X is a halide or a hydroxyl group, wherein the halide is selected from the group consisting of F, Cl, Br, I, and At;

or R^{4e} and R^{4f} form a five -membered heterocyclic ring containing a carbonyl group when R^{4e} is OH, NH_2 or NHMe and R^{4f} is NH_2, such that the nitrogen of R^{4f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{4e} and R^{4g} is H;

2020415711 29 Jan 2025

wherein the protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxymethyl (SEM), $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$.

2. The process of claim 1, wherein:

i) when X in formula (IV) is a halide, the halide of formula (IV) undergoes a coupling reaction with one of the following:

a) a R^{1a}-substituted boronic acid compound or ester including a R^{1a}-substituted boronic acid pinacol ester;

b) a R^{1a}-substituted trifluoroborate compound including a potassium R^{1a}-substituted trifluoroborate; or

c) a R^{1a}-substituted organostannane compound including a R^{1a}-substituted tributylstannane;

to form the compound of formula (I),

wherein R^{1a} is selected from the group consisting of allyl, crotyl, prenyl, benzyl or 2-alkenyl;

or

ii) when X in formula (IV) is hydroxyl, the hydroxyl group of Formula (IV) is converted to a triflate (trifluoromethylsulfonate) group to form a triflate of formula (IV), and the triflate of formula (IV) undergoes a coupling reaction with one of the following:

a) a R^{1a}-substituted boronic acid compound or ester including a R^{1a}-substituted boronic acid pinacol ester;

b) a R^{1a}-substituted trifluoroborate compound including a potassium R^{1a}-substituted trifluoroborate; or

c) a R^{1a}-substituted organostannane compound including a R^{1a}-substituted tributylstannane

to form the compound of formula (I),

wherein R^{1a} is selected from the group consisting of allyl, crotyl, prenyl, benzyl or 2-alkenyl;

2020415711 29 Jan 2025

optionally wherein the coupling reaction i) and ii) is catalysed by a palladium compound in the presence of a base.

3. The process of claim 1 or 2, wherein

in Formula (I):

R^{1a} is independently allyl, crotyl, prenyl, benzyl or 2-alkenyl;

R^{1b} is independently CF_3, OR^2, NH_2, NHC(O)H or NHC(O)Me;

R^{1c} is H;

R^{1d} is independently OH, NH_2, NHC(O)H, NHC(O)Me or NO_2;

R^{1e} is independently C_1-C_6 alkyl, OH, OR^2, NO_2, NHC(O)H, NMe_2, NHMe or SR^2;

R^{1f} is independently H, OH, NO_2, NH_2, $NHSO_2Me$, NHC(O)H, NHC(O)Me, $NHCO(CH_2)NH_2$, $NHCO(CH_2)_2COOH$, $NHCH_2COOR^2$,N(OH)C(O)Me, NHC=NH(NH_2) or COOH;

R^{1g} is independently H, C_1-C_6 alkyl or OH;

R^{1b} and R^{1d} are not the same;

no more than one of R^{1f} or R^{1g} can be H;

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or trifluoromethyl;

or R^{1e} and R^{1f} form a five -membered heterocyclic ring containing a carbonyl group when R^{1e} is OH, NH_2 or NHMe and R^{1f} is NH_2, such that the nitrogen of R^{1f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{1e}, and R^{1g} is H;

in Formula II (Module A):

R^{2b} is independently CF_3, OR^2 or NH_2;

R^{2c} is H;

R^{2d} is independently O-protecting group or NO_2;

X is a halide or a hydroxyl group, wherein the halide is selected from the group consisting of F, Cl, Br, I and At;

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or trifluoromethyl;

2020415711 29 Jan 2025

in Formula III (Module B):

R^{3e} is independently C_1-C_6 alkyl, OR^2, NO_2 or SR^2;

R^{3f} is independently H, O-protecting group, NO_2 or $COOR^2$;

R^{3g} is independently H, C_1-C_6 alkyl, OH or OR^2;

and no more than one of R^{3f} or R^{3g} can be H;

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or trifluoromethyl; and

R^4 is C_1-C_6 alkyl;

or R^{3e} and R^{3f} form a five -membered heterocyclic ring containing a carbonyl group when R^{3e} is OH, NH_2 or NHMe and R^{3f} is NH_2, such that the nitrogen of R^{3f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{3e} and R^{3g} is H;

in Formula IV (Module C):

R^{4b} is independently CF_3 , OR^2 or NH_2;

R^{4c} is H;

R^{4d} is independently O-protecting group or NO_2;

R^{4e} is independently C_1-C_6 alkyl, OR^2, NO_2, or SR^2;

R^{4f} is independently H, O-protecting group, NO_2 or COOH;

R^{4g} is independently H, C_1-C_6 alkyl, OH or OR^2;

no more than one of R^{4f} or R^{4g} can be H;

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or trifluoromethyl; and

X is a halide or a hydroxyl group, wherein the halide is selected from the group consisting of F, Cl, Br, I, and At;

or R^{4e} and R^{4f} form a five -membered heterocyclic ring containing a carbonyl group when R^{4e} is OH, NH_2 or NHMe and R^{4f} is NH_2, such that the nitrogen of R^{4f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{4e} and R^{4g} is H;

wherein the protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxymethyl (SEM), $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$.

2020415711 29 Jan 2025

4. The process of any one of claims 1-3 wherein:

in Formula (I):

R^{1a} is independently allyl, crotyl, prenyl or benzyl;

R^{1b} is independently CF_3, OR^2 or NH_2;

R^{1c} is H;

R^{1d} is independently OH or NO_2;

R^{1e} is independently C_1-C_6 alkyl, OH, OR^2, NO_2 or SR^2;

R^{1f} is independently H, OH, NO_2 or COOH;

R^{1g} is independently H, C_1-C_6 alkyl or OH;

no more than one of R^{1f} or R^{1g} can be H; and

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or trifluoromethyl;

or R^{1e} and R^{1f} form a five-membered heterocyclic ring containing a carbonyl group when R^{1e} is OH, NH_2 or NHMe and R^{1f} is NH_2, such that the nitrogen of R^{1f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{1e} and R^{1g} is H;

in Formula II (Module A):

R^{2b} is independently CF_3, OR^2 or NH_2;

R^{2c} is H;

R^{2d} is independently O-protecting group or NO_2;

X is a halide or a hydroxyl group, wherein the halide is selected from the group consisting of F, Cl, Br, I and At; and

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or trifluoromethyl;

in Formula III:

R^{3e} is independently C_1-C_6 alkyl, OR^2, NO_2 or SR^2;

R^{3f} is independently H, O-protecting group, NO_2 or $COOR^2$;

R^{3g} is independently H, C_1-C_6 alkyl, OH or OR^2;

and no more than one of R^{3f} or R^{3g} can be H;

2020415711 29 Jan 2025

R^2 is independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or trifluoromethyl; and

R^4 is C_1-C_6 alkyl;

or R^{3e} and R^{3f} form a five-membered heterocyclic ring containing a carbonyl group when R^{3e} is OH, NH_2 or NHMe and R^{3f} is NH_2, such that the nitrogen of R^{3f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{3e} and R^{3g} is H;

in Formula IV:

R^{4b} is independently CF_3, OR^2 or NH_2;

R^{4c} is H;

R^{4d} is independently O-protecting group or NO_2;

R^{4e} is independently C_1-C_6 alkyl, OR^2, NO_2 or SR^2;

R^{4f} is independently H, O-protecting group, NO_2 or COOH;

R^{4g} is independently H, C_1-C_6 alkyl, OH or OR^2;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or trifluoromethyl; and


X is a halide or a hydroxyl group, wherein the halide is selected from the group consisting of F, Cl, Br, I and At;

or R^{4e} and R^{4f} form a five-membered heterocyclic ring containing a carbonyl group when R^{4e} is OH, NH_2 or NHMe and R^{4f} is NH_2, such that the nitrogen of R^{4f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{4e} and R^{4g} is H;


wherein the protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxymethyl (SEM), $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$.

5. The process of any one of claims 1-3 wherein the compound according to formula (I) is selected from the group consisting of:


2020415711 29 Jan 2025




1 [KYN-001]




2 [KYN-138]




3 [KYN-139]




4 [KYN-140]




5 [KYN-153]




6 [KYN-134]




7 [KYN-136]



8 [KYN-119]




9 [KYN-130] R = n-propyl
10 [KYN-131] R = iso-propyl
11 [KYN-132] R = CF_3




12 [KYN-133]


2020415711 29 Jan 2025




13 [KYN-114]




14 [KYN-118]




15 [KYN-158]




16 [KYN-157]




17 [KYN-120]




18 [KYN-156]




19 [KYN-160]



20 [KYN-146]




21 [KYN-154]




22 [KYN-124]


2020415711 29 Jan 2025




23 [KYN-125]




24 [KYN-141]




25 [KYN-137]




26 [KYN-129]




27 [KYN-149]




28 [KYN-143]




29 [KYN-128]



30 [KYN-142]




31 [KYN-151]




32 [KYN-148]


2020415711 29 Jan 2025




33 [KYN-126]




34 [KYN-147]




35 [KYN-152]




36 [KYN-150]




37 [KYN-144]




38 [KYN-155]




39 [KYN-165]



40 [KYN-159]




41 [KYN-161]




42 [KYN-162]


2020415711 29 Jan 2025




43 [KYN-163]




44 [KYN-164]




45 [KYN-112]




46 [KYN-145]




47 [KYN-167]




48 [KYN-168]




49 [KYN-169]



50 [KYN-170]



51 [KYN-166]



52 [KYN-171]

2020415711 29 Jan 2025

6. The process of any one of claims 1-3, wherein

in Formula (I):

R^{1a} is allyl, crotyl, prenyl, benzyl or 2-alkenyl

R^{1b} is OR^2, NHC(O)Me or NHC(O)H;

R^{1c} is H;

R^{1d} is OH;

R^{1e} is OR^2;

R^{1f} is NO_2, NHR^3 or NHC=NH(NH_2);

R^{1g} is H;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl or t-butyl; and

R^3 is H, (CO)H, (CO)Me, SO_2Me, CH_2COOR^2, $COCH_2NH_2$ or $CO(CH_2)_nCOOH$ (where n = 0, 1 or 2);

in Formula (II):

R^{2b} is OR^2 or NH_2;

R^{2c} is H;

R^{2d} is -O-protecting group;

X is a halide selected from the group consisting of F, Cl, Br, I and At; and

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl or t-butyl; and

in Formula (III):

R^{3e} is OR^2;

R^{3f} is NO_2;

R^{3g} is H;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl or t-butyl, and

R^4 is C_1-C_6 alkyl;

in Formula (IV):

R^{4b} is OR^2 or NH_2;

R^{4c} is H;

R^{4d} is O-protecting group;

R^{4e} is OR^2;

R^{4f} is NO_2;

2020415711 29 Jan 2025

R^{4g} is H;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl or t-butyl, and


X is a halide selected from the group consisting of F, Cl, Br, I and At;

wherein the protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxymethyl (SEM), $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$; and


wherein formula IV is coupled with a R^{1a} boronic pinacol ester selected from the group consisting of 3-methylbut-2-enylboronic acid pinacol ester, crotylboronic acid pinacol ester, allylboronic acid pinacol ester and benzylboronic acid pinacol ester, catalysed by a palladium catalyst in the presence of a base, to produce the compound of formula (I).

7. The process of any one of claims 1-3 or 6, wherein the compound according to formula (I) are selected for the group consisting of:


2020415711 29 Jan 2025




22 [KYN-124]




23 [KYN-125]




24 [KYN-141]




25 [KYN-137]




27 [KYN-149]




28 [KYN-143]




29 [KYN-128]



30 [KYN-142]




31 [KYN-151]




33 [KYN-126]


2020415711 29 Jan 2025




34 [KYN-147]




35 [KYN-152]




36 [KYN-150]




37 [KYN-144]




38 [KYN-155]



39 [KYN-165]



40 [KYN-159]



50 [KYN-170]

8. The process of any one of claims 1-3 wherein the compound of formula (IV) or (I) undergoes one or more further reactions, selected from one or more of the following:

-reaction with one or more $-NH_2$, NO_2 and/or -OH substituents on formula (I);

-conversion of an $-NH_2$ substituents to methoxyoxoacetamido ($-NHC(O)C(O)OCH_3$) substituents by reaction of the compound containing the NH_2 substituent with methyl chlorooxoacetate in the presence of a base;

2020415711 29 Jan 2025

-conversion of one or more –OH substituents to methyl oxalate substituents by reaction of the compound containing the OH substituent with methyl chlorooxoacetate in the presence of a base;

-Hydrolysis of one or more methoxyoxoacetamido substituents to a -NHC(O)C(O)OH substituents by reaction of the compound containing the N methoxyoxoacetamido substituent with a base;

-Hydrolysis of one or more methyl oxalate substituents to - OH substituents by reaction of the compound containing the methyl oxalate substituent with a base;

-Conversion of one or more $–NH_2$ substituents to guanidine ($-NHC(NH)NH_2$) substituents by reaction of the compound containing the NH_2 substituent with cyanamide in the presence of an acid;

-Conversion of one or more $–NH_2$ substituents to formamide ($-NHC(O)H$) substituents by reaction of the compound containing the NH_2 substituent with ethyl formate;

-Conversion of one or more $–NH_2$ substituents to an acetamido ($-NHC(O)CH_3$) substituents by reaction of the compound containing the NH_2 substituent with acetic anhydride in the presence of a base;

-Conversion of one or more $–NH_2$ substituents to an amide derivative ($-NHC(O)CH_2CH_2C(O)OH$) substituents by reaction of the compound containing the NH_2 substituent with succinic anhydride in the presence of a base;

-Conversion of one or more $–NH_2$ substituents to methyl amine substituents (-NHMe) by reaction of the compound containing the NH_2 substituent with formaldehyde in the presence of triacetoxyborohydride;


-Conversion of one or more –OH substituents to acetate ($-OC(O)CH_3$) substituents by reaction of the compound containing the -OH substituent with acetic anhydride in the presence of a base;

2020415711 29 Jan 2025

-Hydrolysis of one or more acetate substituents may to form - OH substituents by reaction of the compound containing the acetate substituent with a base;

-Reduction of one or more $–NO_2$ substituents to amine substituents by, for example, reaction of the compound containing the NO_2 substituent with Zn in the presence of ammonium chloride.

9. The process according to any one of claims 1-3 wherein the compound according to formula (II) is



Formula (II)

wherein


R^{2b}= OMe;

R^{2c}=H;

R^{2d}=OH or OSEM; and


Hal is Br;

which is prepared according to the following process:



2020415711 29 Jan 2025

10. The process according to any one of claims 1-3 wherein the compound according to formula (III) is



Formula (III)

wherein


R^{3g}=H;

R^{3f}= OSEM;


R^{3e}=OMe; and

R^4=Et;

which is prepared according to the following process:



11. The process of claim 1 wherein formula(II) is Module A, formula (III) is Module B and formula (IV) is Module C according to the following:




2020415711 29 Jan 2025


wherein:

i) Module C is coupled with 3-methylbut-2-enylboronic acid pinacol ester in the presence of tetrakis(triphenylphosphine)palladium(0) and potassium carbonate to afford compound 1-1; and

ii) compound 1-1 is treated with tetrabutylammonium fluoride to afford compound 1, according to the following:



12. A compound according to formula (I)



prepared by a process according to claim 1 or 2,

wherein:

R^{1a} is allyl, crotyl, prenyl, benzyl or 2-alkenyl;

R^{1b} is CF_3, OR^2 or NHR^3;

R^{1c} is H;

2020415711 29 Jan 2025

R^{1d} is OH, O-protecting group, NHR^3 or NO_2;

R^{1b} and R^{1d} are not the same;

R^{1e} is C_1-C_6 alkyl, OH, OR^2, NO_2, NHR^3, $NMeR^3$ or SR^2;

R^{1f} is H, OH, O-protecting group, NO_2, NHR^3, NHC=NH(NH_2), COOH or $N(OH)(CO)CH_3$;

R^{1g} is H, C_1-C_6 alkyl or OH;

no more than one of R^{1f} or R^{1g} can be H;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or a O-protecting group;


protecting group is selected from the group consisting of COMe, *t*-BuSi(CH_3)$_2$, 2-(trimethylsilyl)ethoxymethyl (SEM), $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$;

R^3 is H, CH_3, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $CO(CH_2)_nNH_2$, $CONH_2$, $CO(CH_2)_nCOOH$ or $COCOOR^4$ (where n = 0, 1 or 2); and

R^4 is C_1-C_6 alkyl;

or R^{1e} and R^{1f} form a five-membered heterocyclic ring containing a carbonyl group when R^{1e} is independently OH, NH_2 or NHMe and R^{1f} is NH_2, such that the nitrogen of R^{1f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{1e}; and R^{1g} is H.

13. A compound according to formula (I)



Formula (I)

wherein:

2020415711 29 Jan 2025

R^{1a} is allyl, crotyl, prenyl, benzyl or 2-alkenyl;

R^{1b} is CF_3, OR^2 or NHR^3;

R^{1c} is H;

R^{1d} is OH, O-protecting group, NO_2 or NHR^3;

R^{1e} is C_1-C_6 alkyl, OH, OR^2, NO_2, NHR^3, $NMeR^3$ or SR^2;

R^{1f} is H, OH, O-protecting group, NO_2, NHR^3, $NHC{=}NH(NH_2)$, $COOR^2$, COOH or $N(OH)(CO)CH_3$;

R^{1g} is H, C_1-C_6 alkyl or OH;

only one of R^{1f} or R^{1g} can be H;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or O-protecting group;

protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxymethyl (SEM), $CH(OEt)CH_3$, tetrahydropyranyl or $C(OEt)(CH_3)_2$;

R^3 is H, CH_3, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $CO(CH_2)_nNH_2$, $CONH_2$, $CO(CH_2)_nCOOH$ or $COCOOR^4$ (where n = 0, 1 or 2); and

R^4 is C_1-C_6 alkyl;

or R^{1e} and R^{1f} form a five-membered heterocyclic ring containing a carbonyl group when R^{1e} is independently OH, NH_2 or NHMe and R^{1f} is NH_2, such that the nitrogen of R^{1f} is bridged with the carbonyl group to the oxygen or nitrogen of R^{1e}; and R^{1g} is H;

provided that:

i) when R^{1a} is prenyl, R^{1d} is OH or O-protecting group, R^{1f} is OH or O-protecting group, R^{1g} is H and R^{1e} is OH or OR^2, then R^{1b} cannot be OR^2 where R^2 =methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *t*-butyl, or benzyl; and

ii) R^{1b} and R^{1d} are not the same.

14. A compound of formula (I) according to claim 13 wherein:

R^{1a} is allyl, prenyl or benzyl;

R^{1b} is CF_3 or OR^2;

2020415711 29 Jan 2025

R^{1c} is H;

R^{1d} is OH, NH_2 or N(CO)H;

R^{1e} is OH, OR^2, NO_2, NHR^3, $NMeR^3$ or SMe;

R^{1f} is H, OH, NO_2, NHR^3, NHC=NH(NH_2) or COOH;

R^{1g} is H, C_1-C_6 alkyl or OH;

only one of R^{1f} or R^{1g} can be H;


R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl or t-butyl; and

R^3 is H, CH_3, (CO)H, (CO)Me, SO_2Me, CH_2COOR^2, $COCH_2NH_2$ or $CO(CH_2)_nCOOH$ (where n = 0, 1 or 2);


provided that:

i) when R^{1a} is prenyl, R^{1d} is OH, R^{1f} is OH, R^{1g} is H and R^{1e} is OH or OR^2, then R^{1b} cannot be OR^2 where R^2=methyl, ethyl, isopropyl, propyl, butyl, isobutyl, *t*-butyl, or benzyl.


15. A compound according to claim 13 wherein formula (I) is a compound selected from the group consisting of:




2 [KYN-138]




3 [KYN-139]




4 [KYN-140]




5 [KYN-153]




6 [KYN-134]




7 [KYN-136]




11 [KYN-132]




13 [KYN-114]




14 [KYN-118]




15 [KYN-158]




16 [KYN-157]



17 [KYN-120]




18 [KYN-156]




19 [KYN-160]


2020415711 29 Jan 2025




21 [KYN-154]




22 [KYN-124]




23 [KYN-125]




24 [KYN-141]




25 [KYN-137]




26 [KYN-129]




27 [KYN-149]



28 [KYN-143]




29 [KYN-128]




30 [KYN-142]


2020415711 29 Jan 2025




31 [KYN-151]




32 [KYN-148]




33 [KYN-126]




34 [KYN-147]




35 [KYN-152]



36 [KYN-150]




37 [KYN-144]




38 [KYN-155]


2020415711 29 Jan 2025




39 [KYN-165]




40 [KYN-159]




41 [KYN-161]




42 [KYN-162]



43 [KYN-163]




44 [KYN-164]




46 [KYN-145]

,




47 [KYN-167]




48 [KYN-168]


2020415711 29 Jan 2025




49 [KYN-169]



50 [KYN-170]



51 [KYN-166]



52 [KYN-171]

16. A compound according to claim 13 wherein in formula (I):

R^{1a} is allyl, crotyl, prenyl or benzyl;

R^{1b} is CF_3, OR^2 or NHR^3;

R^{1c} is H;

R^{1d} is OH, NO_2 or NHR^3;

R^{1e} is C_1-C_6 alkyl, OH, OR^2, NO_2, NHR^3 or SR^2;

R^{1f} is H, OH, O-protecting group, NO_2, NHR^3, $NHC{=}NH(NH_2)$, $COOR^2$ or COOH;

R^{1g} is H, C_1-C_6 alkyl or OH;

R^{1b} and R^{1d} are not the same; and

only one of R^{1f} or R^{1g} can be H;

wherein at least one of R^{1b} or R^{1d} is CF_3, NO_2 or NHR^3;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or O-protecting group;


protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxymethyl (SEM), $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$;

2020415711 29 Jan 2025


R^3 is H, CH_3, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $CO(CH_2)_nNH_2$, $CONH_2$, $CO(CH_2)_nCOOH$ or $COCOOR^4$ (where n = 0, 1 or 2); and

R^4 is C_1-C_6 alkyl.

17. A compound according to claim 16 wherein formula (I) is a compound selected from the group consisting of:




11 [KYN-132]




43 [KYN-163]


2020415711 29 Jan 2025




44 [KYN-164]




46 [KYN-145]



48 [KYN-168]



49 [KYN-169]



50 [KYN-170]

18. A compound according to claim 13 wherein in formula (I):

R^{1a} is allyl, crotyl, prenyl or benzyl;

R^{1b} is CF_3, OR^2 or NHR^3;

R^{1c} is H;

R^{1d} is OH, NHR^3 or NO_2;

R^{1b} and R^{1d} are not the same;

R^{1e} is OH or OR^2;

R^{1f} is NO_2, NHR^3, $NHC{=}NH(NH_2)$ or COOH;


R^{1g} is H;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl or trifluoromethyl; and


2020415711 29 Jan 2025

R^3 is H, CH_3, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $COCH_2NH_2$, $CONH_2$ or $CO(CH_2)_nCOOH$ (where n = 0, 1 or 2).


19. A compound according to claim 18 wherein formula (I) is a compound selected from the group consisting of:




21 [KYN-154]




22 [KYN-124]




23 [KYN-125]




24 [KYN-141]




25 [KYN-137]



26 [KYN-129]




27 [KYN-149]




28 [KYN-143]


2020415711 29 Jan 2025




29 [KYN-128]




30 [KYN-142]




31 [KYN-151]




32 [KYN-148]




33 [KYN-126]



34 [KYN-147]




35 [KYN-152]




36 [KYN-150]


2020415711 29 Jan 2025




37 [KYN-144]



38 [KYN-155]



40 [KYN-159]



50 [KYN-170]

20. A compound according to claim 13 wherein in formula (I):

R^{1a} is allyl, crotyl, prenyl or benzyl;

R^{1b} is CF_3, OR^2 or NHR^3;

R^{1c} is H;

R^{1d} is OH, NHR^3 or NO_2;

R^{1e} is C_1-C_6 alkyl, NO_2, NMe_2, NHR^3 or SR^2;

R^{1f} is OH or O-protecting group;

R^{1g} is H;

R^{1b} and R^{1d} are not the same;


R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or O-protecting group;

protecting group is selected from the group consisting of COMe, *t*-$BuSi(CH_3)_2$, 2-(trimethylsilyl)ethoxymethyl (SEM), $CH(OEt)CH_3$, tetrahydropyranyl, or $C(OEt)(CH_3)_2$; and


R^3 is H, CH_3, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $COCH_2NH_2$, $CONH_2$ or $CO(CH_2)_nCOOH$ (where n = 0, 1 or 2).

2020415711 29 Jan 2025


21. A compound according to claim 20 wherein formula (I) is a compound selected from the group consisting of:




13 [KYN-114]




14 [KYN-118]



15 [KYN-158]



16 [KYN-157]



41 [KYN-161]

22. A compound according to claim 13 wherein in formula (I):

R^{1a} is allyl, crotyl or benzyl;

R^{1b} is CF_3, OR^2 or NHR^3;

R^{1c} is H;

R^{1d} is OH, NHR^3 or NO_2;

R^{1e} is OH, OR^2, NO_2, NHR^3 or SR^2;

R^{1f} is H, OH, NO_2, NHR^3, NHC=NH(NH_2) or COOH;

R^{1g} is H, C_1-C_6 alkyl or OH;

such that R^{1b} and R^{1d} are not the same;

and only one of R^{1f} or R^{1g} can be H;

2020415711 29 Jan 2025

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or O-protecting group, wherein the protecting group is selected from the group consisting of COMe, *t*-BuSi(CH_3)$_2$, 2-(trimethylsilyl)ethoxymethyl (SEM), CH(OEt)CH_3, tetrahydropyranyl, or C(OEt)(CH_3)$_2$; and

R^3 is H, CH_3, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $COCH_2NH_2$, $CONH_2$ or CO(CH_2)$_n$COOH (where n = 0, 1 or 2).

23. A compound according to claim 13 wherein in formula (I):

R^{1a} is allyl, crotyl, benzyl or 2-alkenyl;

R^{1b} is OR^2;

R^{1c} is H;

R^{1d} is OH;

R^{1e} is OR^2;


R^{1f} is OH;

R^{1g} is H; and


R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl or O-protecting group, wherein the protecting group is selected from the group consisting of COMe, *t*-BuSi(CH_3)$_2$, 2-(trimethylsilyl)ethoxymethyl (SEM), CH(OEt)CH_3, tetrahydropyranyl, or C(OEt)(CH_3)$_2$.

24. A compound according to claim 22 or 23 wherein formula (I) is a compound selected from the group consisting of:


2020415711 29 Jan 2025




2 [KYN-138]




3 [KYN-139]




4 [KYN-140]



5 [KYN-153]




6 [KYN-134]




7 [KYN-136]

25. A compound according to claim 13 wherein formula (I) is a compound selected from the group consisting of:


2020415711 29 Jan 2025




13 [KYN-114]




14 [KYN-118]




15 [KYN-158]




16 [KYN-157]




17 [KYN-120]




18 [KYN-156]




19 [KYN-160]




21 [KYN-154]




22 [KYN-124]




23 [KYN-125]




24 [KYN-141]




25 [KYN-137]




26 [KYN-129]




27 [KYN-149]




28 [KYN-143]




29 [KYN-128]



30 [KYN-142]




31 [KYN-151]




32 [KYN-148]


2020415711 29 Jan 2025




33 [KYN-126]




34 [KYN-147]




35 [KYN-152]




36 [KYN-150]




37 [KYN-144]




38 [KYN-155]




39 [KYN-165]



40 [KYN-159]




41 [KYN-161]




42 [KYN-162]


2020415711 29 Jan 2025




43 [KYN-163]




44 [KYN-164]




45 [KYN-112]




46 [KYN-145]




47 [KYN-167]




48 [KYN-168]




49 [KYN-169]



50 [KYN-170]



51 [KYN-166]



52 [KYN-171]

2020415711 29 Jan 2025

26. A compound according to claim 13 wherein in formula (I):

R^{1a} is prenyl;

R^{1b} is OR^2;

R^{1c} is H;

R^{1d} is OH;

R^{1e} is OR^2;

R^{1f} is NHR^3 or $NHC=NH(NH_2)$;

R^{1g} is H;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl or t-butyl; and

R^3 is H, CH_3, (CO)H, (CO)Me, SO_2Me, CH_2COOR^2, $COCH_2NH_2$ or $CO(CH_2)_nCOOH$ (where n = 0, 1 or 2).

27. A compound according to claim 13 wherein in formula (I):

R^{1a} is prenyl;

R^{1b} is OR^2;

R^{1c} is H;

R^{1d} is OH:

R^{1e} is OR^2;

R^{1f} is OH;

R^{1g} is C_1-C_6 alkyl or OH; and

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl or t-butyl.

28. A compound according to claim 13 wherein in formula (I):

R^{1a} is allyl, crotyl, prenyl or benzyl;

R^{1b} is CF_3, OR^2 or NHR^3;

R^{1c} is H;

R^{1d} is OH, NO_2 or NHR^3;

R^{1e} is C_1-C_6 alkyl, OH, OR^2, NO_2, NHR^3 or SR^2;

R^{1f} is H, OH, OR^2, NO_2, NHR^3, $NHC=NH(NH_2)$ or COOH;

R^{1g} is H, C_1-C_6 alkyl or OH;

R^2 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, trifluoromethyl, or O-protecting group, wherein the protecting group is selected from the group


consisting of COMe, *t*-BuSi(CH_3)$_2$, 2-(trimethylsilyl)ethoxymethyl (SEM), CH(OEt)CH_3, tetrahydropyranyl, or C(OEt)(CH_3)$_2$;

R^3 is H, CH_3, (CO)H, (CO)Me, SO_2Me, CH_2COOH, CH_2COOR^2, $CO(CH_2)_nNH_2$, $CONH_2$ or $CO(CH_2)_nCOOH$ (where n = 0, 1 or 2);

only one of R^{1f} or R^{1g} can be H; and

at least one of R^{1e} or R^{1f} is – NHC(O)H or NHC(O)Me.


29. A compound according to:



8 [KYN-119]

.

30. A compound according to:



20 [KYN-146]

.

31. A method of treating a cancer comprising administering a therapeutically effective amount of a compound according to any one of claims 13-30 or a pharmaceutically acceptable salt, solvate or pharmaceutical composition including said compound to a patient in need thereof wherein the cancer is selected from the group consisting of: skin cancer including melanoma; CNS cancer, ovarian cancer, renal cancer, prostate cancer, pancreatic cancer, bladder cancer, kidney cancer, hypo-pharynx cancer, pharynx cancer, tongue cancer, colon cancer, breast cancer, lung cancer, liver

2020415711 29 Jan 2025

cancer, brain cancer, glioblastoma and osteoblastic sarcoma cell cancer, connective tissue sarcoma, Ewing's sarcoma, fibrosarcoma, leiomyosarcoma, liposarcoma, osteosarcoma and rhabdomyosarcoma, pharyngeal cancer and neuroblastomas.

32. Use of a compound according to any one of claims 13-30 or a pharmaceutically acceptable salt, solvate or pharmaceutical composition including said compound in the manufacture of a medicament for the treatment of a cancer selected from the group consisting of: skin cancer including melanoma, CNS cancer, ovarian cancer, renal cancer, prostate cancer, pancreatic cancer, bladder cancer, kidney cancer, hypo-pharynx cancer, pharynx cancer, tongue cancer, colon cancer, breast cancer, lung cancer, liver cancer, brain cancer, glioblastoma and osteoblastic sarcoma cell cancer, connective tissue sarcoma, Ewing's sarcoma, fibrosarcoma, leiomyosarcoma, liposarcoma, osteosarcoma and rhabdomyosarcoma, pharyngeal cancer and neuroblastomas.

33. A method of treating a skin disease and/or disorder comprising administering a therapeutically effective amount of a compound according to any one of claims 13-30 or a pharmaceutically acceptable salt, solvate or pharmaceutical composition including said compound to a patient in need thereof.

34. Use of a compound according to any one of claims 13-30 or a pharmaceutically acceptable salt, solvate or pharmaceutical composition including said compound in the manufacture of a medicament for the treatment of a skin disease and/or disorder.

35. The method of claim 33 or the use according to claim 34 wherein the skin disease and/or disorder is atopic dermatitis or psoriasis.

Figure 1:




Figure 2:




Figure 3:




Figure 4:




Figure 5:




Figure 6:




Figure 7:




Figure 8:




Figure 9:




Figure 10:




Figure 11:




Figure 12:






Figure 13:
Concentration-response graphs of compound **1, 8, 20, 27, 28, 31** and **35**

Figure 13.1
Effect of compound **1**:


A.



B.



C.


120
80
40
0
-40
% Effect
10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5
Compound 1 (M)
Inhibition of IL-17A release
Inhibition of cell viability

D.




120
80
40
0
-40
% Effect
10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5
Compound 1 (M)
Inhibition of IL-4 release
Inhibition of IL-2 release
Inhibition of cell viability


Figure 13.2:

Effect of compound **8:**


A.



B.



C.


120
80
40
0
-40
% Effect
10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5
Compound 8 (M)
Inhibition of IL-17A release
Inhibition of cell viability

D.





120
80
40
0
-40
% Effect
10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5
Compound 8 (M)
Inhibition of IL-4 release
Inhibition of IL-2 release
Inhibition of cell viability

Figure 13.3:
Effect of compound **20**:


A.



B.



C.


120
80
40
0
% Effect
10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5
Compound 20 (M)
Inhibition of IL-17A release
Inhibition of cell viability

D.





120
80
40
0
-40
% Effect
10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5
Compound 20 (M)
Inhibition of IL-4 release
Inhibition of IL-2 release
Inhibition of cell viability

Figure 13.4:
Effect of compound **27**


A.



B.



C.


120
80
40
0
-40
% Effect
10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5
Compound 27 (M)
Inhibition of IL-17A release
Inhibition of cell viability

D.





120
80
40
0
-40
% Effect
10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5
Compound 27 (M)
Inhibition of IL-4 release
Inhibition of IL-2 release
Inhibition of cell viability

Figure 13.5:
Effect of compound **28**


A.



B.



C.


120
80
40
0
-40
% Effect
10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5
Compound 28 (M)
Inhibition of IL-17A release
Inhibition of cell viability

D.





120
80
40
0
-40
% Effect
10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5
Compound 28 (M)
Inhibition of IL-4 release
Inhibition of IL-2 release
Inhibition of cell viability

Figure 13.6:
Effect of compound **31**


A.



B.



C.


120
80
40
0
% Effect
10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5
Compound 31 (M)
Inhibition of IL-17A release
Inhibition of cell viability

D.





120
80
40
0
-40
% Effect
10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5
Compound 31 (M)
Inhibition of IL-4 release
Inhibition of IL-2 release
Inhibition of cell viability

Figure 13.7:
The effects of compound **35**


A.



B.



C.


120
80
40
0
% Effect
10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5
Compound 35 (M)
Inhibition of IL-17A release
Inhibition of cell viability

D.




120
80
40
0
-40
% Effect
10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5
Compound 35 (M)
Inhibition of IL-4 release
Inhibition of IL-2 release
Inhibition of cell viability


Figure 14:

A. BNA99 Results


Compound **1** [KYN-001]




Compound **20** [KYN-146]




Compound **27** [KYN-149]






B. BNB04 Results


Compound **1**




Compound **20**



Compound **27**




Comp. **1** Comp. **20** Comp. **27** TMZ




C. BNB18 Results


Compound **1**



Compound **20**



Compound **27**







Figure 15:

A. Concentrations of **27** in different tissues from experimental mice.



B. Concentrations of **27** in isolated tissues from the treated groups.




Figure 16:




Figure 17:



Figure 18:

